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Summary 
Introduction 
Malaria is caused by intracellular organisms that belong to the genus Plasmodium. In 
2015, there were an estimated 438,000 deaths and 214 million clinical illnesses due to 
malaria infection, of which the majority were in sub-Saharan African children below five 
years of age. Amongst the five species that are known to infect humans, Plasmodium 
falciparum causes the most severe disease, mostly in children and pregnant women in 
sub-Saharan Africa. Despite malaria control programs being operational for many years, 
malaria elimination in most endemic regions is far from being achieved. Vaccination is 
considered the most cost effective method of preventing infectious diseases. To date, 
there are no effective vaccines available for parasitic infections, despite the existence of 
strong evidence of acquired immunity in most parasitic infections studied. It is therefore 
highly likely that the addition of an effective tool such as a vaccine to the current malaria 
control strategy would have a strong positive impact on our ability to control this disease. In 
the first part of this thesis, we aimed to investigate the vaccine efficacy as well as the 
cellular and humoral immunity of African paediatric volunteers vaccinated with the most 
clinically advanced malaria vaccine; the RTS, S/AS01. 
 Meanwhile, novel vaccination and testing approaches are being pursued to improve or 
replace the recombinant subunit malaria vaccine approach to meet the goals formulated in 
the Malaria Vaccine Roadmap of WHO (http://www.who.int/immunization/topics/malaria/ 
vaccine_roadmap/en). These goals strategized that by 2030, licensed vaccines targeting 
Plasmodium falciparum and Plasmodium vivax should encompass the following two 
objectives, for use by the international public health community: 
i) First, it should have a protective efficacy of at least 75 percent against clinical 
malaria and be suitable for administration to appropriate at-risk groups in malaria- 
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endemic areas. 
ii) Secondly, it should reduce transmission of the parasite and thereby substantially 
reduce the incidence of human malaria infection; enable elimination in multiple 
settings and be suitable for administration in mass campaigns. 
Currently, the most promising candidate seems to be the whole malaria sporozoite 
approach, which is formed of cryopreserved, purified whole live-attenuated (either by 
irradiation or genetic attenuation) sporozoites. One of the novel tools used to analyze 
induced vaccine efficacy in sub-Saharan Africa experimentally vaccinated volunteers is 
controlled human malaria infection (CHMI). Many CHMIs using infectious mosquito bites or 
purified sporozoites have been successfully conducted in the USA and Europe over many 
years, but this approach had not been employed in sub-Saharan Africa until 2012. The aim 
of the second part of this thesis was to describe the potential of using CHMI as a tool to 
accelerate malaria vaccine development in sub-Saharan Africa and to dissect malaria- 
specific immunity induced by CHMI based on our trial conducted in 2012 in Bagamoyo. 
 
Methods and findings 
In the first part of this thesis (Chapter 4), the aim was to investigate safety, efficacy, cellular 
and humoral immunity in RTS,S/AS01 vaccinated Tanzanian paediatric populations. 
Adverse events were used to determine the safety of the RTS,S/AS01 vaccine in this age 
group (paper I), ELISA to measure the vaccine-induced CS-specific antibodies and 
Luminex to measure vaccine-induced cytokine responses (paper II and III). Furthermore, 
flow cytometry was used to investigate vaccine-induced cellular immune responses (paper 
III). We also looked into the implications and practicalities of immunological sampling in the 
African paediatric population. We did community sensitization and collected blood samples 
from 400 children for immunological study (paper IV). We showed that in 6-12 week old 
infants, vaccine efficacy against clinical malaria 14 months after first vaccination was 
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30.1% (95% CI, 23.6 to 36.1) in the intention-to-treat (ITT) and 31.3% (97.5% CI, 23.6 to 
38.3) in the per-protocol (PP) population. Furthermore, the vaccine efficacy against severe 
malaria was 26.0% (95% CI, −7.4 to 48.6) and 36.6% (95% CI, 4.6 to 57.7) in the ITT and 
PP populations, respectively. The safety of the vaccine in terms of serious adverse events 
showed similar trends in both study groups. We identified two main RTS,S/AS01 vaccine 
induced cellular immune mechanisms:- (i) Th1-related responses such as CS-specific IFN-
g, GM-CSF and IL-15 are associated with protection and (ii) Th2-related responses 
mediated by CS-specific IL5 and RANTES are associated with increased odds of malaria. 
Moreover, antibody avidity alone did not predict protective efficacy in the current study. The 
induction of RTS, S/AS01 protective Th1 and pro-inflammatory responses was lower in 
infants compared to children; a scenario that might explain the lower efficacy observed in 
the infant cohort. Furthermore, we also showed that immunology studies in the paediatric 
population can feasibly be conducted in African research institutions. 
In the second part of this thesis (Chapter 5), we conducted in 2012 the first CHMI using 
cryo-preserved purified non-attenuated sporozoites in Tanzanian adult volunteers with 
previous malaria exposure (paper V). In this study, the humoral and cellular immune 
responses elicited following CHMI were evaluated (paper VI and VII). We used adverse 
events to determine the safety of the CHMI model in malaria pre-exposed volunteers. We 
also used blood slide microscopy to define sporozoite infectivity rates, Luminex assays to 
examine the sporozoite-induced antibodies, B-cell Elispot analysis, single cell RNA 
sequencing, flow cytometry and cell sorting followed by in vitro stimulation assays to 
investigate and define the affected innate and adaptive immune responses following CHMI 
(paper VIII). Our studies showed that: (i) CHMI is safe, tolerable and infective when used 
in malaria endemic regions, (ii) a single dose of intradermal sporozoite (PfSPZ) challenge 
elicited long-lived merozoite-opsonizing antibodies and long-lasting innate and innate-like 
lymphocyte populations, (iii) When we compared Dutch (malaria naïve) and Tanzanian 
xiv
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(malaria exposed) subjects undergoing the same challenge study, Dutch subjects 
responded differently to PfSPZ challenge compared to Tanzanian (malaria pre-exposed) 
subjects. 
Conclusion 
Substantial investment in research and development is needed to develop a highly 
efficacious malaria vaccine. To date, the recombinant subunit vaccines are yet to give the 
desired levels of protection for malaria elimination but seem to prevent malaria disease in 
high transmission settings. Large scale manufacturing, storage and distribution of live 
whole malaria sporozoite-based vaccines for mass administration need further 
development. So far, data generated from the PfSPZ vaccine trials conducted in the USA, 
Europe and in African research institutions imply that malaria naive individuals respond 
better to malaria vaccines than malaria pre-exposed individuals. The question remains to 
be, “what exactly constitutes the reason for lack of durable protection against malaria 
infection in endemic areas?” The most important factor in accelerating future vaccine 
development is a better understanding of the biology and nature of acquired immunity, 
which will lead to improved vaccine design. We have established the foundation for using 
CHMI to assess efficacy of new interventions against malaria and to study the mechanisms 
of the lack of protection conferred by different malaria vaccines in endemic settings. This 
study has opened new doors in the field of malaria intervention, whereby malaria vaccine 
and drug efficacy can be easily tested using CHMI in the target population. 
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Chapter 1: Introduction 
 
1.1. Malaria: overview 
 
1.1.1. The parasites 
 
Malaria infection is caused by intracellular organisms that belong to the genus Plasmodium 
in the Phylum Apicomplexa within the Protista kingdom. The Phylum Apicomplexa is 
estimated to consist of over 5,000 species, many of which are responsible for causing a 
wide range of serious diseases in humans, livestock, wild animals and invertebrates 
(Gubbels and Duraisingh, 2012; Levine, 1988). The genus Plasmodium consists of more 
than 100 species, of which four species have long been recognized to infect humans and 
an additional species, known to naturally infect macaques, has recently also been reported 
to  infect humans (Knowles and Gupta; White, 2008). Malaria is transmitted to humans 
through the bite of infected female anopheline mosquitoes. Out of over 400 anopheline 
species that are known to date, only forty are considered to be dominant vector species 
(Sinka et al., 2012). The prevalence of malaria species of public health importance varies 
worldwide and is linked to the geographical and environmental preferences of the parasite 
(Figure 1) (Blanford et al., 2013). 
 
 
Figure 1: Global distribution of P. falciparum and P. vivax by countries. (Feachem et al., 2009) 
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Below we highlight the characteristics of the five malaria species known to infect homo-
sapiens. 
 
 
1.1.1.1. Plasmodium falciparum 
 
P. falciparum is found in tropical and subtropical areas of the world, and is known to be the 
principal cause of malaria-related morbidity and mortality. Pregnant women, children and 
immunocompromized individuals constitute the most vulnerable population, with over half a 
million deaths in Africa alone estimated to be caused by P. falciparum infection in children 
under five (WHO, 2015). The severity of P. falciparum infection is mainly due to its ability to 
multiply in the red blood cells (RBCs) every 48 hours during its asexual blood stage cycle. 
Destruction of RBCs leads to significant RBC loss and contributes to anaemia, which is 
often observed in chronically infected persons. P. falciparum infection of the RBC leads to 
novel, parasite-encoded protein expression on the surface of infected RBCs (iRBCs). 
These surface expressed proteins, such as the Var gene encoded proteins, enable P. 
falciparum to adhere to endothelial cells in small vasculature (sequestration), hence 
creating chances for physically obstructing small blood vessels in the brain and kidneys. 
The iRBCs rosetting in the brain may result in cerebral malaria, a complication that may 
lead to mental retardation or death (Cooke et al., 2000; Idro et al., 2010). 
 
1.1.1.2. P. vivax 
 
P. vivax is the most prevalent human malaria parasite outside of Africa, due to its 
adaptation to relatively cooler climate zones. Although P.vivax contributes to widespread 
morbidity in endemic areas, P.vivax  infection is rarely severe or fatal  (Howes et al., 2016; 
White., 2011a). P. vivax is well known for its ability to develop dormant stages in the liver 
that can be reactivated. Reactivated P. vivax can cause asexual blood stage infections 
several months or years after the primary infectious mosquito bite. Currently, only 
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Primaquine is known to be an effective treatment against P. vivax dormant liver stage 
forms, with the disadvantage that it requires 14 days of consistent drug adherence with 
significant side effects in glucose-6-phosphate dehydrogenase (G6PD) patients (Ashley et 
al., 2014; John et al., 2012; White, 2011b). 
P. vivax control is challenging due to factors such as its ability to be transmitted by a broad 
range of anopheline vectors species, the early biting behavior of mosquitoes that transmit 
the parasite, the emergence of gametocytes stages before onset of illness and the difficulty 
of diagnosing asexual blood stage infection due to low parasitemia (Bassat et al., 2016). 
 
1.1.1.3. P. ovale 
 
P. ovale is a relatively rare species, mostly found in West-Africa and the Pacific islands. P. 
ovale exhibits Schüffner's dots and infected erythrocytes can be normal or slightly 
enlarged; a characteristic feature that is also shared by P. vivax, making it difficult to 
distinguish the two species microscopically (Collins and Jeffery, 2005a). Similar to P.vivax, 
P.ovale can form a latent liver stage called hypnozoite, which makes the parasite capable 
of causing disease several months or years after primary infection (Collins and Jeffery, 
2005b; Markus, 2011). Furthermore, P. ovale tends to present a low parasite burden and 
mild clinical symptoms, making routine diagnosis challenging. Recently, two P. ovale sub-
species, classic (P. ovale curtis) and variant (P.ovale wallikeri) have been characterized 
(Sutherland et al., 2010). In Africa, the higher prevalence of P. ovale relative to P. vivax 
could be explained by the ability of P. ovale to infect populations carrying the null Duffy 
blood group, which provides natural resistance to P. vivax (Collins and Jeffery, 2005b). 
 
1.1.1.4. P. malariae 
 
P. malariae is found in sub-Saharan Africa, Southeast Asia, Indonesia and in the Western 
Pacific Islands (Collins and Jeffery, 2005a). Compared to the other human malaria parasite 
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species, P. malariae has a distinct asexual blood stage life cycle that lasts for three days. 
Although P. malariae does not cause complicated malaria at the beginning, it is known that 
if untreated, P. malariae patients have higher risk of developing a life-long, chronic 
infection that may result in serious complications such as nephrotic syndrome (Badiane et 
al., 2014). In most cases P. malariae distributions have been found to coincide with that of 
P. falciparum. In malaria-endemic Africa, mixed infections of P. malariae and P. falciparum 
are common. However, to reveal the presence of low-parasitemia P. malariae within mixed 
infections, molecular techniques such as polymerase chain reaction (PCR) are required 
(Collins and Jeffery, 2007). 
 
1.1.1.5. P. knowlesi 
 
P. knowlesi has recently been reported to be a significant cause of zoonotic malaria, 
particularly in Malaysia. P. knowlesi is abundant in Southeast Asia as a natural pathogen 
of long-tailed and pig-tailed macaques. Despite the fact that P. knowlesi morphologically 
resembles P.falciparum and P. malariae, P.knowlesi has a short asexual blood stage cycle 
of approximately 24 hours, unlike P. falciparum and P. malariae which requires 48 hours to 
complete their asexual blood stage cycle. Importantly, P.knowlesi infections can progress 
rapidly from uncomplicated to severe presentations across age groups (Vythilingam et al., 
2016; Wesolowski et al., 2015). 
 
1.1.2. Epidemiology of P. falciparum malaria 
 
P. falciparum is a major cause of malaria that impacts most heavily in children and pregnant 
women in sub-Saharan Africa, Southeast Asia and South America. By 2015, an estimate of 
214 million (range: 149–303 million) cases of malaria have been reported to cause about 
438 000 deaths (range: 236 000–635 000), predominantly in African children younger than 
five years old (WHO, 2015). For the past decades, P. falciparum malaria has become one 
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of the most studied diseases globally. P. falciparum was endemic in Southern   Europe   
and   North   America   until   the   beginning   of   the   20th century. Comprehensive    
surveillance    and    treatment    programs,    including    the    use     of 
Dichlorodiphenyltrichloroethane (DDT) for vector control has since lead to the elimination of 
malaria in these regions.  
 
To date, the importance of malaria remains prominent on a global scale, despite the recent 
decline in malaria cases (Berberian, 1948; Meshnick and Dobson, 2001). Although malaria 
mortality rates amongst children have declined by over 50% within the past decade, the 
WHO 2014 world malaria report indicated that P. falciparum malaria was still responsible for 
about 10% of Africa’s entire disease burden in 2013, with children (WHO, 2014) and in 
primigravidae (Menendez et al., 2000) being the most affected populations. Some of the 
ongoing hurdles in malaria control programs are caused by environmental changes such as 
heavy rains after drought and the associated focal expansion of vectors, socio-economic 
factors and civil wars in some part of Africa leading to mass population movement (White et 
al., 2014). Additionally, the  availability of efficacious drugs is constantly under threat due to 
the development of drug resistance by the parasite and insecticide resistance of the vector 
(Jindal et al., 2014). 
 
1.1.3. Life cycle of P. falciparum 
 
The life cycle of P. falciparum alternates between the human host and the transmitting 
vector, Anopheles mosquito. During its development, the parasite undergoes a number of 
morphological changes  that take place in a variety of tissues in both the mosquito and 
human vector (Bijker et al., 2013; Pradel and Frevert, 2001). Sporozoites, the infectious 
form of P. falciparum, are injected into the human dermis or capillaries during the blood 
meal of an infected female Anopheles mosquito. It is estimated that some of the 
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sporozoites may be contained at the site of injection for up to 6 hours before migrating to 
the liver (Yamauchi et al., 2007). After invading hepatocytes, it takes approximately 6-7 
days for the parasite to multiply within hepatocytes (Pradel and Frevert, 2001).  At the time 
of leaving the liver, several thousand of merozoites are contained within merosomes, 
which is most likely to avoid host cell defense mechanisms (Vaughan et al., 2012). 
Merozoites are finally released from the ruptured merosomes, infecting RBCs to start the 
asexual blood stage development (Cowman and Kappe, 2006). In the erythrocytic phase, 
merozoites undergo asexual multiplication, turning from a ring to a trophozoite stage and 
finally to a schizont stage. When the schizonts reach full maturation, the iRBCs burst; 
freeing the 16-20 newly developed merozoites to invade fresh, non-infected RBCs.  
 
The asexual blood stage developmental cycle lasts for 48 hours and is the cause of the 
symptoms associated with malaria disease. During this stage, a proportion of merozoites 
will commit to differentiate into male and female gametocytes (Alano, 2007). After a female 
mosquito feeds on human blood containing gametocytes, the gametocytes are released 
from the iRBCs in the mosquito midgut and develop into gametes. The fertilized female 
macrogametes develop into zygotes and then into actively moving ookinetes that traverse 
the midgut epithelium and further develop to oocysts. Fully developed and matured 
oocysts release sporozoites that migrate through the body cavity to the salivary gland. The 
cycle of human infection begins again when the infected female mosquito feeds on the 
next human host (Arama and Troye-Blomberg, 2014; Baer et al., 2007; White et al., 2014) 
(summarized in Figure 2). 
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Figure 2: Plasmodium species life cycle in both mosquito vector and human host 
 
The malaria parasite life cycle involves two hosts. The female Anopheles mosquito and the human host (1). Sporozoites injected by 
mosquito migrate and infect liver cells (2) and mature into schizonts (3), which rupture and release merozoites (4). After this initial 
replication in the liver (exo-erythrocytic schizogony-A), the parasites undergo asexual multiplication in the erythrocytes (erythrocytic 
schizogony-B). Merozoites infect red blood cells (5). The ring stage trophozoites mature into schizonts, which rupture releasing 
merozoites (6). Some of the merozoites differentiate into sexual erythrocytic stages (gametocytes) (7). The gametocytes, male and 
female, are ingested by an Anopheles mosquito during a blood meal (8). The parasites multiplication in the mosquito is known as the 
sporogonic cycle(C). While in the mosquito's stomach, the microgametes penetrate the macrogametes generating zygotes (9). The 
zygotes in turn become motile and elongated (ookinetes) (10) which invade the midgut wall of the mosquito where they develop into 
oocysts (11). The oocysts grow, rupture, and release sporozoites (12), which make their way to the mosquito's salivary glands. 
Inoculation of the sporozoites into a new human host perpetuates the malaria life cycle (1) (CDC, 2013). 
 
 
1.1.4. Pathogenesis of P. falciparum malaria 
 
The P. falciparum liver stage in humans is clinically silent and therefore inherently difficult 
to study. Clearly, the liver stage does not cause obvious signs and symptoms of ongoing 
malaria infection. In contrast, the pathogenesis of P. falciparum malaria disease during the 
erythrocytic life cycle stage has been well studied. P. falciparum malaria pathogenesis is 
initiated when merozoites invade the RBC. The different pathophysiological outcomes of P. 
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falciparum asexual blood stage infection are summarized in Figure 3. After RBC invasion, 
a principal ligand known as P. falciparum erythrocyte membrane protein 1 (PfEMP1) starts 
to be expressed on the surface, which is encoded by a highly polymorphic multigene 
family, also known as the var genes (with around 60 copies per genome) (Newbold et al., 
1999). PfEMP1 has been reported to play a pivotal role in P. falciparum malaria 
pathogenesis by mediating the cytoadherence of iRBCs to endothelial surface receptors in 
the capillaries (Cooke et al., 2000). The sequestration of iRBCs is the result of the 
interaction between parasites-derived proteins present on surface of iRBCs (mainly 
PfEMP1) and several host molecules expressed on the surface of small blood vessel 
endothelial cells. Some key receptors for parasite adhesion are known, and include 
chondroitin sulfate A (CSA), the intercellular adhesion molecule 1 (ICAM1) and CD36. 
These parasite–host protein interactions have been found to be associated with pathology 
in the placenta (CSA), brain (ICAM-1) and in other organs (CD36) (Cooke et al., 2000).  
Recently, the involvement of intravascular fluid depletion during severe malaria and 
impaired microcirculation leading to cardiac dysfunction has been reported. However, such 
findings warrant further detailed clinical evaluation (Mishra et al., 2013). A huge increase in 
parasite density and biomass during erythrocytic cycle leads to the systemic release of 
pro-inflammatory cytokines including tumor necrotic factors (TNF). It is thought that TNF 
production levels regulated by the promoter region contribute to pathophysiological 
processes such as anaemia and cerebral malaria (McGuire et al., 1999). Combining these 
processes of cytokine release, innate immune system hyperactivation, vascular 
obstruction, inflammation and damage leads to a multitude of organs to be affected 
including the kidney, brain, lung, heart and placenta (Figure 3) (Gazzinelli et al., 2014). 
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Figure 3: A series of pathogenesis that is suggested to occur during different stages of malaria parasite life cycle in human 
host 
 
(a) After a mosquito bite, sporozoites travel to the liver to infect hepatocytes and develop into merozoites that are released in the 
bloodstream. Repeated cycles of red blood cell (RBC) invasion, replication and merozoite release will result in the exponential growth of 
the parasite population and lead to disease. IRBCs will circulate containing ring-stage parasites, and a small proportion of merozoites 
will develop into male and female gametocytes that infect mosquitoes, completing the parasite life cycle. (b) The removal of iRBCs by 
splenic macrophages or the uptake of free haemozoin results in the activation of innate immune receptors and cytokines which cause 
paroxysms and induce the expression of adhesion molecules that helps mediate parasite sequestration. The sequestration of iRBCs 
disrupts blood flow, promotes blood clots, injures endothelial cells and ruptures vascular walls, leading to the extravasation of vascular 
content and local tissue inflammation. These mechanisms contribute to acute respiratory distress, cerebral malaria or placental malaria. 
The sequestration of infected reticulocytes is less intense. Haemolysis of infected and bystander (uninfected) RBCs, uptake of altered 
RBCs by splenic macrophages and cytokine-induced impairment of erythropoiesis cause anaemia. Free haemoglobin catalyses 
oxidative damage, hypoxia and lactic acidosis, promoting metabolic acidosis, which is aggravated by the altered renal function that is 
observed in patients with malaria.(Adapted from: Nature Reviews Immunology) (Gazzinelli et al., 2014) 
 
 
 
1.1.5. Malaria diagnosis 
 
Early diagnosis and treatment of malaria can substantially reduce disease-related 
morbidity and mortality and further contributes to the reduction of malaria transmission. 
Malaria diagnosis involves identifying malaria parasites or antigens/products in a patient´s 
blood (Tangpukdee et al., 2009). Microscopy has been the gold standard for malaria 
diagnosis for many years both in research and in the field. This method detects parasites 
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in the capillary blood of infected individuals via thick and thin blood smears. In many cases, 
reliable and accurate microscopy results can only be achieved if the test is performed by 
qualified and well trained microscopists. However, in the real-life situation of many 
resource constrained settings, lack of reliable electricity supply to operate microscopes, 
shortage of high quality reagents supply and the low level of training of the microscopists 
to perform routine blood slide reading constitute serious challenges to the utilization of 
microscopy for public health purposes (Michael, 2015). 
 
Recently, a rapid, sensitive and easy to use malaria diagnostic test has been introduced 
widely, which relies on the detection of parasite specific antigens such as P. falciparum 
Histidine-Rich Protein 2 (PfHRP2), Plasmodium lactate dehydrogenase (PLDH) or 
Aldolase (PfAldolase), (WHO, 2011). These rapid diagnostic tests (RDTs) do not require 
trained personnel or specialized equipment for malaria diagnosis and therefore they have 
been massively distributed into the public health system (T3 program:  
http://www.who.int/malaria/areas/test_treat_track/en/). However,  RDTs are also 
associated with  disadvantages; for example they are relatively expensive, do not quantify 
parasites, only have a sensitivity of around 100 parasites/microliter of blood and are 
sensitive to environmental storage temperature and humidity (WHO, 2011; 
Wongsrichanalai et al., 2007). In addition, P. falciparum-specific species identification is 
possible only with PfHRP2 based kits, with other human malaria species indistinguishable 
and grouped under non-P.falciparum. RDTs based on pLDH can distinguish between P. 
falciparum, P. vivax and the other malaria species (pan-malaria), however they lack 
sensitivity compared to PfHRP2-based RDTs (Wongsrichanalai et al., 2007).  
Molecular biological techniques based on polymerase chain reaction (PCR) have shown 
higher sensitivity compared to RDT and are also able to distinguish not only between 
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different Plasmodium species but also between different P. falciparum strains 
(Gunawardena and Karunaweera, 2015; Shaukat et al., 2012). QPCR based detection of 
malaria infection is also suitable for accurate quantification of malaria parasites. However, 
qPCR for malaria diagnosis is not wide-spread since it is expensive, requires well-
maintained equipment and higher level technical expertise, currently limiting its use to 
research purposes (Zimmerman and Howes, 2015). 
 
1.1.6. Current malaria control strategies 
 
Malaria control means reduction of disease incidence, prevalence, morbidity or mortality 
within a focal area to an acceptable level following proper intervention strategies. 
Elimination is defined as taking control one step further and aims at reducing incidence in a 
certain geographical region close to zero. While malaria eradication is defined as 
permanent global reduction of the incidence of infection to zero, extinction is reduction of a 
specific infectious agent to a point that it no longer exists in nature or in the laboratory 
(Andrews and Langmuir, 1963). The current malaria control strategy encompasses two 
major domains: (i) prevention; which works against the transmission of the parasite from 
mosquito vector to humans and (ii) case management; that focuses on the development of 
illness and severe disease. Global disease control efforts have successfully impacted on (i) 
control of many infectious diseases including malaria, (ii) elimination of diseases such 
poliomyelitis in many countries and (iii) eradication of diseases such as smallpox. 
Internationally, the call towards malaria elimination and eventual eradication has turned out 
challenging, in regards to translating it into reality in the near future (MMWR, 1999; WHO, 
2014). Currently, 80 countries with ongoing malaria transmission are classified by WHO as 
being in the malaria elimination phase and 4 countries, namely United Arab Emirates, 
Morocco, Turkmenistan and Armenia, have been recently certified by WHO to have 
eliminated the disease (Cibulskis et al., 2016; Newby et al., 2016). 
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1.1.6.1. Malaria vector control 
 
Vector control is considered an essential tool in malaria control strategies and is mainly 
based on targeting mosquitoes, the vector for transmission (Giardina et al., 2014). This 
has been possible through large scale implementation of indoor residual spraying of 
insecticides and insecticide treated bed nets as well as by draining bodies of stagnant 
water, which is the habitat of the larvae stage. These approaches successfully led to 
malaria elimination in Europe and the USA. In Africa, there have been undeniable 
advances in the fight against malaria in recent years, whereby we could see a trend of 
malaria incidence dropping by around 37% in most malaria endemic areas since 2000 
(Cotter et al., 2013; Mharakurwa et al., 2013; Roucher et al., 2014). It is most likely that 
the use of insecticide treated bed nets, indoor residual spraying and rapid treatment of 
malaria cases have played an important role in getting closer to the  malaria-specific 
target of the Millennium Development Goals (target C), which aims to reduce the 
incidence of malaria by 75% (WHO, 2015). However, some studies caution this 
optimism and have reported lack of evidence for significantly decreasing malaria 
incidence based on these interventions, questioning the universal trend across settings 
and transmission intensities (Okiro et al., 2011, 2013). 
 
 
1.1.6.2. Malaria treatment 
 
Malaria is curable and preventable if treated adequately and promptly. However, P. 
falciparum parasites have developed resistance against the cheapest and most widely 
used antimalarial including chloroquine and Sulfadoxine-Pyrimethamine (SP) (Schneider 
and Kim, 2013). WHO recommends artemisinin-based combination therapies (ACTs) for 
the treatment of uncomplicated P. falciparum malaria. Amongst ACTs, Artemisinin-
lumefantrine (ALU) is used as first line therapy for uncomplicated malaria according to 
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Tanzanian National Guidelines for Malaria Diagnosis and Treatment (Adjuik et al., 2004; 
WHO, 2016). The ongoing emergence of antimalarial drug resistant parasite strains in 
South-East-Asia and appearance of pyrethroid resistant vector strains throughout sub-
Saharan Africa are a considerable threat to the current global malaria control programmes 
(Menard and Dondorp, 2017; Mulamba et al., 2014). Drug development of a single 
compound takes up to an average of 15 years through different stages of clinical 
development. In recent years, thousands of chemical structures have gone through pre-
clinical testing and some even reached early clinical testing (Gamo et al., 2010).  With no 
new drug class expected to reach the market for at least the next five years, there is a 
need to strengthening current malaria surveillance programs to ensure proper use of 
available antimalarial drugs and early resistance detection (Roses, 2008). 
 
Learning from the regions that have successfully eliminated malaria in the past, it is 
obvious that malaria could be controlled and focally eliminated with a combination of 
complementary strategies put in place. As we embark on eliminating malaria in Africa, a 
combination of the current control strategies as well as novel approaches, which include 
simple, robust and sensitive diagnostic tools, better drugs as well as an effective vaccine 
will be required (WHO, 2015).  
 
1.1.6.3. Malaria vaccines 
 
To date, vaccination is the most cost effective method of preventing infectious diseases 
(Karunamoorthi, 2014; Loucq, 2013). The potential of vaccination programmes to control 
viral and bacterial diseases such as poliomyelitis, measles, diphtheria, tetanus, rabies and 
the eradication of smallpox in humans have been remarkable success stories of vaccines 
(Loucq, 2013). Development of an effective malaria vaccine has been a major goal of 
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malaria researchers for many decades. The revised malaria vaccine technology roadmap is 
targeting to have a vaccine that will achieve malaria elimination in multiple settings and at the 
same time being highly efficacious against clinical malaria by 2030 (WHO, 2013).The 
complexity of the Plasmodium life cycle, lack of clear understanding of important biological 
processes that lead to potent, long-lasting host immune responses and the high parasite 
diversity have severely hampered efforts to develop an effective malaria vaccine (Crompton 
et al., 2010). For many decades, scientists have explored several vaccine design 
approaches that target different stages of the parasite life cycle. These include pre-
erythrocytic, blood-stage and transmission blocking vaccine approaches (Hill, 2011; Wang et 
al., 2009). So far RTS,S/AS01E is the only vaccine to show a partial protective effect against 
clinical malaria among young children in a phase 3 clinical trial and WHO has planned for an 
implementation programme (MVIP) in three countries beginning from 2018 (WER-WHO, 
2016).  
 
1.2. Immune responses against malaria 
 
1.2.1. Humoral immunity against malaria 
 
Antibodies have long been known to play a critical role in natural immunity against malaria. 
The most direct evidence that antibodies are important mediators of immunity to malaria 
comes from passive transfer studies, in which antibodies from malaria-immune adults were 
successfully used to treat patients with severe malaria. Studies in mice deficient in Fc-γ 
receptors further supported an important role for antibodies in protection (Cohen et al., 
2010; Sabchareon et al., 1991). Antibodies may protect an individual against malaria by a 
variety of mechanisms, including inhibition of sporozoites or merozoite invasion of host 
cells. Furthermore, studies have demonstrated that antibodies in the plasma of malaria 
immune volunteers (Hill et al., 2013) and RTS,S/AS01E vaccine immunized volunteers 
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(Schwenk et al., 2003) were able to opsonize free merozoites and sporozoites, 
respectively, and mediate in-vitro phagocytosis by monocytes. 
 
Although natural malaria infections fail to induce sterile protection - even after several 
years of repeated exposure to the parasite- a partially protective, short-lived antibody 
response could be observed (Kinyanjui et al., 2007). Studies have shown that children 
from malaria endemic regions build up partial immunity that protects against severe 
disease as they grow older - however a complete sterile immunity has very rarely been 
reported (Portugal et al., 2013). Moreover, the partially induced natural immunity has 
shown to wane as person moves away from malaria endemic regions into a region without 
malaria exposure. During the Plasmodium life cycle, the parasite expresses a wide range 
of highly polymorphic proteins (Doolan et al., 2009). The complex interplay of polymorphic 
parasite proteins with the host immune system is most likely the reason for partial 
protection observed under natural exposure. Therefore, naturally developing immunity 
against malaria is not a good guideline for developing an effective vaccine against the 
disease (Waters, 2006). 
 
1.2.2. Cellular immunity against malaria 
 
Studies have associated cellular immune responses, particularly CD8+ T cells secreting 
IFN-g, with pre-erythrocytic immunity (Epstein et al., 2011; Malik et al., 1991). Some 
evidence suggests that cellular immune responses induced by malaria infection may protect 
against both pre-erythrocytic and erythrocytic parasite stages (Schneider and Kim, 2013). 
The pre-erythrocytic stage parasite develops within the hepatocytes, thereby making 
infected hepatocytes targets for cytotoxic, major histocompatibility complex class I (MHC 
class I) restricted CD8 T cells (Epstein et al., 2011; Guebre-Xabier et al., 1999). It is 
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commonly thought that this kind of immunity is dependent on the expression of parasite 
antigens on the hepatocyte surface in conjunction with MHC class I (Villarino and Schmidt, 
2013a). The MHC molecules are key players in regulating adaptive immune responses 
following invasion of foreign pathogens. Two major classes of MHC molecules, namely 
MHC class I and MHC class II, have been identified (Erickson, 1987; de Groot et al., 2016). 
MHC class I molecules are found on most cell types, and function by binding and 
presenting endogenously, intracellularly derived peptides to CD8 T cells. MHC class II 
molecules reside on the surface of professional antigen presenting cells and function by 
binding exogenously derived proteins that will be processed intracellularly to be presented 
to CD4 T cells. The importance of MHC molecules on influencing the outcome of a 
protective vaccine response has been demonstrated (O et al., 2014). Good  peptide binding 
to the MHC groove is essential, but not the sole determinant of antigen presentation 
(Wieczorek et al., 2017). The development of a peptide-based malaria vaccine should also 
consider the influence of MHC genotypes in the immune responses of target population 
(Comber and Philip, 2014; Wieczorek et al., 2017). T cell mediated mechanisms that result 
in destruction of malaria infected hepatocytes in humans are not well elucidated. They may 
include cell death induced by contact between the lymphocyte effector and target cells, 
killing through release of  cytokines  such  as  interferon gamma  (IFN-g)  that induce 
hepatocytes to produce nitric oxide or destruction via antibody-dependent cellular 
cytotoxicity (Seguin et al., 1994; Trimnell et al., 2009; Villarino and Schmidt, 2013b). IRBCs 
do not express MHC class I or class II molecules. This renders erythrocytes not a direct 
target for T- cell recognition and effector mechanisms. However, the iRBCs are liable to 
binding of antibodies that target surface-exposed foreign antigens. This binding could result 
in opsonization, thereby making the parasitized erythrocytes more susceptible to clearance 
by phagocytic cells in the spleen and destruction by complement fixation (Doll and Harty, 
2014; Urban et al., 1999). 
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1.3. Malaria pre-existing responses and the magnitude of vaccine induced 
immunity 
 
Recent studies have revealed that pre-existing immunity may modulate the magnitude and 
specificity of immune responses induced by subsequent immunizations (Bergmann-Leitner 
et al., 2012; Kannanganat et al., 2010). Pre-existing immunity was demonstrated to 
impede the ability of human adenoviruses to induce strong innate and adaptive immune 
responses when used as a vaccine delivery system (Croyle et al., 2008; Kannanganat et 
al., 2010). Whether the observed slow development of protective immunity in populations 
living in malaria endemic areas reflects the down regulation of T cell specific immunity 
following natural parasite infection remains to be revealed. Malaria specific memory B cells 
(MBCs) can be maintained for many years, even after absence of repeated exposure 
(Migot et al., 1995; Ndungu et al., 2013). However, there is also evidence demonstrating 
that protective immunity gradually declines if a person moves away from a malaria 
endemic area for a longer time period (Färnert et al., 2015). The role of pre-existing 
immunity on the development of vaccine induced immunity needs further investigation. A 
better defined role of pre- existing immunity on vaccine-induced immunity in the endemic 
population would aid our understanding of how individuals previously exposed to malaria 
will respond to different immunization regimens. 
 
1.4. Malaria vaccines development 
 
Vaccines are tailored to induce protective immune responses against infectious diseases 
when applied prior to the contact with the pathogen itself (Riedel, 2005). For many years, 
malaria vaccine development has faced a number of challenges. Amongst those is the 
ability of the parasite to evade host immune responses by camouflaging itself through 
expression of various antigenic forms in both the mosquito vector (Ramphul et al., 2015) 
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and human host (Stanisic et al., 2013; Wykes et al., 2014; Zheng et al., 2014). 
Immunological assays and system biology approaches have been used to predict the 
antigen targets that may serve as better candidates for today’s vaccine development 
programs (Hagan et al., 2015). For nearly half a century, different vaccine development 
approaches have been employed. However, knowledge gaps of protective immune 
mechanisms that develop under natural conditions severely hamper these programs. 
 
Likewise, the lack of vaccine-induced protection observed thus far for most malaria vaccine 
candidates as they progress into human clinical trials makes malaria vaccine development 
highly empirical (Bouharoun-Tayoun et al., 1990; Nakaya and Pulendran, 2015; Plotkin, 
2008; Weiss and Jiang, 2012). To date, many of the current malaria vaccine development 
strategies have focused on utilizing (i) multiple components that will be effective against 
more than one parasite life cycle stage, (ii) multiple epitopes to overcome genetic and 
antigenic variation and (iii) multiple components that will induce both humoral and cellular 
immune responses. The ideal vaccine does not only prevent clinical disease but also 
infection and blocks transmission (Doolan and Hoffman, 1997; Kumar et al., 2002; Lozano 
and Patarroyo, 2007; Shi et al., 1999). 
 
Three stages of the parasite life cycle have been pursued as targets by different vaccines, 
namely the pre-erythrocytic stage vaccines, the asexual blood stage vaccines and a 
vaccine targeting the parasite within the vector thus preventing transmission. An overview 
of the vaccine approaches targeting the different life cycle stages are given below (Figure 
4): 
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Figure 4: Stages in P. falciparum life cycle that are deemed potential target for vaccine development 
 
An infected female anopheles mosquito bite injects sporozoites into capillaries (1). The sporozoites pass quickly into the human liver 
(2). The sporozoites multiply asexually in the liver cells over the next 7 to 10 days, causing no symptoms (3). In an animal model, the 
parasites, in the form of merozoites, are released from the liver cells in vesicles, journey through the heart, and arrive in the lungs, 
where they settle within lung capillaries. The vesicles eventually disintegrate, freeing the merozoites to enter the blood phase of their 
development (4). In the bloodstream, the merozoites invade red blood cells (erythrocytes) and multiply again until the cells burst. 
Then they invade more erythrocytes. This cycle is repeated, causing fever each time parasites break free and invade blood cells (5). 
Some of the infected blood cells leave the cycle of asexual multiplication. Instead of replicating, the merozoites in these cells develop 
into sexual forms of the parasite, called gametocytes that circulate in the blood stream (6). When a mosquito bites an infected human, 
it ingests the gametocytes, which develop further into mature sex cells called gametes (7). The  fertilized  female  gametes  develop  
into actively moving ookinetes that  burrow  through  the  mosquito's  midgut  wall  and  form  oocysts  on  the  exterior surface (8).  
Inside the oocyst, thousands of active sporozoites develop. The oocyst eventually bursts, releasing sporozoites into the body cavity 
that travel to the mosquito's salivary glands (9). The cycle of human infection begins again when the mosquito bites another person 
(10) (PATH- MVI, 2014). 
 
 
 
1.4.1. Pre-erythrocytic malaria vaccine approaches 
 
The pre-erythrocytic (PE) stage malaria vaccine development approach has recently 
attracted the attention of many scientists in the field, since it has shown the most 
promising outcomes when compared with vaccines aimed at targeting other malaria 
developmental stages. The PE vaccine approach aims at targeting the infective stage of 
P. falciparum, the sporozoite and the liver stage. Sporozoites can be targeted by 
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neutralizing antibodies that remove infective sporozoites from the circulation and prevent 
them from reaching the liver (Behet et al., 2014; Nahrendorf et al., 2014). If sporozoites 
escape from these antibodies and other innate immune mechanisms they will find their 
final destination – the liver hepatocytes. It is thought that liver stage parasites are 
recognized by CD8+ T cells that target and selectively kill these infected liver cells. In 
summary, these immune effector arms prevent merozoites being released to iRBC 
thereby preventing the development of clinical symptoms (Chakravarty et al., 2007; 
Reyes-Sandoval et al., 2011; Weiss and Jiang, 2012). 
 
1.4.1.1. Recombinant PE vaccine approaches 
 
The most researched PE vaccine stage protein is the P. falciparum circumsporozoite (CS) 
protein. This protein is expressed in abundance during sporogony, the sporozoite stage 
and the early hepatic stages of P. falciparum infection (Coppi et al., 2011). This protein is 
known to be an important mediator of sporozoite gliding motility and cell traversal in the 
midgut of the mosquito and within hepatocytes of the mammalian host (Coppi et al., 2011). 
Antibodies directed against CS protein have been shown to reduce the ability of the 
parasite to glide and traverse into the hepatocytes and hence are indirectly associated with 
reduced risk of clinical malaria (John et al., 2008). The critical roles of CSP as an 
immunodominant antigen that induce protection against PE stage of P. falciparum have 
been well characterized in pre-clinical studies in animals (Kumar et al., 2006). The NANP 
repeat domain is known to be a B-cell epitope and the C-terminal region is known to be a 
T-cell epitope (Cohen et al., 2011). Moreover, studies conducted in rodent models and 
humans have shown that antibodies directed to NANP CSP repeat region have 
consistently demonstrated the ability to neutralize sporozoites infectivity (Mehlhorn, 2011). 
Under natural conditions, sporozoites are known to travel rapidly to the liver after mosquito 
bite delivery hence creating limited time for the humoral immunity to act on them. The C-
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terminal non-repetitive region of CSP can be processed by professional antigen presenting 
cells o r  infected hepatocytes and  presented on the surface to initiate CD4 and CD8 T cell 
responses (Gordon et al., 1995; Singh et al., 2007). The discovery that a genetically 
engineered hepatitis B viral envelope can be used as a carrier matrix for different peptides 
lead to the use of this technology to design a CSP-based malaria vaccine that utilizes the 
hepatitis B surface antigen (HBsAg) in this manner (Rutgers et al., 1988). 
The RTS, S malaria vaccine - developed by GlaxoSmithKline (GSK) Biologicals - is the 
most advanced malaria subunit vaccine. It consists of a hybrid molecule of CSP and 
HBsAg and free HBsAg recombinantly expressed by S. cerevisiae. This hybrid molecule 
encompasses a part of the central repeat and the C-terminal region which are fused to the 
N-terminal region of HBsAg. The vaccine assembles itself into particles that also include 
unfused HBsAg (Kester et al., 2007). Furthermore, RTS, S is powered by a complex 
adjuvant (AS) system (Cohen et al., 2010), either AS02 (Quillaja saponiria 21 (QS21), 
monophosphoryl lipid A (MPL) and an oil-in-water emulsion) or AS01 (QS21, MPL and 
liposomes) (Stoute et al., 1997) (Figure 5). 
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Figure 5: Schematic representation of RTS,S vaccine particle assembly 
 
A central tandem repeat (B-cell epitope) and C-terminal region of the P.falciparum circumsporozoite protein (T-cell epitope) are fused 
to N-terminal of the S antigen of Hepatitis B virus (HBsAg) (B) and co-expressed together with unfused HBsAg S in C.cereviciae yeast 
to form a vaccine particle (Cohen et al., 2011). 
 
 
 
In its first clinical development phase conducted in malaria naïve volunteers, the 
RTS,S/AS01 vaccine has shown to be safe and immunogenic. In malaria semi-immune 
individuals, RTS,S/AS01 has been clearly shown to induce protective antibodies in 
infants in Mozambique (Aponte et al., 2007). When co-administered within the expanded 
program on immunization (EPI) scheme in Tanzanian infants (Abdulla et al., 2008) 
protection against clinical malaria was observed. In the phase 3 trial, three primary doses 
of vaccine was reported to reduce cases of clinical malaria by 28% and 18% in 5-17 
months (children) and 6-12 weeks (infants) respectively (RTS,S Clinical Trials 
Partnership, 2015). Furthermore, analysis of pooled data from several phase 2 studies 
revealed that efficacy against clinical malaria was inversely related to transmission 
intensity (Bejon et al., 2013). In general, RTS,S/AS01 vaccine efficacy was shown to be 
about 36% in the first year; waning off to an efficacy of 2.5% in the fourth year, followed 
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by a partial rebound in clinical malaria cases during the fifth year in a high malaria 
exposed cohort (Olotu et al., 2016). The efficacy of 4.4% that was obtained during a 7 
year follow-up compromised the benefits of the efficacy shown during the short term 
follow-up. In a phase III clinical trial conducted in 7 African countries in 11 trial centers 
with a wide range of malaria endemicity, RTS, S/AS01 was generally reported to have 
higher vaccine efficacy in children (5-17 months) than in infants (6-12 weeks) providing 
protection against clinical and severe malaria for up to 1.5 years following third 
vaccination (RTS,S Clinical Trials Partnership, 2014). These outcomes of the phase III 
RTS,S/AS01 vaccine trial have been somewhat disappointing (RTS,S Clinical Trials 
Partnership, 2014; RTS,S Clinical Trials Partnership et al., 2012)) but provided the proof 
that large phase III vaccine trials can be conducted in Sub-Saharan Africa. Although 
RTS,S/AS01 was approved by the European Medicines Agency for active immunization 
of children aged 6 weeks to 17 months against malaria, the WHO did not recommend the 
inclusion of RTS,S/AS01 in the Expanded Programme of Immunizations. The 
RTS,S/AS01 vaccine will be tested in a pilot study for larger scale implementation under 
real-life settings in Ghana, Kenya and Malawi starting in 2018 
(http://www.path.org/news/press-room/809/). 
 
1.4.1.2. Viral vectored PE vaccine approaches 
 
Poxvirus vectors have been the most studied live viral system for delivering antigens in 
human and animal models, since their use in smallpox eradication in the 1970’s (Limbach 
and Paoletti, 1996; Moss, 2011). This virus has been demonstrated to be a useful vector 
for vaccination purposes, due to its ability to generate recombinant viruses that express a 
variety of foreign antigens, and which confer protection to immunized animals (Jacobs et 
al., 2009; Sánchez-Sampedro et al., 2015). An example of a PE subunit malaria vaccine 
with a multi-epitope was developed in the United Kingdom by a group from Oxford 
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University (Prieur et al., 2004). Since then, the Oxford group has been conducting a 
cascade of clinical trials with a prime boost approach aiming at provoking T-cell immune 
responses against liver stage parasites. In early 2002, a vaccine construct consisting of 
attenuated fowl pox virus strain 9 (FP9) with multi epitope fused to thrombospondin related 
adhesion protein (ME-TRAP) entered clinical trials in British and Gambian volunteers 
(Moorthy et al., 2004). TRAP is a PE protein that plays a major role in parasite gliding 
motility and infectivity of liver cells (Sultan et al., 1997). However, no protection was 
demonstrated when tested against febrile disease in children living in malaria endemic 
areas (Bejon et al., 2006). 
 
Adenovirus vectors are amongst the few other viruses that attracted the attention of the 
vaccine research and development field. The replication-deficient adenovirus serotype 5 
(Ad5) vector can be produced by having part of its genome removed and replaced by 
insertion of a foreign, non-viral target DNA (Bangari and Mittal, 2006). In the malaria 
vaccine field, the use of the Ad5 vectors remains challenging, as pre-existing neutralizing 
antibodies against the adenovirus vector were found to be associated with failure to induce 
appropriate immune responses in vaccinated individuals, both in the USA and Africa 
(Fausther-Bovendo and Kobinger, 2014; Nwanegbo et al., 2004; Saxena et al., 2013). 
Recombinant adenovirus serotype 5 (Ad5) vector expressing circumsporozoite protein 
(CSP) given either alone or together with apical membrane antigen 1 (AMA-1) expressing 
Ad5 virus was demonstrated to have increased IFN-Jspecific CD8 T cell responses, albeit 
low antibodies responses. Additionally, the CHMI conducted with volunteers immunized 
using Ad5 with CSP and AMA-1 did not show protective efficacy (Sedegah et al., 2011). 
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1.4.2. DNA vaccine approaches 
 
In the early 1990’s, advance in molecular biology technology lead to the finding that DNA 
or RNA inoculated directly into mice resulted in induction of cellular immune responses 
(Wolff et al., 1990). A vaccine trial conducted in the mouse model revealed that the 
injection of an influenza hemagglutinin glycoprotein-encoding plasmid via the skin or 
muscular route could induce protective immunity against a challenge with a lethal influenza 
virus (Fynan et al., 1993). The success of the DNA vaccine approach was also 
demonstrated in early stages of clinical trials (phase I) for different diseases (Khan et al., 
2013). However, currently there is no single DNA based malaria vaccine that has moved to 
phase II clinical trials. This calls for a better design of DNA vaccine constructs and 
incorporating better promoters driving the gene expression in vivo, as well as novel 
delivery technologies that can enhance immune responses in humans (Ferraro et al., 
2011). 
 
1.4.3. The live attenuated whole parasite based vaccine approaches 
 
The failure in clinical advancement for many subunit malaria vaccine approaches re- 
stimulated the concept of using whole sporozoites as a PE malaria vaccine. In the early 
70’s, research revealed that immunization of mice and humans with radiation-attenuated 
sporozoites delivered by mosquitos could confer sterile protection against experimental 
malaria challenge (Clyde et al., 1973). Since then, the sporozoite-based approach has 
been considered as a gold standard for evaluation of malaria vaccine and drug efficacy in 
humans. CHMI studies that involve infecting healthy volunteers with live malaria 
sporozoites through infected mosquito bites was limited so far to few sites in Europe 
(Oxford and Nijmegen) and the USA (University of Maryland and NIH). In sub-Saharan 
Africa, the lack of phase I clinical trial facilities, trained medical and laboratory teams, 
together with the absence of high security mosquito rearing facilities has so far prohibited 
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testing in this important target population (Shekalaghe et al., 2014). 
 
The recent technological advancements driven by the biotechnology company Sanaria 
(http://www.sanaria.com) to manufacture large quantities of aseptic, purified, 
cryopreserved P. falciparum sporozoites (PfSPZ) that meet stringent regulatory standards 
and which can be administered intravenously to volunteers using needles has opened up 
the possibility for testing PE vaccines at an early developmental stage in sub-Saharan 
countries (Hoffman et al., 2010). The whole sporozoite approach, either in the form of 
radiation-attenuated sporozoites (RAS) (Clyde et al., 1973; Nussenzweig et al., 1969), 
genetically attenuated   parasites   (GAPs)   (Mueller et al., 2005)   or   wild   type   (WT) 
sporozoites under chloroquine prophylaxis (CPS) (Putrianti et al., 2009; Roestenberg et al., 
2009), have been proven to confer protection against experimental sporozoite challenge in 
malaria naïve volunteers (Doolan and Hoffman, 2000; Epstein et al., 2011). Amongst these 
possible whole parasite vaccine approaches, RAS and GAP are seen by many scientists 
as the most promising candidates for vaccination of humans against malaria (Mac-Daniel 
et al., 2014). The recent study conducted in the USA has demonstrated that the irradiated 
sporozoites (irrSPZ)-based vaccines can provide 100% short-term protection against 
homologous CHMI, making it one of the major leaders in the malaria vaccine field (Seder 
et al., 2013). 
 
1.4.4. Blood stage malaria vaccines approaches 
 
Asexual blood stage malaria vaccine approaches aim at reducing the growth rate of blood 
stage infections which will in turn prevent or curb clinical disease severity. It has been 
suggested that people who have survived several encounters of malaria exposure develop 
natural immunity over time (Doolan et al., 2009). The goal of this type of a vaccine 
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approach would therefore be to accelerate development of blood stage immunity without 
suffering the consequences of infection. Several products that fall under this category have 
been developed or are under initial stages of development. Few candidates have entered 
phase 1b and 2b clinical trials (WHO, 2015). P. falciparum merozoite surface protein 3 
(MSP3) has undergone extensive testing in clinical trials. This 48 kDa protein contains both 
conserved and divergent regions in a wide range of P. falciparum isolates. In the early 
eighties, Khusmith S et al. reported that a combination of serum from immune West African 
adults and monocytes from malaria non-exposed individuals was able to suppress in vitro 
the proliferation of P. falciparum parasites (Khusmith and Druilhe, 1983). Many research 
groups were engaged in identifying which component within these West African sera could 
be responsible for mediating this parasite growth inhibitory effect. Oeuvray et al., 
demonstrated that antibodies against MSP3 function in cooperation with blood monocytes 
to promote asexual blood stage killing in an antibody-dependent cellular inhibition assay 
(Oeuvray et al., 1994). Long term clinical protection from malaria disease was associated 
with the IgG3 isotype of antibodies binding to MSP3 (Roussilhon et al., 2007). 
To date, several clinical trials have been conducted to test a multivalent MSP3 subunit 
malaria vaccine produced in Escherichia coli. This MSP3 subunit vaccine was proven to be 
safe and immunogenic in pre-clinical studies (Bang et al., 2011), phase 1a clinical trials in 
European volunteers (Audran et al., 2005) and several phase 1b clinical trials involving 
volunteers from malaria endemic countries (Lusingu et al., 2009; Nebie et al., 2009; Sirima 
et al., 2009). The improvement of the vaccine with a view to inducing highly protective 
immune responses is on-going. A phase 2b proof-of-concept clinical trial to assess the 
protective effect of the MSP3 long synthetic peptide vaccine against all clinical malaria 
episodes in children aged 12-48 months is on-going in West Africa (Clinical trial.gov, 
2015). 
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The most advanced subunit blood stage vaccines is GMZ2, which has successfully 
reached phase 2 testing. The GMZ2 vaccine is composed of a fusion of the P. falciparum 
glutamate-rich protein (GLURP) and merozoite surface protein 3 (MSP3). This vaccine was 
demonstrated to be safe and immunogenic in a phase 1a study conducted in malaria naïve 
European volunteers (Esen et al., 2009) as well as when given intramuscularly in a phase 
1b trial conducted in semi-immune African volunteers (Bélard et al., 2011). A recent study 
has shown that GMZ2 elicits high levels of antibodies in both non-exposed and malaria-
exposed volunteers with broadly neutralizing activity in vitro against a variety of P. 
falciparum strains (Jepsen et al., 2013). However, a phase 2b randomized, controlled trial 
of the efficacy of three doses of GMZ2 performed in Burkinabe, Gabonese, Ghanaian and 
Ugandan children resulted in an efficacy of just 14% [95% CI: 3.6%, 23%] by ATP analysis, 
when the cohort was adjusted for age and site. Despite  the low efficacy, the GMZ2 was 
shown to be well tolerated, immunogenic and protected children from developing clinical 
disease and reduced the incidence of malaria (Bélard et al., 2011; Sirima et al., 2016). 
From such findings, it’s obvious that improvement of the efficacy of GMZ2 vaccine is a 
critical requirement. Other asexual blood stage antigens that have undergone extensive 
testing as blood stage candidates are MSP 1 (Lin et al., 2014)() and AMA1 (Harvey et al., 
2014)(). Both of these antigens have provided limited protection against clinical disease, 
most likely due to the enormous sequence polymorphisms of these vaccine candidates 
that exist in field populations (Sheehy et al., 2012; Thera et al., 2011) 
A whole iRBC approach has also been proposed, resembling the whole sporozoite 
approach in the sense that the complete organism is used as vaccine. The development of 
this approach faces challenges in terms of manner of attenuation, scaling up of production 
and GMP compliant production (Stanisic and Good, 2015).  
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1.4.5. Malaria transmission blocking vaccines  
 
The growing interest in intervening with the parasite life cycle by generating antibodies that 
block transmission from the human host to the mosquito has led to advancements in 
developing transmission blocking vaccines (TBV). TBV are expected to complement other 
malaria vaccines and intervention strategies such as bed nets and to reduce the spread of 
drug resistant malaria parasite strains. The concept of developing TBVs has been around 
for many years, but few scientists choose to implement research in this area. Until recently, 
relatively few TBV candidates are in the early developmental phases. In a study performed 
in the mouse model, it was demonstrated that immunizing mice with Pfs25-CP VLPs (a 
Pfs25 recombinant protein fused to the Alfalfa mosaic virus coat protein) using either a 
two-dose or a single-dose vaccination regimen induced functional antibodies that exhibited 
parasite transmission activity through a six month study period (Jones et al., 2013). A 
phase 1a trial conducted at the John Hopkins Centre for Immunization Research, USA 
showed that significant antibody responses were detectable in volunteers who completed 
the lowest scheduled doses of Pfs25/ISA 51 vaccine but showed high reactogenicity(Wu et 
al., 2008). In addition to P. falciparum TBVs, the recent published data also showed that a 
DNA plasmid containing the P. vivax gametocyte genes Pvs48/45 and Pvs47 could induce 
antibodies that significantly reduced the proliferation of P. vivax oocysts in the mosquito 
mid gut (Tachibana et al., 2015). Recombinant protein from P. vivax ookinetes surface 
protein (Pvs25) was expressed in S. cerevisiae, purified and formulated in Alhydrogel. In a 
phase I study, this vaccine formulation induced transmission blocking immunity against P. 
vivax (Malkin et al., 2005). 
 
1.5. Controlled human malaria infection in malaria endemic countries 
 
CHMI are a critical component of research and development in malaria vaccine and drug 
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development. The availability of a standardized CHMI model to predict outcomes in clinical 
evaluation in the field will help evade the current problem of a lack of predictive assays or 
good correlates of protection (Moorthy et al., 2009). CHMI through infected mosquitoes is 
the most commonly practiced method but only few centers globally have the capacity to 
infect mosquitoes with a laboratory strain of malaria that is easily treatable by Chloroquine. 
In recent years, Sanaria Inc., USA has produced at GMP standard fully infectious, aseptic, 
purified P. falciparum sporozoites (PfSPZ challenge), which opened the possibility of 
conducting CHMI using a syringe and needle all over the world. A similar technique has led 
to the manufacturing of irradiation attenuated sporozoites, which could be used as a 
malaria vaccine candidate (Hoffman et al., 2010). The safety of CHMIs has been 
extensively demonstrated already over 80 years ago, when it was used as treatment of 
neuro-syphilis (O’LEARY PA, 1927).  In 1986, the first CHMI study using infected 
mosquitoes that had been fed on cultured P. falciparum gametocytes was reported (Chulay 
et al., 1986). The potency and viability of PfSPZ challenge was further demonstrated in a 
clinical evaluation study conducted in Europe and in the US whereby to date, over 1000 
volunteers have participated in CHMI studies (Chulay et al., 1986; Sauerwein et al., 2011; 
Spring et al., 2014). Results from these studies report reproducible and high infection rates 
in study subjects in combination with a good safety profile. CHMI have not been routinely 
performed in people living in malaria endemic Africa. Although it is possible to find 
volunteers with minimal malaria exposure in Africa, it is not clear whether the CHMI studies 
will have the same success rate and resulting immune responses when compared to 
malaria naïve adults from Europe and USA. These knowledge gaps, together with 
availability of sites in an endemic area with the infrastructure required for assessing 
participant safety and qualified medical staff creates the possibility of conducting CHMI 
studies in Tanzania. These studies will allow early evaluation of vaccine induced protection 
and novel drugs in one of the main target populations. It is hoped that performing CHMI 
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studies in malaria endemic countries will contribute to the acceleration of malaria vaccine 
and drug development by increasing the number of trials that can be conducted 
simultaneously (Chilengi, 2009). 
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2. Rationale and research questions addressed in this thesis 
 
Development of a malaria vaccine that targets the pre-erythrocytic stages of P. 
falciparum has recently attracted the attention of many research groups. One of the 
most advanced malaria vaccine candidates to date is the recombinant subunit 
vaccine, the RTS,S/AS01. RTS,S/AS01 has been under extensive research since 
the 1980’s, and has demonstrated the ability to reduce the rate of acquisition of 
new blood stage infections and the multiplicity of infections in vaccinees. The broad 
evidence from challenge studies conducted in the USA and in African adult or 
paediatric field trials with varying transmission intensities, suggests a critical role for 
CSP-specific antibodies and/or CD4+ T cells in protection against infection. 
However, until lately, there has been no consensus on the immunological 
mechanisms that led to such findings and no clear correlate of protection for 
RTS,S/AS01 vaccine has been described. The first section of this thesis aims to 
address following research questions (Aim 1): 
1. Is the RTS,S/AS01 vaccine safe, tolerable with improved or similar efficacy 
during large multicenter phase III trial when compared to outcome of phase II 
studies?  
2. What will be the acceptability and feasibility of collecting PBMC samples from 
children aged 5 to 17 months at first bleeding for ancillary cellular immunology 
studies in Bagamoyo? 
3. What are the markers of RTS,S/AS01 induced immune responses and do they 
correlate to vaccine induced protection in different age groups conducted in 
African children? 
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Most recombinant subunit malaria vaccines have failed to induce high level and 
long lasting protection. Novel approaches are being tested to improve vaccine 
induced protection. The most promising approach is the whole sporozoite based 
vaccine, which uses the whole organism either irradiation inactivated or in its live 
non-attenuated form under drug coverage.  
 
CHMI has been successfully conducted in more than 1,500 volunteers in the US 
and Europe, but until 2012 it had not been employed in volunteers living in sub-
Saharan Africa. The mechanisms of protective immunity after natural malaria 
infection or CHMI of malaria pre-exposed individuals remain subject of further 
investigation. We have conducted CHMI using cryo-preserved purified non-
attenuated sporozoites in adult male Tanzanian volunteers with previous malaria 
exposure in order to address following research questions (Aim 2): 
1. Is intradermal injection of PfSPZ challenge to malaria pre-exposed subjects 
safe and infective in comparison to malaria-naïve subjects?  
2. How does the immune response of malaria pre-exposed compare to malaria-
naïve subjects after exposure to similar doses of PfSPZ challenge? 
3. What are the changes in humoral and cellular immune responses following 
PfSPZ challenge? 
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3. Aims of my thesis  
 
3.1. Aim 1:  
To evaluate the safety, immunogenicity and protective efficiency of the 
RTS,S/AS01 vaccine in Tanzanian infants and children during a phase III 
multicenter clinical trial. 
 
To address Aim 1, we monitored adverse events to determine safety of 
RTS,S/AS01; we used ELISA to measure vaccine induced CSP-specific 
antibodies; Luminex to measure ex-vivo vaccine induced cytokine 
production as well as polychromatic flow cytometry to investigate quality 
and quantity of vaccine induced cellular immune responses. 
 
3.2. Aim 2:  
To evaluate safety, infectivity, humoral and cellular immune responses 
following intradermal CHMI in malaria pre-exposed Tanzanian adults. 
 
To address aim 2, we determined the safety of CHMI in malaria pre-
exposed volunteers by monitoring adverse events; we used blood slide 
microscopy to define sporozoites infectivity rate; Luminex to examine 
CHMI induced antibodies; B-cell Elispot to monitor MBC; single cell RNA 
sequencing, flow cytometry, cell sorting and stimulation assays to 
investigate innate immune responses following CHMI. 
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Investigation of vaccine efficacy, and cellular and humoral 
immunity in RTS,S/AS01E vaccinated volunteers in Tanzania 
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A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants 
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Background
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and 
severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing 
phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.
Methods
We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 
6 to 12 weeks of age at the time of the first vaccination in conjunction with Ex-
panded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. 
Vaccine efficacy against the first or only episode of clinical malaria during the 
12 months after vaccination, a coprimary end point, was analyzed with the use of 
Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy 
against severe malaria, safety, and immunogenicity were also assessed.
Results
The incidence of the first or only episode of clinical malaria in the intention-to-treat 
population during the 14 months after the first dose of vaccine was 0.31 per person-
year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a 
vaccine efficacy of 30.1% (95% confidence interval [CI], 23.6 to 36.1). Vaccine effi-
cacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine ef-
ficacy against severe malaria was 26.0% (95% CI, −7.4 to 48.6) in the intention-to-
treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. 
Serious adverse events occurred with a similar frequency in the two study groups. 
One month after administration of the third dose of RTS,S/AS01, 99.7% of children 
were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 
209 EU per milliliter (95% CI, 197 to 222).
Conclusions
The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest pro-
tection against both clinical and severe malaria in young infants. (Funded by 
 Glaxo SmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S 
ClinicalTrials.gov number, NCT00866619.)
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Considerable gains have been achieved in malaria control during the past decade.1,2 Nonetheless, malaria remains a 
major public health concern. In 2010, an estimat-
ed 216 million cases of malaria and 655,000 
malaria-related deaths occurred, with the vast 
majority of deaths occurring in African children.1
The RTS,S/AS01 candidate malaria vaccine tar-
gets the pre-erythrocytic stage of the Plasmodium 
falciparum parasite. It was developed to reduce 
clinical and severe malaria in African children. 
Ideally, it would be administered through the 
well-established Expanded Program on Immuni-
zation (EPI).
In 2011, we reported the results for the first 
coprimary end point from an ongoing phase 3 
trial, which showed that during 12 months of 
follow-up, RTS,S/AS01 had an efficacy against 
clinical and severe malaria of 55.8% (97.5% con-
fidence interval [CI], 50.6 to 60.4) and 47.3% (95% 
CI, 22.4 to 64.2), respectively, among children 5 to 
17 months of age at enrollment (per-protocol 
analysis).3 Vaccine efficacy against severe malaria 
among children 6 to 12 weeks of age and those 
5 to 17 months of age combined was 34.8% 
(95% CI, 16.2 to 49.2) during an average of 11 
months of follow-up (range, 0 to 22). We now 
report on the second coprimary end point from 
the same trial: efficacy against clinical malaria 
during 12 months of follow-up among infants 
6 to 12 weeks of age at enrollment, when RTS,S/
AS01 was coadministered with EPI vaccines.
Me thods
STUDY DESIGN
Details of the study methods have been described 
previously3-7 and are provided in the Supplemen-
tary Appendix and the study protocol, both of 
which are available with the full text of this ar-
ticle at NEJM.org. This phase 3, randomized, 
controlled, double-blind trial is being conducted 
at 11 centers in 7 African countries with a range 
of malaria-transmission intensity (Fig. S1 in the 
Supplementary Appendix). The trial is designed 
to evaluate vaccine efficacy, safety, and immuno-
genicity for 32 months after the first dose of 
study vaccine in children 6 to 12 weeks of age or 
5 to 17 months of age at enrollment. The trial 
includes three study groups in each age category: 
infants who received three doses of RTS,S/AS01 
administered at 1-month intervals and a booster 
dose 18 months after the third dose, infants who 
received three doses of RTS,S/AS01 at 1-month in-
tervals without a booster dose, and a control group 
of infants who received a non-malaria compara-
tor vaccine. The analysis described in this report 
combines the first two groups (referred to as the 
RTS,S/AS01 group) and compares this group with 
the control group6 14 months after the first dose 
of vaccine administered in children 6 to 12 weeks 
of age (Fig. S2 in the Supplementary Appendix). 
The trial protocol was approved by all relevant 
ethics review boards and national regulatory au-
thorities (Tables S1A and S1B in the Supplemen-
tary Appendix). Written informed consent was 
obtained from the children’s parents or guard-
ians. The study was undertaken in accordance 
with Good Clinical Practice guidelines.8
STUDY OVERSIGHT
The trial was sponsored by GlaxoSmithKline Bio-
logicals (GSK), the vaccine developer and manu-
facturer, and funded by both GSK and the Pro-
gram for Appropriate Technology in Health (PATH) 
Malaria Vaccine Initiative, which received a grant 
from the Bill and Melinda Gates Foundation. 
All study centers received study grants from the 
Malaria Vaccine Initiative, which also provided 
funding for authors’ travel and accommodations 
related to this trial. All the authors reviewed all 
manuscript drafts, approved the final version of 
the manuscript, and made the decision to submit 
it for publication. No GSK authors were involved in 
the collection or analysis of the data; the analysis 
was performed by an independent statistician. The 
authors had full access to the results. The authors 
remain unaware of study-group assignments in 
this ongoing trial and do not have access to the 
raw data at this point. Details of the contributions 
of all the authors to the study are available in the 
Supplementary Appendix. The Clinical Trials Part-
nership Committee and Writing Group vouch for 
the completeness and accuracy of the data pre-
sented and for the fidelity of this report to the 
study protocol.
RANDOMIZATION AND VACCINATION
From December 2009 through January 2011, a to-
tal of 6537 infants 6 to 12 weeks of age were ran-
domly assigned to one of the three study groups 
in a 1:1:1 ratio. Three doses of the RTS,S/AS01 or 
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the comparator vaccine, meningococcal sero-
group C conjugate vaccine (Menjugate, Novartis), 
were coadministered with EPI vaccines according 
to the World Health Organization EPI schedule.9 
EPI vaccines comprised a diphtheria–tetanus–
whole-cell pertussis–hepatitis B–Hemo phil us in-
fluenzae type b pentavalent vaccine (Tritanrix HepB 
Hib, GSK) and an oral poliovirus vaccine con-
taining serotypes 1, 2, and 3 (Polio Sabin, GSK). 
The study and pentavalent vaccines were admin-
istered intramuscularly at different protocol-speci-
fied injection sites.
SURVEILLANCE FOR CLINICAL AND SEVERE MALARIA
Passive surveillance for malaria began at the time 
of the first vaccination. Parents or guardians of 
the study participants were encouraged to seek 
care at a health facility if the child had any signs 
of illness, and transportation was facilitated. All 
participants who presented to a study facility 
with reported or documented fever during the 
previous 24 hours were evaluated for malaria.
The primary efficacy end point for this analy-
sis was the incidence of clinical malaria, defined 
as an illness in a child who was brought to a study 
facility with an axillary temperature of 37.5°C or 
higher and P. falciparum asexual para sitemia at a 
density of more than 5000 parasites per cubic 
millimeter or a case of malaria meeting the pri-
mary case definition of severe malaria (Table S2 
in the Supplementary Appendix). Different para-
site thresholds were used for secondary case 
definitions (Table 1). Participants who were hos-
pitalized were evaluated for severe malaria on 
the basis of a protocol-defined algorithm (Table 
S3 in the Supplementary Appendix).4,10
SAFETY SURVEILLANCE
Data regarding serious adverse events were re-
corded by means of passive surveillance begin-
ning after the first dose of vaccine. Verbal autop-
sies were conducted for deaths that occurred 
outside study facilities.11 Information was col-
lected on all unsolicited reports of adverse events 
that occurred within 30 days after vaccination 
and on reactogenicity (pain, swelling, redness at 
the injection site, drowsiness, fever, irritability or 
fussiness, or loss of appetite) within 7 days after 
vaccination among the first 200 participants en-
rolled at each center. Symptom intensity was as-
sessed with the use of standardized methods 
(Table S4 in the Supplementary Appendix). Infor-
mation on related adverse events within 30 days 
after vaccination was collected for all partici-
pants. Study clinicians used clinical judgment to 
decide whether an adverse event was likely to be 
related to the vaccine. In an analysis of previous 
RTS,S studies, rash was observed more frequently 
in children vaccinated with RTS,S than in con-
trols.12 Rashes and mucocutaneous diseases oc-
curring within 30 days after vaccination and sei-
zures occurring within 7 days after vaccination 
were reported according to Brighton Collabora-
tion guidelines13,14 (see the Methods section in 
the Supplementary Appendix).
IMMUNOGENICITY
Anti-circumsporozoite antibodies were measured 
by means of enzyme-linked immunosorbent 
 assay15 in the first 200 infants enrolled at each 
study center at screening and 1 month after dose-3. 
An antibody titer of 0.5 EU per millimeter or 
greater was considered to be positive.
LABORATORY AND RADIOLOGIC PROCEDURES
Laboratory and radiologic procedures have been 
reported previously5 and are described in the 
Supplementary Appendix.
STATISTICAL ANALYSIS
The statistical methods have been described in 
detail previously.3,7 We used Cox regression mod-
els (1 minus hazard ratio) to evaluate vaccine ef-
ficacy against the first or only episode of clinical 
malaria, using the study center as a stratification 
factor that allowed for differential baseline haz-
ards. For the coprimary end point, vaccine effi-
cacy against clinical malaria during 12 months 
of follow-up in the two age categories, 97.5% 
confidence intervals were used, ensuring an 
overall two-sided alpha level of 5%. The propor-
tionality of hazards was evaluated by means of 
Schoenfeld residuals and models, including time-
varying covariates. Secondary analyses, which 
included evaluations based on other case defini-
tions and an analysis including multiple episodes 
of clinical malaria, were performed with the use 
of negative binomial regression. Vaccine efficacy 
against severe malaria was defined as 1 minus 
the risk ratio and is presented with 95% confi-
dence intervals and Fisher’s exact P values.
Primary analyses of vaccine efficacy were 
based on the per-protocol population, which in-
cluded all participants who received three doses 
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of a study vaccine coadministered with EPI vac-
cines and who were included in efficacy surveil-
lance, starting 14 days after the third dose of a 
study vaccine. The modified intention-to-treat 
population included all participants who received 
at least one dose of a study vaccine. In the ad-
justed analyses, vaccine efficacy was adjusted 
for study center and distance to the nearest out-
patient facility (≤5 km vs. >5 km). Data were 
censored 14 months after the first dose of vac-
cine, or at the date of emigration, withdrawal of 
consent, or death.
Serious adverse events were coded from clini-
cian-assigned diagnoses according to the pre-
ferred terms of the Medical Dictionary for Regulatory 
Activities16 and were based on available clinical 
and laboratory evidence.
The primary analysis of immunogenicity was 
based on the per-protocol population. Anti-cir-
cumsporozoite antibody titers were plotted and 
evaluated after the third dose of a study vaccine 
on the basis of seropositivity levels and geomet-
ric mean titers.
R esult s
STUDY POPULATION
In total, 6537 infants 6 to 12 weeks of age were 
enrolled; 6003 (91.8%) were included in the per-
protocol analysis (Fig. 1, and Fig. S3 in the Sup-
plementary Appendix). Baseline demographic 
characteristics were similar in the two study 
groups (Table S5 in the Supplementary Appen-
dix). The numbers of participants and malaria 
episodes according to study center are shown in 
Table S6 in the Supplementary Appendix. As ex-
pected, the majority of malaria episodes were 
reported by centers in areas with the highest 
transmission; 43.5% of all clinical malaria epi-
sodes were reported by two high-transmission 
sites in western Kenya. These two sites, combined 
with the site in Nanoro, Burkina Faso (where 
transmission is high but seasonal), accounted for 
72.6% of clinical malaria episodes in this analy-
sis. The rate of use of insecticide-treated nets was 
85.8% overall and was similar in the two study 
groups. Indoor residual spraying was conducted 
as a public health intervention at four study cen-
ters; at those centers, spraying coverage was low 
(Table S7 in the Supplementary Appendix).
VACCINE EFFICACY AGAINST CLINICAL AND SEVERE 
MALARIA
In the per-protocol population, the incidence of a 
first or only episode of clinical malaria meeting 
the primary case definition during 12 months of 
follow-up was 0.37 per person-year in the RTS,S/
AS01 group and 0.48 per person-year in the con-
trol group, for a vaccine efficacy of 31.3% (97.5% 
CI, 23.6 to 38.3). Kaplan–Meier curves are shown 
in Figures 2A and 2B. Vaccine efficacy was not 
constant over time (P<0.001 by Schoenfeld re-
siduals), with efficacy higher at the beginning 
than at the end of the follow-up period (Table S8 
in the Supplementary Appendix). Vaccine effica-
cy against all clinical malaria episodes was 32.9% 
(95% CI, 26.3 to 38.8). Estimates of efficacy 
against clinical malaria were consistent across 
all case definitions and in both adjusted and 
intention-to-treat analyses (Table 1).
At least one episode of severe malaria occurred 
in 58 of 3995 infants (1.5%) in the RTS,S/AS01 
group and in 46 of 2008 infants (2.3%) in the 
control group, for a vaccine efficacy of 36.6% 
(95% CI, 4.6 to 57.7) in the per-protocol popula-
tion. In the intention-to-treat population, at least 
one episode of severe malaria occurred in 77 of 
4358 infants (1.8%) in the RTS,S/AS01 group and 
in 52 of 2179 infants (2.4%) in the control 
group, for a vaccine efficacy of 26.0% (95% CI, 
−7.4 to 48.6) (Table 1, and Tables S15 and S16 in 
the Supplementary Appendix).
SAFETY
Serious Adverse Events
Serious adverse events were reported in 17.9% (95% 
CI, 16.8 to 19.1) of recipients of the RTS,S/AS01 
vaccine and in 19.2% (95% CI, 17.6 to 20.9) of 
recipients of the meningococcal vaccine (Table 2, 
and Table S9 in the Supplementary Appendix). A 
total of 94 infants died: 66 of 4358 infants (1.5%; 
95% CI, 1.2 to 1.9) in the RTS,S/AS01 group and 
28 of 2179 infants (1.3%; 95% CI, 0.9 to 1.9) in the 
control group. Causes of death were similar in 
the two groups; none of the deaths were thought 
to be related to vaccination (Table S10 in the Sup-
plementary Appendix). Serious adverse events that 
were considered to be related to a study vaccine 
occurred in 7 infants: 4 of the 4358 infants in the 
RTS,S/AS01 group and 3 of the 2179 infants in 
the control group; 4 events (2 in each group) 
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6537 Underwent randomization and
received study vaccine
545 Were not eligible
364 Did not meet criteria
2 Died
84 Withdrew consent
65 Moved or were lost to follow-up
30 Had other reasons
4358 Received dose 1 of RTS,S/AS01
(ITT population)
2179 Received dose 1 of control
vaccine (ITT population)
213 Did not complete
vaccination
27 Died or withdrew
for medical
reasons
47 Had consent with-
drawn or parent or
guardian declined 
to participate
84 Moved or were 
lost to follow-up
55 Had other reasons
503 Did not
complete
visit 16
37 Died
16 Had consent
withdrawn
450 Moved or
were lost to
follow-up
260 Did not
complete
visit 16
21 Died
4 Had consent
withdrawn
235 Moved or
were lost to
follow-up
150 Were not included 
in the per-protocol
analysis
7 Did not meet 
inclusion criteria
113 Were out of
interval for dose
regimen
16 Were lost to 
follow-up after
dose 3
14 Had other
reasons
82 Were not included 
in the per-protocol
analysis
5 Did not meet 
inclusion criteria
64 Were out of
interval for dose
regimen
3 Were lost to 
follow-up after
dose 3
10 Had other
reasons
89 Did not complete
vaccination
9 Died or withdrew 
for medical
reasons
20 Had consent with-
drawn or parent or
guardian declined 
to participate
38 Moved or were 
lost to follow-up
22 Had other reasons
4235 Received dose 2 2134 Received dose 2
4145 Received dose 3 2090 Received dose 3
3642 Attended visit 16
(12 mo after dose 3)
1830 Attended visit 16
(12 mo after dose 3)
3995 Were included in the
per-protocol population
2008 Were included in the
per-protocol population
7082 Infants were assessed for eligibility
Figure 1. Enrollment of Infants 6 to 12 Weeks of Age.
ITT denotes intention to treat.
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were episodes of fever for which infants were hos-
pitalized for investigation. One infant (in the con-
trol group) had anaphylaxis, one infant (in the 
RTS,S/AS01 group) had a suspected injection-site 
infection related to the pentavalent vaccine, and 
one infant (in the RTS,S/AS01 group) had repeat-
ed febrile seizures associated with a respiratory 
infection. The frequency of seizures within 7 days 
after vaccination, reported previously, was simi-
lar in the two study groups.3
Meningitis of any cause was reported as a 
serious adverse event in 11 infants: 9 of the 4358 
infants in the RTS,S/AS01 group and 2 of the 
2179 infants in the control group (relative risk in 
the RTS,S/AS01 group, 2.3; 95% CI, 0.5 to 10.4). 
A pathogen was identified for 7 of the events 
(salmonella in 3 episodes of meningitis and 
pneumococcus in 4 episodes). The 4 remaining 
events, with no pathogen identified, were re-
ported by a single study center (3 episodes of 
meningitis in the RTS,S/AS01 group and 1 epi-
sode in the control group). Of the 11 episodes of 
meningitis, 2 were new (1 due to pneumococcus 
and 1 due to salmonella); the 9 other episodes have 
been reported previously.3 Investigator-driven 
medical review of previously reported meningitis 
episodes led to reclassification of 1 episode as 
an episode of pneumonia and reclassification of 
4 episodes without cause as 2 episodes of pneu-
mococcal meningitis and 2 of salmonella men-
ingitis. Four of the episodes of meningitis oc-
curred within 30 days after vaccination.
Adverse Events
Unsolicited reports of adverse events within 30 days 
after vaccination were recorded with similar fre-
quency in the RTS,S/AS01 group (79.4%; 95% CI, 
77.2 to 81.5) and in the control group (81.3%; 
95% CI, 78.3 to 84.1). No clinically important 
imbalances were observed (Table S11A in the 
Supplementary Appendix). Information on unso-
licited reports of adverse events related to the 
vaccine or leading to withdrawal within 30 days 
after vaccination is shown in Table S11B in the 
Supplementary Appendix. The frequency of solic-
ited reports of local symptoms was similar 
among infants who received the RTS,S/AS01 vac-
cine and among those who received the menin-
gococcal vaccine and was lower than that ob-
served with the pentavalent vaccine (Table S13 in 
the Supplementary Appendix). Systemic reacto-
genicity was higher in the RTS,S/AS01 group 
than in the control group (Fig. 3, and Table S12 
in the Supplementary Appendix). Postvaccination 
fever was reported after 30.6% of doses (95% CI, 
29.2 to 32.0) in the RTS,S/AS01 group and after 
21.1% of doses (95% CI, 19.4 to 22.8) in the con-
trol group. A temperature higher than 39°C was 
reported after less than 1% of doses. The inci-
dence of mucocutaneous disease was similar in 
the two study groups (Table S14 in the Supplemen-
tary Appendix).
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Figure 2. Cumulative Incidence of a First or Only Episode of Clinical Malaria 
(Primary Case Definition).
The cumulative incidence of clinical malaria in infants 6 to 12 weeks of age 
at enrollment is shown for the 12 months of follow-up after the third dose of 
a study vaccine in the per-protocol population (Panel A) and for the 14 months 
of follow-up after the first dose of vaccine in the intention-to-treat population 
(Panel B).
Page 60 of 222
RTS,S/AS01 Malaria Vaccine in African Infants
n engl j med 367;24 nejm.org december 13, 2012 2291
IMMUNOGENICITY
Before vaccination, 34.3% and 35.2% of infants in 
the RTS,S/AS01 and control groups, respectively, 
were positive for anti-circumsporozoite antibodies 
but at low titers (Fig. S4 in the Supplementary 
Appendix). One month after the third dose of the 
study vaccine, 99.7% of infants in the RTS,S/AS01 
group were positive for anti-circumsporozoite an-
tibodies, with a geometric mean titer of 209 EU 
per milliliter (95% CI, 197 to 222).
Discussion
This phase 3 trial showed that in young infants, 
the RTS,S/AS01 candidate vaccine provided mod-
est protection against malaria when coadminis-
tered with EPI vaccines. The efficacy of RTS,S/
AS01 reported here is lower than that observed in 
a phase 2 trial involving infants at three of the 
phase 3 trial sites, in which RTS,S/AS01 was co-
administered with EPI vaccines. In that trial, geo-
Table 2. Serious Adverse Events in Infants 6 to 12 Weeks of Age at Enrollment during 14 Months after the First Dose 
of Vaccine (Intention-to-Treat Population).
Variable
RTS,S/AS01 Vaccine
(N = 4358)
Control Vaccine 
(N = 2179)
No. of  
Infants % (95% CI)
No. of  
Infants % (95% CI)
Serious events in all infants
≥1 Serious adverse event 782 17.9 (16.8–19.1) 419 19.2 (17.6–20.9)
≥1 Serious adverse event, excluding malaria 760 17.4 (16.3–18.6) 407 18.7 (17.1–20.4)
≥1 Fatal serious adverse event* 66 1.5 (1.2–1.9) 28 1.3 (0.9–1.9)
≥1 Serious adverse event related to vaccine 4 0.1 (0.0–0.2) 3 0.1 (0.0–0.4)
≥1 Serious adverse event within 30 days  
after vaccination
192 4.4 (3.8–5.1) 96 4.4 (3.6–5.4)
Events with an incidence ≥0.5%†
Pneumonia 302 6.9 (6.2–7.7) 152 7.0 (5.9–8.1)
Gastroenteritis 260 6.0 (5.3–6.7) 139 6.4 (5.4–7.5)
Malaria 184 4.2 (3.6–4.9) 115 5.3 (4.4–6.3)
Anemia 90 2.1 (1.7–2.5) 58 2.7 (2.0–3.4)
Febrile convulsion 82 1.9 (1.5–2.3) 46 2.1 (1.5–2.8)
Bronchiolitis 28 0.6 (0.4–0.9) 21 1.0 (0.6–1.5)
Convulsion 41 0.9 (0.7–1.3) 19 0.9 (0.5–1.4)
Bronchopneumonia 35 0.8 (0.6–1.1) 20 0.9 (0.6–1.4)
Upper respiratory tract infection 36 0.8 (0.6–1.1) 19 0.9 (0.5–1.4)
Salmonella sepsis 26 0.6 (0.4–0.9) 16 0.7 (0.4–1.2)
Malnutrition 29 0.7 (0.4–1.0) 7 0.3 (0.1–0.7)
Sepsis 26 0.6 (0.4–0.9) 10 0.5 (0.2–0.8)
HIV infection‡ 27 0.6 (0.4–0.9) 9 0.4 (0.2–0.8)
Enteritis 11 0.3 (0.1–0.5) 12 0.6 (0.3–1.0)
Urinary tract infection 16 0.4 (0.2–0.6) 10 0.5 (0.2–0.8)
Measles 20 0.5 (0.3–0.7) 7 0.3 (0.1–0.7)
Pyrexia 15 0.3 (0.2–0.6) 11 0.5 (0.3–0.9)
* More than one fatal serious adverse event could be attributed to a single infant if there was more than one underlying 
cause of death (e.g., meningitis and sepsis).
† Events are listed according to the preferred terms in the Medical Dictionary for Regulatory Activities.
‡ HIV denotes human immunodeficiency virus.
Page 61 of 222
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 367;24 nejm.org december 13, 20122292
metric mean titers of anti-circumsporozoite anti-
bodies after vaccination were similar to those 
measured here, but vaccine efficacy against clini-
cal malaria was 61.6% (95% CI, 35.6 to 77.1).17 
Although we wish to avoid overinterpretation of 
the results of this previously reported small 
phase 2 trial with wide confidence intervals, it is 
notable that this higher estimate of efficacy 
comes from a study conducted at sites in areas 
with low-to-moderate malaria transmission. It is 
possible that the pooled estimate across the 11 
centers in the phase 3 trial obscures differences 
in vaccine efficacy according to transmission in-
tensity and that these two sets of results are com-
patible with each other.
The efficacy of the RTS,S/AS01 vaccine re-
ported here is also lower than that reported previ-
ously among older children recruited for this trial 
at the same study centers.3 A likely explanation 
for the lower vaccine efficacy among infants is an 
age-dependent differential immune response to 
the vaccine. This concept is supported by the lower 
anti-circumsporozoite antibody titers observed in 
infants (geometric mean titer, 209 EU per millili-
ter; 95% CI, 197 to 222) as compared with titers 
in older children (621 EU per milliliter; 95% CI, 
592 to 652), reported previously.3 Although the 
titer of anti-circumsporozoite antibodies is not 
an established correlate of the level of protection, 
an association with efficacy has been observed in 
several trials.17-21 Infants may have mounted a 
lower immune response than older children ow-
ing to coadministration of RTS,S/AS01 with rou-
tine EPI vaccines, an inhibitory effect of mater-
nally derived anti-circumsporozoite antibodies, an 
absence of priming with hepatitis B vaccine or 
with P. falciparum infection, or the infant’s imma-
ture immune system.
Coadministration of RTS,S/AS01 with the pen-
tavalent vaccine and the oral poliovirus vaccine 
might have resulted in immune interference and 
contributed to the lower anti-circumsporozoite 
antibody titers in the younger infants. Two phase 2 
studies have explored the immunologic response 
to the related RTS,S/AS02 vaccine, either when 
co administered with a diphtheria–tetanus–pertus-
sis–hepatitis B vaccine or when given 2 weeks 
afterward. The geometric mean titer of anti-
circumsporozoite antibodies was lower when vac-
cines were coadministered than when they were 
staggered (70 EU per milliliter [95% CI, 54 to 90] 
vs. 200 EU per milliliter [95% CI, 151 to 265]).20,21 
However, vaccine efficacy against infection was 
similar in the two trials (65.2% [95% CI, 20.7 to 
84.7] during 6 months after vaccination and 65.9% 
[95% CI, 42.6 to 79.8] during 3 months after vac-
cination, respectively).
An absence of priming with hepatitis B vac-
cine or with P. falciparum infection may also have 
contributed to the lower anti-circumsporozoite 
antibody titers. In this trial, infants simultaneously 
received a hepatitis B surface antigen (HBsAg)–
containing combination vaccine and the RTS,S 
vaccine, which contains HBsAg fused as a carrier 
protein to the circumsporozoite protein. Immune 
interference on concurrent administration of sim-
ilar protein components has been described.22 
In contrast, in older children vaccinated against 
hepatitis B, memory T-cell reactivation may have 
enhanced the anti-circumsporozoite antibody re-
sponse to RTS,S/AS01.22 One study showed a 
tendency toward higher anti-circumsporozoite 
antibody responses in children who had been 
vaccinated against hepatitis B than in children 
who had not previously received hepatitis B vac-
cine.23 Maternally derived antibodies can inter-
fere with the immune response in young infants; 
such interference is common with live vaccines, 
such as the measles vaccine, but can also occur 
with some protein vaccines.24,25 Similarly, pas-
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Figure 3. Incidence of Solicited Reports of Adverse Events 
during the 7-Day Postvaccination Period after Each Dose 
(Intention-to-Treat Population).
Solicited reports of adverse events during the 7-day 
postvaccination period were recorded and analyzed in 
the first 200 infants enrolled at each study site.
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sively acquired antibodies to either HBsAg or the 
circumsporozoite components of the RTS,S/AS01 
vaccine might have suppressed immune respons-
es. Finally, although most protein vaccines and 
polysaccharide–protein conjugate vaccines are 
immunogenic in young infants, improved immu-
nogenicity and efficacy have often been achieved 
when vaccination has extended beyond the first 
few months of life.22,26,27
As previously reported in older children,3 sta-
tistical models indicated nonproportionality of 
hazards over time. This could be due to waning 
vaccine efficacy, differential acquisition of natu-
ral immunity, or other factors that may influ-
ence the model,28 such as heterogeneity of expo-
sure, the vaccine effect at the individual level, or 
both.29,30 If vaccine efficacy does wane, this 
might contribute to the lower observed efficacy 
among infants than among older children, espe-
cially because young infants may be less sus-
ceptible to malaria in the immediate postvacci-
nation period owing to maternally acquired 
immunity, fetal hemoglobin, lower exposure, and 
other factors.31
The 11 sites of the phase 3 trial cover a wide 
range of malaria-transmission intensity. The in-
clusion of sites in high-transmission or seasonal-
transmission areas and the large proportion of 
cases of severe and clinical malaria from these 
sites might have contributed to the lower vaccine 
efficacy among infants in this trial than in ear-
lier trials involving infants. The implications of 
the large representation of malaria episodes 
from high-transmission areas may become ap-
parent when site-specific data are analyzed at a 
later date, as specified by the protocol. Esti-
mates of site-specific vaccine efficacy and the 
corresponding estimates of clinical or severe 
malaria episodes averted will help to determine 
what role this vaccine might have in malaria 
control. Exploration of factors that might affect 
vaccine efficacy, including the effect of maternal 
antibodies, the role of immune interference by 
EPI vaccines, the effect of the RTS,S/AS01 boost-
er, and status with respect to previous exposure 
to P. falciparum parasites, will provide crucial in-
formation for the further development of this 
vaccine and for other malaria vaccines under 
development.32
Overall, fatal, or vaccine-related serious ad-
verse events were balanced between the study 
groups. In the previous analysis, which included 
infants and older children, the incidence of men-
ingitis was imbalanced between the RTS,S/AS01 
and control groups.3 The imbalance remains, but 
we now have clarified that the majority of cases 
had a bacterial cause. We will continue to mon-
itor the incidence of meningitis throughout the 
trial. The imbalance in the incidence of rash, 
observed in previous RTS,S studies,12,33 was not 
confirmed in this larger trial.
This phase 3 trial shows efficacy of the 
RTS,S/AS01 vaccine. Data from the remainder of 
this trial and additional studies in progress will 
contribute to the understanding of the complex 
interplay among the intensity of exposure to ma-
laria, the immune response, and vaccine efficacy.
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Abstract
Background: The malaria vaccine RTS,S induces antibodies against the Plasmodium falciparum circumsporozoite
protein (CSP) and the concentration of Immunoglobulin G (IgG) against the repeat region of CSP following vaccination
is associated with protection from P. falciparum malaria. So far, only the quantity of anti-CSP IgG has been measured
and used to predict vaccination success, although quality (measured as avidity) of the antigen-antibody interaction shall
be important since only a few sporozoites circulate for a short time after an infectious mosquito bite, likely requiring fast
and strong binding.
Methods: Quantity and avidity of anti-CSP IgG in African infants who received RTS,S/AS01E in a 0-1-2-month or a
0-1-7-month schedule in a phase 2 clinical trial were measured by enzyme-linked immunosorbent assay. Antibody
avidity was defined as the proportion of IgG able to bind in the presence of a chaotropic agent (avidity index). The
effect of CSP-specific IgG concentration and avidity on protective efficacy was modelled using Cox
proportional hazards.
Results: After the third dose, quantity and avidity were similar between the two vaccination schedules. IgG avidity after
the last vaccine injection was not associated with protection, whereas the change in avidity following second and third
RTS,S/AS01E injection was associated with a 54% risk reduction of getting malaria (hazard ratio: 0.46; 95% confidence
interval (CI): 0.22-0.99) in those participants with a change in avidity above the median. The change in anti-CSP
IgG concentration following second and third injection was associated with a 77% risk reduction of getting malaria
(hazard ratio: 0.23, 95% CI: 0.11-0.51).
Conclusions: Change in IgG response between vaccine doses merits further evaluation as a surrogate marker for
RTS,S efficacy.
Trial registration: ClinicalTrials.gov Identifier NCT00436007.
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Background
Malaria has an enormous public health impact and new
preventive interventions are urgently needed. After more
than 100 years of research on malaria vaccines, RTS,S
was the first pre-erythrocytic vaccine candidate that en-
tered phase III clinical development [1-3]. RTS,S con-
tains hepatitis B surface antigen (HBsAg) together with a
fusion protein of HBsAg and a carboxy-terminal frag-
ment of Plasmodium falciparum circumsporozoite pro-
tein (CSP), co-expressed in yeast and formulated with a
proprietary adjuvant (AS01). The exact mechanism of
RTS,S-mediated protection is not known, although Im-
munoglobulin G antibodies (IgG) against the CSP repeat
region are likely to play an important role since the con-
centration of anti-CSP IgG partly explains protection in
most studies that assessed efficacy of RTS,S in African
children [4-6]. In addition, passive transfer of anti-CSP
IgG can protect animals from subsequent challenge
[7,8]. Besides concentration, many other properties de-
termine antibody function. Among them are availability
of effector molecules, post-translational modification,
isotype, subclass, affinity and avidity of antibodies. It is
difficult to measure all these characteristics in one sam-
ple, particularly in the small sample volumes obtained
during clinical trials in infants. Affinity, defined as the
strength of interaction between an epitope and an anti-
body binding site, would be a particularly interesting
variable to measure in the context of anti-CSP IgG-
mediated immunity, since the time of interaction with
the parasite is short (less than 30 minutes [9]), sporozo-
ites are strongly diluted and few. In fact, only one suc-
cessful hepatocyte infection is sufficient to initiate and
maintain blood stage infection. Studies in mice have
shown that high antibody affinity against a synthetic
CSP immunogen is positively associated with protection
[8,10] and most studies in humans indicate that anti-
CSP IgG concentration explains only parts of the
vaccine-mediated protection. Increase in antibody affin-
ity after repeated antigen exposure is the result of affin-
ity maturation due to somatic hypermutation. The rate
and extent of maturation may be influenced by several
factors, including nature, route and dose of the antigen,
adjuvants and carriers as well as the immunization
schedule. In the present study antibody avidity was mea-
sured. It is a representation of the strength of interaction
between antibodies and antigens in a complex and be-
sides antibody affinity, valences of antibodies and anti-
gens as well as structural features of the complex are
important determinants of avidity. For CSP, it has been
shown that the use of some adjuvants can increase the
avidity of anti-CSP IgG after vaccination of human vol-
unteers [11]. In this study IgG avidity against the repeat
region of CSP was measured after the second and third
injection of RTS,S/AS01E in infants that received the
vaccine as part of a phase IIb clinical trial to assess safety
and efficacy of RTS,S/AS01E in the age-group targeted by
the expanded programme on immunization (EPI) [5,12].
Methods
Clinical trial
The objective of the study was to explore the effect of
anti-CSP IgG avidity on RTS,S vaccine efficacy in naturally
exposed infants. Details of the clinical trial have been pub-
lished previously [5,12]. Briefly, safety and efficacy of RTS,
S/AS01E when given through the EPI was assessed in 511
children from Gabon, Ghana and Tanzania. Participants
were randomly assigned to one of three intervention arms:
1) RTS,S/AS01E as three injections, one month apart (0, 1,
2 months schedule [012]; n = 170), 2) RTS,S/AS01E ex-
tended schedule (0, 1, 7 months schedule [017]; n = 170)
or 3) control (EPI vaccines alone; n = 171). Malaria was
defined as parasitaemia >500 parasites per μl and an axil-
lary temperature >37°C. The efficacy of RTS,S against first
malaria episodes, detected by passive case detection, was
equivalent in the two schedules one year after the third
injection. The study followed Good Clinical Practice
guidelines, the Declaration of Helsinki (4th revision) and
received approval from the appropriate local and national
ethics committees of each site. In addition, ethical re-
view by the ethics committees of the London School of
Hygiene and Tropical Medicine Ethic Committee, the
Swiss Tropical Institute Committee and the Western
Institutional Review Board was sought. The trial is
registered with ClinicalTrials.gov (NCT00436007).
Antibody measurements
Antibodies against CSP were measured by evaluating
IgG responses against the CSP-repeat region, using a
validated enzyme-linked immunosorbent assay (ELISA)
with R32LR as the coating antigen [13]. An anti-CSP
IgG titre of 0.5 ELISA units per millilitre (EU/mL) or
greater was considered to be positive. For measurements
of avidity of IgG against the repeat region of CSP,
samples were evaluated as described [13], but in two dif-
ferent plates; one treated with a chaotropic agent and
one untreated plate. As chaotropic agent a 1 M solution
of ammonium thiocyanate (NH4SCN) was added in the
treatment plate while 0.05% Tween-20 in PBS was added
in the untreated plate and both CSP ELISA plates were
further washed and developed as described [13]. The
avidity index (AI) was calculated as the ratio of the con-
centration of anti-CSP IgG (EU/ml) that remained
bound to the coated antigen after treatment with
NH4SCN, divided by the concentration of IgG (EU/ml)
that remained bound to the coated antigen in the un-
treated plate. Anti-CSP IgG quantification and avidity
were measured at the Center for Vaccinology, Ghent
University Hospital, Belgium.
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For statistical modelling the logarithm of anti-CSP IgG
concentration was used since previous data showed that
log-transformation results in a better fit to the normal
distribution. AI was analysed in the two RTS,S-vacci-
nated arms and after the second and third vaccination.
Since the majority of infants before vaccination and
those receiving control vaccine do not have measurable
anti-CSP IgG, AI cannot be calculated. Delta AI (dAI)
was defined as the difference in AI between the second
and third vaccination. Similarly, delta CSP (dCSP) was
defined as the difference in anti-CSP IgG concentration
between the second and third vaccination.
Statistics
Analysis of the effect of IgG avidity on protective effi-
cacy was exploratory and not detailed in the statistical
analysis plan of the original study. IgG responses be-
tween the groups were analysed by descriptive statistics
and represented as boxplots together with the individual
measurements. The effect of anti-CSP IgG concentration
and AI on risk of malaria was calculated using the
according-to-protocol (ATP) dataset with a Cox propor-
tional hazards model in R v2.15.2. For statistical model-
ling antibody concentrations were log-transformed. To
calculate the effect of dAI and dCSP on the occurrence
of malaria episodes with a Cox proportional hazards
model, values were dichotomized on the median dAI or
dCSP and labelled as ‘high’ and ‘low’, respectively. All
models included the covariates schedule and site. If ap-
propriate, other covariates were added as reported in the
results section. A p-value below 0.05 was considered sig-
nificant and 95% confidence intervals (95% CI) are given
where appropriate.
Results
After screening 605 participants, 170 received RTS,S in
the standard (012) and 170 in the extended (017)
schedule, as depicted on the CONSORT flowchart of
the primary study (Figure 1). Samples from 315 (300
ATP) participants were available for immunological
analysis (012: n = 154 [148]; 017: n = 161 [152]). Paired
immunological samples to calculate dAI were available
from 187 (179 ATP) participants (012: n = 103 [100];
017: n = 84 [79]).
As reported earlier [5], high anti-CSP IgG titres after
three vaccine injections were associated with a reduc-
tion in subsequent incidence of clinical malaria: the
hazard ratio of a ten-fold increase in anti-CSP IgG was
0.52 (95% CI: 0.34-0.81), which corresponds to a 48%
risk reduction.
Absolute AI after two (012: 35.9, 017: 34.9; t-test p = 0.57)
and three (012: 41.2, 017: 39.3; t-test p = 0.22) RTS,S injec-
tions were similar between the two vaccination schedules
(Figure 2). As expected, an increase in AI between the
second and third vaccination was present (Figure 3). In-
crease in delta AI (dAI) was slightly, albeit not statistically
significant, higher in the 017 (7.1) group compared to the
012 (4.2) group (delta: 3.0; 95% CI: −0.3-6.1; t-test p = 0.08).
To explore the effect of AI, dAI and dCSP on malaria
risk, three Cox proportional hazard models were defined
and tested. AI after the third injection, corrected for site,
schedule and anti-CSP IgG concentration, did not ex-
plain a significant reduction in risk of clinical malaria
(Model 1; hazard ratio: 0.99, 95% CI: 0.97-1.02). Partici-
pants were then divided on the median in dCSP and dAI
‘high’ and ‘low’ responders and included as categorical
variable in the model. Classification as ‘high-dCSP’ was
associated with a significant risk reduction (77%) com-
pared to the ‘low dCSP’ group in a model corrected for
site and schedule (Model 2; hazard ratio: 0.23, 95% CI:
0.11-0.51). When dAI, corrected for site, schedule and
dCSP was analysed, the hazard ratio between high and
low responders separated by the median, was 0.46
(Model 3; 95% CI: 0.22-0.99; Wald test p = 0.049), hence
classification as ‘high dAI’ group member is associated
with a 54% risk reduction (Figure 4).
Discussion
The complex interplay of vaccine-primed immune medi-
ators that define a successful response upon pathogen
encounter is not well understood. Cellular and humoral
components have important roles, although in various
compositions, depending on the pathogen and the host.
Antibodies are the prototypic vaccine-induced immune
mediators and play an important role in anti-malarial
immunity during the pre-erythrocytic [8,10] as well as
the erythrocytic stage [14] of the disease, as shown by
passive transfer experiments in mice and man. The sheer
concentration of antigen-specific antibodies is normally
used to measure immunization success and serves as a
surrogate to estimate protective efficacy. The clinical de-
velopment of RTS,S is a unique opportunity to investi-
gate the effect of further variables such as antibody
avidity, isotype or subclass on vaccine efficacy, since
clinical (true) efficacy is known [5], being 57% (95% CI:
33–73) with the 012 schedule and 32% (95% CI: 16–45)
following the 017 schedule.
Here, anti-CSP IgG avidity was measured to assess if it
predicts vaccine efficacy in a phase II clinical trial of
RTS,S independent of anti-CSP IgG concentration
[5,12]. Regardless of the vaccination scheme and site,
avidity did not improve prediction over anti-CSP IgG
concentration alone. This may mean that: i) the assay is
not sensitive enough to reflect avidity; ii) collinearity be-
tween antibody concentration and avidity blurs the effect
of avidity; or, iii) that avidity is not an important deter-
minant of vaccine efficacy. In this study IgG concentra-
tion and avidity was measured after the second and third
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vaccine injection. This approach is valid to assess if the
immune system reacted to vaccination successfully.
Since kinetics of IgG vary over time and the study was
performed under natural exposure to malaria parasites,
the time of encounter with the parasite becomes an im-
portant variable. This is in contrast to controlled human
malaria infection (CHMI) studies, where the time of in-
fection is defined. Hypothetically, the difference in IgG
concentration (and avidity) between second and third
vaccination could be a better predictor of effective
antibody-mediated protection than concentration after
the third vaccine injection, because it better reflects the
Figure 1 CONSORT study flow chart.
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further evolution of antibody responses until next para-
site encounter. The present data argue for the use of this
approach since it was shown that a high dCSP predicts
protective efficacy and dAI explains part of the protec-
tion in the RTS,S vaccinated children (Model 3). How
AI evolves over time and if it is a useful predictor of
vaccine efficacy remains to be validated with further, in-
dependent and confirmatory studies.
Nevertheless, this observation adds a new component
to the search of correlates of protection and the under-
standing of the immune responses elicited by pre-
erythrocytic malaria vaccine candidates such as RTS,S.
Since adjuvants also have a profound effect on the speed
of avidity maturation [11], the effect of avidity on vac-
cine efficacy could even be analysed with interventional
studies that assess the effect of timing between immuni-
zations (as in this study) and different adjuvants on pro-
tective efficacy while direct measures of maturation of
the immune system such as single-cell based sequencing
of IgG genes of anti-CSP memory B-cells [15,16] are
performed. This may be particularly interesting for anti-
gens such as CSP that are not highly immunogenic per
se, because highly immunogenic antigens often induce
antibodies with strong avidity over a short period of time
and a threshold antibody concentration is appropriate to
predict their efficacy [17]. Other studies in the develop-
ment of RTS,S (e.g., challenge experiments [18] and the
recently completed phase III trial [1-3]) will certainly
provide additional information and may establish the
measurement of avidity as one biomarker for vaccine effi-
cacy. Additionally, such knowledge may guide the design
of next generation vaccines and administration schemes.
Conclusions
So far, the most robust correlate of protection for the mal-
aria vaccine candidate RTS,S is anti-circumsporozoite
(CSP) IgG concentration following immunization. Pre-
clinical data and theoretical considerations suggest that
avidity may have an additional impact on protective
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Figure 4 Kaplan Meier plot of malaria episodes over time in
participants classified as having high (black) or low (grey) dAI.
Figure 2 Box-plot and single measurements of absolute AI at
second and third vaccination using two vaccination schedules
(012 or 017).
Figure 3 Box-plot and single measurements of difference in AI
(dAI) between second and third vaccination using two
vaccination schedules (012 or 017). Note that for the analysis of
dAI only paired samples were used (n = 179).
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efficacy. It is shown that an increase in anti-CSP IgG con-
centration and avidity between second and third vaccine
injection is associated with a strong risk-reduction for
malaria after immunization. This finding shall influence
the way of analysis of immunological correlates of protec-
tion since using change in antibody concentration and
avidity rather than single measurements enables improved
modelling of immune-effector function at the time of
pathogen encounter and hence more powerful prediction
of vaccine efficacy.
Consent
Written informed consent was obtained from each
child’s parent(s). Illiterate parents were informed about
the study in the presence of an impartial and literate wit-
ness and informed consent was documented by thumb-
print of the parent and signature of the witness.
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Background. The RTS,S/AS01E malaria vaccine has moderate efficacy, lower in infants than children. Current efforts to enhance 
RTS,S/AS01E efficacy would benefit from learning about the vaccine-induced immunity and identifying correlates of malaria pro-
tection, which could, for instance, inform the choice of adjuvants. Here, we sought cellular immunity-based correlates of malaria 
protection and risk associated with RTS,S/AS01E vaccination.
Methods. We performed a matched case-control study nested within the multicenter African RTS,S/AS01E phase 3 trial. 
Children and infant samples from 57 clinical malaria cases (32 RTS,S/25 comparator vaccinees) and 152 controls without malaria 
(106 RTS,S/46 comparator vaccinees) were analyzed. We measured 30 markers by Luminex following RTS,S/AS01E antigen stimula-
tion of cells 1 month postimmunization. Crude concentrations and ratios of antigen to background control were analyzed.
Results. Interleukin (IL) 2 and IL-5 ratios were associated with RTS,S/AS01E vaccination (adjusted P  ≤ .01). IL-5 circumsporo-
zoite protein (CSP) ratios, a helper T cell type 2 cytokine, correlated with higher odds of malaria in RTS,S/AS01E vaccinees (odds 
ratio, 1.17 per 10% increases of CSP ratios; P value adjusted for multiple testing = .03). In multimarker analysis, the helper T cell type 
1 (TH1)–related markers interferon-γ, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subsequent 
malaria, in contrast to IL-5 and RANTES, which increased the odds of malaria.
Conclusions. RTS,S/AS01E-induced IL-5 may be a surrogate of lack of protection, whereas TH1-related responses may be 
involved in protective mechanisms. Efforts to develop second-generation vaccine candidates may concentrate on adjuvants that 
modulate the immune system to support enhanced TH1 responses and decreased IL-5 responses.
Keywords. malaria; vaccine; immunity; cellular immune responses; cytokines.
 
RTS,S/AS01E is the most advanced malaria vaccine candidate in 
development, having completed a phase 3 trial in Africa, in which 
the 1-year vaccine efficacy (VE) against clinical malaria was 56% 
in children aged 5–17 months and 31% in infants aged 6–12 weeks 
[1–3]. The mechanisms of RTS,S/AS01E-induced protection and 
the reasons for the moderate efficacy and the lower protection 
in infants than children remain unclear. Identifying immune 
correlates of protection can shed light on these questions, help 
improve RTS,S/AS01E, and rationally design the next generation 
of malaria vaccines to control and eliminate this disease.
RTS,S is a subunit vaccine targeting the pre-erythrocytic stage 
of Plasmodium falciparum infection and is based on the circum-
sporozoite protein (CSP). The vaccine consists of a recombinant 
protein containing part of the CSP fused to and coexpressed 
with the hepatitis B surface antigen (HBsAg). RTS,S in the phase 
3 trial was formulated with the AS01 adjuvant that consists of 
3-O-desacyl-4′-monophosphoryl lipid A (MPL), QS21, and lipos-
omes. In previous trials, RTS,S induced high titers of anti-CSP 
immunoglobulin G (IgG) [4–10], which recently were shown to 
correlate with the magnitude and duration of VE in children and 
infants [11, 12]. Unlike antibodies, cellular responses in endemic 
areas are low to moderate and mainly based on helper T cell type 1 
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(TH1) responses, specifically CD4
+ T cells expressing, interleukin 
(IL) 2, tumor necrosis factor (TNF), and interferon (IFN)–γ [4–9]. 
No investigated cellular response has predicted RTS,S-induced 
protection consistently in pediatric phase 2 trials [7, 8].
RTS,S/AS01E-induced cellular immunity is probably com-
plex and involves different cell types and immune mediators. 
Most studies performed to date measured a limited number 
of parameters, restricted by the reduced amounts of blood 
obtained in children. Multiplex bead arrays and the Luminex 
platform allow multiparameterization of numerous markers 
in small volumes. Use of this technology in 2 studies includ-
ing a limited number of markers suggested that RTS,S vacci-
nation elicited secretion of the cytokines IL-2 and IL-4 [4, 9]. 
Herein, we used a multiplex immunoassay to measure cellular 
responses following ex vivo stimulations with vaccine antigens 
in cells freshly isolated at pre- and postimmunization in chil-
dren and infants from 3 African sites of the phase 3 trial.
METHODS
Study Design
Written informed consent was obtained from children’s par-
ents/guardians before recruitment. The study protocol was 
approved by all relevant ethics review boards and national 
regulatory authorities (Supplementary Methods). We per-
formed a matched case-control study nested within the RTS,S/
AS01E phase 3 trial, described elsewhere [3]. In brief, the trial 
enrolled infants (6–12 weeks) and children (5–17 months) 
who were vaccinated with either RTS,S/AS01E or a compara-
tor vaccine—that is, rabies vaccine (children) or meningo-
coccal C conjugate vaccine (infants), administered at study 
months zero, 1, and 2. Peripheral blood mononuclear cells 
(PBMCs) were collected and stimulated ex vivo at month 0 
before vaccination and 30 days after the third dose of vaccine 
(M3) from 368 children in 3 trial sites: Bagamoyo (Tanzania), 
Lambaréné (Gabon), and Manhiça (Mozambique); and from 
219 infants in Manhiça and Lambaréné (only M3). This study 
included all malaria cases detected 1–12 months postvacci-
nation from the according-to-protocol immunology cohort 
whose samples were available (Figure 1 , Supplementary Table 
1). Malaria cases were defined as subjects who sought care at 
a health facility and had any P. falciparum asexual parasitemia 
by blood smear. Controls were matched to cases based on site, 
age group, and time of vaccination and follow-up. Up to 1:4 
case:controls (average 1:3) were selected among RTS,S/AS01E 
vaccinees, and 1:2 case:controls were selected among com-
parator vaccinees. Investigators conducted assays blinded to 
vaccination and protection status.
Peripheral Blood Mononuclear Cell Stimulations and Multiplex Bead 
Array Assay
PBMCs were stimulated fresh with peptide pools covering the 
2 vaccine antigens: CSP (31 peptides) and HBsAg (53 peptides) 
[7]. Dimethyl sulfoxide, the solvent for peptide pools, was used 
alone as a background control (henceforth “background” or 
“mock stimulation”). Thirty cytokines, chemokines, and growth 
factors were quantitated in cell supernatants using the Cytokine 
Human Magnetic Panel from Life Technologies (Supplementary 
Methods).
Selection of Markers and Metrics for Primary Analysis in a Pilot Study
Four cytokines (IL-2, IL-5, IL-17, and IFN-γ) were selected as 
primary markers for primary and secondary analyses in a pilot 
study that included 153 children who were not in the main 
matched case-control study. Markers were selected based on 
immunogenicity (Supplementary Table 2), precision, reliability, 
accuracy, uniqueness, and biological relevance. The primary 
outcome for antigen-specific responses was defined in the pilot 
study as the ratio between the crude concentration after anti-
gen stimulations (CSP or HBsAg) and after mock stimulations 
(Supplementary Methods).
Statistical Analysis
Primary analysis of immunogenicity and correlates of protec-
tion was based on ratios of primary markers at M3 and focused 
on RTS,S/AS01E vaccinees and CSP responses. To distinguish 
correlates of RTS,S/AS01E-induced immunity from correlates 
of naturally acquired immunity, results of RTS,S/AS01E and 
comparator vaccinees were contrasted through interaction tests 
with vaccination group.
Marker responses between RTS,S/AS01E and comparator 
vaccinees were contrasted through linear models and t tests. 
Impact of baseline ratios on postvaccination ratios was assessed 
through linear regression models, with baseline ratios as predic-
tors. Analyses of correlates of protection were based on compar-
isons of cases and controls for CSP ratios in logistic regression 
models with a random intercept to account for matching strata. 
Odds ratios (ORs) were scaled to represent a 10% increase in 
ratios or in concentrations. Additionally, for interpretability, rel-
evant ORs were scaled based on standard deviations. To identify 
groups of markers associated with malaria, marker ratios were 
analyzed in combination and selected through regression with 
elastic net and through partial least squares discriminant anal-
ysis (PLS-DA).
All tests were 2-sided and considered statistically significant 
to a .05  α-level. Analyses were adjusted for multiple testing 
through permutation (maximum T). P values for the 4 primary 
markers were adjusted (P-adj) separately from the 24 second-
ary markers. P values for CSP and HBsAg stimulations were 
adjusted separately. Adjustments for multiple testing when 
assessing interactions with vaccination status, age group, or sex 
were done through Holm (primary markers) and Benjamini-
Hochberg (secondary markers) approaches. When age interac-
tions were statistically significant, the age-specific association 
was reported. Analyses were conducted using the R software 
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1137 RTS,S/AS01E vaccinees 
705 children/ 432 infants 
584 comparator vaccinees 
371 children/ 213 infants 
709 vaccinees had PBMC  
413 children/ 296 infants 
382 vaccinees had PBMC 
228 children/ 154 infants 
372  vaccinees had  
PBMC stimulations 
236 children/ 137 infants‡ 
32 cases analyzed 
16 children/16 infants 
106 controls analyzed§ 
53 children/53 infants 
25 cases analyzed 
17 children/8 infants 
46 controls analyzed§ 
30 children/16 infants 
428 not selected for 
cellular component* 
  
14 children had M0 
samples available 
46 children had M0 
samples available 
12 children had M0 
samples available 
202 not selected for 
cellular component* 
  
18 children had M0 
samples available 
 210 vaccinees had  
PBMC stimulations 
131 children/ 79 infants‡ 
193 had < 6.6 
million cells 
97 were included in 
a separate B-cell study 
47 had missing 
samples   
32 cases by M12† 
16 children/16 infants 
341 controls by M12 
220 children/121 infants 
188 controls by M12 
117 children/71 infants 
109 had < 6.6 
million cells 
41 were included in 
a separate B-cell study
22 had missing 
samples 
  
25 cases by M12† 
17 children/8 infants 
9 did not meet inclusion 
criteria for the clinical trial 
341 excluded 
56 did not receive 3 doses of    
the study vaccine 
192 did not comply with 
primary vaccination 
schedule 
82 had blood collected 
outside of the period 
specified in the protocol 
11 other reason  
1721 subjects were included in the M067 ATP criteria for 
Bagamoyo, Lambaréné and Manhiça  
 
4272 subjects enrolled in the ITT phase 3 RTS,S/AS01E 
Trial (M055) for Bagamoyo, Lambaréné and Manhiça 
2071 subjects were included in the M067 ITT cohort for 
Bagamoyo, Lambaréné and Manhiça  
 
RTS,S/AS01E Comparator 
Figure 1. Study profile. *Based on the study protocol, only a subset of vaccinees were enrolled for the cellular component of the immunology study MAL067 (M067), 
ancillary to the RTS,S/AS01E phase 3 trial MAL055 (M055). ‡Per study protocol, peripheral blood mononuclear cells (PBMCs) were supposed to be freshly stimulated and 
have supernatant collected whenever >6.6 million cells were harvested. The priority was to cryopreserve 5 million PBMCs. Stimulations were performed when additional 
PBMCs were available for at least circumsporozoite protein and mock stimulations (0.8 million each). In the Manhiça site, after we collected samples from 292 subjects in 
each age cohort, all subsequent samples were assigned to a different study involving B cells and no fresh stimulations were performed. †Four subjects (1 RTS,S/AS01E- and 
3 comparator-vaccinated children) who were not originally in the according-to-protocol cohort were inadvertently included in the analysis. The subjects had the blood sample 
collected more than the 30 days after the primary vaccination defined in the protocol. §Up to 1:4 case:controls (average 1:3) were selected among RTS,S/AS01E vaccinees, 
and 1:2 case:controls were selected among comparator vaccinees. Controls that were not matched to any case were not analyzed. Abbreviations: ATP, according-to-protocol; 
ITT, intention-to-treat; M0, study month 0; M12, study month 12; PBMC, peripheral blood mononuclear cell. 
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package [13]. Secondary analysis and details are described in 
the Supplementary Methods.
RESULTS
Study Population and Markers at Preimmunization
Samples from 209 subjects were analyzed (Figure 1). Among 
RTS,S/AS01E vaccinees, 15 cases and 51 controls were from 
Bagamoyo, 1 case and 2 controls from Lambaréné, and 16 cases 
and 53 controls from Manhiça. Vaccinees in Bagamoyo and 
Lambaréné were all children, and in Manhiça nearly all were 
infants (95%). Preimmunization CSP ratios in RTS,S/AS01E- 
and comparator-vaccinated children (baseline samples were not 
collected in infants) were comparable, except for IFN-γ, which 
was statistically significantly higher in RTS,S/AS01E vaccinees 
(Supplementary Table 3).
Immunogenicity Markers
When comparing CSP ratios between RTS,S/AS01E and com-
parator vaccinees at M3, only IL-2 was significantly higher 
in RTS,S/AS01E than in comparator vaccinees (Figure 2A, 
Supplementary Figure 1A). For HBsAg ratios, IL-2 and the 
helper T cell type 2 (TH2) cytokine IL-5 were significantly 
higher in RTS,S/AS01E vaccinees (Figure 2B, Supplementary 
Figure 1B). The effect of vaccination on ratios was comparable 
in children and infants and in both sexes (P-adj > .10 for inter-
action with age and with sex).
Concentrations of primary markers IL-2 and IL-5 after CSP 
and HBsAg stimulations were significantly higher in RTS,S/
AS01E than in comparator vaccinees (Supplementary Figure 2). 
Unlike analysis with ratios, concentrations after CSP, HBsAg, and 
mock stimulations were different between age groups for several 
markers (P-adj for interaction with age <.05; Supplementary 
Table 4). In children, CSP and background responses of most 
of these markers were higher in RTS,S/AS01E vaccinees than 
in comparator vaccinees, including the TH1-related cytokines 
IFN-γ, IL-12, IL-15, and the proinflammatory markers TNF 
and IL-1β (Table 1; Supplementary Table 4). In contrast, no dif-
ferences in marker concentrations between vaccination groups 
were detected in infants. No differences in immunogenicity by 
sex were found (P-adj > .10 for interaction with sex).
Impact of Preimmunization Markers on RTS,S/AS01E Immunogenicity
Baseline responses to CSP due to previous immunity or to 
HBsAg due to hepatitis B vaccination (included in the expanded 
program of immunization) could affect immunogenicity of 
RTS,S/AS01E in children. Therefore, we analyzed the impact 
of prevaccination ratios of primary markers on the postvacci-
nation ratio of the same or any other marker (Supplementary 
Table 5). For CSP ratios in RTS,S/AS01E-vaccinated children, 
baseline IFN-γ was consistently and positively correlated with 
postvaccination ratios of some markers, including the immu-
nogenicity marker IL-2, the TH1-related cytokine IL-15, and 
the homeostatic cytokine IL-7 (Supplementary Figure 3). For 
HBsAg ratios, baseline IFN-γ was negatively correlated with 
some postvaccination CSP ratios, including IFN-α, IFN-γ, 
and vascular endothelial growth factor (VEGF). Baseline IL-2 
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Figure  2. Circumsporozoite protein (CSP; A) or hepatitis B surface antigen 
(HBsAg; B) primary marker ratios 1 month postimmunization with RTS,S/AS01E or 
a comparator vaccine. Diamonds show geometric means of CSP or HBsAg ratios 
to controls and bars show the 95% confidence intervals. P values were computed 
through t tests of the log10-transformed ratios and were adjusted for multiple test-
ing (P-Adj) through a permutation approach. Only statistically significant P values 
are shown. There were 137 RTS,S/AS01E and 70 comparator vaccinees for CSP (A) 
and 133 RTS,S/AS01E and 63 comparator vaccinees for HBsAg (B). Abbreviations: 
CSP, circumsporozoite protein; HBsAg, hepatitis B surface antigen; IFN-γ, interferon 
gamma; IL, interleukin.
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HBsAg ratios correlated with higher levels of some postvacci-
nation CSP ratios (eg, IFN-α). Few baseline HBsAg ratios were 
associated with postvaccination HBsAg ratios in RTS,S/AS01E 
vaccinees (Supplementary Table  5), and most associations 
were weak and different from associations with CSP ratios. In 
contrast, no clear associations were detected in comparator 
vaccinees.
Correlates of Clinical Malaria: Single-Marker Analysis
Figure 3 shows the ORs for 10% increases in postvaccination CSP 
ratios of primary and secondary markers and malaria in RTS,S/
AS01E (Figure 3A) and comparator vaccinees (Figure 3B). 
Only IL-5 was significantly associated with the odds of malaria 
in RTS,S/AS01E vaccinees (OR, 1.17 per 10% increases of IL-5 
CSP ratios [95% confidence interval, 1.03–1.38]). Although the 
Table 1. Comparisons of Marker Concentrations After Circumsporozoite Protein Stimulations in RTS,S/AS01E and Comparator Vaccinees by Age Cohort 
When Significant Age Interactions Were Detected
Children Infants Difference Age Groups
Marker RTS,S/AS01E (n = 69) Comparator (n = 47) P Valuea RTS,S/AS01E (n = 69) Comparator (n = 24) P Valuea P Valueb Adjusted P Valueb
IFN-γ 36 (24–54) 15 (10–25) .008 11 (7–16) 10 (4–22) .88 .002 .007
G-CSF 1314 (1081–1598) 885 (658–1190) .03 629 (511–774) 693 (452–1062) .69 <.001 <.001
GM-CSF 345 (265–451) 159 (98–258) .007 145 (104–201) 149 (71–313) .95 <.001 <.001
IL-10 337 (260–437) 180 (112–289) .03 128 (98–166) 164 (93–290) .44 <.001 <.001
IL-12 2090 (1650–2647) 1094 (739–1619) .007 841 (687–1029) 811 (533–1232) .88 <.001 <.001
IL-15 162 (137–191) 104 (81–134) .005 110 (96–127) 110 (73–168) 1 .01 .03
IL-1β 2491 (2142–2898) 1285 (833–1984) .007 1210 (1019–1438) 1145 (792–1656) .79 <.001 <.001
IL-1RA 3422 (2763–4238) 2166 (1605–2924) .02 1653 (1400–1952) 1505 (913–2479) .73 <.001 <.001
IP-10 32 (27–40) 26 (22–30) .07 23 (20–25) 22 (17–28) .85 .003 .009
TNF 1297 (1035–1625) 521 (303–898) .004 287 (193–425) 316 (168–594) .8 <.001 <.001
Data are presented as geometric mean, pg/mL (95% confidence interval) unless otherwise indicated.
Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-γ, interferon gamma; IL, interleukin; IP, interferon-gamma- 
induced protein; TNF, tumor necrosis factor.
aP values for the comparison of RTS,S and comparator vaccinees were computed based on t tests of log10-transformed values.
bP values for assessing differences between age cohorts (interaction with age) were computed through linear regressions and were adjusted for multiple testing using a Holm approach for 
primary markers and a Benjamini-Hochberg approach for secondary markers.
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Figure 3. Correlation between clinical malaria and circumsporozoite protein (CSP) marker ratios in RTS,S/AS01E vaccinees (A) and comparator vaccinees (B). Odds ratios 
and 95% confidence intervals per 10% increase in primary and secondary marker ratios (CSP ratio to control) 1 month postimmunization. Blue indicates markers that were 
significantly associated (without adjustment for multiple testing) with clinical malaria in logistic mixed-effects models. P values were adjusted (P-Adj) for multiple testing 
through a permutation approach. N = 137 RTS,S/AS01E vaccinees and 70 comparator vaccinees. *The association between clinical malaria and the interleukin 5 ratios was 
different between RTS,S/AS01E and comparator vaccinees, with P value for interaction test adjusted for multiple testing = .049. Abbreviations: EGF, epidermal growth factor; 
FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IFN, 
interferon; IL, interleukin; IP, interferon-gamma-induced protein; MCP, monocyte chemoattractant protein; MIG, monokine induced by IFN-γ; MIP, macrophage inflammatory 
protein; OR, odds ratio; RANTES, regulated on activation normal T-cell expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. 
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chemokine RANTES (regulated on activation normal T-cell 
expressed and secreted) was also associated with increased odds 
of malaria in RTS,S/AS01E vaccinees (OR, 1.09 [confidence 
interval, 1.01–1.22]), the association was not significant after 
adjusting for multiple testing. The ORs of IL-5 and RANTES, 
scaled by changes in standard deviation units of the ratio, 
were 2.29 and 1.61, respectively. Furthermore, the association 
of IL-5 with malaria was specific to RTS,S/AS01E vaccinees 
(P-adj = .049 for vaccination interaction; Supplementary Table 
6). No marker was associated with malaria in comparator 
vaccinees. Based on these results, we explored the association 
of IFN-γ/IL-5 ratio with malaria, and a higher ratio was found 
to be protective against malaria (P = .004; Supplementary 
Figure 4).
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The associations of nearly half of the markers with malaria 
varied between children and infants, including IFN-γ (Figure 4; 
Supplementary Table  6). In children, increases in CSP ratios 
of several markers significantly increased the odds of malaria. 
On the contrary, increases in CSP ratios of TH1 and proin-
flammatory cytokines IFN-γ, IL-15, and TNF and the granu-
locyte colony-stimulating factor (G-CSF) in infants protected 
from malaria. Sex of vaccinees did not confound associations 
between ratios and malaria—that is, neither impacted ORs nor 
P values (data not shown).
In secondary analyses (data not shown), we found that 
marker concentrations were not correlated with malaria.
Correlates of Clinical Malaria: Multiple-Marker Analysis
When analyzing combinations of marker ratios in models 
selected by elastic net, IFN-γ (OR, 0.90), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (OR, 
0.94), IL-15 (OR, 0.93), IL-5 (OR, 1.38), and RANTES (OR, 
1.15) were predictive of malaria in RTS,S/AS01E vaccinees 
(Supplementary Figure 5). Two components identified by 
PLS-DA were independently protective against malaria in 
RTS,S/AS01E vaccinees (Figure 5). In line with previous results, 
the markers that contributed more (loadings > <−0.3 or >0.3) to 
1 component were GM-CSF, IFN-γ, IL-5, and RANTES and to 
the other component were IL-15, IL-5, and RANTES.
DISCUSSION
We found that IL-5 CSP ratios at postvaccination increased 
the odds of malaria in RTS,S/AS01E-vaccinated children and 
infants, a result that could explain the lack of protection in 
numerous vaccinees through a different mechanism than the 
previously reported strain-specific VE in children [14]. In 
multimarker analysis, IL-5 and RANTES increased the odds 
of malaria in RTS,S/AS01E vaccinees, whereas the TH1-related 
markers IFN-γ, IL-15, and GM-CSF were correlated with RTS,S/
AS01E-induced protection. IFN-γ and IL-15 were also asso-
ciated with protection in single-marker analysis in infants, as 
well as TNF and G-CSF. Although associations of marker ratios 
with vaccination were comparable between age groups, associa-
tions with concentrations were significantly different for several 
markers. Proinflammatory and the above-reported protective 
markers were significantly higher in RTS,S/AS01E-vaccinated 
than in comparator-vaccinated children, but these differences 
were not observed in infants. These results suggest that RTS,S/
AS01E is less immunogenic in infants, and may explain the 
lower VE in this age group [12]. Of note, RTS,S/AS01 responses 
were higher for HBsAg than CSP. This may be due to a higher 
immunogenicity of HBsAg than CSP, to the higher proportion 
of HBsAg in the RTS,S vaccine, or to hepatitis B vaccination.
IL-5 is mainly produced by activated TH2 cells and restricted 
to effector memory T cells that are differentiated after recurrent 
antigenic exposure [15, 16]. IL-5 has never been examined in 
RTS,S trials, although IL-4, another TH2 cytokine, was previ-
ously found to be elevated in RTS,S-vaccinated infants [4]. In 
a preclinical study, the AS01B and AS02A adjuvants induced 
IL-5 in addition to IFN-γ responses [17]. To our knowledge, 
there is no epidemiological evidence of IL-5 association with 
occurrence of clinical malaria. Functional polarity between 
TH1 and TH2 responses could partially explain the association 
of IL-5 with malaria in RTS,S/AS01E vaccinees. IL-5+ TH2 cells 
probably constrain protective TH1 responses and inhibit several 
macrophage functions [18]. Exploratory analyses of IFN-γ/IL-5 
ratios indicate that a skewed response to TH2 increases the odds 
of malaria. Additionally, the effect of IL-5 in promoting eosin-
ophil responses [18] could contribute to the increased odds of 
malaria. Eosinophils have important regulatory functions and 
may restrict inflammation and increase plasma cell responses 
[19]. RANTES, the other marker that increased the odds of 
malaria, is produced by memory T cells and macrophages in 
PBMCs [18, 20] and is involved in chemoattraction of T cells 
and, together with IL-5, of eosinophils [18]. We speculate that 
IL-5 and RANTES in RTS,S/AS01E vaccinees could be acting 
together on eosinophils to regulate antibody responses through 
plasma cells, jeopardizing protective responses.
IFN-γ, mainly produced by T cells and natural killer (NK) 
cells, seems to be involved in the protection mediated by 
pre-erythrocytic vaccines [21]. CSP-specific IFN-γ T-cell and 
NK cell responses were elicited by RTS,S vaccination in adult 
challenge studies [22–24] and in clinical trials from endemic 
areas [4, 6, 7, 9], but their effect on protection remains unclear. 
TH1 responses are involved in protection against intracellular 
pathogens through cell-mediated immunity, and IFN-γ is cru-
cial for parasite killing through the induction of nitric oxide [18, 
21]. IL-15, a cytokine produced by dendritic cells and mono-
cytes in PBMCs, is important for activation of NK and T cells, 
including NK T cells and CD8+ T cells, which may be involved 
in RTS,S/AS01E-induced cellular responses to liver-stage par-
asites. GM-CSF, produced by TH1 and TH17, NK, and B cells 
and macrophages, induces effector functions in granulocytes, 
monocytes, macrophages, and eosinophils, is critical for den-
dritic cells, and increases IFN-γ secretion [25]. Therefore, IL-15 
and GM-CSF could contribute to induction or enhancement of 
TH1-mediated protective responses.
Detected age differences in immunogenicity are in line with 
immune ontogeny. Newborns have a biased cellular response 
toward a TH2 profile, due to diminished TH1 and proinflam-
matory responses that persist during the first months of life 
and increase around 12 months of age [26, 27]. Therefore, the 
age differences in RTS,S immunogenicity may be explained by 
diminished responsiveness in infants that may impact any vac-
cine [26, 27] depending on the adjuvant and antigen immuno-
genicity. Curiously, we detected similar marker differences in 
the mock stimulations, reflecting nonspecific responses upon 
RTS,S/AS01E vaccination. A nonspecific effect of RTS,S has not 
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been observed, but the nonspecific effect of other vaccines in 
early life has been described [28–30]. Surprisingly, despite low 
immunogenicity in infants, more markers were correlated with 
protection in infants than in children, including the TH1-related 
cytokines IFN-γ, IL-15, and TNF. On the contrary, in children, 
some markers including TNF were associated with increased 
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Figure 5. Association of combinations of circumsporozoite protein (CSP) marker ratios with clinical malaria with the combinations obtained through partial least squares 
(PLS) regression in RTS,S/AS01E vaccinees. Bars quantify the importance (loadings) of each marker (using CSP to control ratios) for specific marker combinations (PLS com-
ponent) that were significantly associated with clinical malaria (component 1 association with clinical malaria was not statistically significant, P = .2). Markers that sub-
stantially contributed for the component (loadings <-0.3 or >0.3) are highlighted in blue. Odds ratio and predictive accuracy (area under the receiver operating characteristic 
curve) from univariate and multivariate models with the selected combination of markers as variables are shown. N = 137 RTS,S/AS01E vaccinees. Abbreviations: AUC, area 
under the receiver operating characteristic curve; CI, confidence interval; EGF, epidermal growth factor; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating 
factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; IP, interferon-gamma-induced protein; MCP, 
monocyte chemoattractant protein; MIG, monokine induced by IFN-γ; MIP, macrophage inflammatory protein; OR, odds ratio; RANTES, regulated on activation normal T-cell 
expressed and secreted; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
Page 81 of 222
754 • CID 2017:65 (1 September) • Moncunill et al
odds of malaria. Despite this apparent paradox, different levels 
of cytokines may have different effects. For instance, moder-
ate levels of cytokines like TNF have been described to control 
P. falciparum infection [31], but exacerbated levels are biomark-
ers of proinflammatory responses involved in pathogenesis 
of malaria [32]. Also, differences may be given by diverse cell 
origin as monocytes, macrophages, NK cells, and also effector 
memory and central memory T cells may produce it.
Several baseline marker ratios had an impact on postim-
munization ratios in children. Responses affected included the 
immunogenicity marker IL-2, the protective cytokines IFN-γ 
and IL-15, and IL-7, IFN-α, and VEGF, which were associated 
with higher odds of malaria in children. This suggests that 
immune status and previous responses to malaria and hepati-
tis B vaccine may influence RTS,S/AS01E immunogenicity. If 
malaria baseline immunity alters vaccine responses, it could 
further explain the lower VE in infants. Indeed, IgG data against 
CSP suggest that baseline levels have an impact on immuno-
genicity [12]. Also, baseline cell composition and inflam-
mation have previously been associated with RTS,S efficacy 
[33] and postvaccination responses in other vaccine studies 
[34–36]. Future work assessing cell phenotypes and activation, 
cytokine-expressing CD4+ T cells, and antibody responses to 
CSP and HBsAg at baseline may help confirm this hypothesis.
Imbalances in age distribution across sites and the nonavail-
ability of baseline samples in infants may limit the strength of 
some of our conclusions. Most children were from Bagamoyo 
and infants from Manhiça, but because malaria transmission 
was similar in both sites, it is unlikely that age differences were 
confounded by study site. Finally, our study did not include 
samples from areas of high endemicity, nor had information 
about other factors, for example, coinfections that could impact 
vaccine responses.
In summary, we identified 2 possible different and antagon-
istic cellular immune mechanisms induced by RTS,S/AS01E 
vaccination: IL-5 (and RANTES) TH2 responses associated 
with increased odds of malaria; and IFN-γ and other TH1-
related responses (GM-CSF, IL-15) associated with protection. 
Moreover, we detected lower induction of protective TH1 and 
proinflammatory responses by RTS,S/AS01E in infants than 
children, whereas TH2 responses were similar, which could 
contribute to the decreased VE in infants. Further analysis of 
cytokine-expressing cells together with isotypes and specifici-
ties of antibody responses to RTS,S/AS01E will clarify the role 
of these identified correlates in protection or lack thereof. Our 
findings may transcend antigen specificity and underscore the 
need to understand the impact of baseline immune status and 
factors that may modulate any pediatric vaccine responses in 
Africa. Our results reveal undesirable vaccine responses that 
may abrogate the protection of RTS,S/AS01E and other vac-
cines, but that might be overcome by improved formulations. 
Adjuvants that modulate the immune system to support a 
potent TH1 response during the first months of life and avoid 
counteracting responses may be required.
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 Introduction 
 
Malaria remained a major public health concern for many decades. Highly efficacious malaria 
vaccines are considered to be the cornerstone for successful malaria eradication (1). The RTS, S 
malaria vaccine; a GlaxoSmithKline (GSK) Biologicals design, is a mixture of RTS, the chimeric 
recombinant protein containing polypeptide region of circumsporozoite protein (CSP), the hepatitis 
B virus surface antigen (HBsAg), and S, the recombinant protein containing HBsAg alone (2). RTS, 
S adjuvated with AS01 has been shown to be safe and to induce significant protection against 
Plasmodium falciparum (P.falciparum) infection and or clinical malaria in naïve adult (3), semi- 
immune adults (4) semi-immune children (5,6) and infants (7,8). In previous studies, the RTS, S 
vaccination have proved to induce high anti-CSP IgG titre and modest cellular immune responses 
(9,10). However the role of cell-mediated-immunity in RTS, S-induced protection is as yet 
unresolved. There remained inconclusive results to the induction of cytotoxic T cells by TRS, S, 
although significant Th1 cytokines-mediated responses have been demonstrated (11–19). In naïve 
adults there are indication that cellular immunity to CSP may be important. IL-2 and IFN-g 
responses assessed by ex-vivo ELISpot were higher in protected than infected individual (12). In 
addition, analysis of IL2, IFN-g TNF and CD40L by intracellular cytokines staining (ICS) and flow 
cytometry suggested that higher CD4+ Th1 cell responses might be associated with protection. A 
recent study showed that frequencies of TNF and IL2 producing T effector and T effector memory 
cells restimulated with CSP peptide were higher in protected non-immune vaccinees (20).  In 
African children IL2, IFN-g, and TNF cytokine responses are produced among vaccinated 
individuals after stimulation of fresh whole blood with CSP and HBs peptide; albeit in low 
magnitude with heterogeneity in the intensity of responses. In Gabonese children, IL2 CD4+ T cell 
responses could be detected upon CSP antigen re-stimulation after RTS, S/AS0 vaccination (17). In 
Tanzania, CD69 expressing T cells were present in the higher numbers in vaccinated than 
unvaccinated children after stimulation of peripheral blood mononuclear cells with CSP and HBs 
peptide (21). In Mozambican infants, increased levels of secreted IFN-g, IL2, and IL4 to both 
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 vaccine antigen components were observed in supernatants as well as IFN- and ILs by ICS up to ten 
weeks post dose 3 (16). Secreted IL-2 was the strongest and most frequent CSP-specific responses 
and was detected in more than 25% of the RTS, S/AS01 immunized infants at ten weeks post dose 
3. The induction of CD8+ T cells remained inconclusive and has been detected in only this trial in 
Mozambique (16). However, the key question regarding the mode of action of RTS, S and the 
duration of protection elicited by the vaccine remain open. There is only few studies that tried to 
identify markers associated with RTS,S induced protection against malaria using gene expression 
microarrays (22,23). A study carried out in naïve USA adult volunteers vaccinated with RTS, 
S/AS01 or RTS, S/AS02 and experimental challenged with P.falciparum showed different gene 
expression in four components of immunoproteasome. Those genes are responsible for processing  
of peptide for MHC presentation distinguished protected and no-protected individuals before the 
parasites challenge (24). It remains to be established whether similar patterns would apply  to 
children from malaria endemic area naturally exposed to P.falciparum and other infections. Here we 
report an analysis of cellular immune responses of children enrolled, between the 5-17 months of 
age, in a Phase IIIb trial of RTS, S/AS01 in Bagamoyo Tanzania. 
 
 
Materials and 
methods Ethical 
consideration 
The protocol was approved by institutional review boards (IRBs) of the Ifakara Health Institute 
(IHI/IRB/No.A59) and National Institute for Medical Research Tanzania (NIMR/ HQ/R.8a/Vol. 
IX/792), and the Ethikkommission beider Basel (EKBB), Basel, Switzerland (EKBB 319/11). The 
protocol was also approved by TFDA (Ref. No. CE.57/180/04/41), and the trial was registered at 
ClinicalTrials.gov (NCT00866619). The study was conducted in accordance with Good Clinical 
Practice guidelines. Before enrolment into the study, the parents or guardians of a child participants 
were given an inform consent form to read and upon understanding it, they were allowed to give the 
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 will for their child to participate in trial. No child was recruited in the study without  having 
informed consent process completed. 
 
 
Study site and design 
 
This ancillary immunology arm of the phase 3, randomized, controlled, double-blind trial was 
conducted at 11 centers in 7 African countries with a range of malaria-transmission intensity. The 
Ifakara health institute, Bagamoyo branch, Tanzania was part of 11 sites in seven African countries 
that participated in the whole study. The main trial was designed to evaluate vaccine efficacy, 
safety, and immunogenicity during an average period of 49 months (range: 41–55 months) after the 
first dose of study vaccine in children and an average period of 41 months (range: 32–48 months) 
after the first dose of study vaccine in young infants. Children with a moderate or severe illness, a 
major congenital defect, malnutrition requiring hospitalization, a haemoglobin concentration 5.0 
g/dl, or ,8 g/dl with clinical signs of decompensation, a history of atypical febrile seizures, a 
neurological disorder, or WHO stage III or stage IV HIV disease at the time of recruitment were 
considered not eligible for participating in trial. Insecticides treated nets were provided or made 
available to any child who presented for screening. 
Blood sample collection and processing 
 
A total of 400 children aged between 5 -17 months were recruited out of 800 children enrolled for 
the main study. 3.8 mL of whole blood were collected into cell preparation tubes (CPT Vacutainer 
BD), from each child at baseline, 3, 21 and 32 months after first vaccination. Additionally, at 
months 20, approximately 0.2 mL blood was collected into a filter paper blood spots for the parasite 
genotyping. Blood were transported at room temperature to the laboratory for processing within 1 
hour after collection, as this was critical for the quality and sensitivity of cell mediated immune 
assays. 
In the lab, blood were centrifuged and processed according to manufacture instructions. Plasma was 
separated and aliquoted into 2 mL cryovials and frozen at -80ºC.     PBMCs were collected from the 
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 tubes, washed, counted using Countess automated cell counter from Invitrogen and stored at -80ºC 
for 18-24 hrs before transferred into liquid nitrogen (LN2) for longer storage. At least 5 million 
PBMCs per volunteer per bleeding time point were frozen down in LN2 and the left over PBMC 
were used for fresh stimulations onsite with Dimethyl sulfoxide (DMSO), CSP, Phytohemagglutinin 
(PHA), Apical membrane antigen 1 (AMA1) and Hepatitis B antigen (HBsAg). The erythrocyte 
pellets form the CPT tubes were carefully collected and stored for retrospective determination of P. 
falciparum infections. 
 
 
Recovery and viability of PBMCs from Bagamoyo after thawing the cryopreserved 
cells 
 
To assess whether the stored PBMC are viable and the vials have the sufficient number of cells for 
the purpose of our analysis, subjects with more than one vials stored (N=115) were selected for 
participating in this pilot study. Only the baseline and month 3 PBMCs were included in this 
experiment. Briefly PBMC sample were thawed from the liquid nitrogen, washed, re-suspended into 
culture medium (RPMI 1640, 10% FBS) and then counted using GUAVA technologies (Germany). 
The numbers counted and the viabilities obtained from this count were recorded as day 1. The cells 
were then left incubated overnight with culture medium (RPMI 1640, 10% FBS) and then washed, 
re-suspended into culture medium and counted to obtain the recovery count. The number counted 
and viabilities obtained were recorded as day 2. 
 
 
Intracellular cytokine staining (ICS) 
 
To test the functionality of cryopreserved PBMCs, the rate of IFN-g/IL-2 secretion was determined 
using PBMCs from 115 children. The PBMC were stimulated by the CSP and HBsAg antigen  
which are the components of the RTS, S vaccine. Intracellular cytokine staining assays were 
performed and IL-2 and IFN-g responses quantified by flow cytometry. The IL-2 and IFN-g were 
selected as marker of functionality based of the previous studied outcomes that showed IFN-g/IL-2 
responses following vaccination with RTS, S (25). ICS was performed according to the published 
method by Moncunill et al (26). Briefly, PBMC samples from 115 RTS, S vaccinated children were 
stimulated  with  CSP,  and  HBsAg,  and  stained  with  commercial  available  reagents  (26).   The 
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 primary measurement in this study was the cytokine response for CD4+ and CD8+ T-cell subsets 
producing IFN-γ and/or IL-2 to CSP and HBsAg.  Data was acquire by flow cytometry directly  
from the plates using the high throughput sampler (HTS) until reaching dead volume of at least 50 
μL. 
 
 
Statistical analysis 
 
Descriptive statistics are used to describe participant’s recruitment patterns with relative to the 
villages of their origin. The Fisher’s exact Test were used to calculate the IL-2/IFN-g responses 
rates and the difference between day 1 and day 2 viability and recovery were tested by using Mann 
Whitney test by using a GraphPad Prism 6 (USA). The p<0.05 were considered significant. 
Results 
 
Recruitment outcome and study sampling adherence 
 
Recruitment for this study took place between mid-September 2009 and February 2010. A total of 
400 children were recruited at the baseline. However, only 356 met according to protocol (ATP) 
criteria and their data were used in this analysis. The number of recruitment for each month varied 
substantially with the lowest number observed at the beginning of the study recruitment, September 
2009. However, the recruitment was improved on October and November, before falling again in 
December to February, albeit remained above the original number (Figure 1). 
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 Percentage of children recruited at Bagamoyo study area by month 
 
 
 
 
 
 
 
N  =  3 5 6 
 
 
 
 
 
 
 
   4 .4 9 % S e p t 2 0 0 9 
   3 5 .3 9 %   O c t 2 0 0 9 
   2 5 .8 4 %   N o v 2 0 0 9 
   1 4 .0 4 % D e c 2 0 0 9 
   1 0 .6 7 % J a n 2 0 1 0 
   9 . 5 5 % F e b r 2 0 1 0 
 
 
 
 
Figure 6: Number of children enrolled in Bagamoyo study site by months during recruitment period 
 
 
 
 
Furthermore, despite that the study follow up persisted intensively for nearly 3 years, our data 
demonstrate that, on the subsequent visit, adherence remained higher on month 3 (99.2%), month 21 
(90.5%) and on month 32 (90.5%). The overview of sample collected during the course of this study 
is depicted in Table 1. 
 
 
Table 1 : Overview of the number of subjects recruited in Bagamoyo site at baseline and those 
adhering to subsequent sample collection visit (3, 20, 21, 32 months) after vaccination. 
 
Sample type Baseline Month 3 Month 20 Month 21 Month 32 
PBMC 356 (100%) 353 (99.2%) 0 322 (90.5%) 318 (89.3%) 
Plasma 356 353 0 322 318 
Filter paper 0 0 336 0 0 
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 Additionally, we investigated amongst the sample collected, the number of subjects who had their 
PBMCs successfully stimulated on site. Our data suggest that over ninety percent of children had  
the correct amount of blood collected hence demonstrate the efficient of our phlebotomist. (Table 2) 
 
 
 
Table 2: Overview of the total number of PBMCs collected during all time points (3, 20, 21, 32 
months) and those stimulated onsite. In bracket is the percentage of total number within respective 
time point. 
 
Time points Total PBMC collected 
(%) 
Freshly stimulated 
(%) 
Not stimulated 
Baseline 356 (100%) 316 (88.8%) 40 (11.2%) 
Month 3 353 (99.2%) 338 (95.8%) 15 (4.3%) 
Month 21 322 (90.5%) 314 (97.5%) 8  (2.5%) 
Month 32 318 (89.3%) 288 (90.6%) 30 (9.4%) 
 
 
 
 
 
 
Community awareness influences the number of participant recruited across the study area 
To investigate the influence of community responses amongst villages, we stratified the subjects 
groups according to their village of origin. A total of 21 villages were included in the study area. 
This includes Bago, Chasimba, Dunda, Fukayosi, Kerege, Kidomole, Kiwangwa,  Kongo, 
Magomeni, Makurunge, Mapinga, Masuguru, Mataya, Matimbwa, Mkenge, Msinune, Mwavi, 
Mwetemo, Yombo and Zinga. Together, our data demonstrated that, Magomeni and Kiwangwa had 
the highest frequency of subject participation compared to the other villages (Figure 2). Several 
clinical trials studies have been previously conducted in Kiwangwa and Magomeni, this could 
explanation the higher frequency seen in the two villages as community is aware of the clinical trials 
therefore it was not questionable to agree to participate. 
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 Frequency of children recruited at Bagamoyo study area by village 
 
 
 
 
Figure 2: Frequencies of children recruited per village within Bagamoyo clinical trial study area 
 
 
 
 
Recovery and viability of PBMCs from children at point of collection varies between 
time points 
The recovery of PBMCs isolated from all the bleeding time points were measured at baseline (mean 
 
± SME) (4.54+0.43 million cells/ml of blood), month 3 (6.47±0.12 million cells/ml of blood),  
month 23 (5.58 ± 0.11 million cells/ml of blood) and Month 32 (4.39 ± 0.84 million cells/ml of 
blood) (Figure 3). Additionally, the overall percentage viability for the isolated PBMC at different 
time points was (86.1% ± 0.57 million cells/ml of blood) at baseline, (81.3 ± 0.79 million cells/ml of 
blood) at month 23, (99.7 ± 0.14 million cells/ml of blood) at month 32. Viability data for the month 
3 samples was not obtained (Figure 4). 
Page 93 of 222
 Number of peripheral blood mononuclear cells (PBMCs) recovered from the samples 
collected in Bagamoyo 
 
 
 
 
 
1 8 
1 6 
1 4 
1 2 
1 0 
8 
6 
4 
2 
0 
M0 M3 M21 
M32 
Time Point 
 
 
 
Figure 3: Shown are sampling time points M0, M3, M23 and M34 of the Bagamoyo cohort 
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Figure 4: Total viable PBMC counted upon day of thawing (day1-yield) and after over-night rest in 
culture media (day2- recovery). Differences analysed by Wilcoxon non-parametric non-paired test 
(N=115) 
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 Recovery and viability of PBMCs from Bagamoyo after thawing the cryopreserved 
cells 
 
To assess the quality of stored PBMC in terms of viability and quantity (numbers), subjects with 
more than one vials stored (N=115) were selected for participating in this pilot study. The data 
suggest an evidence of significant difference in number of PBMC recovery between thawing and 
resting time points, (p = 0.0072) (Figure 5). However, our data do not show any evidence of 
differences in PBMCs viabilities between the day of thawing (day1) and after over-night resting in 
culture (day2) (p = 0.2666) (Figure 6) 
 
 
 
 
Total PBMC recovered after thawing and over-night rest in culture media 
 
 
 
 
 
Figure 5: Total viable PBMC counted upon day of thawing (day1-yield) and after over-night rest in 
culture media (day2- recovery). Differences analysed by Wilcoxon non-parametric non-paired test 
(N=115) 
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 Percentage viability upon thawing and after overnight rest in 
 
 
 
Figure 6: Percentage PBMC viability upon day of thawing (day1) and after over- 
nigh rest in culture media (day2). Differences analysed by Wilcoxon non-parametric 
non-paired test (N=115) 
 
 
 
 
The CD4+ T cells but not CD8 T cells from cryopreserved PBMCs from Tanzanian 
children secretes IFN-g and IL-2 cytokines following stimulation with HBsAg and 
CSP antigens 
To test the functionality of cryopreserved PBMCs, the rate of IFN-g/IL-2 was determined using 
PBMCs from 115 children. Our data shows that the stored PBMC remained functional after 5 years 
of storage in LN2. Albeit in low magnitude, the CD4-T cells and not CD8 T cell were found to  
secret IL-2 and IFN-g cytokines (Table 3). The flow cytometer gating strategies is shown in figure 
7 
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 Table 3: T cell responses analysed base on their IFN-g and IL-2 secretion rate following stimulation 
with CSP and HBsAg of cryopreserved PBMCs from Tanzania children. 
 
 
T cell Antigen N Filtered IFN-g/IL-2 95%CI 
CD4+ CSP 184 26 8/158 (5.1%) (2.8%, 9.7%) 
 
HBsAg 114 40 12/65 (18.5%) (10.9&, 29.6%) 
CD8+ CSP 184 35 0/149 (0.0%) (0.0%, 2.5%) 
 HBsAg 114 60 0/54 (0.0%) (0.0%, 6.6%) 
The Fisher’s exact test were used to determine the proportional of IL2 and IFN-g producing T cell 
 
 
Flow cytometer gating strategies 
 
Figure 7: Example of the staining and gating strategy for PBMC stimulated with Staphylococcal 
enterotoxin B (SEB). All gates for non-functional markers were defined using fluorescence minus  
one (FMO) controls whereas gates for functional markers were defined using the unstimulated 
samples. A: Gating hierarchy to identify NK cells, NKT-like cells, CD4+ and CD8+ T cells, and TFH-like 
cells. Initial gating is done on FSC-H and FSC-A to discriminate singlets, followed by the exclusion of 
events collected during a period of time early in collection when fluctuations may occur. In this 
example,  there  were  no  problems  of  fluctuations  and  the  time  gate  was  minimized  to   avoid 
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 exclusion of any events. Dead cells and monocytes are excluded by an amine reactive dye and the 
CD14 marker in the same dump channel. Lymphocytes are gated using FSC-A and SSC-A.  
Subsequent gating discriminates two subsets of NK cells by CD56 and CD3 expression  
(CD56dimCD3- and CD56hiCD3-) and NKT-like cells (CD56+CD3+). Within the gate of lymphocytes, 
CD3+ cells are identified, followed by identification of CD4+ and CD8+ T cells. Of note, NKT-like cells 
are not excluded from classical T cells and therefore are overlapping populations. Finally, TFH-like 
cells are identified as CXCR5+ CD45RA- CD4+ T cells that have a low expression of CCR7 and arePD- 
1+. B: Functional markers for CD4+ and CD8+ T cells. A gate is applied for each cytokine, not taking 
into account the coexpression of other markers. Boolean gates are then created based on these 
gates to identify cells expressing different combinations of markers. C: The expression level of CCR7 
and CD45RA is examined within CD4+ and CD8+ T-cell subsets to later provide insight into the 
memory phenotype of the antigen specific cells. 
 
 
 
 
Discussion 
 
We found that the CD4 T cells but not CD8 T cells in PBMCs collected from Tanzanian children 
secretes IFN-g and IL-2 after stimulation with HBsAg and CSP antigen invitro. In line with our 
finding, the IFN-g and IL-2 secreting CD4 T cell were demonstrated in several RTS, S studies 
previously conducted in rhesus primate (25), naive adult individuals (20),and in children and infants 
living in malaria endemic regions (18). This finding implies that the quality of PBMC collected in 
Bagamoyo site during the course of RTS, S study was well maintained even after five years of 
storage in LN2. The result of this pilot study highlights the need for further analysis to evaluate in 
lager sample size the cellular and humoral immune responses induced by RTS, S malaria vaccine in 
paediatric population in natural transmission settings. Efficient recovery, higher percentage of 
viability and functionality of PBMCs are essential for reliable investigation of the ways in which the 
immune system responds to a certain interventions. However, blood sampling in paediatric 
population for the purpose of assessment of their immune responses has been very challenging 
amongst the parents, researchers and ethics committees (27). This is because the children become 
restless during blood draw and the mother gets nervous witnessed blood is taken from her child. In 
the current study we managed to collect 3.8 ml of blood from each child and isolate PBMC. From 
this  we  showed  that,  an  average  of  4.5  million  lymphocytes  per  millilitre  of  blood  could  be 
Page 98 of 222
 recovered from children aged between 5 and 17 months old. To date, data indicative of how many 
PBMCs can be obtained in a millilitre of blood collected from African children population are 
scarce. This study took advantage of samples collected during the RTS, S/AS01 clinical trial 
conducted in Bagamoyo Tanzania to establish the average number of PBMCs, their viability and 
functionality. This information may be helpful in planning future sample repositories or as a 
comparison for other immunological studies involving African paediatric population. 
At the beginning of the study we thought to recruit more that 90% of children within 3 months of 
recruitment period. However this was not achieved and instead the recruitment rate of  
approximately 5- 35% was attained. The possible explanation for this was that, parents needed time 
to digest information given during sensitization meetings and decide whether they need their child  
to be included in the study of not. We could show that the recruitment rate went up on the October 
2009, implying that parents were content with the study information hence became willing to let 
their children participate. On the other hand, it could be that sensitization meetings were not 
sufficient enough to convince parent to participate, hence parents needed time to see what happened 
to those who were convinced at the first place. However, despite slow rate of recruitment, adherence 
was well maintained. Approximately 99% of all children recruited at baseline attended the month 3 
visit and blood was drawn from them for different laboratory tests. On the subsequent visit, 
adherence slightly went down up to 89% by the end of the study on month 32 of follow up. Such 
adherence after three years of follow up suggests that the follow up system was well set and village 
health care workers were performing the duty of trucking the participants efficiently. The elevated 
frequencies of participation observed in Kiwangwa and Magomeni area remains to be revealed as 
the two area represent different geographical backgrounds (rural and urban respectively). 
Furthermore, this finding suggests that the parents were satisfied with the services they received in 
the context of RTS, S clinical trial benefits, the reason why they opt to continue participating for 
such long time. Our data also shows that an average of 93% (range 88.8% to 97.5%) of all samples 
collected in respective time point, the PBMCs were stimulated onsite. The ability to obtain   enough 
number of cells for onsite stimulation reflects the availability of sufficient amount of blood from the 
collection clinic. 
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 We further demonstrated that the average recovery of freshly isolated PBMCs from all the bleeding 
time points were 5.25 million cells/ml of blood (range 4.39 to 6.47 million cells/ml of blood). 
Additionally, the overall percentage viability for the isolated PBMC at different time points was 
89.0% (range from 81.3% to 99.7%). The quality (viability) of PBMC stored in LN2 and quantity 
(numbers) is critical for generation of credible immune response data. Our data suggest an evidence 
of significant difference in number of PBMC recovery between thawing and resting time points. 
However, we could not see any evidence of differences in PBMCs viabilities between the day of 
thawing (day1) and after over-night resting of PBMCs in culture (day2). The difference in numbers 
observed between time of thawing and after resting in culture is not uncommon, as some PBMCs  
are lost during the washing steps of thawing procedures while the remaining PBMC showed similar 
viability. The major limitation for this was CPT tube that resulted in occurrence of some red blood 
cell contamination in the isolated PBMC hence creating difficulties in counting. The volume of 
blood collected from children was also variable as it was difficult to obtain the exactly stipulated 
blood volume form these children. Overall, we found that sufficient PBMC could be obtained   from 
3.8 mls of blood in African paediatric population and hence more studies in how immune responses 
in children responds to various interventions could possibly be conducted in African settings. 
 
 
Conclusion 
 
The study of cellular immune responses amongst African paediatric population remained to be 
challenging due to difficulties in obtaining enough blood samples. However, children are most 
vulnerable population for many infectious diseases. Securing adequate information on how their 
immune functions responds against different infections is critical for development of interventions 
such as drugs and vaccine for children population. Vaccine studies including malaria vaccines are 
conducted in paediatric population residing in malaria endemic areas, and it is hoped that results 
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 from these studies will highlight the possibilities of involving children as the target population on 
validating the information obtained in previous clinical trial phases conducted in adults regarding 
Ag-specific CD4 and CD8 T cells responses. 
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Controlled Human malaria infections as a tool to accelerate malaria 
vaccine development in Africa and to dissect malaria specific 
immunity 
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Abstract. Controlled human malaria infection (CHMI) by mosquito bite has been used to assess anti-malaria inter-
ventions in > 1,500 volunteers since development of methods for infecting mosquitoes by feeding on Plasmodium
falciparum (Pf) gametocyte cultures. Such CHMIs have never been used in Africa. Aseptic, purified, cryopreserved Pf
sporozoites, PfSPZ Challenge, were used to infect Dutch volunteers by intradermal injection. We conducted a double-
blind, placebo-controlled trial to assess safety and infectivity of PfSPZ Challenge in adult male Tanzanians. Volunteers
were injected intradermally with 10,000 (N = 12) or 25,000 (N = 12) PfSPZ or normal saline (N = 6). PfSPZ Challenge
was well tolerated and safe. Eleven of 12 and 10 of 11 subjects, who received 10,000 and 25,000 PfSPZ respectively,
developed parasitemia. In 10,000 versus 25,000 PfSPZ groups geometric mean days from injection to Pf positivity by thick
blood film was 15.4 versus 13.5 (P = 0.023). Alpha-thalassemia heterozygosity had no apparent effect on infectivity. PfSPZ
Challenge was safe, well tolerated, and infectious.
INTRODUCTION
Controlled human malaria infection (CHMI), intentional
infection of subjects with malaria parasites, has been used
for treating patients with syphilis1,2 and in research for nearly
a century.3 Since the development in the 1980s of methods for
infecting mosquitoes by feeding on Plasmodium falciparum
(Pf) gametocyte cultures,4–6 CHMI has been used repeatedly
and successfully in more than 1,500 volunteers in the United
States and Europe.6–10 Africa suffers the most morbidity and
mortality from malaria, and thus could benefit significantly
by using CHMI to facilitate development of new vaccines, drugs,
and diagnostics for malaria, and for understanding innate and
acquired resistance to the parasites that cause malaria. How-
ever, until now such CHMIs had never been used in Africa.
There are a number of reasons why CHMI has not been
established in Africa. One is that the phase 1 clinical trial
facilities and teams necessary to safely and professionally
carry out such trials have not been available until recently
for such studies. A second reason is that from 1985 to 2010,
all CHMI studies in which volunteers were infected with
Pf sporozoites were conducted by exposure to the bites of
Pf-infected Anopheles mosquitoes not native to Africa, and
produced in high security facilities difficult to establish,
run, and maintain in Africa. To address the first limitation,
we established a phase 1 clinical trial center at the Ifakara
Health Institute (IHI), Bagamoyo, Tanzania. At the same
time it became possible to manufacture aseptic, purified,
cryopreserved Pf sporozoites (PfSPZ) that are highly infec-
tious, a product called PfSPZ Challenge.11–13 When young
adult Dutch volunteers were injected intradermally (ID) with
doses of 2,500, 10,000, or 25,000 PfSPZ (divided into
two 50 mL injections), five of six volunteers developed
parasitemia in all three groups, and the time from injec-
tion of PfSPZ Challenge to detection of parasites by thick
blood smear was ~13 days in all three groups. Thus, there
was infection, but no dose response, presumably because
increasing the dose did not increase the numbers of spo-
rozoites that exited the skin, entered the circulation, and
invaded hepatocytes.12
To begin the process of understanding how to use PfSPZ
Challenge in Africans, we conducted a double-blind, placebo-
controlled trial to assess the safety and infectivity of ID-
administered PfSPZ Challenge in 30 male, highly educated,
Tanzanian residents of Dar es Salaam, Tanzania, who had
had minimal exposure to Pf malaria during the previous
5 years. As a bridge to the Dutch study, one group received
the regimen used in one of the Dutch groups; 5,000 PfSPZ in
50 mL were injected ID into the deltoid area of both upper
arms for a total of 10,000 PfSPZ.12 In a second group we
increased the dose to 25,000 PfSPZ, and based on findings in
murine model systems, which suggested ways to improve the
efficiency of ID injections,14 we divided the total dosage into
four injections of 6,250 PfSPZ, each in 10 mL.
As in Dutch12 and British13 subjects, PfSPZ Challenge was
safe, well tolerated, and infectious in young adult Tanzanian
males. In the bridging group the infection rate, but not the
pre-patent period, was comparable to that observed for the
same dose in young adult Dutch subjects. These findings pro-
vide the foundation for using CHMI with PfSPZ Challenge
to assess the protective efficacy of antimalarial vaccines and
drugs in Africa.
MATERIALS ANDMETHODS
Study design and population. This single center, double-blind,
randomized, controlled trial was conducted in Bagamoyo,
*Address correspondence to Stephen L. Hoffman, Sanaria Inc.,
9800 Medical Center Drive, Rockville, MD 20850. E-mail: slhoffman@
sanaria.com
†These authors contributed equally to this study.
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Tanzania between February and August 2012. Thirty healthy
male volunteers 20 to 35 years of age were recruited from
higher learning institutions in Dar es Salaam. Screening for
eligibility took place at the newly established Bagamoyo
Clinical Trial Unit (BCTU) of the Ifakara Health Institute
(IHI). Volunteers were screened using predetermined inclu-
sion and exclusion criteria based on clinical examinations
and laboratory tests. These included medical history and
physical examinations, and standard hematology, biochemis-
try, malaria, human immunodeficiency virus, hepatitis B and
C, and sickle cell tests. In addition subjects were screened
for a-thalassemia. In the initial screening a-thalassemia trait
was an exclusion criterion because of a theoretical concern
that these individuals might be less susceptible to Pf infec-
tion. As screening progressed it became clear that a sub-
stantial proportion of the local population was heterozygous
for a-thalassemia and it would be important to include this
population in the volunteer pool to understand if the hetero-
zygous condition was more resistant to malaria infection by
experimental challenge and pose an obstacle that would
need to be addressed in future vaccine studies. Volunteers
who indicated that they had not had an episode of docu-
mented malaria in the past 5 years were included. They also
had malaria thick smears, and any subject who was positive
was excluded.
Screening for a+ and a0 a-thalassemia caused by deletions.
One milliliter (1 mL) of venous blood was collected in
EDTA tubes and stored at −80°C. The DNA was extracted
from 100 mL of whole blood with ZR Genomic DNA-Tissue
MiniPrep (ZymoResearch, Irvine, CA) according to manu-
facturer’s recommendations. We used primers to amplify the
alpha 2 globin gene as a control and the 3.7 kb, 4.2 kb, and
20.5 kb deletion junction fragments of the a-thalassemia
variants that could be easily identified by size as described.15
The multiplex polymerase chain reaction (PCR) primers
used were a 2/3.7del F, 3.7del/20.5del R, a2 R, 4.2del F,
4.2del R, and 20.5del F. The PCR reaction contained addi-
tionally 1 + Q-solution 2.5 U HotStarTaq DNA poly-
merase in supplied reaction buffer (Qiagen, Valencia, CA)
and 100 ng of genomic DNA. Reactions were carried out
on a thermal cycler (Gene Amp 2700, Applied Biosystems,
Foster City, CA), with an initial 15-minute denaturation at
96°C, 30 cycles of 98°C for 45 seconds, 60°C for 90 seconds,
72°C for 135 seconds, and a final extension at 72°C for
5 minutes. Following amplification, 10 mL of the product were
electrophoresed through a 1.5% agarose gel with 0.6 mg/mL
ethidium bromide in 1 + TBE buffer first at 7 volts/cm for
1 hour followed by 3 volts/cm for an additional 2 hours. The
gel was visualized on an UV transilluminator. The wild-type
aa/aa loci yielded a PCR product of 1,800 base pair (bp),
whereas the 3.7 kb deletion, 4.2 kb deletion and 20.5 kb
deletion resulted in PCR products of 2,029 bp, 1,628 bp,
and 1,007 bp, respectively.
Screening for a+ and a0 a-thalassemia caused by non-
deletion mutations. The three exons of each alpha 2 and
alpha 1 gene were amplified and sequenced to determine all
non-deletional mutations that cause a+ and a0 a-thalassemia.
Each 25 uL reaction contained 0.5 mM of each primer hem
alpha F, hem alpha 1 R, hem alpha 2 R, and also 1 +Q-solution
2.5 U HotStarTaq DNA polymerase in supplied reaction
buffer (Qiagen) and 100 ng of genomic DNA. Reactions
were carried out on a thermal cycler (Gene Amp 2700,
Applied Biosystems), with an initial 15-minute denaturation
at 95°C, 38 cycles of 95°C for 20 seconds, 60°C for 20 sec-
onds, 72°C for 90 seconds, and a final extension at 72°C
for 5 minutes. Following amplification, 5 mL of product was
electrophoresed through a 1.5% agarose gel with 0.6 mg/mL
ethidium bromide in 1 + TBE buffer at 7 volts/cm for 1 hour.
The gel was visualized on an UV transilluminator. Resulting
PCR products were purified with a QIAquick PCR Purifica-
tion Kit (Qiagen) and sequenced on both strands with the
Big Dye Terminator v3.1 sequencing kit on an ABI 3130XL
sequencer (Applied Biosystems). The Sequence reads were
aligned against reference genes for hemoglobin alpha 1
and 2 (NCBI Gene ID: 3039 and 3040, GRCh37.p10) and
polymorphisms were identified according to human dbSNP
(Build 137). Sequence analysis was done by the Geneious 6.1.5
software package.
All volunteers gave written informed consent before
screening and being enrolled in the study. The trial was
performed in accordance with Good Clinical Practices, an
Investigational New Drug (IND) application filed with the
U.S. Food and Drug Administration (US FDA) (IND 14267),
and an Investigational Medical Product Dossier (IMPD) filed
with the Tanzanian Food and Drug Administration (TFDA).
The protocol was approved by institutional review boards
(IRBs) of the Ifakara Health Institute ((IHI/IRB/No25) and
National Institute for Medical Research Tanzania (NIMR/
HQ/R.8a/Vol.IX/1217), and the Ethikkommission beider Basel
(EKBB), Basel, Switzerland (EKBB 319/11). The protocol
was also approved by TFDA (Ref. No. CE.57/180/04A/50), and
the trial was registered at ClinicalTrials.gov (NCT01540903).
Intervention and randomization. The intervention mate-
rial was aseptic, purified, cryopreserved PfSPZ (PfSPZ Chal-
lenge) isolated from salivary glands of aseptically reared
mosquitoes.16,17 Details regarding the production, cryopres-
ervation quality control, potency, and CHMI have been
described.11–13,18,19 The lot of PfSPZ Challenge used in this
study had been manufactured and then cryopreserved in
liquid nitrogen vapor phase (LNVP) 12 months before
administration. It was a different lot than the lot used in
the Netherlands12; however, it was the same lot that was
used in Oxford in which 5 of 6 volunteers who received
2,500 PfSPZ ID and 6 of 6 volunteers who received
25,000 PfSPZ IM developed malaria.13 The results of the
sporozoite membrane integrity (viability) and 6-day hepa-
tocyte potency assay (potency) were similar to those for
the previous trials (Supplemental Table 1).12,13
Thirty eligible volunteers were randomly allocated to
the experimental (PfSPZ Challenge) or control (normal
saline) groups. Twenty-four volunteers received PfSPZ Chal-
lenge and six received normal saline (BD Medical/Surgical, BD
Pre-filled Normal Saline Flush Syringe, Columbus, Nebraska).
The volunteers and clinicians were blinded as to whether the
volunteers received PfSPZ Challenge or normal saline.
CHMI. Administration of PfSPZ Challenge and immedi-
ate follow-up. PfSPZ Challenge was administered ID in
two different dose groups. Twelve volunteers were inocu-
lated with 10,000 PfSPZ ID in two injection sites, one
50 mL injection in each deltoid, each injection containing
5,000 PfSPZ. Twelve volunteers were inoculated with
25,000 PfSPZ ID in four injection sites, two 10 mL injections
in each deltoid, each injection containing 6,250 PfSPZ. Three
control volunteers were assigned to each of the two dose
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groups and were inoculated with normal saline in the same
way as those in that experimental group.
Immediately before use, a vial of PfSPZ Challenge was
thawed and diluted with phosphate buffered saline con-
taining human serum albumin in an aseptic environment. It
was then injected by a blinded nurse within 30 minutes
of thawing. After injection, volunteers were observed in the
injection room for at least 5 minutes and thereafter were
escorted by a nurse to the ward.
Diagnosis of malaria. Thick blood smears were obtained
every 12 hours on Days 5 through 14 after injection with
saline or PfSPZ Challenge and daily on Days 15 through
21 until positive or until Day 21. After initiation of treat-
ment of a positive thick smear, thick smears were assessed
until three consecutive daily smears were negative after treat-
ment. Thick smears were also assessed on Day 28 after CHMI.
Slide preparation and reading was performed following
a standard procedure. In brief, 10 mL of blood was placed
uniformly on a 10 mm + 20 mm area of the slide, air dried,
and stained with Giemsa, pH 7.2. Microscopes were cali-
brated and the number of passes/fields required to read
0.5 mL blood was determined. This amount of blood was
assessed for the primary reads to determine if the slide
was negative. If the volunteer was symptomatic, double this
amount of blood was read. A blood smear was declared
positive when one reader saw two parasites in 0.5 mL of
blood and the presence of parasites was independently
confirmed by a second reader. The pre-patent period was
defined as the period between inoculation of PfSPZ Chal-
lenge and appearance of the first positive blood smear.
Retrospectively, parasitemias were also determined by quan-
titative polymerase chain reaction (qPCR) performed on all
samples collected after CHMI, as previously described.20
Treatment of malaria. Those who became smear positive
were treated with a standard 3-day regimen of artemether/
lumefantrine (Coartem), and were discharged after three con-
secutive negative smear results. Those who did not become
positive during the first 21 days after CHMI were discharged
and returned on Day 28. On this day, the study was unblinded
and those who had received PfSPZ Challenge and had not
developed infection were treated with artemether/lumefantrine
(Coartem) irrespective of the blood smear results. All volun-
teers were seen on Days 56 and 168.
Assessment of adverse events. The volunteers were observed
in the ward for 24 hours after administration of PfSPZ Chal-
lenge and discharged to home. They were given diaries and
thermometers for recording of adverse events and tempera-
tures. Volunteers returned on Day 5 after administration of
PfSPZ Challenge for admission to the ward for assessment
of safety and diagnosis and treatment of malaria.
During the period of follow-up all symptoms and signs
(solicited and unsolicited) were recorded and graded by
the attending physician as follows: mild (easily tolerated),
moderate (interferes with normal activity), or severe (pre-
vents normal activity). Axillary temperature was recorded as
grade 1 (> 37.5–38.0°C), grade 2 (> 38.0–39.0°C), or grade 3
(> 39.0°C). Hematological and biochemical parameters
were assessed minimally on Days 5, 9, 12, 28, 56, and 168
after inoculation of PfSPZ Challenge, and on the day of
parasite positivity (day of initiating treatment). For those
individuals who did not become positive by thick blood smear,
these assays were also conducted on Days 15, 18, and 21 after
inoculation of PfSPZ Challenge. Results were graded accord-
ing to a predetermined table (Supplemental Table 2 adapted
from FDA guidelines, http://www.fda.gov/downloads/Biologics
BloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Vaccines/ucm091977.pdf). Adverse events were
divided into those that occurred during the 5 days after inocu-
lation of PfSPZ Challenge, and were attributed to the admin-
istration of the study product, and those that occurred from
Day 6 onward, and were attributed to Pf infection (malaria).
The possibility of cardiac damage was assessed, because
a cardiac-related serious adverse event (SAE) had been
reported in 2007 in the Netherlands in a volunteer who was
immunized with an experimental Pf subunit vaccine, under-
went CHMI by exposure to the bites of five Pf-infected
mosquitoes, developed malaria, and was treated with an anti-
malarial.21 In case symptoms or signs that could be related to a
cardiac event developed during the study, blood was collected
at baseline to be able to determine if there was any difference
in the results of assays used to assess cardiac damage (e.g.,
troponins) before the trial began and at the time of such
an event. We note that after our clinical trial in Tanzania,
another cardiac event occurred in a volunteer in a PfSPZ-
CVac vaccine trial in the Netherlands after CHMI by mos-
quito bite, diagnosis of malaria, and initiation of treatment.22
Genotyping of parasites. At the time of diagnosis and
before treatment 4 mL of blood were collected for geno-
typing by microsatellite analysis to determine if the para-
sites were derived from PfSPZ Challenge (Pf NF54) or from
a naturally acquired infection. The DNA was isolated from
blood specimens using the QIAamp DNA Blood Midi Kit
(Qiagen). Microsatellite markers Poly alpha, PfPK2, TA81,
ARA2, TA87, and TA40 were amplified using hemi-nested
PCR.23,24 Capillary electrophoresis was performed using an
Applied Biosystems 3730XL 96-capillary DNA sequencer
and software. Capillary electrophoresis output files were
analyzed using Genemapper 4.0 (Applied Biosystems). Geno-
mic control strains 3D7 and HB3 (ATCC-MR4, Manassas
VA) were included to determine characteristic peak mor-
phology for each microsatellite locus and control for slight
variations among runs. Microsatellite peaks above the
threshold of 100 relative fluorescent units exhibiting charac-
teristic morphology were scored. Peak sizes were deter-
mined by manual inspection of each electropherogram and
then normalized against the Pf 3D7 control. Normalized peak
sizes were compared with those observed in Pf NF54.
Statistical analysis. Data analysis was performed using
SAS software version 9.3 (SAS Institute Inc., Cary, NC).
Descriptive statistics were assessed, specifically the geometric
mean, for the parasitemia results. Thick blood smear and
qPCR results were compared between the 10,000 and 25,000
PfSPZ groups using a non-parametric test (Wilcoxon rank-
sum test, two-tailed). The effects of a-thalassemia hetero-
zygosity on parasitemia were compared within each group by
non-parametric tests (Wilcoxon rank-sum test, two-tailed).
Proportions were compared using c2 test (two-tailed).
RESULTS
Volunteers. In total 323 volunteers were recruited from
higher learning institutions during the first information
meeting. Out of these, 30 met eligibility criteria and were
enrolled and randomized to the 10,000 PfSPZ dose (N = 12),
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25,000 PfSPZ dose (N = 12), or control (N = 6) groups
(Figure 1 and Table 1). In groups 1, 2, and the control
group, 7, 1, and 2 volunteers were heterozygous for the
a-thalassemia trait, respectively.
Parasitemia. Thick blood smear. Eleven volunteers who
received 10,000 PfSPZ (Table 2A) and 10 volunteers who
received 25,000 PfSPZ (Table 2B) developed parasitemia
detected by thick blood smear and confirmed by qPCR.
One of the other two subjects in the 25,000 PfSPZ group
was treated for a false positive thick blood smear on
Day 11 (qPCR was negative), and was eliminated from the
analysis. The second other volunteer in the 25,000 PfSPZ
group was treated for a false positive thick blood smear on
Day 19; qPCR was negative throughout for this volunteer,
and this volunteer was considered to have not developed
parasitemia as no subject in the study developed parasitemia
by qPCR after Day 16, and this volunteer was followed by
qPCR through Day 19. Thus, 11 of 12 volunteers in the
10,000 PfSPZ group and 10 of 11 evaluable volunteers in the
25,000 PfSPZ group developed Pf parasitemia after ID injec-
tion of PfSPZ Challenge. Volunteers in the 10,000 PfSPZ
group had a significantly different pre-patent period than in
the 25,000 PfSPZ group (geometric mean [GM] of 15.4 and
13.5 days, Wilcoxon, P = 0.023). The GM parasite densities
were 8.9 and 7.0 parasites/mL blood, respectively, at the time
of first thick smear positivity.
qPCR. Parasitemia was determined by qPCR on all sam-
ples collected after CHMI. The qPCR was performed retro-
spectively, after volunteers had been diagnosed and treated.
The sensitivity of qPCR was considered to be 20 parasites/mL
of blood. The qPCRs were first positive 9.0 to 16.0 days after
inoculation of PfSPZ Challenge (Table 2). Consistent with
thick blood smear results, the volunteers in the 10,000 PfSPZ
group had a longer time to positive qPCR than those in the
25,000 PfSPZ group (GM of 12.6 and 11.1 days, respectively),
however the difference did not reach the level of statistical
significance (Wilcoxon, P = 0.076). The GM parasite densities
were 0.11 and 0.16 parasites/mL blood (110 and 160 parasites/
mL blood), respectively, at the time of first qPCR positivity.
The GM parasite densities by qPCR at the time of thick smear
diagnosis in the two groups were 4.1 and 1.6 parasites/mL,
respectively. qPCR was negative throughout the 21-day follow-
up for the slide-negative volunteer who received 10,000 PfSPZ,
and through Day 19 for the subject who received 25,000 PfSPZ
and was treated on Day 19. It was also negative in all normal
saline controls, except for one specimen on Day 19, which
was determined to be caused by mislabeling of a specimen
from a PfSPZ Challenge subject. Parasite growth was cyclical
and similar in both dose groups (Figure 2). Using a pre-
viously described method,25 the parasite multiplication rate
in the bloodstream could not be determined with confidence
because of the high variability of the amplification dynamics
among individual subjects. However, there did not appear to
Figure 1. Flow chart of recruitment and study design.
Table 1
Volunteer characteristics*
Control
(normal saline)
Group 1
(10,000 PfSPZ)
Group 2
(25,000 PfSPZ)
N = 6 N = 12 N = 12
Sex
Male 6 12 12
Age at screening (years)
Mean ± SD 25.7 ± 3.0 25.9 ± 1.6 24.6 ± 2.3
Median 25.2 25.5 24.5
Min, max 21.5, 30.9 24.3, 30.5 20.7, 27.2
BMI (kg/m2)
Mean ± SD 20.7 ± 2.4 21.7 ± 3 20.5 ± 2.3
Median 19.3 20.7 19.7
Min, max 19, 24 18.4, 27.9 17.3, 25.4
Height (cm)
Mean ± SD 168 ± 4.3 168.5 ± 8.2 171.7 ± 5.6
Median 166 169 172
Min, max 164, 174 158, 182 162, 179
Weight (kg)
Mean ± SD 58.4 ± 6.3 61.7 ± 9.8 60.5 ± 8.8
Median 58.3 60.8 60.5
Min, max 51, 66 47, 79 45.5, 81.5
*BMI = body mass index.
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be a significant difference between the replication rate in the
Tanzanians and the replication rate in the Dutch subjects.12
Parasite genotypes. Parasites from the positive volunteers
were genotyped at six polymorphic microsatellite loci to con-
firm that they were from PfSPZ Challenge (Pf NF54) and not
acquired by natural exposure to infected mosquitoes in the
Bagamoyo area. Parasites from all 21 volunteers had identi-
cal microsatellite signatures to Pf NF54 (Table 3), indicat-
ing that they were infected with the challenge strain and
not locally transmitted Pf parasites. Later, on Days 67 and
89 after CHMI, two volunteers developed Pf malaria. These
infections were also genotyped and both carried non-Pf
NF54 alleles at all six microsatellite loci (Table 3), indicat-
ing that they were infected with naturally acquired, locally
transmitted Pf parasites.
Effect of a-thalassemia heterozygosity on parasitemia. The
GM parasite density for volunteers who were heterozygous
for a-thalassemia and those who were non-a-thalassemic
in the 10,000 PfSPZ were not significantly different at the
time of detection of parasites by microscopy, 11.1 versus
6.9 Pf/mL blood, respectively (Wilcoxon, P = 0.5498) (Table 4).
The GM time to blood smear positivity (pre-patent period)
was also not significantly different between a-thalassemia
heterozygous and non- a-thalassemia volunteers, 15.4 and
15.4 days, respectively, in the 10,000 PfSPZ group (Wilcoxon,
P = 0.7922). In the 25,000 PfSPZ group, the parasite den-
sities at the time of detection of parasites by microscopy
was 4.0 parasites/mL blood in the one a-thalassemia hetero-
zygous volunteer and 7.4 parasites/mL blood (GM) in non-a-
thalassemia volunteers. The time to blood slide positivity in the
single a-thalassemia heterozygous subject was no different from
GM time to blood slide positivity in the non-a-thalassemia
subjects, 12.7 versus 13.6 days (Table 4).
Adverse events (AEs). Clinical adverse events.A summary
of the number of volunteers in each group with AEs during
the 28 days after injection of normal saline or PfSPZ Chal-
lenge is shown in Table 5. The occurrence of AEs was
similar in all groups. Most AEs recorded after administra-
tion of PfSPZ were consistent with symptoms and/or signs
associated with clinical malaria. Table 6 provides the total
number of AEs that occurred during Days 0–28 broken
down by Grade (1–3); 75% were Grade 1. Table 7 delineates
the specific solicited and unsolicited AEs that occurred
during Days 0–28 after injection of normal saline or PfSPZ
Challenge. There were 63 AEs in groups 2 (10,000 PfSPZ)
and 3 (25,000 PfSPZ) and only nine of the 63 AEs (14%)
occurred during the first 5 days after injection of PfSPZ
Challenge. There were no acute systemic allergic reactions
after the injection. The most common study-related events
were headache, malaise, fatigue, and arthralgia, all symp-
toms consistent with malaria. Surprisingly, saline control
subjects who did not have malaria had these symptoms
Table 2
A. Thick smear and qPCR results, group 1 (10,000 PfSPZ)
Volunteer code
Thick smear qPCR
Pre-patent
period (day)
Parasite density
at diagnosis (Pf/mL)
qPCR
positive (day)
Parasite density at
first day positive (Pf/mL)
Parasite density by qPCR at time
of diagnosis by thick smear (Pf/mL)
10002-20 18.6 5.0 16.0 0.24 0.01
10023-20 18.7 15.0 15.0 0.12 13.00
30035-20 18.7 5.0 14.0 0.04 11.00
40010-20 N/A N/A N/A N/A N/A
50041-20 14.6 4.0 13.0 0.36 3.00
60008-20 12.8 4.0 10.5 0.11 8.00
60026-20 12.7 11.0 11.5 0.21 9.00
70001-20 14.2 80.0 11.0 0.21 23.00
70014-20 15.8 21.0 12.5 0.03 83.00
70031-20 14.2 11.0 11.0 0.05 17.00
70044-20 17.6 6.0 15.0 0.07 6.00
90047-20 13.7 4.0 11.0 0.09 0.10
Geom. mean 15.4 8.9 12.6 0.11 4.10
No. of positives 11/12 11/12
B. Thick smear and qPCR results, group 2 (25,000 PfSPZ)
20056-20 18.7 5 16.0 0.13 14.00
20064-20 11.1 7 9.0 0.07 5.00
20070-20 12.6 13 9.5 0.07 5.00
30053-20 13.7 4 12.0 0.17 0.17
30060-20 13.5 7 11.0 1.00 0.40
40055-20 N/A N/A* N/A N/A N/A
40068-20 13.4 7 11.0 0.26 2.00
50050-20 12.7 7 10.0 0.04 10.00
50057-20 N/A N/A† N/A N/A N/A
60051-20 12.7 4 11.0 0.13 1.00
60072-20 14.0 7 11.5 0.17 1.00
80058-20 13.7 15 11.0 0.36 0.12
Geom. mean 13.5 7 11.1 0.16 1.60
No. of positives 10/11 10/11
*This volunteer was treated on Day 19 as a result of reporting of a positive thick blood smear. Review of this thick blood smear indicated that it was negative, and all qPCR results on
this volunteer were negative. Thus, this volunteer was considered as negative for Plasmodium falciparum infection for subsequent analyses, because no volunteers first became qPCR positive
on Day 19 or later.
†This volunteer was treated on Day 11 as a result of reporting of a positive thick blood smear. Review of this thick blood smear indicated it was negative, and all qPCR results on
this volunteer were negative. Thus, it is not known if this volunteer would have developed Plasmodium falciparum infection, and this volunteer has been excluded from the analysis. Thus,
11 volunteers were considered to be in this group, and 10 were documented to have developed P. falciparum parasitemia.
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at a frequency similar to that of subjects who received
PfSPZ Challenge.
Clinical serious adverse events (SAEs)—all unrelated.
There were two subjects who had unrelated SAEs in this
study. The first SAE was in a 26-year-old volunteer who
was diagnosed as having gastroenteritis/dysentery of grade 3
severity at the time of hospitalization, which was 33 days
post administration of PfSPZ Challenge. The second SAE
occurred in a 22-year-old volunteer who was admitted to
the hospital and diagnosed with severe malaria (axillary
temperature > 40°C, altered mental status, and smear posi-
tive) on day 89 after administration of PfSPZ Challenge (the
volunteer was previously treated and successfully cleared of
parasites on Day 14 post inoculation of PfSPZ Challenge).
Parasites taken from this volunteer at the time of diagno-
sis of severe malaria were genotyped using microsatellite
markers, and these parasites were shown not to be the Pf
NF54 parasites in PfSPZ Challenge (see above, and Table 3).
Both volunteers with SAEs recovered uneventfully.
Laboratory test abnormalities. Serum chemistries (glucose,
creatinine, aspartate aminotransferase [AST], alanine amino-
transferase [ALT], and bilirubin) and hematological parame-
ters (e.g., hemoglobin, white blood cell count, platelet count)
were assessed beginning on Day 5 after inoculation of normal
Figure 2. Parasite density as measured by qPCR in the 10,000 (A) and 25,000 (B) PfSPZ dose groups. Panels A (N = 11) and B (N = 10)
show individual and geometric mean parasite density (parasites/mL) of positive volunteers from day of inoculation through last day of
positivity after initiation of treatment. Panel C shows an overlay of geometric mean parasite densities with confidence intervals (95%) of
positive volunteers in each group (Black line = Group 1, 10,000 PfSPZ; Grey line = Group 2, 25,000 PfSPZ).* *For Panel B, the geometric
mean was calculated excluding the single volunteer who first became positive on Day 16.
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saline or PfSPZ Challenge. When assessed on Day 5 after
inoculation of normal saline and PfSPZ Challenge, labora-
tory abnormalities were infrequent and self-limited and simi-
lar in incidence rate among all three groups (Supplemental
Table 3). From Day 6 to Day 28 post inoculation the inci-
dence rate of abnormalities was slightly increased, but the
incidence rate of abnormalities was similar in normal saline
controls and those who received PfSPZ Challenge (Supple-
mental Table 3).
DISCUSSION
In this study, we showed for the first time that inoculation
of healthy, young adult, African males with aseptic, purified,
cryopreserved P. falciparum sporozoites, a product called
PfSPZ Challenge, was safe, well tolerated, and infective. In
fact, the infection rates in the Tanzanians were as good, if
not better than the infection rates in young adult Dutch
with no previous exposure to malaria.12
Eleven of 12 subjects who received 10,000 PfSPZ ID in
two divided 50 mL doses and 10 of 11 who received 25,000
PfSPZ ID in four divided 10 mL doses became parasitemic.
In the Netherlands, 5 of 6 who received 10,000 and 5 of 6
who received 25,000 PfSPZ ID in two divided 50 mL doses
became parasitemic.
However, the GM pre-patent period for the Tanzanians
who received the 10,000 PfSPZ dosage regimen was
15.4 days, and the GM pre-patent period for the Dutch
was 12.6 days (P = 0.0192, Wilcoxon 2-tailed). There are
multiple possible explanations for the prolonged pre-patent
period in the Tanzanians. One is that naturally acquired
immunity reduced the number of parasites that invaded or
fully developed in the liver, thereby reducing the numbers of
parasites that were released from the liver and prolonging
the pre-patent period. Another possibility is that the repli-
cation rate in the blood was reduced as a result of natu-
rally acquired immunity or innate resistance, and that this
reduced replication prolonged the pre-patent period. Unfor-
tunately, the variability in the qPCR results did not allow for
definitively determining if this was the case, but it appeared
Table 3
Microsatellite genotypes of Pf infections in volunteers after PfSPZ
Challenge
Strain or
sample ID
Microsatellite Loci*
TA81 Poly a PfPK2 TA40 ARA2 TA87
DNA controls HB3 131 178 190 205 61 103
3D7 122 148 166 220 64 94
NF54 122 148 166 220 64 94
Post-CHMI infections 7059065 122 148 166 220 64 94
8059066 122 148 166 220 64 94
9059067 122 148 166 220 64 94
2058376 122 148 166 220 64 94
3059070 122 148 166 220 64 94
4059071 122 148 166 220 64 94
5059072 122 148 166 220 64 –†
6059073 122 148 166 220 64 94
7059074 122 148 166 220 64 94
8059075 122 148 166 220 64 94
9059076 122 148 166 220 64 94
1059077 122 148 166 220 64 94
2059078 122 148 166 220 64 94
3059079 122 148 166 220 64 94
4059080 122 148 166 220 64 94
5059081 122 148 166 220 64 94
3059088 122 148 166 220 64 94
7059083 122 148 166 220 64 94
8059084 122 148 166 220 64 94
9059085 122 148 166 220 64 94
6059082 122 148 166 220 64 94
Subsequent infections 4155794 118 155 157 228 59 103
7060514 118 155 163 217 87 88
Gray shading indicates microsatellite alleles shared with NF54.
*Numbers represent microsatellite sizes in nucleotide base pairs, as determined by
capillary electrophoresis.
†Did not amplify.
Table 4
Pre-patent periods and parasite densities by microscopy by a-thalassemia status
Heterozygous Normal
Volunteer ID
Pre-patent
period (Days)
Parasite density
at diagnosis Volunteer ID
Pre-patent
period (Days)
Parasite density
at diagnosis
Group 1*
90047-20 13.74 4.0 50041-20 14.64 4.0
70001-20 14.11 80.0 60008-20 12.75 4.0
60026-20 12.71 11.0 70044-20 17.63 6.0
70014-20 15.76 21.0 70031-20 14.16 11.0
10002-20 18.64 5.0 10023-20 18.73 15.0
30035-20 18.66 5.0
Geom. mean 15.43 11.1 15.42 6.9
No. positive 6/7 5/5
Group 2*
60051-20 12.72 4.0 30053-20 13.72 4.0
80058-20 13.68 15.0
20056-20 18.67 5.0
40068-20 13.44 7.0
30060-20 13.47 7.0
50050-20 12.72 7.0
60072-20 14.04 7.0
20070-20 12.62 13.0
20064-20 11.05 7.0
Geom. mean 12.72 4.0 13.59 7.4
No. positive 1/1 9/10
*The proportion of volunteers who were heterozygous for a-thalassemia trait was higher in the 10,000 PfSPZ group than in the 25,000 PfSPZ group (chi-squared, 2-tailed, P = 0.011). There were
no statistically significant differences in infection rates, parasitemia, or parasites/mL blood between subjects heterozygous for a-thalassemia trait, and those who were not.
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that the replication rate was similar to the 11.5-fold replica-
tion rate every 48 hours seen in the Dutch volunteers.12
Thus, we do not know why the pre-patent period was
longer in the Tanzanians. However, because the replica-
tion rates seemed to be similar in the Dutch and Tanzanian
subjects, we think that there may have been fewer mero-
zoites released from the livers of the Tanzanians.
Interestingly, the GM pre-patent period in the group that
received 25,000 PfSPZ was significantly different (13.5 days)
than was the pre-patent period in the group that received
10,000 PfSPZ (15.4 days) (P = 0.023). This 2-day difference
can only partially be accounted for by increasing the numbers
of PfSPZ by 2.5-fold. It is likely that more efficient adminis-
tration of the PfSPZ contributed to the delay by increasing
the number of sites of administration from two to four and
decreasing the volume of the injections from 50 to 10 mL, as
we have seen in mice.14
Hemoglobinopathies, disorders of hemoglobin structure,
and production, are one of the most common monogenic
disorders in humans. a-thalassemia is a hemoglobinopathy
resulting from deletion of one (−a) or both (–) a genes from
chromosome 16. Its wide distribution in populations living
in places like Tanzania, where malaria has been or still is
present, has been hypothesized to result from protection
against severe or lethal malaria.26 This study was not
designed (i.e. powered) to be able to assess the differences in
infection rates, pre-patent periods, and parasite densities
between individuals with and without a-thalassemia trait.
Nonetheless, there was no indication of any differences
between those carrying this trait and those who did not
have it. This finding is consistent with a number of field
studies that showed that individuals who were heterozygous
or homozygous for a-thalassemia had similar rates of asymp-
tomatic parasitemia and similar manifestations of uncompli-
cated malaria as non-thalassemic individuals.27
Administration of PfSPZ Challenge was extremely well
tolerated. There were no serious adverse events. In fact,
the incidence rate of AEs was the same in the control group
that received normal saline as it was in the groups that
received PfSPZ Challenge (Tables 5–7). Very few of the
AEs occurred during the first 5 days after inoculation of
PfSPZ Challenge, and thus very few were attributed to the
injection of PfSPZ Challenge (Table 7). Most occurred
during the period when the volunteers were being diag-
nosed with Pf parasitemia and being treated. However, even
during this period the incidence rate was similar in the
control and experimental groups. One of the striking find-
ings was how few symptoms and signs attributable to Pf
parasitemia were experienced by the subjects who developed
malaria. In the Dutch study 9 of 18 volunteers reported fever,
whereas only 2 of 24 (P = 0.004, Fisher’s exact test, 2-tailed)
reported fever in this study. In the Netherlands 5 of
18 had chills, whereas in this study only 1 of 24 had chills
(P = 0.068).12 We assume this low level of symptoms and
signs was attributable to naturally acquired or innate immu-
nity, which ameliorated clinical manifestations.
A panel of six polymorphic microsatellite loci was success-
fully used to identify challenge strain (Pf NF54) infections
and differentiate them from naturally acquired P. falciparum
parasites circulating in Bagamoyo. This technique has been
previously shown to be highly effective at differentiating
genetic variants of P. falciparum within countries and across
Table 5
Number of volunteers with clinical adverse events, Days 0–28 post
injection*
Saline
control
(N = 6)
Group 1
(10,000 PfSPZ)
(N = 12)
Group 2
(25,000 PfSPZ)
(N = 12)
Adverse events
(no. of volunteers, %)
n (%) n (%) n (%)
Any adverse event 6 (100) 9 (75) 9 (75)
Serious adverse event 0 0 0
Solicited adverse event 6 (100) 9 (75) 9 (75)
Unsolicited adverse event 2 (33) 6 (50) 2 (17)
*A volunteer was counted at most once within each event type.
Table 6
Number of clinical adverse events, Days 0–28 post-injection
Saline
control
(N = 6)
Group 1
(10,000 PfSPZ)
(N = 12)
Group 2
(25,000 PfSPZ)
(N = 12)
Total number of AEs 22 42 42
Total solicited AEs
Grade 1 14 30 34
Grade 2 4 2 6
Grade 3 2* 1† 0
Total unsolicited AEs
Grade 1 2 8 1
Grade 2 0 0 1
Grade 3 0 1‡ 0
Total SAEs 0 0 0
An adverse event (AE) was recorded more than once if it resolved and subsequently
reappeared during the 28-day interval.
*Severe rash and pruritis (each grade 3) in a volunteer beginning 10 days post-injection.
†Severe headache attributable to controlled human malaria infection (CHMI).
‡Pharyngitis, etiology unclear, resolved after 3 days.
SAE = serious adverse event.
Table 7
Specific solicited and unsolicited adverse events, Days 0–28 post–
injection*
Adverse event
Saline
control
Group 1
10,000 PfSPZ
Group 2
25,000 PfSPZ
N = 6 N = 12 N = 12
Total AEs 21 (2) 30 (3) 34 (6)
Fever 0 0 2
Headache 6 (1) 7 7 (1)
Malaise 1 5 (1) 4
Fatigue 3 (1) 5 6 (2)
Myalgia 3 2 1
Arthralgia 3 2 4
Nausea and/or vomiting 0 0 0
Chills 0 0 1
Diarrhea 0 0 0
Constipation 0 1 0
Abdominal pain 1 0 1 (1)
Chest pain/discomfort 0 1 0
Palpitations 0 0 0
Shortness of breath 0 0 0
Dizziness 1 0 0
Erythema, swelling,
or pruritis at injection site
0 0 3 (2)
Rash or pruritus remote
to injection site
2 0 0
Itching throat 0 0 1
Loss of appetite 0 3 (1) 1
Pain on swallowing/pharyngitis 1 2 0
Back pain 0 1 (1) 0
Neck pain 0 1 0
Elevated axillary temp. 0 0 3
*A volunteer was counted at most once within each event type, even if the AE cleared
and reappeared. All AEs were considered either possibly or probably related to the injec-
tion of study product or malaria. Numbers in parentheses occurred within the first 5 days
after injection of study product.
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larger geographic regions.28–32 Here, we show that the assay
is also sensitive enough to generate reliable multi-locus geno-
types from infected blood with parasite densities as low as
five parasites/mL blood. Although microsatellites are useful
in identifying the infecting strain, they do not provide infor-
mation on genetic regions of vaccine-induced selection or
escape following heterologous challenge. Future studies will
include genome-wide characterization of breakthrough infec-
tions in PfSPZ Vaccine11,18,19 trials using DNA microarrays
and genome sequencing to assess cross-strain protection and
identify loci under vaccine-induced immune selection. This
approach may help to pinpoint the genetic regions encod-
ing the key antigens responsible for driving strain-specific
immune responses and inform the development of next-
generation multivalent whole organism vaccines in the event
that efficacy is found to be strain-specific.
In conclusion, we have established the foundation for
using CHMI with PfSPZ Challenge in Africans to establish
the efficacy of new interventions against malaria and to study
the mechanisms of protection conferred by hemoglobinopathies,
glucose 6 phosphate dehydrogenase deficiencies, and innate
and acquired immunity to malaria in settings where malaria
is endemic. Improvements in administration, such as direct
venous inoculation (DVI) (Mordmueller B, submitted), will
soon be used in Bagamoyo in CHMI studies to assess the
protective efficacy of the PfSPZ Vaccine19 in Tanzanians.
Received February 26, 2014. Accepted for publication May 25, 2014.
Published online July 28, 2014.
Note: Supplemental tables appear at www.ajtmh.org.
Acknowledgments: We thank all volunteers and staff of the Ifakara
Health Institute, Bagamoyo Research and Training Centre, Sanaria
Inc., and Swiss Tropical and Public Health Institute who contributed
so much to this project. Special thanks to Yonas Abebe, Alexander
Hoffman, Thomas L. Richie, and Robert C. Thompson of Sanaria
for editorial, legal, and administrative support, and the Sanaria
manufacturing, quality control, regulatory, and clinical teams. We
thank Rose Minja, Hery Mwandolela, and Ally Mtoro for safety
review of volunteers during the trial and pharmacist Abel Mdemu
for verification of formulation. We appreciate the advice of Barney
Graham, David Diemert, and Zulfiqarali Premji, members of the
Safety Monitoring Committee.
Financial support: The Tanzanian Commission on Science and Tech-
nology (COSTECH), the Ifakara Health Institute, and the Swiss
Tropical Public Health Institute provided funding for this clinical trial.
The development, manufacturing, and quality control release and
stability studies of PfSPZ Challenge were supported in part by an
NIAID Small Business Innovation Research grant, 5R44AI058375.
Disclosure: Sanaria Inc. manufactured PfSPZ Challenge, and Protein
Potential LLC is affiliated with Sanaria. Thus, all authors associated
with Sanaria or Protein Potential have potential conflicts of interest.
There are no other conflicts of interest.
Authors’ addresses: Seif Shekalaghe, Mastidia Rutaihwa, Mwajuma
Chemba, Maximillian Mpina, Omar Ali Juma, Beatus Simon, Omar
Lweno, Paul Mutani, Ali Hamad, Ali Mohammed, Alwisa Urassa,
Tutu Mzee, and Salim Abdulla, Ifakara Health Institute, Bagamoyo
Research and Training Centre, Bagamoyo, Tanzania, E-mails:
sshekalaghe@ihi.or.tz, mrutaihwa@ihi.or.tz, mchemba@ihi.or.tz,
Ojuma@ihi.or.tz, bbongole@ihi.or.tz, mmpina@ihi.or.tz, olweno@ihi
.or.tz, pmutani@ihi.or.tz, ahamad@ihi.or.tz, amohammed@ihi.or.tz,
aurassa@ihi.or.tz, tmzee@ihi.or.tz, and sabdulla@ihi.or.tz. Peter F.
Billingsley, Eric R. James, Anusha Gunasekera, AnitaManoj, Elizabeth
Saverino, Debbie Padilla, Adam Ruben, and Stephen L. Hoffman,
Sanaria Inc., Rockville, MD, E-mails: pbillingsley@sanaria.com,
ejames@sanaria.com, agunasekera@sanaria.com, amanoj@sanaria
.com, esaverino@sanaria.com, dpadilla@sanaria.com, aruben@sanaria
.com, and slhoffman@sanaria.com. Claudia A. Daubenberger, Tobias
Schindler, and Maximillian Mpina, Department of Medical Parasi-
tology and Infection Biology, Swiss Tropical and Public Health Insti-
tute, Basel, Switzerland, and University of Basel, Basel, Switzerland,
E-mails: Claudia.Daubenberger@unibas.ch, Tobias.Schindler@stud
.unibas.ch, and Max.Mpina@hotmail.com. Eric Huber, Department
of Medicines Research, Swiss Tropical and Public Health Institute,
Basel, Switzerland, E-mail: Eric.Huber@unibas.ch. L. W. Preston
Church, Hospital Epidemiologist and Head Division of Infectious
Diseases VA Hospital, Charleston, SC, E-mail: lwpchurch@sanaria
.com. Cornelus C. Hermsen and Robert W. Sauerwein, Radboud Uni-
versity Nijmegen Medical Center, Department of Medical Micro-
biology, Nijmegen, The Netherlands, E-mails: R.Hermsen@ncmls.ru.nl
and R.Sauerwein@mmb.umcn.nl. Christopher Plowe and Meera
Venkatesan, Howard Hughes Medical Institute and University of
Maryland Center for Vaccine Development, Baltimore, MD, E-mails:
cplowe@medicine.umaryland.edu and mvenkate@medicine.umaryland
.edu. Philip Sasi, Muhimbili University of Health and Allied Sci-
ences, Dar es Salaam, Tanzania, E-mail: philip.sasi@gmail.com. B.
Kim Lee Sim, Sanaria Inc., and Protein Potential LLC, Rockville,
MD, E-mail: ksim@protpot.com. Marcel Tanner, Department of Epi-
demiology and Public Health, Swiss Tropical and Public Health Insti-
tute, Basel, Switzerland, and University of Basel, Basel, Switzerland,
E-mail: Marcel.Tanner@unibas.ch.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited.
REFERENCES
1. Mayne B, 1933. The injection of mosquito sporozoites in malaria
therapy. Public Health Rep 48: 909–913.
2. Mayne B, Young M, 1941. The technique of induced malaria
as used in the South Carolina State Hospital. J Vener Dis Inf
22: 271–276.
3. Boyd MF, 1949. Malariology: A Comprehensive Survey of All
Aspects of This Group of Diseases from a Global Standpoint.
Philadelphia, PA: W. B. Saunders.
4. Ifediba T, Vanderberg JP, 1981. Complete in vitro maturation
of Plasmodium falciparum gametocytes. Nature 294: 364–366.
5. Campbell CC, Collins WE, Nguyen Dinh P, Barber A, Broderson
JR, 1982. Plasmodium falciparum gametocytes from culture
in vitro develop to sporozoites that are infectious to primates.
Science 217: 1048–1050.
6. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR,
Quakyi IA, Carter R, Trosper JH, Hockmeyer WT, 1986.
Malaria transmitted to humans by mosquitoes infected from
cultured Plasmodium falciparum. Am J Trop Med Hyg 35:
66–68.
7. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries
L, Davis JR, Herrington DA, Clyde DF, Shmuklarsky MJ,
Schneider I, McGovern TW, Chulay JD, Ballou WR,
Hoffman SL, 1997. Clinical manifestations of Plasmodium
falciparum malaria experimentally induced by mosquito
challenge. J Infect Dis 175: 915–920.
8. Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M,
de la Vega P, Sacci J, Richie TL, Hoffman SL, 2007. Safety
and clinical outcome of experimental challenge of human
volunteers with Plasmodium falciparum-infected mosquitoes:
an update. J Infect Dis 196: 145–154.
9. Roestenberg M, O’Hara GA, Duncan CJ, Epstein JE, Edwards
NJ, Scholzen A, van der Ven AJ, Hermsen CC, Hill AV,
Sauerwein RW, 2012. Comparison of clinical and parasito-
logical data from controlled human malaria infection trials.
PLoS ONE 7: e38434.
10. Laurens MB, Duncan CJ, Epstein JE, Hill AV, Komisar JL,
Lyke KE, Ockenhouse CF, Richie TL, Roestenberg M,
Sauerwein RW, Spring MD, Talley AK, Moorthy VS, 2012.
A consultation on the optimization of controlled human
malaria infection by mosquito bite for evaluation of candi-
date malaria vaccines. Vaccine 30: 5302–5304.
11. Hoffman SL, Billingsley P, James E, Richman A, Loyevsky M,
Li T, Charkravarty S, Gunasekera A, Chattopadhyay R, Li
INJECTION OF TANZANIANS WITH P. FALCIPARUM SPOROZOITES 479
Page 114 of 222
M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes
S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe
CV, Sim BKL, 2010. Development of a metabolically active,
non-replicating sporozoite vaccine to prevent Plasmodium
falciparum malaria. Hum Vaccin 6: 97–106.
12. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER,
Bastiaens GJ, Teirlinck AC, Scholzen A, Teelen K, Arens T,
van der Ven AJ, Gunasekera A, Chakravarty S, Velmurugan
S, Hermsen CC, Sauerwein RW, Hoffman SL, 2013. Con-
trolled human malaria infections by intradermal injection
of cryopreserved Plasmodium falciparum sporozoites. Am J
Trop Med Hyg 88: 5–13.
13. Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ,
Edwards NJ, Poulton ID, Kimani D, Williams AR, Anagnostou
NA, Roberts R, Kerridge S, Voysey M, James ER, Billingsley
PF, Gunasekera A, Lawrie AM, Hoffman SL, Hill AV, 2013.
Optimizing controlled human malaria infection studies using
cryopreserved parasites administered by needle and syringe.
PLoS ONE 8: e65960.
14. Ploemen IH, Chakravarty S, van Gemert GJ, Annoura T, Khan
SM, Janse CJ, Hermsen CC, Hoffman SL, Sauerwein RW,
2013. Plasmodium liver load following parenteral sporozoite
administration in rodents. Vaccine 31: 3410–3416.
15. Tan AS, Quah TC, Low PS, Chong SS, 2001. A rapid and reli-
able 7-deletion multiplex polymerase chain reaction assay for
alpha-thalassemia. Blood 98: 250–251.
16. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A,
Loyevsky M, Chakravarty S, Plowe CV, Sim BK, Edelman R,
Hoffman SL, 2010. Plasmodium falciparum malaria challenge
by the bite of aseptic Anopheles stephensi mosquitoes: results
of a randomized infectivity trial. PLoS ONE 5: e13490.
17. Laurens MB, Billingsley P, Richman A, Eappen AG, Adams
M, Li T, Chakravarty S, Gunasekera A, Jacob CG, Sim
BK, Edelman R, Plowe CV, Hoffman SL, Lyke KE, 2013.
Successful human infection with P. falciparum using three
aseptic Anopheles stephensi mosquitoes: a new model for
controlled human malaria infection. PLoS ONE 8: e68969.
18. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens
MB, Gunasekera A, Chakravarty S, James ER, Sedegah M,
Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada
A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C,
Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas
N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R,
Richie TL, Seder RA, Hoffman SL, 2011. Live attenuated
malaria vaccine designed to protect through hepatic CD8+T
cell immunity. Science 334: 475–480.
19. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN,
Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera
A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M,
Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH,
Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders
JG, Nason MC, Richardson JH, Murphy J, Davidson SA,
Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke
KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim
BK, Ledgerwood JE, Graham BS, Hoffman SL, for the VRC
312 Study Team, 2013. Protection against malaria by intra-
venous immunization with a nonreplicating sporozoite vaccine.
Science 341: 1359–1365.
20. Adegnika AA, Verweij JJ, Agnandji ST, Chai SK, Breitling
LP, Ramharter M, Frolich M, Issifou S, Kremsner PG,
Yazdanbakhsh M, 2006. Microscopic and sub-microscopic
Plasmodium falciparum infection, but not inflammation caused
by infection, is associated with low birth weight. Am J Trop
Med Hyg 75: 798–803.
21. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G,
Stalenhoef A, Druilhe P, Sauerwein R, van der Ven A, 2009.
Cardiac complication after experimental human malaria
infection: a case report.Malar J 8: 277.
22. van Meer MP, Bastiaens GJ, Boulaksil M, de Mast Q, Gunasekera
A, Hoffman SL, Pop G, van der Ven AJ, Sauerwein RW, 2014.
Idiopathic acute myocarditis during treatment for controlled
human malaria infection: a case report.Malar J 13: 38.
23. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP,
1999. Twelve microsatellite markers for characterization
of Plasmodium falciparum from finger-prick blood samples.
Parasitology 119: 113–125.
24. Shaukat AM, Gilliams EA, Kenefic LJ, Laurens MB,
Dzinjalamala FK, Nyirenda OM, Thesing PC, Jacob CG,
Molyneux ME, Taylor TE, Plowe CV, Laufer MK, 2012.
Clinical manifestations of new versus recrudescent malaria
infections following anti-malarial drug treatment. Malar J
11: 207.
25. Roestenberg M, de Vlas SJ, Nieman AE, Sauerwein RW,
Hermsen CC, 2012. Efficacy of preerythrocytic and blood-
stage malaria vaccines can be assessed in small sporozoite
challenge trials in human volunteers. J Infect Dis 206: 319–323.
26. Harteveld CL, Higgs DR, 2010. Alpha-thalassaemia. Orphanet
J Rare Dis 5: 13.
27. Taylor SM, Parobek CM, Fairhurst RM, 2012. Hemoglobinopa-
thies and the clinical epidemiology of malaria: a systematic
review and meta-analysis. Lancet Infect Dis 12: 457–468.
28. Baliraine FN, Afrane YA, Amenya DA, Bonizzoni M, Vardo-
Zalik AM, Menge DM, Githeko AK, Yan G, 2010. A
cohort study of Plasmodium falciparum infection dynamics
in Western Kenya Highlands. BMC Infect Dis 10: 283.
29. Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, Nale J,
Kiniboro B, Buckee CO, Tavul L, Siba PM, Reeder JC, Barry
AE, 2010. Multilocus haplotypes reveal variable levels of
diversity and population structure of Plasmodium falciparum
in Papua New Guinea, a region of intense perennial trans-
mission.Malar J 9: 336.
30. Griffing SM, Mixson-Hayden T, Sridaran S, Alam MT,
McCollum AM, Cabezas C, Marquino Quezada W, Barnwell
JW, De Oliveira AM, Lucas C, Arrospide N, Escalante AA,
Bacon DJ, Udhayakumar V, 2011. South American Plasmodium
falciparum after the malaria eradication era: clonal popula-
tion expansion and survival of the fittest hybrids. PLoS ONE
6: e23486.
31. Mobegi VA, Loua KM, Ahouidi AD, Satoguina J, Nwakanma
DC, Amambua-Ngwa A, Conway DJ, 2012. Population genetic
structure of Plasmodium falciparum across a region of diverse
endemicity in West Africa.Malar J 11: 223.
32. Yalcindag E, Elguero E, Arnathau C, Durand P, Akiana J,
Anderson TJ, Aubouy A, Balloux F, Besnard P, Bogreau
H, Carnevale P, D’Alessandro U, Fontenille D, Gamboa
D, Jombart T, Le Mire J, Leroy E, Maestre A, Mayxay M,
Menard D, Musset L, Newton PN, Nkoghe D, Noya O,
Ollomo B, Rogier C, Veron V, Wide A, Zakeri S, Carme
B, Legrand E, Chevillon C, Ayala FJ, Renaud F, Prugnolle
F, 2012. Multiple independent introductions of Plasmodium
falciparum in South America. Proc Natl Acad Sci USA 109:
511–516.
480 SHEKALAGHE AND OTHERS
Page 115 of 222
Supplemental Table 1
Results of potency and sporozoite membrane integrity assays (SMIA) on the lot of PfSPZ Challenge used in the clinical trial in Bagamoyo,
Tanzania*
Time point
Potency
(no. of parasites expressing PfMSP-1/well)
% Viability
(sporozoite membrane integrity assay)
Fresh 32.7 ± 1.5 98.2%
Release 29.3 ± 3.1 87.4% ± 5.9%
3 Month 27.3 ± 0.6 84.6% ± 1.9%
6 Month 26.7 ± 1.5 83.6% ± 5.5%
Post-last clinical dose–Oxford13 9 Month 26.3 ± 2.5 86.3% ± 6.5%
12 Month 27.3 ± 0.6 86.2% ± 1.3%
Post-last clinical dose–Tanzania (18 month) 24.0 ± 1.7 81.7% ± 2.6%
*Fresh PfSPZ used for the lot of PfSPZ Challenge used in this clinical trial produced 10% more PfMSP-1-expressing parasites in this assay than did PfSPZ that had been cryopreserved
for several days (Release). At 18 months, several weeks after inoculation of the last volunteers in Bagamoyo, the PfSPZ had a 27% reduction in potency by this assay as compared with
fresh PfSPZ. There was an 11% reduction in the results of the sporozoite membrane integrity of cryopreserved PfSPZ at the time of Release, as compared with fresh PfSPZ. At 18 months,
several weeks after inoculation of the last volunteers in Bagamoyo, the PfSPZ had a 17% reduction in the SMIA as compared with fresh PfSPZ.
Supplemental Table 2
Normal ranges at BRTC Laboratory and corresponding modified FDA Guidelines for toxicity grading*
Test Normal Range Grade 1 Grade 2 Grade 3 Grade 4
Sodium (meq/l)–hypernatremia 136–146 N/A 146–147 148–150 > 150
Sodium (meq/l)– hyponatremia 132–135 130–131 125–129 < 125
Potassium (meq/l)– hyperkalemia 3.5–5 5.1–5.2 5.3–5.4 5.5–5.6 > 5.6
Potassium (meq/l)– hypokalemia N/A 3.3–3.4 3.1–3.2 < 3.1
Creatinine (mmol/L) 53–106 107–150 151–177 178–221 > 221 or requires dialysis
Glucose (mmol/L)–hyperglycemia 3.89–6.0 6.01–6.94 6.95–11.1 > 11.1
Glucose (mmol/L)– hypoglycemia 3.61–3.88 3.05–3.60 2.50–3.04 < 2.50
AST (U/L) 5–34 1.1–2.5 + ULN 2.6–5 + ULN 5.1–10 + ULN >10 + ULN
ALT (U/L) 0–55 1.1–2.5 + ULN 2.6–5 + ULN 5.1–10 + ULN >10 + ULN
Bilirubin (mmol/L) 0–6.1 1.1–1.5 + ULN 1.6–2.0 + ULN 2.0–3.0 + ULN > 3.0 + ULN
Total white blood count + 1,000/mL 3.2–11.7 2.5–3.1 1.5–2.5 1.0–1.5 < 1.0
Neutrophil count + 1,000/mL 2.0–6.9 1.5–1.999 1.0–1.499 0.500–0.999 < 0.500
Lymphocyte count + 1,000/mL 0.87–3.19 0.750–0.869 0.500–0.749 0.250–0.499 < 0.250
Eosinophil count + 1,000/ mL 0–0.7 0.701–1.5 1.501–5.0 > 5.0
Hemoglobin (g/L) 12.9–18.3 12.5–13.5 10.5–12.4 8.5–10.4 < 8.5
Platelets + 1,000/mL 146–345 125–145 100–124 25–99 < 25
*Guidance for Industry - Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials – 2007 (http://www.fda.gov/downloads/
BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf). AST = aspartate aminotransferase; ALT = alanine aminotransferase; ULN =
upper limit of normal.
Supplemental Table 3
Laboratory abnormalities that developed after administration of normal saline or PfSPZ Challenge from Day 5 through Day 28 post inoculation
Normal saline controls
(N = 6)
1st day AE noted*
(maximum Grade)†
10,000 PfSPZ
(N = 12)
1st day AE noted
(maximum Grade)*
25,000 PfSPZ
(N = 12)
1st day AE noted
(maximum Grade)*
Increased AST 6 (2), 14 (2) 9 (1), 9 (2), 12 (1), 12 (2) 5 (3), 14 (3), 15 (1), 18 (2)
Increased ALT 14 (3), 15 (1) 9 (2), 12 (1) 5 (2), 14 (2), 15 (1)
Increased Bilirubin 9 (2)
Increased Creatinine 18 (1)
Hypoglycemia 5 (2), 28 (1) 15 (1) and 19 (1), 15 (1), 15 (1) 5 (2) and 12 (3)
Hyperglycemia 5 (2) 5 (2), 15 (1) 5 (1), 5 (2), 11 (1), 13 (2), 13 (2), 19 (2)
Leukopenia 18 (1)
Leukocytosis 14 (1)
Neutropenia 5 (1) and 18 (1), 6 (1) and 28 (2),
9 (2), 27 (1)
5 (2), 5 (2), 9 (1), 12 (1) and
18 (1), 12 (1), 27 (1), 28 (1)
5 (2), 12 (1), 27 (2)
Lymphopenia 21 (1) 15 (1), 18 (2) 14 (1), 14 (3), 15 (1)
Eosinophilia 5 (1)
Anemia 28 (1), 28 (1) 11 (1), 15 (2)
Thrombocytopenia 6 (1) 5 (2) and 12 (2), 9 (2), 13 (3), 18 (1) 15 (1)
Proteinuria 5 (3), 5 (2), 12 (2), 12 (2), 28 (3) 5 (2), 9 (2)
Hematuria 28 (2)
*Each entry represents a specific, different laboratory abnormality.
†For those designated “and”, the abnormality occurred, resolved, and recurred.
AE = adverse event; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
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Impact of Malaria Preexposure on Antiparasite Cellular and Humoral
Immune Responses after Controlled Human Malaria Infection
Joshua M. Obiero,a* Seif Shekalaghe,b Cornelus C. Hermsen,a Maxmillian Mpina,b Else M. Bijker,a Meta Roestenberg,a*
Karina Teelen,a Peter F. Billingsley,c B. Kim Lee Sim,c Eric R. James,c Claudia A. Daubenberger,d,e Stephen L. Hoffman,c
Salim Abdulla,b Robert W. Sauerwein,a Anja Scholzena
Radboud University Medical Center, Department of Medical Microbiology, Nijmegen, The Netherlandsa; Ifakara Health Institute, Bagamoyo Research and Training Center,
Bagamoyo, Tanzaniab; Sanaria Inc., Rockville, Maryland, USAc; Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Basel,
Switzerlandd; University of Basel, Basel, Switzerlande
To understand the effect of previous malaria exposure on antiparasite immune responses is important for developing successful
immunization strategies. Controlled human malaria infections (CHMIs) using cryopreserved Plasmodium falciparum sporozo-
ites provide a unique opportunity to study differences in acquisition or recall of antimalaria immune responses in individuals
from different transmission settings and genetic backgrounds. In this study, we compared antiparasite humoral and cellular im-
mune responses in two cohorts of malaria-naive Dutch volunteers and Tanzanians from an area of lowmalarial endemicity, who
were subjected to the identical CHMI protocol by intradermal injection of P. falciparum sporozoites. Samples from both trials
were analyzed in parallel in a single center to ensure direct comparability of immunological outcomes. Within the Tanzanian
cohort, we distinguished one group with moderate levels of preexisting antibodies to asexual P. falciparum lysate and another
that, based on P. falciparum serology, resembled the malaria-naive Dutch cohort. Positive P. falciparum serology at baseline
was associated with a lower parasite density at first detection by quantitative PCR (qPCR) after CHMI than that for Tanzanian
volunteers with negative serology. Post-CHMI, both Tanzanian groups showed a stronger increase in anti-P. falciparum anti-
body titers than Dutch volunteers, indicating similar levels of B-cell memory independent of serology. In contrast to the Dutch,
Tanzanians failed to increase P. falciparum-specific in vitro recall gamma interferon (IFN-!) production after CHMI, and in-
nate IFN-! responses were lower in P. falciparum lysate-seropositive individuals than in seronegative individuals. In conclu-
sion, positive P. falciparum lysate serology can be used to identify individuals with better parasite control but weaker IFN-! re-
sponses in circulating lymphocytes, whichmayhelp to stratify volunteers in futureCHMI trials in areaswheremalaria is endemic.
In 2012, Plasmodium falciparummalaria caused an estimated 207million cases and 627,000 deaths, of which 90% occurred in
children under 5 years of age and in pregnant women in sub-
Saharan Africa (1). Major control efforts have been implemented
with some success (2, 3), butmalaria eradicationwill likely require
a safe and highly protective vaccine. Subunit vaccines have thus far
shown moderate efficacy at best. RTS,S is the only vaccine candi-
date in phase 3 trials but, despite averting substantial numbers of
malaria cases (4), shows only 30 to 50% reduction in clinical dis-
ease after 12months depending on both age andmalaria endemic-
ity and even less after 18 months (5–7). These results stress the
need for more effective second-generation vaccines. Key require-
ments are not only the identification of novel immunogens but
also a better understanding of protection-related immune re-
sponses. This includes the effect of previous malaria exposure on
immune responses upon reexposure or vaccination (8, 9).
During the past 3 decades, controlled humanmalaria infection
(CHMI) trials have become an indispensable tool not only in as-
sessing the efficacy of candidate vaccines (10, 11) but also in eval-
uating immune responses induced by exposure to themalaria par-
asite (12–15). CHMI trials have so far been performed in countries
were malaria is not endemic in previously unexposed individuals
(11, 16–19). A logical next step is to study the potential differences
in the acquisition, maintenance, or recall of immune responses in
individuals from different transmission settings and genetic back-
grounds (20, 21). The availability of aseptic, purified, cryopre-
served, live P. falciparum sporozoites (PfSPZs; PfSPZ Challenge)
(22) opens up opportunities to carry out CHMI trials in countries
where malaria is endemic, since it bypasses the need for infecting
local Anopheles mosquitoes with P. falciparum or importing P.
falciparum-infected mosquitoes to the trial site. The first PfSPZ
Challenge trial in malaria-naive Dutch volunteers demonstrated
an infectivity rate of 83% after intradermal injections, indepen-
dent of the dose given (23). Recently, PfSPZ Challenge was used
for the first time during a CHMI trial in healthy adult male Tan-
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zanian volunteers, resulting in similar infection rates (24). As a
follow-up, we here present results of themalaria-specific humoral
and cellular immune responses in Tanzanians and Dutch volun-
teers who were inoculated intradermally with the same number of
live PfSPZs during these CHMI studies.
MATERIALS AND METHODS
Human ethics statement. The Dutch trial (23) was approved by the Cen-
tral Committee for Research Involving Human Subjects of The Nether-
lands (NL31858.091.10) and registered at Clinicaltrials.gov, identifier
NCT 01086917. The Tanzanian trial (24) was approved by institutional
review boards of the Ifakara Health Institute (IHI/IRB/No25), the Na-
tional Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/
1217), the Ethikkommission beider Basel (EKBB), Basel, Switzerland
(EKBB 319/11), and the Tanzanian Food and Drug Administration (ref-
erence no. CE.57/180/04A/50) and registered at Clinicaltrials.gov, identi-
fier NCT 01540903. All study teams complied with the Declaration of
Helsinki and good clinical practice, including monitoring of data, and all
volunteers gave written informed consent.
Clinical trial design. Samples for immunological analysis were ob-
tained from two CHMI trials (23, 24).
The first trial, performed at Radboud University Medical Center, Ni-
jmegen, The Netherlands, was composed of 18 healthy Dutch subjects
between the ages of 19 and 30 years with no history of malaria. Any vol-
unteer who was positive for P. falciparum serology or had resided in an
area wheremalaria is endemic within the previous 6months was excluded
from the trial. Three groups (n! 6 per group) were infected by intrader-
mal injections of 2,500, 10,000, or 25,000 cryopreserved PfSPZs (NF54
strain). By day 21, 15/18 volunteers had developed parasites detectable by
positive blood thick smear (TS), 5/6 in each group (23). There were no
differences in parasite densities at diagnosis between the three dose groups
(23). For immunological analysis, nine P. falciparum-positive volunteers
of the 10,000 (n! 4) and 25,000 (n! 5) PfSPZ dose groups were selected
based on availability of plasma and peripheral blood mononuclear cells
(PBMCs).
The second trial was carried out in Bagamoyo, Tanzania, with volun-
teers residing in Dar es Salaam (an area where malaria is hypoendemic).
Twenty-four males between 20 to 35 years of age were enrolled and con-
firmed to be free of parasites by real-time quantitative PCR (qPCR). Sub-
jects with a self-reported history of clinical malaria in the previous 5 years
were excluded. The volunteers were divided into two groups with 12 vol-
unteers per group and infected by intradermal injections of either 10,000
or 25,000 PfSPZs (NF54 strain). A total of 21/24 became both qPCR and
blood smear positive by day 21 after infection (24). The three P. falci-
parum-negative volunteers were excluded from analysis in the present
study.
PBMCs, citrate anticoagulated plasma samples from Dutch volun-
teers, and serum samples from Tanzanian volunteers were collected and
cryopreserved 1 day before challenge (pre-CHMI) and after treatment
(post-CHMI; day 35 and day 28 after infection).
DNA extraction and qPCR analysis. A total of 5 "l Zap-Oglobin II
lytic reagent (BeckmanCoulter) was added to 500"l of EDTAblood, after
which the samples were mixed and stored at#80°C.
DNA extraction and quantification of parasitemia by qPCR in the
Dutch CHMI trial were performed in Nijmegen as described previously
(25), with slightmodifications. Briefly, after thawing, samples were spiked
with murine white blood cells as an extraction control, and DNA was
extracted with a MagnaPure LC isolation station. For detection of the
extraction control and P. falciparum, primers for the murine albumin
gene and P. falciparum 18R rRNA were used as described previously (25).
Additionally, the P. falciparum 18R rRNATaqManMGBprobe AACAAT
TGG AGG GCA AG–6-carboxyfluorescein (FAM) was used.
DNA extraction and qPCR in the Tanzanian trial were carried out at
the Leiden University Medical Center, Leiden, The Netherlands, as de-
scribed previously (26). Phocine herpesvirus 1 (PhHV-1)was added to the
isolation lysis buffer to serve as an internal control. For quantification of
PhHV, the primers GGGCGAATCACAGATTGAATC and GCGGTTCC
AAACGTACCAAand the probeCy5-TTTTTATGTGTCCGCCACCATC
TGGATC were used.
P. falciparum (NF54 strain) standard curves for both qPCRassayswere
prepared in Nijmegen by titration of ring-stage-infected red blood cells
(RBC) in uninfected human blood. The two qPCR assays in both sites
were confirmed to yield the same results when quantifying the P. falcipa-
rum content in sequential samples from four CHMI volunteers.
Parasite material for immunological analysis. The P. falciparum
NF54 strain used in both CHMI trials is the parental strain of the 3D7
clone (27). P. falciparum (NF54 strain) blood-stage parasites were cul-
tured in RPMI 1640 containing 10% human A$ serum and a 5% hemat-
ocrit erythrocyte suspension in a semiautomated culture system and reg-
ularly screened for mycoplasma contamination. For in vitro stimulation
assays, asynchronous parasites harvested at a parasitemia of approxi-
mately 10 to 20%were purified by centrifugation on a 63%Percoll density
gradient to obtain mature asexual stages. This resulted in concentrations
of parasitemia levels of about 80 to 90%, consisting of more than 95%
schizonts/mature trophozoites.P. falciparum-infectedRBC (PfRBC)were
washed twice in RPMI, cryopreserved in glycerol-containing freeze me-
dium, and used upon thawing in stimulation assays. Mock-cultured unin-
fected erythrocytes (uRBC)were obtained similarly and served as the control.
P. falciparum lysate for enzyme-linked immunosorbent assay (ELISA)
was prepared by extracting purified schizonts/mature trophozoites with
1% sodium desoxycholate and 2.5 "l phenylmethanesulfonyl fluoride
protease inhibitor for 15 min at room temperature (RT).
Recombinant and synthetic proteins. Recombinant proteins of cir-
cumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were used
to probe humoral responses toward preerythrocytic stages, while crude P.
falciparum lysates were used to assess antibody reactivity toward blood
stages. Apical membrane protein 1 (AMA-1) and exported protein 1
(EXP-1) are expressed in both preerythrocytic and asexual stages.
Full-length P. falciparum NF54 CSP with repeats was produced in
Escherichia coli by Gennova Biopharmaceuticals Ltd., Pune, India. A re-
combinant LSA-1 construct, LSA-NRC, was expressed in E. coli, incorpo-
rating the N- and C-terminal regions of the protein and two of the cen-
trally placed 17-amino-acid repeats for the 3D7 LSA-1 sequence
(PlasmoDB-PF3D7_1036400) (28). Both the N- and C-terminal regions
as well as the repeats are highly conserved between NF54 and 3D7. The
major difference is the greater number of repeats, which are the primary
target of anti-LSA-1 antibodies (29), in the NF54 sequence than in the
3D7 sequence (30). Amino acids 25 to 545 of codon-optimized AMA-1 of
the P. falciparum FVO strain were expressed in the methylotrophic yeast
Pichia pastoris (31, 32). A peptide covering the C-terminal amino acids 73
to 162 of the integral parasitophorous vacuolar membrane protein EXP-1
(Swiss-Prot Database primary accession number P04926) was chemically
synthesized using solid-phase 9-fluorenylmethoxy carbonyl (Fmoc)
chemistry and differs from the 3D7 sequence only by a single amino acid
in position 160 (33).
ELISA to assess antibody reactivity.Ninety-six-well Polystyrene flat-
bottom plates (Nunc Maxisorp; Thermo Scientific) were coated with 2
"g/ml of CSP, EXP-1, and AMA-1, 0.25 "g/ml of LSA-1, or P. falciparum
lysate at the equivalent of 20,000 PfRBC/well in phosphate-buffered saline
(PBS) and incubated overnight at 4°C. Plates were blocked with 5% milk
in PBS. All of the following washing steps were carried out with PBS-
0.05% Tween (PBST). Using 1%milk in PBST, plasma or serum samples
were serially diluted in duplicate starting at 1:50 to 1:800 for protein an-
tigen and 1:250 to 1:4,000 for P. falciparum lysate and incubated for 3 h at
room temperature. Bound IgGwas detected using horseradish peroxidase
(HRP)-conjugated anti-human IgG (Thermo Scientific; diluted 1:60,000 in
sample buffer). Plates were developed using tetramethylbenzidine (TMB)
peroxidase substrate (tebu-bio). The reaction was stopped using an equal
volume of 0.2 M H2SO4, and absorbance was measured with a spectropho-
tometer plate reader at 450 nm (Anthos 2001 ELISA plate reader).
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A serial dilution of a pool of sera from 100 hyperimmune Tanzanian
(HIT) (20) individuals living in an area where malaria is highly endemic
was used as a reference standard and was included on each plate. The
reactivity for each antigen in undiluted HIT serum was defined as 100
arbitrary units (AUs). Optical density (OD) values were converted into
AUs by using the four-parameter logistic curve fit using the Auditable
Data Analysis andManagement System for ELISA (ADAMSEL-v1.1; http:
//www.malariaresearch.eu/content/software).
For each antigen, all time points of an individual volunteer were as-
sayed on the same plate. To determine whether Tanzanians had a positive
P. falciparum serology (by recognition of P. falciparum lysate), the mean
($2 standard deviations [SD]) baseline antibody titer against P. falcipa-
rum lysate of the Dutch volunteers was used as the cutoff for positivity.
In vitro PBMC stimulation assay to assess cellular responses. Ve-
nous whole blood was collected into citrated Vacutainer CPT cell prepa-
ration tubes (Becton Dickinson). PBMCs were obtained by density gradi-
ent centrifugation, washed three times in cold PBS, counted, frozen at 107
cells/ml in fetal calf serum (FCS) with 10% dimethyl sulfoxide, and stored
in vapor-phase nitrogen. After being thawed, PBMCs were counted and
cultured at a concentration of 500,000 cells/well in a 96-well round-bot-
tom plate and stimulated in duplicate at a ratio of 1:2 with 106 P. falcipa-
rum NF54-infected RBC or uRBC for either 24 h or 6 days in a total
volume of 200 "l.
Flow cytometry. Cells were stained and analyzed by flow cytometry
either directly ex vivo or after 24 h or 6 days of in vitro stimulation. Cells
were stained first for viability with LIVE/DEAD fixable Aqua dead cell
stain (Invitrogen) or fixable viability dye eFluor 780 (eBioscience) and
later with three different staining panels for surface markers: for the 24-h
stain, CD3 PerCP (UCH1; BioLegend), CD56-phycoerythrin (PE)
(HCD56; Biolegend), anti-T-cell receptor (TCR) Pan%/&-PE (IMMU510;
Beckman Coulter), CD4 Pacific Blue (OKT4; Beckman Coulter), CD8
allophycocyanin (APC)-H7 (SK1; BD Pharmingen), CD45RO energy
coupled dye (ECD) (UCH1; Beckman Coulter), and CD62L PeCy7
(DREG56; eBioscience); for the ex vivo stain, the only changes from the
previous stain were CD3 V500 (clone SP342; BD Horizon) and CD8
PerCP (RPA-T8; BioLegend); and for the third-panel 6-day stain, CD3
PeCy7 (OKT3; BioLegend) and CD8 PerCP (RPA-T8; BioLegend). For
intracellular staining, cells were incubated with different monoclonal an-
tibodies (MAbs) depending on the staining panels. After 30 min of incu-
bation at RT, cells were washed and permeabilized with Foxp3 fix/perm
buffer (eBioscience) for 30 min on ice and stained in permeabilization
buffer (eBioscience) with IFN-% fluorescein isothiocyanate (FITC)
(4S.B3; eBioscience; 24-h stain) and Foxp3 eF660 (PCH101; eBioscience;
ex vivo stain) or Ki67 FITC (B56; BD Pharmingen) and Foxp3 eF660
(PCH101; eBioscience; 6-day stain). Cells were collected on a CyAn ADP
9-color flow cytometer (Dako/Beckman Coulter) and analyzed using
FlowJo software (Tree Star, Inc.) version 9.6. All assays were conducted
with the same batches of PfRBC and uRBC, with all time points of one
volunteer assayed in one experiment to prevent interassay variations.Nat-
ural killer T cells (NKT) and gamma delta T cells (%&T) were analyzed in
the same gate and henceforth are referred to as NKT-%&T cells.
Statistical analysis. Statistical analysis was performed in GraphPad
Prism 5. Differences within the cohorts and between time points were
analyzed per volunteer by aWilcoxonmatched-pairs signed-rank test and
those between groups were analyzed by a Mann-Whitney U test. The
relationship between baseline antibody titers and the increase in antibody
titers was analyzed by Spearman correlation, and P values of'0.05 were
considered statistically significant. Cellular responses were corrected for
the background by subtracting responses to uRBC from responses to
PfRBC for each sample; resulting negative values were set to zero.
RESULTS
Tanzanian volunteers have higher baseline antibody titers than
Dutch subjects. Pre-CHMI antibody titers were significantly
higher in Tanzanian than in the malaria-naive Dutch volunteers
for crude P. falciparum lysate (P ' 0.03), with 12/21 Tanzanians
having titers higher than the mean ($2 SD) titers of Dutch vol-
unteers. This was also true for pre-CHMI antibodies to the indi-
vidual parasite antigens AMA-1 (P' 0.015; 13/21) and CSP (P'
0.04; 15/21), and the same trend was found for EXP-1 (P' 0.06;
8/21) (Fig. 1A). Elevated LSA-1 antibody titers were found in 5/21
Tanzanians, but there was no significant difference between Dutch
and Tanzanians at the group level (P' 0.16). Within the Tanzania
cohort, therewasawide rangeofpre-CHMIantibodyresponses,with
some volunteers showing only low responses, comparable to those of
the Dutch cohort. To address whether there was a general division
into high and low responders to malaria antigens, we stratified Tan-
zanian individuals based on their reactivity to P. falciparum lysate
(containing a large number of late-liver- and blood-stage antigens)
(Fig. 1B).Compared to theirP. falciparum lysate-seronegative coun-
terparts (n! 9), seropositive Tanzanians (n! 12) had significantly
higher antibody titers against the cross-stage antigens AMA-1 (P!
0.005; 7.6-fold higher median titer) and EXP-1 (P ! 0.04; 5.4-fold
higher). The same trend was found for the sporozoite antigen CSP
(P ! 0.09; 2.4-fold higher) and the liver-stage antigen LSA-1 (P !
0.06; 1.7-fold) (Fig. 1C).
P. falciparum lysate seropositivity prior to CHMI is associ-
ated with reduced initial blood-stage parasitemia. We next as-
sessedwhether preexisting humoral responsesmight be associated
with the control of parasites in Tanzanian volunteers. In line with
stronger humoral responses in the Tanzanian cohort than in the
Dutch cohort at baseline, Tanzanian volunteers became qPCR
positive significantly later than the Dutch volunteers (Fig. 2A),
with a median prepatent period of 11.0 days (interquartile range
[IQR], 11.0 to 13.5) in Tanzanians and 10.0 days (9.5 to 11.0) in
Dutch volunteers (P ! 0.009). Similarly, prepatency by TS was
also longer in Tanzanians (median [IQR], 13.7 days [12.75 to
16.7]) than in the Dutch (12.6 days [12.3 to 14]) (P! 0.035). The
time between detection by qPCR and by TS was comparable for
both cohorts (median [IQR] forTanzanians, 2.6 days [2.2 to 3.15];
Dutch, 3.0 days [2.0 to 3.15]; P! 0.88), but Dutch volunteers had
a significantly higher peak parasite density (median number of
parasites/milliliter [IQR] for Tanzanians, 12,000 [6,800 to
15,000]; Dutch, 74,000 [26,000 to 190,000]; P ! 0.02), possibly
due to slight differences in the thick smear protocol between the
two sites. Within the Tanzanian cohort, there was no significant
difference in time to qPCR-detectable parasitemia between volun-
teers who were either P. falciparum lysate seropositive or serone-
gative at baseline (P! 0.16) (Fig. 2B), norwas there a difference in
prepatency by TS (P! 0.41) or time between detection by qPCR
and TS (P ! 0.15). However, seropositive Tanzanian volunteers
had a significantly lower parasite load at the time of first qPCR-
detectable parasitemia than their seronegative counterparts (P!
0.033) (Fig. 2C). This difference remained evident, but became
smaller, by the time the first peak in parasite loadwas reached (P!
0.05; Fig. 2D). Across all Tanzanian volunteers, pre-CHMI anti-
body titers for CSP (Pearson r ! 0.45, P ! 0.04), but no other
antigens, correlated significantly with prepatancy by qPCR (see
Fig. S1 in the supplemental material).
P. falciparum-specific antibody responses are more effi-
ciently increased in Tanzanians than in Dutch volunteers after
CHMI. Post-CHMI, antibody responses increased significantly in
the Tanzanian volunteers for P. falciparum lysate (P ' 0.001;
15/21 with a(3-fold increase in titers), AMA-1 (P! 0.002; 6/21),
EXP-1 (P ' 0.0001; 14/21), LSA-1 (P ! 0.001; 5/21), and CSP
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(P ' 0.001; 11/21) (Fig. 3A). In contrast, the Dutch volunteers
showed significant increased titers only against EXP-1 (P! 0.004;
7/9), CSP (P ! 0.008; 6/9), and P. falciparum lysate (P ! 0.008;
3/9), while responses to LSA-1 and AMA-1 remained low and
unaltered (Fig. 3B). Compared to the Dutch, Tanzanians showed
a trend for stronger induction or boosting of responses based on
the overall fold increase in titers to P. falciparum lysate, AMA-1,
and LSA-1 (Fig. 3C) and significantly higher absolute increases in
titers for these antigens (Fig. 3D). Volunteers in both cohorts were
subjected toCHMIwith either 10,000 or 25,000 PfSPZs.However,
the only significant difference in antibody responses between the
two dose groups was a slightly higher response in the 25,000 than
in the 10,000 dose group for P. falciparum lysate in Dutch volun-
teers (P ! 0.04) and a similar trend for the Tanzanians for CSP
(P! 0.07) (see Fig. S2 in the supplementalmaterial). Post-CHMI,
P. falciparum lysate-seronegative Tanzanians had a significantly
stronger fold increase in antibody titers against AMA-1 (P! 0.02)
and EXP-1 (P! 0.04) than seropositive individuals, with a similar
trend for P. falciparum lysate (P ! 0.082) and CSP (P ! 0.095),
but no difference in LSA-1 responses (P! 0.80) (Fig. 3E). For the
entire cohort, the fold increase of P. falciparum lysate (P! 0.01)
and AMA-1 (P! 0.001) responses upon CHMI correlated nega-
tively with the baseline response. The absolute increase in titers,
however, was not different for any of the antigens between the two
FIG 1 Baseline malaria-specific antibody titers indicate previous exposure in Tanzanian volunteers. Antibody reactivity against crude P. falciparum lysate and
the P. falciparum antigens AMA-1, EXP-1, LSA-1, and CSP was tested prior to malaria infection. A pool of sera from 100 hyperimmune Tanzanians (HIT) was
used as a reference. Reactivity for each antigen in undilutedHIT serumwas set at 100 arbitrary units (AUs). (A) Responses betweenDutch (D; circles; n! 9) and
Tanzanian (T; squares; n ! 21) cohorts were compared using a Mann-Whitney U test. (B) Tanzanian volunteers were stratified based on P. falciparum lysate
recognition at baseline as Sero$ (n! 12; black box plots) or Sero# (n! 9; white box plots), using themean$ 2 SD of Dutch volunteers (gray circles) as a cutoff
for positivity. (C) Pre-CHMI responses of seropositive and seronegative Tanzanians were analyzed by ELISA for individual P. falciparum antigens and compared
by Mann-Whitney U test. Scatter plots show individual data points, horizontal lines indicate the median of the group, and error bars indicate the interquartile
range (IQR). Dashed lines indicate the mean$ 2 SD of antibody titers in Dutch volunteers for each respective antigen.
FIG 2 Preexposure to malaria is associated with difference in prepatency and parasitemia after CHMI. Parasitemia after CHMI was determined by qPCR. The
day of first parasite detection by qPCR after PfSPZ injection is shown for Dutch (D; gray circles; n! 9) compared to Tanzanians (T; gray squares; n! 21) (A)
and for P. falciparum-seropositive (n! 12; black squares) and -seronegative (n! 9; white squares) Tanzanian volunteers (B). The parasite load (number of P.
falciparum parasites per milliliter of blood) at the first day of qPCR-detectable parasitemia (C) and the time of first peak parasite density (D) are shown for P.
falciparum-seropositive (n! 12; black squares) and -seronegative (n! 9; white squares) Tanzanian volunteers. Data are shown as median) IQR. Groups were
compared by a Mann-Whitney U test.
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groups (Fig. 3F). Notably, P. falciparum lysate-seronegative Tan-
zanians thereby also showed a greater absolute increase in anti-
body titers than malaria-naive Dutch volunteers.
Dutch but not Tanzanian volunteers show cellular recall re-
sponses induced by CHMI. To analyze the acquisition of cellular
responses after CHMI, we investigated in vitro IFN-% responses
upon incubation with PfRBC for 24 h (Fig. 4A and B). At baseline,
P. falciparum-specific IFN-% responses were comparable between
Dutch and Tanzanians for all cell subsets except for NKT-%&T
cells, which showed slightly higher responses in the Dutch (P !
FIG3 Increased humoral responses inDutch andTanzanians after CHMI. Antibody titers weremeasured 4weeks (Tanzanians; squares; n! 21) (A) and 5weeks
(Dutch; circles;n! 9) (B) after intradermal infectionwith PfSPZs.Graphs show the antibody reactivity (AUs) pre-CHMI (black) andpost-CHMI (white) against
crude P. falciparum lysate, AMA-1, EXP-1, LSA-1, and CSP. Plots show individual data points, with lines connecting the two time points for each volunteer.
Responses in the two cohorts pre- and post-CHMI were compared by using a Wilcoxon matched-pairs signed-rank test. The fold increase (ratio of AU
post-CHMI/AU pre-CHMI) (C, E) and absolute increase in antibody reactivity (AU post-CHMIminus AU pre-CHMI) (D, F) were calculated for Dutch versus
Tanzanian volunteers (C, D) and in Tanzanian volunteers classified as P. falciparum lysate seropositive or seronegative at baseline (E, F). Data are shown as
whisker plots, with boxes indicating the median and IQR, and whiskers indicating the minimum/maximum values. Responses were compared using a Mann-
Whitney U test.
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FIG 4 Dutch but not Tanzanian volunteers show increased P. falciparum-specific in vitro IFN-% production after CHMI. PBMCs collected pre- and post-CHMI
fromDutch (D; circles;n! 9; post! 35 days afterCHMI) andTanzanian (T; squares;n! 21; post! 28 days afterCHMI) volunteerswere stimulatedwith PfRBC
for 24 h. (A) After stimulation, cells were stained for surface expression of CD3, CD4, %&TCR, CD8, and CD56 to gate lymphocyte subsets. NKT and %&T were
gated as a combined population. (B) Intracellular IFN-% is shown for total lymphocytes after 24 h of uRBC or PfRBC stimulation. Graphs show the proportions
of cells with P. falciparum-specific IFN-% production, comparingDutch and Tanzanian volunteers pre-CHMI (C) and post-CHMI (D), and comparing pre- and
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0.077) (Fig. 4C). Post-CHMI, previously malaria-naive Dutch
volunteers showed significant increases in P. falciparum-specific
IFN-% production by all lymphocyte subsets analyzed (CD4$,P!
0.004; CD8$, P ! 0.009; CD56dim, P ! 0.004; CD56bright NK,
P! 0.008; NKT-%&T, P! 0.004) (Fig. 4E to I). In contrast, Tan-
zanian volunteers showed little or no increase in IFN-%-produc-
ing cells (CD4$, P! 0.74; CD8$, P! 0.065; CD56dim, P! 0.49;
CD56bright NK, P! 0.75; NKT-%&T, P! 0.92). In both cohorts
and at both time points, CD56brightNK cells showed significantly
higher IFN-% responses than CD56dimNK cells (Dutch pre/post-
CHMI, P! 0.004; Tanzanian pre/post-CHMI, P! 0.0001). Sig-
nificantly increased IFN-% responses were found in both the effec-
tor (CD4$, P! 0.004; CD8$, P! 0.008) and central (CD4$, P!
0.004; CD8$, P ! 0.012) memory T-cell compartments in the
Dutch cohort, while the Tanzanians showed no such increase (see
Fig. S3 in the supplemental material). As a result, post-CHMI
IFN-% responses in the Dutch were significantly higher for all cell
subsets than in the Tanzanian cohort (Fig. 4D). Within the Tan-
zanian cohort, there was an overall trend for higher P. falciparum-
specific pre-CHMI IFN-% responses in those volunteers that had
particularly short prepatency by qPCR (see Fig. S1 in the supple-
mental material). CD8$ T cells from Dutch (P ! 0.04) but not
Tanzanian (P ! 0.47) volunteers showed increased proliferative
responses post-CHMI (see Fig. S4A in the supplementalmaterial).
The proliferation of CD4$ T cells in response to PfRBC was not
significantly altered post-CHMI in either cohort (P ! 0.25 in
Dutch and P! 0.11 in Tanzanians) (see Fig. S4B).
Analyzing the lymphocyte subset compositions in both co-
horts, we found that they were largely stable between pre- and
post-CHMI time points, with the exception of a prominent and
significant post-CHMI increase of the NKT-%&T proportion in
the Dutch volunteers and a clear decrease of CD56dim NK pro-
portions in both cohorts. There was further no significant differ-
ence in the proportions of CD4$ CD45RO$ Foxp3$ T cells be-
tween the two cohorts, which could have explained differences in
responsiveness (see Table S1 in the supplemental material). For
the Tanzanian cohort, we observed a significant reduction of
Foxp3$ T cells post-CHMI (P! 0.008), while for the Dutch vol-
unteers there was no change (P ! 0.44). Stimulation with the
phorbol myristate acetate (PMA) and ionomycin mitogens
showed that lymphocytes of both Dutch and Tanzanian volun-
teers were fully functional and able to produce IFN-% at compa-
rable levels both pre- and post-CHMI (see Fig. S4C).
Reduced innate IFN-! responses in Tanzanian volunteers
are associatedwith preexisting humoral immunity and thus po-
tential preexposure. Finally, we analyzed whether the degree of
preexposure reflected by differences in malaria-specific humoral
immunity might affect cellular recall responses to PfRBC. Cells
from P. falciparum lysate-seronegative Tanzanian volunteers had
significantly higher responses to PfRBC (pre-CHMI) than those
from seropositive Tanzanian volunteers (NKT-%&T, P ! 0.05;
CD56dim, P ! 0.01; CD56bright NK, P ! 0.04) and were of a
magnitude comparable to those observed in the Dutch volunteers
(Fig. 5). CD4$ and CD8$ T cells showed a similar pattern, al-
though the difference between seropositive and seronegative Tan-
zanians did not reach statistical significance (Fig. 5A and B). Post-
CHMI, these differences remained, and there was no increase in
these responses in either of the two groups.
DISCUSSION
In the present study, we performed a side-by-side comparison of
antimalarial immune responses initiated or recalled by CHMI in
two cohorts of young adults, fromTheNetherlands andTanzania,
with different malaria exposure histories and genetic back-
grounds. Recruitment of Tanzanian volunteers took place in Dar
es Salaam, an urban areawheremalaria is hypoendemic. Inclusion
criteria into this CHMI trial were tailored to ensure minimal re-
cent exposure to P. falciparum: Tanzanian volunteers had not ex-
perienced a clinical episode ofmalaria for 5 years, as self-reported,
and were confirmed free of parasites by qPCR before CHMI took
place. Nevertheless, more than 50% of the 21 Tanzanian volun-
teers had a positive P. falciparum lysate serology before CHMI
post-CHMI responses within each cohort for CD4$ T cells (E), CD8$ T cells (F), CD56dimNK cells (G), CD56bright NK cells (H), and NKT-%&T cells (I). For
each volunteer, all time points were measured in a single experiment. Data are shown as whisker plots with boxes indicating the median with IQR and whiskers
the minimum/maximum values (C and D) or individual data points with lines connecting the two time points for each volunteer (E to I). All responses were
corrected for the background by subtracting responses to uRBC. Responses pre-CHMI and post-CHMI were compared using a Wilcoxon matched-pairs
signed-rank test.
FIG 5 P. falciparum-specific in vitro IFN-% production by innate lymphocytes from Tanzanian volunteers is dependent on baseline serological status. PBMCs
collected from Tanzanian volunteers who either had a positive P. falciparum (Sero$; n ! 12; black squares) or negative P. falciparum (Sero#; n ! 9; white
squares) serology prior to challenge (baseline) were stimulated with PfRBC for 24 h and stained for intracellular IFN-%. Panels show IFN-% production by
lymphocyte subsets: (A) CD4$ T cells; (B) CD8$ T cells; (C) NKT-%&T cells; (D) CD56dim; (E) CD56bright NK cells. Data are shown as median ) IQR of
responses corrected for the background by subtracting responses to uRBC. Differences in responses between the seropositive and seronegative groups were
analyzed by aMann-Whitney U test. P. falciparum-specific IFN-% responses of pre-CHMI PBMCs frommalaria-naive Dutch volunteers (D; n! 9; gray circles),
who had negative P. falciparum serology, are shown as a comparator.
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based on P. falciparum lysate ELISA, which is a standard exclusion
criterion in Dutch CHMI trials. In line with this, increased base-
line antibody titers for the P. falciparum antigens CSP, LSA-1,
EXP-1, and AMA-1 were found in the Tanzania cohort and par-
ticularly in those with positive serology for P. falciparum lysate.
This clearly indicates previous exposure to the malaria parasite in
this cohort. Asymptomatic infections, which can often occur in
people living in areas with low malarial endemicity (34), in the 5
years of no self-reported clinical malaria preceding CHMI might
have led to a maintenance of higher antibody responses.
As might be expected, preexisting antibodies to P. falciparum
antigens appeared to have an effect on the outcome of CHMI.
Tanzanians had a significantly longer prepatency based on qPCR
detection than the previously malaria-naive Dutch. Furthermore,
P. falciparum lysate-seropositive Tanzanians had a lower parasite
load at the time of first detection by qPCR and at the time of the
first peak of parasite load than seronegative Tanzanians. The first
peak of blood-stage parasitemia can be used as a proxy for parasite
liver load (16, 35). Our results might therefore indicate the emer-
gence of fewer parasites from the liver and hence better control of
either initiation or progression of liver-stage infection in preex-
posed individuals within the Tanzanian cohort and in Tanzanians
than in the Dutch cohort. In line with such an effect of preexisting
antisporozoite immunity would be the observation that those
Tanzanian volunteers with a longer prepatancy by qPCR also had
higher baseline antibody titers against the sporozoite antigenCSP.
However, the first detection by qPCR in both the Dutch and Tan-
zanians after intradermal PfSPZ injection was uncharacteristically
late compared to that for infection by mosquito bite routinely
conducted in The Netherlands and elsewhere (11, 16, 18, 19, 23,
24, 35). This is likely due to less efficient liver-stage infection by
this route and hence a low initial blood-stage load that reaches the
qPCR detection limit only later. A lower first detectable para-
sitemia in seropositive Tanzanians than in seronegative Tanzani-
ans might therefore additionally be attributed to the control of
blood-stage replication prior to qPCR detection. Antibodies di-
rected against AMA-1, for instance, are known to interfere with
blood-stage multiplication (36) but can also confer protection
against liver-stage infection (37). Since recognition of both cross-
stage and liver-stage antigens was stronger in the Tanzanian co-
hort than in the Dutch, and particularly in the seropositive indi-
viduals, both possibilities remain open. Our data, however,
support antibody control of blood-stage replication only during
the initial phase of sub-qPCR-detectable parasitemia: while para-
site multiplication based on PCR data could not be directly com-
pared due to the high variability of the amplification dynamics
(24), there was no difference between prepatency by TS and qPCR
in the two Tanzanian groups.
Upon CHMI, Dutch volunteers showed a slight but significant
induction of humoral responses against CSP, P. falciparum lysate,
and EXP-1, while Tanzanians boosted responses to all antigens
examined. Reactivity to the CSP sporozoite antigen is expected
after PfSPZ inoculation and consistent with previous findings (38,
39). Increased antibody responses against P. falciparum lysate and
EXP-1 likely reflect cross-stage reactivity between late-liver-stage
and blood-stage merozoites, while exposure to developing liver
stages (LSA-1) in naive volunteers appears insufficient to induce a
detectable antibody response. Similarly, limited exposure to
blood-stage-expressed AMA-1, due to early curative treatment,
appears to prevent induction of detectable titers in naive volun-
teers, which is consistent with results even after multiple CHMIs
(39). Consistent with preexposure, Tanzanians showed on the
group level a greater increase in titers for P. falciparum lysate,
AMA-1, and LSA-1 than the previously malaria-naive Dutch.
Within the Tanzanian cohort, P. falciparum lysate-seronegative
Tanzanians showed a similar absolute and accordingly much
greater fold increase in antibody titers than their seropositive
counterparts. At baseline, these volunteers had significantly lower
responses to most parasite antigens than their seropositive coun-
terparts and largely resembled the malaria-naive Dutch cohort.
The fact that this group showed a greater increase in antibody
titers than theDutch strongly suggests that despite largely negative
P. falciparum serology, these individuals have a stable P. falci-
parum-specificmemory B-cell repertoire (40, 41). Given the same
increase in absolute antibody titers, their memory B-cell reper-
toire appears to be of a magnitude similar to that of the P. falcip-
arum lysate-seropositive Tanzanians, despite lower circulating
plasma antibody levels.
Of note, humoral responses were assessed using a number of
recombinant or synthetic proteins, which are not fully identical to
the sequences of these proteins expressed by the NF54 strain used
in both CHMI trials. While most antigens used in this study were
of the 3D7 sequence and thus closely resemble theNF54 sequence,
AMA-1 responses were assessed using the FVO strain sequence.
AMA-1 is known for its extensive antigenic polymorphism and to
cause strain-specific immunity (42, 43). Nevertheless, there is a
significant antigenic overlap between AMA-1 alleles allowing for
cross-reactivity across different strains, both in terms of func-
tional activity and recognition, which affects mainly the magni-
tude of the response (42, 44–46). Based on these data, we consider
it unlikely that assessment of AMA-1 responses using the NF54 or
3D7 sequence would have yielded different qualitative results.
However, absolute titers would likely have been higher when us-
ing the AMA-1 sequence homologous to the CHMI strain.
Another potential confounder is the fact that the P. falciparum
strains that Tanzanian volunteers were naturally exposed to prior
to CHMI with P. falciparum NF54 are unknown. As any study
examining preexposed individuals, analysis of antigen-specific re-
sponses against polymorphic antigens has therefore the additional
limitation that it is difficult to match this unknown exposure his-
tory. This has to especially be taken into account when investigat-
ing CHMI-induced boosting of potential preexisting responses in
this cohort, which might be masked by using antigens of different
strain origins. However, despite the fact that Tanzanians likely
experienced exposure to a variety of P. falciparum strains prior to
CHMI, there was (i) a clear division into seropositive and serone-
gative individuals not just by total P. falciparum NF54 lysate but
also by all individual antigens analyzed and (ii) a clearly stron-
ger increase in antibody titers in Tanzanians than in malaria-
naive Dutch volunteers to several antigens, including AMA-1.
We cannot exclude, however, that this might have even been
more pronounced when using antigens of different strain ori-
gins for analysis.
Although the Tanzanian volunteers in the present study
showed evidence of humoral immune memory, parasite-specific
IFN-% production by adaptive T-cell subsets was not higher than
in malaria-naive Dutch volunteers at baseline and remained un-
changed after CHMI. In contrast, previously naive Dutch volun-
teers showed a significant increase in IFN-% production by CD4
and CD8 T-cell subsets after a primary infection, consistent with
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what has been shown previously (47, 48). The lack of increased
proliferative and Th1 responses 1 month after CHMI in Tanza-
nian volunteers could be partially due to immunosuppression fol-
lowing exposure to blood-stage parasites during CHMI. Such T-
cell immunosuppression is well described for malaria (49–58)
and, although usually resolved within 2 weeks (52, 53), can persist
formore than 4 weeks (50). That Dutch volunteers are not equally
affected by this might be due to the fact that such immunosup-
pressive effects appear to bemore pronounced in immune than in
nonimmune donors, as shown elsewhere (59). T regulatory cells
(Tregs) are one potential mediator of suppressed IFN-% produc-
tion by adaptive cells. Increased Treg numbers during or after
malaria are a well-reported phenomenon (60), and malaria para-
sites can enhance the suppressive activity of Tregs (61). While
Dutch and Tanzanian volunteers had similar Treg proportions,
we cannot exclude that Tregs in Tanzanian volunteers might be
functionally more active, potentially due to past priming in ma-
laria infections. That this apparent lack of a Th1 immune response
in the Tanzanian cohort is malaria specific is supported by the fact
Dutch andTanzanian volunteers showed similar Th1 responses to
mitogen stimulation both pre- and post-CHMI. Nevertheless, an
additional influence of genetic background, which may explain
differential P. falciparum-specific responses described in settings
where malaria is endemic, cannot be excluded (62, 63).
NK cells are rapidly activated by malaria parasites, contribute
to the early IFN-% response during blood-stage infection (64), and
can eliminate infected erythrocytes in vivo in a contact-dependent
manner (65). Importantly, there is a functional dichotomy: the
rarer CD56bright cells are more prominent in lymphatic tissues
and are superior cytokine producers, while the CD56dim subset
harbors a stronger cytotoxic potential (66–68). However, NK cells
have usually been examined as one population, and the exact con-
tributions ofCD56dimandCD56brightNK cell subsets tomalaria
immunity thus remain to be established. An in vitro study on
PBMCs frommalaria-naive donors found greater IFN-% produc-
tion byCD56bright than byCD56dimNKcells only in response to
cytokines but not upon PfRBC stimulation (69). However, con-
sistent with their generally reported greater cytotoxic potential,
only CD56dim cells showed degranulation upon PfRBC stimula-
tion (69). Our findings that CD56bright NK cells show a greater
IFN-% response thanCD56dimNKcells to PfRBCboth before and
after a primarymalaria infection, as well as amemory-like effect of
this response, are in line with findings from a previous CHMI trial
(70). Tanzanian volunteers showed the same functional difference
between the two NK cell subsets but no memory effect in either
subset after CHMI. It was previously shown that depletion of*+T
cells abrogates memory-like IFN-% responses of innate cells oth-
erwise observed after CHMI (47, 70). Therefore, the absence of
increased PfRBC-specific*+T-cell responses post-CHMI in Tan-
zania volunteers might be one reason why P. falciparum-specific
IFN-% production by NK cells and other innate lymphocytes
(NKT and %& T cells) was also not increased post-CHMI. The fact
that P. falciparum lysate-seronegative Tanzanians had higher in-
nate IFN-% responses than did seropositive Tanzanians already at
baseline is a further indication that reduced Th1 responses are
likely linked to the degree of previous malaria exposure. Of note,
the proportion of CD56bright cells remained unaltered after
CHMI, while the CD56dim subset had a smaller contribution to
the PBMC compartment post-CHMI in both cohorts. It remains
to be established whether this means that, in contrast to memory-
like IFN-% production, other NK cell functions, such asmigration
out of the circulation and engagement in antimalaria immune
responses at other sites, such as the spleen, are unaffected and fully
functional in preexposed individuals.
Within the Tanzanian cohort, there was no association of pre-
existing P. falciparum-specific IFN-% responses by T-cell subsets
or innate lymphocytes with the parasitological outcome of CHMI,
i.e., prepatency or parasite load at first detection by qPCR. If at all,
those with higher IFN-% responses to blood-stage PfRBC had a
shorter prepatency. This does not, however, exclude that cellular
responses play a role in the prolonged prepatency of Tanzanian
volunteers and specifically those with positive P. falciparum serol-
ogy. One possible reason for the lack of such an association is that
PfRBC were chosen as a stimulus for P. falciparum-specific re-
sponses. This was done due to the relatively large antigenic overlap
between blood-stage and (late) liver-stage parasites (71, 72).How-
ever, responses to sporozoite and early-liver-stage antigens, which
may be more relevant when assessing responses responsible for
reducing the parasite load by targeting the earlier stages of infec-
tion, are likely to be missed using PfRBC as a stimulus. Moreover,
our analysiswas restricted toP. falciparum-specific IFN-%produc-
tion, and it is likely that other responses, for instance, degranula-
tion as a proxy for cytotoxicity, may be more relevant readouts
(71). Finally, the only accessible compartment for analysis of cel-
lular responses in these human trials was peripheral blood. P. fal-
ciparum-specific responses, and particularly those responsible for
reducing liver infection, might, however, be enriched or primarily
located in other sites, for instance, in tissue-resident memory cells
in the liver (73, 74). This might be even more pronounced in
preexposed individuals, where such a tissue-resident memory
population might have already been established.
Noteworthy, the differential immune responses described
herein may explain why Tanzanian volunteers reported fewer
clinical symptoms, such as fever, than their Dutch counterparts
during CHMI after PfSPZ injection (24). On the one hand, pre-
existing antibody responses may reduce the initial parasite load
and mediate antidisease immunity. Additionally, the relatively
lowerP. falciparum-specific cellular Th1 responses observed in the
Tanzanian cohort than in the Dutch cohort might also be benefi-
cial. Dutch volunteers preexposed to infected mosquito bites un-
der chloroquine prophylaxis exhibited stronger IFN-% produc-
tion and earlier clinical symptoms when reexposed to blood-stage
parasites thanmalaria-naive volunteers during their first infection
(15). Thus, a shift away from Th1 responses in preexposed volun-
teersmaymake them less vulnerable to fever and other inflamma-
tion-induced symptoms.
In conclusion, our data show that previousmalaria exposure is
associated with some degree of parasite control during liver-stage
or early-blood-stage infection after CHMI, humoral immune
memory, and reduced antiparasite Th1 responses in the circulat-
ing lymphocyte compartment. Positive P. falciparum lysate serol-
ogy can be used to identify individuals with better parasite control
but weaker peripheral blood Th1 responses, which may help to
stratify volunteers in future CHMI trials in areas where malaria is
endemic. However, assessment ofmemory B-cell responsesmight
be explored as a potentially better tool than serology to define
preexposure per se. Important questions to be addressed in future
studies include (i) which readouts other than Th1 responses
should be used to determine immunization-induced cellular im-
munity and (ii) how differences in preexisting malaria-specific
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immune responses affect the outcome of whole parasite immuni-
zation and vaccination approaches in areas where malaria is en-
demic.
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Abstract 
Background:  
Controlled human malaria infections (CHMI) provide a unique platform for malaria research. 
Data describing CHMI-induced immune responses have been largely confined to malaria 
naive populations. Here, we assessed changes in malaria-specific humoral immune response 
in malaria pre-exposed healthy Tanzanian volunteers after a single intradermal application of 
purified, metabolically active P. falciparum sporozoites (PfSPZ challenge). 
Methods: 
We compared side by side changes in serum antibody levels using malaria antigen specific 
multiplex bead arrays, antibody secreting memory B cell (MBC) responses and functional 
merozoite opsonization activity in each volunteer. We analyzed the results from pairs of visits 
using the Wilcoxon signed ranks test. 
Results:  
When compared to baseline, peak antibody titers binding to recombinant MSP-1 (alleles 3D7 
and FVO), AMA-1, CSP and LSA-1 were observed on day 28 after PfSPZ challenge. 
Antibodies binding to CelTOS, EBA-175 and SSP2did not alter.MSP-1 and AMA-1 specific 
antigen secreting cells (ASCs) measured in peripheral blood where highest on day 28 after 
PfSPZ challenge, but rapidly declined to near baseline levels on day 168. Merozoite 
opsonizing antibody responses increased following PfSPZ challenge in some but not all 
individuals. When volunteers were stratified according to baseline opsonizing activity, low 
baseline responders showed significantly increase of merozoite opsonizing activity on days 
28, 56 and 168 after PfSPZ challenge, while no change occurred in the group with high 
opsonization at baseline. Outcomes of multiplex bead arrays, B-cell ELISpot analysis and 
merozoite opsonization assays in each volunteer followed similar trends after PfSPZ 
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challenge, suggesting that boosting of pre-erythrocytic and asexual blood stage humoral 
immune responses can be assessed reliably by three assessment methods. 
Conclusion:  
PfSPZ challenge induces a significant albeit short lived boost in pre-erythrocytic and stage 
transcending specific antibody levels and ASCs. The changes in merozoite opsonizing 
antibodies were strongly influenced by pre-existing immunity, as only volunteers with a low 
level of opsonizing antibodies at baseline showed a consistent increase 6 months following 
the CHMI.CHMI studies in malaria pre-exposure volunteers paves the way towards a greater 
understanding of the immunological conditions that favor the development of lasting 
protective humoral malaria immunity in vaccine target population. 
 
Clinical trials 
Gov.identifier: NCT01540903 
 
Keywords 
Plasmodium falciparum, controlled human malaria infection, multiplex bead array, antibody 
secreting cells, merozoite opsonization, malaria semi-immune individuals  
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Background 
Malaria is a preventable and treatable vector borne disease caused by parasite of the genus 
Plasmodium ,with P. falciparum responsible for the majority of malaria morbidity and 
mortality in Sub-Saharan Africa [1].The P. falciparum life cycle alternates between the 
female mosquito and the human host. In humans, after sporozoite inoculation, P. falciparum 
undergoes pre-erythrocytic liver stage development followed by the asexual blood stages, 
with parasites replicating in the red blood cells[1]. Asexual blood stage parasitemia is then 
followed by sexual stage development in the human host. After feeding on parasite-carrying 
humans, sexual replication occurs within the mosquito and is followed by sporozoite 
development in the salivary gland, and thus completes the cycle. The critical role of 
antibodies in protection against severe and clinical malaria in humans has been unequivocally 
established in passive transfer experiments[2][3]. Naturally acquired humoral immune 
responses in malaria have been described in many immuno-epidemiological studies 
[4][5].Repeated malaria infections may result in clinical immunity that is hardly ever 
completely protective against infection. This phenomenon is multifactorial, due to both 
extensive P. falciparum antigen diversity and a failure to mount appropriately long-lived 
humoral responses[6,7]. Memory B cells (MBC), together with bone marrow resident long 
lived plasma cells, are thought to be the foundation of humoral immune memory after 
pathogen or vaccine exposure [8]. These B cells are responsible for the rapid, high titer, high 
affinity secondary antibody responses elicited upon re-exposure to the same infection or 
vaccine[9,10]. In malaria, several studies have demonstrated that MBC are present at low 
frequency following natural exposure, and that ‘atypical’ MBC that have been linked to 
impaired humoral immunity in HIV can be detected as well in malaria exposed 
volunteers[11,12].  
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CHMI has become the cornerstone of early clinical testing of potential malaria vaccine 
candidates, including the current most advanced malaria vaccine, RTS,S[13]. Until recently, 
CHMI studies were limited to few research institutions in the USA and Europe due to the 
requirement for rearing P. falciparum infected mosquitoes in the laboratory[14].CHMI 
studies present an ideal setting to analyze cellular and humoral immunity to P. falciparum 
antigens since the infection occurs under highly defined conditions with well-known dosages 
and genotypes [14]. Recently, accessibility to cryo-preserved, metabolically active 
P. falciparum sporozoites has enabled the first CHMI studies to occur in malaria endemic 
countries [15]. To date, CHMI has been widely deployed to study immune responses against 
the pre-erythrocytic stage in both naïve and semi-immune population[16–21].However, there 
remains no consensus on how immune responses against P. falciparum vary between diverse 
ethnic populations, and the impact of transient, low-density blood stage infections on malaria 
immunity has not been thoroughly investigated [22,23]. Questions like the impact of previous 
malaria exposure on infection dynamics, consequences of haemoglobinopathies on asexual 
blood stage development, infection dosing and application routes can now be addressed in 
malaria endemic settings through CHMI studies [22]. Here we describe the dynamics of 
humoral immune responses targeting pre-erythrocytic, stage transcending (MSP-1 and AMA-
1) and asexual blood stage parasites using three complementary approaches after a single 
intradermal inoculation of purified, metabolically active P. falciparum sporozoites [21].  
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Material and methods 
Ethics statement 
The study was approved by the ethics committee of the National Institute of Medical 
Research, Tanzania (NIMR/HQ/R.8a/Vol.IX/1217), the ethics committee of Basel, 
Switzerland (EKBB 319/11) and the institutional review board of the Ifakara Health Institute 
(IHI) (IHI/IRB /No25). The study protocol was approved by the Tanzania Food and Drug 
Authority (TFDA) (Ref. No. CE.57/180/04A/50).The trial was registered at 
ClinicalTrials.gov (NCT01540903). Written informed consent was obtained from all 
participants. All the trial procedures were conducted by following the ICH-GCP guidelines 
for protection of human well-being. 
 
Study participants 
This study took place between February and August 2012 at the Ifakara Health Institute, 
Bagamoyo Research and Training Centre, located about 70 miles north from Dar-es-Salaam, 
Tanzania. Thirty participants, aged between 20 and 35 years old, were recruited from Dar-es- 
Salaam Institute of Technology (DIT), College of Business Education (CBE) and Institute of 
Finance management (IFM). These colleges enroll students from all over Tanzania. 
Participant inclusion and exclusion criteria and dose assignment for the groups have been 
explained elsewhere [21]. Volunteers who indicated to have no documented evidence of 
malaria episodes in the past 5 years were included. At enrollment, volunteers were tested for 
malaria infection using thick blood smear and only microscopy blood smear negative 
volunteers were enrolled in the trial [21].  
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Peripheral Blood Mononuclear Cell collection  
Blood samples were drawn by venipuncture into sodium citrate-containing cell preparation 
tubes (BD, Vacutainer CPT) on days 0, 28, 56 and 168 after sporozoite inoculation. PBMC 
were isolated according to the manufacturer’s instructions, frozen in fetal bovine serum 
(FBS) (PAA laboratory GmbH) containing 10%  dimethyl sulfoxide (DMSO; Sigma- 
Aldrich, St. Louis, MO), and stored in liquid nitrogen (-191ºC). PBMC samples collected at 
the different time points from one distinct subject were always thawed and assayed in 
parallel. 
 
Serum and plasma sample collection  
Serum was collected from 4 mL of whole blood in blood collection tubes with clot activators 
(Becton Dickinson, 369032) and allowed to stand at room temperature for 1 hour to facilitate 
clot formation. Blood collection tubes were then centrifuged at 2000 x g for 10 minutes at 22 
ºC, and aliquots of serum stored at -80°C. Plasma was obtained from BD Vacutainer CPT 
immediately prior to collection of PBMCs, aliquoted and stored at -80°C. 
 
Antibody Luminex analysis 
Nine recombinant proteins were coupled to Magplex magnetic microspheres (Luminex Corp., 
Austin, Texas)whose fluorescent signature was detected in ten different regions using 
xMAP® technology: Region 33: anti-Human IgG F(ab’)2(Sigma, Tres Cantos, Spain); 
Region 35: Bovine Serum Albumin(BSA);  Region 36: Apical membrane antigen 1, 3D7 
strain (AMA-1 3D7);  Region 38: 42 kDa merozoite surface protein 1, 3D7 strain (MSP-
1423D7); Region 42: 42 kDa merozoite surface protein 1, FVO strain (MSP-142FVO)¸ Region 
43: fragment II of region II of the 175 kDa erythrocyte binding protein (EBA-175, or PfF2);  
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Region 44: Cell traversal protein for ookinetes and sporozoites (CelTOS); Region 45: liver-
stage antigen 1 (LSA-1); Region 46: sporozoite surface protein 2 (SSP2); Region 52: 
circumsporozoite surface protein (CSP); AMA-1 3D7 strain and EBA-175 were produced at 
the International Centre for Genetic Engineering and Biotechnology, New Delhi, India 
(ICGEB).  MSP-142 3D7 and FVO strains were produced at the Walter Reed Army Institute 
of Research, (WRAIR) Silver Spring, MD, USA. The pre-erythrocytic antigens CelTOS, 
LSA-1, SSP2 and CSP were produced at Protein Potential, LLC in Rockville, Maryland, 
USA. 
The multiplex suspension array technology (SAT) panel was prepared as previously reported 
[23,24], with the following alteration: super-paramagnetic polystyrene 6.5 µm COOH-
microspheres were coupled to corresponding antigens. Briefly, microspheres were washed 
and activated with Bead Activation Buffer (100mM monobasic sodium phosphate, pH 6.2) 
and simultaneous addition of Sulfo-NHS (N-hydroxysulfosuccinimide) and EDC (1-Ethyl-3- 
[3-dimethylaminopropyl] carbodiimide hydrochloride) at 50 mg/ml in a total volume of 
100µL for 20 min. Microspheres were coupled overnight at 4ºC with optimized 
concentrations of corresponding protein in 500 µL PBS or MES reactions, then blocked with 
500 µL PBS-BN (PBS with 1% BSA and 0.05% sodium azide), quantified and stored in 
multiplex aliquots at 1,000 microspheres/µL/region (or single-plex for region 33 anti-human 
IgG F(ab’)2 at 2,000 microspheres/µL) in PBS-BN, protected from light at 4ºC. An 11-point 
standard curve was used in each 96-well flat bottom mylar plate (Greiner One). A 2-fold 
serial dilution starting at 150 ng/mL ChromPure purified human IgG (Jackson Immuno 
Research Laboratories) was mixed with region 33 (anti-Human IgG) microspheres in single 
plex at 2,000 microspheres per well and placed for 1 h at room temperature at the same time 
that serum samples for the study were incubated with the multiplex microsphere mix at 1,000 
microspheres per region per well. Study samples, positive and negative controls were tested 
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in duplicates at dilutions 1:500 and 1:20000. The plate was washed three times with 200 
µL/well of PBS with 0.05% Tween20 (PBST) on a magnetic 96-well plate block. Anti-human 
IgG-biotin (Sigma, Tres Cantos, Spain) diluted 1:1000 in PBS-BN was added at 100 µL per 
well and incubated at room temperature with agitation and protection from light for 45 min. 
Plates were washed as before, and streptavidin-R-phycoerythrin diluted 1:1000 in PBS-BN 
was added at 100 µL per well and incubated for 25 min as before. Plates were washed as 
before and microspheres were resuspended in 100 µL of PBS-BN per well and read using a 
Luminex 200 instrument with xPONENT version 3.1 (Luminex Corp, Texas). At least 50 
beads per analyte were acquired per sample. Crude median fluorescence intensity (MFI) and 
background fluorescence from blank wells were exported. A 5-parameter logistic regression 
with inverse variance weighting (1/MFI2) was selected for the standard curve fitting due to 
superior fit with antibody data: 
𝑦𝑦 = 𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚 +  𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚 − 𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚(1 + � 𝑚𝑚𝐸𝐸𝐸𝐸50�𝛽𝛽)ϵ 
Where Amin is the lower asymptote, Amax is the upper asymptote, β is the slope at the inflection 
point of the sigmoidal curve, EC50 is the concentration at the inflection point, and 𝜖𝜖 is a 
factor of asymmetry. The parameters of the standard curve in each plate were used to estimate 
the unit concentration (units relative to ng/mL IgG) for each analyte. The standard curve for 
each Luminex assay plate was used to normalize the estimated concentration of antibodies to 
each antigen, reported as antibody units (AU, or Units) per mL, through interpolation. 
Measurements above and below the limits of quantification were given arbitrary high and low 
Unit values beyond the dynamic range, respectively.   
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Memory B cell ELISpot analysis 
P. falciparum antigen-specific ASCs were quantified by a modified version of the recently 
developed method [25]. Briefly, PBMCs were thawed and cultured with stimulation media 
consisting of 10%FBS in RPMI 1640, plus a cocktail of polyclonal activators: 20 ng/ml β-
mercaptoethanol, 2.5 µg/ml CpG oligonucleotide ODN-2006 (Eurofins MWG/Operon, 
Huntsville, AL), 20ng/ml Protein A from Staphylococcus aureus Cowan (SAC) (Sigma-
Aldrich, St. Louis, MO), 50ng/ml pokeweed mitogen (Sigma-Aldrich), and 50 ng/ml 
recombinant IL-10 (BD Biosciences) at 37 ºC in 5% CO2 atmosphere for six days. 
Afterwards, cells were collected, washed and distributed in 96-well ELISpot plates (Millipore 
Multiscreen HTS IP Sterile plate 0.45 µm, hydrophobic, high-protein binding). To detect 
ASCs, ELISpot plates (Millipore) were prepared by coating with either a 10 µg/ml solution of 
polyclonal goat antibodies specific for human IgG (Caltag H17000) to detect all IgG- 
secreting cells, a 1% solution of bovine serum albumin (BSA) as a non-specific protein 
control, a 5 µg/ml solution of MSP1 (1:1 mixture of FVO and 3D7 strains) or a 5 µg/ml 
solution of AMA-1 (3D7 strain only). Sources of these recombinant antigens are described in 
the Luminex section above. All Plates were then blocked using 1 % bovine serum albumin. 
Stimulated PBMCs were washed and tested in duplicate over five serial dilutions starting at 
5x105 cells/well and six serial dilutions starting at 4 x 104 cells/well for the detection of 
antigen-specific ASCs and total IgG ASCs, respectively. After a six-hour incubation, plates 
were washed in PBS and 0.05% PBS-Tween20 (PBST), and incubated at 4°C overnight with 
a 1:1000 dilution of alkaline phosphatase-conjugated goat antibodies specific for human IgG 
[(gamma)-Invitrogen] in PBST. Plates were washed, developed with BCIP/NBT, thoroughly 
washed again with ddH2O and dried in the dark. ELISpot plates were quantified using an 
AID Elispot reader (Start V-spot reader spectrum) and reported as frequencies of ASCs per 
106 PBMCs. The limit of detection of the ASCs ELISpot assay for this analysis was five 
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ASCs per 106 PBMC based on the mean of ASCs in the 1% BSA control. Assay failure was 
defined as fewer than 1000 IgG+ ASCs per 106 PBMCs after the six-day culture. 
 
Merozoite Phagocytosis Assay 
Merozoite phagocytosis assays were performed as described previously [26,27], with minor 
alterations. Briefly, magnetically-purified schizonts were treated with E64 for 8 hours [28], 
and then passed through a 1.2-μm filter to release merozoites. Haemozoin was removed by 
magnetic separation, and purified merozoites were then stained with Ethidium Bromide 
(EtBr). Merozoites were incubated with the study participant’s plasma at 1:4000 dilutions and 
then combined with the THP-1 cells at a ratio 6:1. THP-1 mediated phagocytosis was arrested 
after 40 minutes. The percentage of EtBr fluorescent THP-1 cells was determined by flow 
cytometry (FacsCalibur, BD Sciences). Plasma pools from Australian and malaria hyper-
immune adults collected in Papua New Guinea were used as non-exposed and hyper-immune 
controls, respectively. 
 
Statistical methods 
We displayed the log-transformed response variables using dot plots and scatter plots. We 
summarized the skewed outcomes using the median and 90% central range, and compared the 
results from pairs of visits using the Wilcoxon signed ranks test. We defined high and low 
responders using the median value as a cut-off. The analyses were carried out in R version 
3.1.0.[29] 
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Results 
Participants and study details 
Thirty healthy male volunteers were recruited into this CHMI study. Two groups of 12 
volunteers received 1x104and 2x104of live, purified, non-attenuated P. falciparum sporozoites 
(PfSPZ challenge) intra-dermally, respectively. As a third group, six volunteers served as 
double-blinded placebo controls and were treated essentially the same except that they 
received saline instead of PfSPZ challenge. The participants demographic information such as 
age, weight, height and BMI have been described[21]. Three participants that received PfSPZ 
were excluded from the analysis presented here because they did not develop asexual blood 
stage parasitemia[21]. Remaining 27 participants were followed up for all scheduled visits at 
days 0, 9, 28, 56and 168 except for another three participants for which one volunteer missed 
day 168visit and two volunteers were excluded due to suspected clinical malaria episodes 
between study days 56 and 168.  
 
Serum antibody levels binding to pre-erythrocytic and asexual blood stage antigens 
during CHMI 
We assessed IgG antibody levels binding to known malaria antigens in serum samples 
collected at days 0, 9, 28, 56 and 168 using multiplex bead arrays. Antigens tested included 
liver stage antigen 1 (LSA-1), circumsporozoite protein (CSP), Cell-traversal protein for 
ookinetes and sporozoites (CelTOS), sporozoite surface protein 2 (SSP2), merozoite surface 
protein 1 (MSP-1 allele 3D7), MSP-1 (allele FVO), erythrocyte binding antigen 175 (EBA-
175), and the apical membrane antigen 1 (AMA-1).At baseline, all participants had detectable 
antibodies against the CSP, MSP-1 and AMA-1. Four (14.8%) volunteers lacked detectable 
antibody responses against LSA-1 and CelTOS and three volunteers (11.1%)were negative 
for SSP2 (Figure 1). 
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Figure 1: 
Multiplex-bead array based analysis of pre-erythrocytic, stage-transcending and asexual 
blood stage malaria antigen-specific serum antibody levels in PfSPZ challenged (left column) 
and placebo controls (right column).Mean log 10 antibody unit (AU) after CHMI binding to 
(a) MSP-1, (allele 3D7), (b) MSP-1,(allele FVO), (c) AMA-1, (allele 3D7), (d) CSP, (e) 
LSA-1. Error bars indicate 95% confidence intervals of the mean. Solid circles: Volunteers 
infected with P. falciparum sporozoites, empty circles: saline control volunteers. 
 
 
 
 
 
a
b
c
d
e
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
0 9 28 56 168 0 9 28 56 168
days since CHMI
lo
g1
0 
un
its
Page 144 of 222
IgG antibody levels against MSP-1 (allele 3D7) (a), MSP-1 (allele FVO) (b), AMA-1 (allele 
3D7) (c), CSP (d), LSA-1 (e) increased significantly, with the highest responses measured on 
day 28 after PfSPZ challenge(Figure 1, left column). Little variation in all malaria antigen 
specific humoral immune responses were measured over time in the placebo controls (Figure 
1, right column). Antibody levels binding to EBA-175, CelTOS and SSP2 did not differ over 
the study period (Supplementary Figure 1). Although the inoculated sporozoites expressed the 
3D7 allele of MSP-1, IgG responses to both MSP-1 alleles (3D7 and FVO) increased 
significantly (Table 1). 
 
Relative changes of MSP-1 (alleles 3D7 and FVO), AMA-1, CSP and LSA-1 specific 
antibody levels from each individual’s baseline results are given in Table 1.Significant 
increases in relation to baseline were observed on days 28 and 56. On day 168, antibody 
levels targeting MSP-1 and CSP only remained significantly higher when compared to 
baseline, which was more pronounced for the 3D7 allelic form of MSP-1.  
 
Antigen Day 28 vs 0 p-value Day 56 vs 0 p-value Day 168 vs 0 p-value 
 
MSP-1 
(3D7) 
32065  
(-1407,1990947) <0.001 
14039  
(-794, 450948) <0.001 
2372  
(-4068, 
160994) 0.008 
 
MSP-1 
(FVO) 
26743  
(-1216,2059911) <0.001 
13219  
(-621,567900) <0.001 
860  
(-
9882,335375) 0.03 
 
AMA-1 
 
4523  
(-15264,100269) 0.046 
5244  
(-11788, 70530) 0.03 
506  
(-
31431,36785) 0.70 
 
CSP 
 
475  
(36,4400) <0.001 
270  
(-168,4759) <0.001 
126  
(-289,2890) 0.04 
 
LSA-1 
 
44  
(-30,2001) 0.01 
22  
(-186,1543) 0.05 
0  
(-231,828) 0.94 
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Table 1: 
Summary of differences in IgG responses (shown as AU) between time points days 28, 56 
and 168in relation to baseline of CHMI. The 90% central range is given in brackets. The p-
values shown are obtained from the Wilcoxon matched-pairs signed-rank test. 
 
MSP1 and AMA1 specific memory B cell responses are boosted after intradermal 
PfSPZ challenge 
Next we used the B cell EliSpot analysis to follow frequencies of ASCs in peripheral blood 
[30]. At baseline, 10 out of 27 (37 %) and 12 out of 27(44%) participants had ASC against 
MSP-1 (both alleles were tested in combination) and AMA-1, respectively (range MSP-1: 1-
60 spots/million PBMC and range AMA-1: 1-20 spots/million PBMC). The number of MSP-
1 and AMA-1 specific ASCs cells was determined relative to the total number of IgG-
producing cells measured in the same experiment (baseline range of total IgG-producing cells 
1,250-25,988) as described in [30]. The number of MSP-1 and AMA-1 specific ASCs 
increased following CHMI and reached an observed peak at day 28, with a rapid decline on 
days 56 and 168 (Figures 2A and 2C). The number of MSP-1 and AMA-1specific ASCs in 
the saline inoculated group remained largely unchanged over the time course followed 
(Figure 2B and 2D). Importantly, the total number of IgG-producing cells remained 
unchanged during the CHMI (Supplementary Figure 2). 
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Figure 2: MSP-1 and AMA-1 specific ASCs increase after intradermal PfSPZ challenge 
The log of the proportion of MSP-1specific ASCs(a) and AMA-1 specific ASCs(b) in PfSPZ 
challenge inoculated volunteers (closed circles) are shown. In Figure 2B and 2D, respective 
results obtained from placebo control volunteers are depicted (open circles).  
 
The relative increases of MSP-1 and AMA-1 specific ASCs in comparison to baseline values 
are given in Table 2. Between baseline, days 28 and 56, statistically significant increases 
were observed for both antigens. On day 168, ASCs have returned to baseline levels, most 
likely reflecting a rapid decline of circulating ASCs frequencies. 
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Antibody secreting cells Day 28  
versus 0 
p 
value 
Day 56  
versus 0 
p 
value 
Day 168  
versus 0 
p 
value 
Log % MSP-1specific 
ASCs/total ASCs 
0.18  
(-0.003, 
6.86) 
 0.068  
(-0.01, 
2.43) 
0.001 0.0  
(-0.13, 
0.89) 
0.26 
Log % AMA-1specific 
ASCs/total ASCs 
0.028  
(-0.05, 
0.35) 
0.007 0.029  
(-0.05, 
0.16) 
0.05 0.005  
(-0.215, 
0.074) 
0.55 
 
Table 2: 
Relative increase in MSP-1 and AMA-1specific ASCs presented as the median of the 
differences between day 28, 56 and 168 and baseline. The 90% central range is given in 
brackets. The p-values are obtained from the Wilcoxon matched-pairs signed-rank test. 
 
Merozoite opsonizing antibodies increase following PfSPZ challenge 
Merozoite opsonizing antibodies have been demonstrated to be a robust correlate of natural 
acquired immunity to malaria[31]. Therefore, we assessed whether the increase of IgG 
antibodies binding to MSP-1 and AMA-1 following CHMI (measured by multiplex bead 
array and B cell EliSpot analysis) corresponded to an increase in functional merozoite 
opsonizing antibodies. Using a validated in vitro phagocytosis assay [26,27] (Supplementary 
Figure 3), merozoite opsonizing antibodies were observed in all individuals prior to CHMI - 
strongly suggesting prior malaria exposure (Figure 3). In the PfSPZ challenged group, an 
increase in opsonizing antibodies were observed (Figure 3A) while the saline controls did not 
change over time (Figure 3B). 
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Figure 3A                                                Figure 3B 
 
 
  Figure 3C     Figure 3D 
 
Figure 3:Opsonization of merozoites increases after intradermal PfSPZ challenge. 
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Increase in opsonizing antibody responses in (a) all PfSPZ challenged volunteers post CHMI, 
(b) placebo controls (c) in PfSPZ challenged volunteers with low baseline opsonizing activity 
(d) in PfSPZ challenged volunteers with high baseline opsonizing activity.  
 
Baseline levels of merozoite opsonizing antibodies were diverse in our volunteers. We 
investigated whether the baseline activity of opsonizing antibodies influenced subsequent 
responses to CHMI. Participants were grouped into high and low responders using the median 
value of the baseline as cut-off value. Participants with lower levels of opsonization activity 
at baseline showed strong induction of opsonization at 28, 56and 168 days following 
sporozoite inoculation (Figure 3C). In contrast, individuals displaying high baseline 
opsonization activity showed no increase following CHMI (Figure 3D).To directly test 
whether the volunteers with low and high responses at baseline had different responses after 
CHMI, we used an interaction test. The increase in merozoite opsonization after CHMI was 
significantly greater for the baseline low versus high responders at day 28 (p=0.04) and day 
56 (p=0.01). We found no correlation between baseline opsonization activity and parasite pre-
patent period. 
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 Median difference  
(90% central range) p-value 
All Volunteers combined   
Day 9 vs day 0 -1.7 (-7.4, 4.8) 0.12 
Day 28 vs day 0 0.07 (-10.7, 40.5) 0.26 
Day 56 vs day 0 0.5 (-6.5, 38.1) 0.12 
Day 168 vs day 0 3.0 (-8.2, 32.6) 0.11 
Low baseline responders   
Day 9 vs day 0 -1.46 (-5.96, 5.96) 0.49 
Day 28 vs day 0 17.04 (-1.5, 45.31) 0.01 
Day 56 vs day 0 18.91 (-1.33, 40.18) 0.01 
Day 168 vs day 0 12.05 (-0.93, 31.37) 0.001 
High baseline responders   
Day 9 vs day 0 -2.08 (-7.85, 4.36) 0.28 
Day 28 vs day 0 0.07 (-12.89, 18.23) 0.58 
Day 56 vs day 0 0.53 (-7.11, 19.36) 0.70 
Day 168 vs day 0 3.46 (-9.73, 27.13) 0.70 
 
Table 3: 
Relative increase in merozoite opsonization activity presented as the median of the 
differences between day 28, 56 and 168 and baseline. The 90% central range is given in 
brackets. The p-values are obtained from the Wilcoxon matched-pairs signed-rank test. 
 
Comparison of malaria specific humoral immunity measurements after CHMI in 
individual volunteers  
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The serum and PBMC samples collected after a defined challenge of a single P. falciparum 
strain enabled us to compare consequences for malaria specific humoral immunity using three 
different methods, namely multiplex bead array, B cell ELISpot analysis and in vitro 
merozoite opsonization assay. Interestingly, a high degree of concordance was observed 
between MSP-1(allele 3D7)ASCs, MSP-1(allele3D7)bead array and merozoite opsonization 
assays (Figure 4). For example, volunteer 10023 showed significant increases while volunteer 
20064 remained low in all three measurement methods (Figure 4).AMA-1specific responses 
were comparable to the MSP-1specific humoral immune responses (Supplementary Figure 
4A). Humoral immune responses in the control group showed little variation throughout the 
follow up period confirming that the alterations in antibody measures were induced by the 
PfSPZ challenge (Supplementary Figure4B). 
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Figure 4: 
Comparison of malaria antigen specific humoral immune responses upon PfSPZ challenge in 
Tanzanian adults. Results from each volunteer are depicted. Red lines: Bead array-based 
detection of MSP-1 specific serum antibodies; Blue lines: B cell ELISpot analysis; Green 
lines: merozoite opsonization assay. 
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Discussion 
We demonstrate here that a single intradermal inoculation with aseptic, purified, cryo-
preserved non-attenuated sporozoites in semi-immune adult Tanzanian volunteers boosted 
pre-erythrocytic and stage-transcending malaria-specific humoral immunity. Volunteers 
participating in the CHMI were recruited from higher education institutions living in Dar es 
Salaam for reduced likelihood of heavy malaria pre-exposure. At enrollment, study 
participants with lowest CSP and EXP-1 specific serum antibodies antibody levels were 
selected from a larger pool of eligible volunteers. However, since anti-malarial antibodies 
were detected in baseline samples across the three monitoring techniques used here, these 
volunteers are unlikely to be malaria-naive. Those volunteers who became blood smear 
positive after CHMI were treated with a 3-day regimen of Artemether/lumefantrine 
(Coartem), and were discharged from the research hospital after three consecutive negative 
blood smear results. Retrospective analyses of blood samples collected during CHMI by the 
more sensitive quantitative PCR showed that subclinical, asexual blood-stage parasitemia was 
present for 2-3 days prior to drug treatment [21]. Therefore, the low-density asexual blood-
stage infection experienced by CHMI participants likely explains the boost in stage-
transcending and asexual blood stage immunity. 
 
Here, we tested for antibodies to recombinant CSP and LSA-1 by multiplex bead array. Both 
antigens are exclusively expressed by sporozoites and liver-stage parasites. IgG antibodies to 
these antigens increased rapidly following CHMI, suggesting that inoculated sporozoites and 
developing liver stage parasites resulted in recall of pre-existing immunity. The increase in 
CSP and LSA-1 specific antibodies after CHMI are in line with results published by Obiero et 
al.[32], however, we included in our study a longer follow up period after PfSPZ challenge 
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PAPER VIII 
 
Controlled human malaria infection leads to long-lasting changes 
in innate and innate-like lymphocyte populations 
 
The article has been published in the Journal of Immunology (2017). Doi: 
10.1056/NEJMoa1208394 
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The Journal of Immunology
Controlled Human Malaria Infection Leads to Long-Lasting
Changes in Innate and Innate-like Lymphocyte Populations
Maxmillian Mpina,*,†,1 Nicholas J. Maurice,‡,1 Masanao Yajima,‡,x,1 Chloe K. Slichter,‡,{,1
Hannah W. Miller,‡,1 Mukta Dutta,‡ M. Juliana McElrath,‡,{ Kenneth D. Stuart,‖
Stephen C. De Rosa,‡ John P. McNevin,‡ Peter S. Linsley,# Salim Abdulla,**
Marcel Tanner,*,† Stephen L. Hoffman,†† Raphael Gottardo,‡ Claudia A. Daubenberger,*,†
and Martin Prlic‡,{
Animal model studies highlight the role of innate-like lymphocyte populations in the early inflammatory response and subsequent
parasite control following Plasmodium infection. IFN-g production by these lymphocytes likely plays a key role in the early control
of the parasite and disease severity. Analyzing human innate-like T cell and NK cell responses following infection with Plasmodium
has been challenging because the early stages of infection are clinically silent. To overcome this limitation, we examined blood
samples from a controlled human malaria infection (CHMI) study in a Tanzanian cohort, in which volunteers underwent CHMI
with a low or high dose of Plasmodium falciparum sporozoites. The CHMI differentially affected NK, NKT (invariant NKT), and
mucosal-associated invariant T cell populations in a dose-dependent manner, resulting in an altered composition of this innate-
like lymphocyte compartment. Although these innate-like responses are typically thought of as short-lived, we found that changes
persisted for months after the infection was cleared, leading to significantly increased frequencies of mucosal-associated invariant
T cells 6 mo postinfection. We used single-cell RNA sequencing and TCR ab-chain usage analysis to define potential mechanisms
for this expansion. These single-cell data suggest that this increase was mediated by homeostatic expansion-like mechanisms.
Together, these data demonstrate that CHMI leads to previously unappreciated long-lasting alterations in the human innate-
like lymphocyte compartment. We discuss the consequences of these changes for recurrent parasite infection and infection-
associated pathologies and highlight the importance of considering host immunity and infection history for vaccine design.
The Journal of Immunology, 2017, 199: 000–000.
I nfection with the apicomplexan parasite Plasmodium falci-parum causes malaria and resulted in an estimated 214million clinical cases of disease and 438,000 deaths globally
in 2015 (1). Children are particularly vulnerable until the age of
5 y, when they become more resistant to severe forms of malaria.
P. falciparum sporozoites (PfSPZs) are transmitted to the human
host during feeding of infected female Anopheles mosquitoes.
These sporozoites travel through blood vessels to the liver where
they develop into the symptomatically silent pre-erythrocytic life
cycle stage. Immunization with high numbers of attenuated
PfSPZs can induce protection against malaria infection (2–7).
Importantly, resistance to disease is rather short-lived due to the
development of short-lived immunological memory (8). Over time,
repeated exposure eventually leads to decreased disease symptoms;
however, resistance against subsequent infections is limited. Pre-
erythrocytic stage–specific protective immunity requires a
combination of liver-resident adaptive cellular immune mech-
anisms, including cytotoxic CD8 T cells and CD4 T cells that
secrete IFN-g and provide help to sporozoite-neutralizing Ab-
producing B cells (8, 9), but other immune processes may be of
importance as well. Innate-like lymphocyte responses precede
adaptive immune responses, and animal model data suggest that
these early immune responses are critical for the outcome of
subsequent adaptive immune responses (8).
Innate-like lymphocytes have been studied in a variety of in-
fections because of their ability to rapidly secrete IFN-g and TNF-a
and other effector molecules that control early inflammatory re-
sponses and pathogen load (10, 11). These innate and innate-like
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subsets include NK cells, NKT (invariant NKT [iNKT]) cells, and
mucosal-associated invariant T (MAIT) cells. NK cells (CD32
CD56+) are abundant in human blood (∼13% of lymphocytes) and
liver (∼31% of lymphocytes) (12). NK cell function is controlled
by a balance of inhibitory (recognizing MHC class I) and acti-
vating signals, such as stress-induced ligands from the ULBP
family (13). MAIT cells (CD3+ CD161hi Va7.2+) make up 1–8%
of T cells in blood and mucosal tissues and 20–45% of T cells in
the liver (14, 15). The MAIT cell TCR consists of an invariant
TCRa-chain (Va7.2) and a limited range of possible b-chains (16,
17), but MAIT cells have recently been shown to have greater
TCR heterogeneity than initially expected (18–20). The MAIT
TCR recognizes Ag in the context of the MHC-related protein 1,
which includes bacterial metabolites of the riboflavin synthesis
pathway (21). We demonstrated that inflammatory and TCR sig-
nals synergize to induce MAIT cell effector function (22), al-
though inflammatory signals can be sufficient to activate
MAIT cells (23, 24). iNKT cell (CD3+ Va24Ja18+) abundance is
substantially lower in humans compared with the mouse model
system. iNKT cells typically account for ∼0.02% of T cells in
blood and ∼0.5% of T cells in the liver (25). The iNKT cell TCR
consists of an invariant TCRa chain (Va24Ja18) and a limited
range of possible b-chains (typically V b 11), and it recognizes
lipids presented by the MHC class I–like protein CD1d (26).
A shared feature of these cell populations is their ability to
quickly respond to inflammatory signals, such as IL-12, IL-15, and
IL-18 (26, 27). A consequence of this inflammation-mediated
activation is the acquisition of effector function, including ex-
pression of IFN-g and granzyme B (grzB) (23). IFN-g is of par-
ticular interest because it seems critical in mediating immunity
against the parasite (28–35). Importantly, although inflammation
appears limited during the liver stage of malaria, the proin-
flammatory response is pronounced during the asexual blood
stage, with an increase in IL-12 and IL-18 serum concentrations
(36–39). Thus, the initial inflammatory environment elicited by
the infection may be sufficient to activate these cell populations,
leading to secretion of effector molecules, such as IFN-g and
TNF-a. Importantly, animal model data suggest that the early
inflammatory environment, and particularly IFN-g, seems to play
an important role in the ensuing parasite control, as well as disease
progression, including the development of cerebral malaria (10,
40, 41). It is unknown how accurately the mouse model mimics
these innate-like lymphocyte responses in human infection be-
cause, to our knowledge, the function and fate of NK and innate-
like T cells following Plasmodium infection of humans have not
been elucidated in detail.
To address this question, we specifically examined changes in the
NK cell, NKT cell, and MAIT cell populations using samples from
a controlled human malaria infection (CHMI) study in a Tanzanian
cohort of young adult males (age 20–35 y) exposed to aseptic
PfSPZs (PfSPZ challenge) (42). We found that CHMI significantly
affected the NK and MAIT cell population frequencies and
that changes in the MAIT cell population persisted for
$168 d postinfection. To further interrogate these changes in
MAIT cell frequency, we used a novel method to reconstruct TCR
ab-chain usage from single-cell RNA-sequencing (RNAseq) data.
Analysis of these data suggests that the MAIT cell population
rebound after the blood-stage parasitemia is driven by homeostatic
expansion mechanisms. Together, these data demonstrate that
CHMI induces long-lasting changes in the composition of the
innate-like lymphocyte compartment, with the most pronounced
changes occurring in the MAIT cell population. We discuss the
implications of these data in the context of recurrent infection,
pathology, and vaccine development.
Materials and Methods
Ethics statement
PBMCs analyzed in this study were collected during the CHMI trial
conducted in Tanzania and described in Shekalaghe et al. (42). This CHMI
was conducted as a single-center, randomized, double-blind controlled trial
enrolling volunteers following predefined inclusion and exclusion criteria.
All volunteers gave written informed consent before screening and being
enrolled in the study, and the trial was performed in accordance with Good
Clinical Practices, an investigational new drug application filed with the U.S.
Food and Drug Administration (14267), and an Investigational Medical
Product Dossier filed with the Tanzanian Food and Drug Administration.
The protocol was approved by institutional review boards (IRBs) of the
Ifakara Health Institute (IHI/IRB/No25), the National Institute for Medical
Research, Tanzania (NIMR/HQ/R.8a/Vol.IX/1217), and the Ethikkom-
mission Beider Basel (Basel, Switzerland; EKBB 319/11). The protocol
was also approved by the Tanzanian Food and Drug Administration
(Reference Number CE.57/180/04A/50), and the trial was registered at
https://clinicaltrials.gov/ (NCT01540903).
Samples analyzed
Cryopreserved samples including only the participant identifier (ID; no
personal or identifiable information) from this study were sent from the
Ifakara Health Institute to the Fred Hutchinson Cancer Research Center for
analysis with approval by the IRB (number 7349). In the 2.5 3 104 (25K)
PfSPZ group, one volunteer had to be excluded from the analysis as a
result of premature malaria treatment, and only volunteers who developed
asexual blood-stage parasites after administration of Sanaria PfSPZ chal-
lenge were included in the analysis. Venous blood was drawn prior to the
intradermal injection of PfSPZ challenge (day 0) and at subsequent time
points (days 9, 28, 56, and 168) (42). Volunteers were monitored for onset
of the asexual blood-stage parasitemia by examination of thick blood
smears by microscopy and were treated with a curative dose of Coartem
following national guidelines. A very limited number of samples were also
available from blood drawn at the time of microscopy-based diagnosis of
asexual blood-stage parasitemia. Importantly, although these volunteers
were not malaria naive, they had not had a documented malaria episode in
the past 5 y. PBMC samples were stored in liquid nitrogen and then
shipped to the Vaccine and Infectious Disease Division, Fred Hutchinson
Cancer Research Center for analysis by flow cytometry or RNAseq or were
used for ex vivo–stimulation assays. Lymphocyte counts of volunteers
participating in this CHMI were collected using a Sysmex XS-800i ma-
chine.
Flow cytometry
For the phenotypic identification of lymphocyte populations, bulk PBMCs
or sorted MAIT cells were stained with Aqua Live/Dead Fixable Dead Cell
Stain (Invitrogen). Our gating strategy and representative FACS plots are
shown in Supplemental Fig. 2, and our four FACS analysis panels are
shown in Supplemental Fig. 3.
Cell sorting
PBMCs were stained with the described sort panel and sorted on a FAC-
SAria (BD) into complete RP10. Populations sorted were CD8+ MAIT
(CD3+CD8+CD161hiVa7.2+) cells. All sorts were performed on a FAC-
SAria II.
Single-cell RNAseq processing, sequencing, and alignment
After flow sorting, single cells were captured on the Fluidigm C1 Single-
Cell Auto Prep System (C1), lysed on a chip, and subjected to reverse
transcription and cDNA amplification using the SMARTer Ultra Low Input
RNA Kit for the Fluidigm C1 System (Clontech, Mountain View, CA).
Sequencing libraries were prepared using the Nextera XT DNA Library
Prep Kit (Illumina, San Diego, CA), according to C1 protocols (Fluidigm).
Barcoded libraries were pooled and quantified using a Qubit Fluorometer
(Thermo Scientific, Life Technologies, Grand Island, NY). Single-read
sequencing of the pooled libraries was carried out on a HiScanSQ or a
HiSeq2500 sequencer (Illumina) with 100-base reads, using TruSeq v3
Cluster and SBS kits (Illumina) with a target depth . 2.5 M reads. Se-
quences were aligned to the UCSC Human Genome Assembly version 38,
and gene expression levels were quantified using RSEM and TPM values
loaded into R for analyses. We used the MAST analysis platform (23) for
subsequent single-cell analysis steps. Quality-control parameters for the
single-cell RNAseq data included expression of $500 genes, alignment
rate . 80%, library size .10,000, and exon rate . 30% (all four criteria
have to be met to for a single cell to be included). MAIT cells were
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analyzed directly after sorting and were not stimulated prior to single-cell
RNAseq processing.
MAIT cell–stimulation assay
A total of 2000–20,000 CD8+ MAIT cells was left untreated or were
treated with IL-12 (eBioscience), IL-15 (eBioscience), and IL-18 (MBL) at
100 ng/ml or with a combination of the cytokines and anti-CD3/CD28–
coupled beads (Invitrogen). At 20 h, GolgiPlug (BD) was added at a
1:1000 final dilution. For intracellular staining, cells were fixed with
Cytofix/Cytoperm and permeabilized with Perm/Wash (both from BD), per
the manufacturer’s instructions, and stained for intracellular cytokines.
Samples were run on an LSR II (BD) and analyzed using FlowJo software
(TreeStar).
Statistical analysis
Statistical significance comparing control and treated subjects was assessed
using a Type II ANOVA for a linear mixed-effect model with patient-level
random intercepts, with a level of 5%. R functions lmer and Anova in lme4
and car packages were used for the calculations. Comparison of time
points with each other was done using a paired t test with false discovery
rate (FDR) correction.
Results
Innate-like lymphocyte frequencies change in a PfSPZ
infection dose–dependent manner
To study the innate-like lymphocyte response to PfSPZ infection,
we analyzed samples from a trial conducted in African volunteers
pre-exposed to malaria with intradermal application of 1 3 104
(10K) or 25K purified, cryopreserved nonattenuated PfSPZs (n =
12 each group). Eleven of twelve volunteers in the 10K PfSPZ
group and 10 of 11 evaluable volunteers in the 25K PfSPZ group
developed asexual blood-stage parasitemia after intradermal in-
jection of PfSPZs (42). Blood was drawn prior to the intradermal
challenge (day 0) and at subsequent time points (days 9, 28, 56,
and 168) (42). Volunteers were monitored for the onset of the
blood parasitemia stage by blood smear and were treated with
Coartem following a positive blood smear to clear the infection. A
very limited number of samples were also available from blood
drawn at the time of blood parasitemia diagnosis. Importantly,
although these volunteers were not malaria naive, they had not had
a documented malaria episode in the past 5 y. Thus, the design of
this study allowed us to determine how NK, iNKT, and MAIT cell
function and frequencies change early (day 9) following CHMI
and to longitudinally examine the duration of these changes in a
cohort that is highly relevant for malaria vaccine efforts.
We initially determined whether an infection with 10K or 25K
PfSPZs affects the composition of the innate-like lymphocyte
compartment in the venous blood by flow cytometry. We exam-
ined the frequency of MAIT cells (CD3+Va7.2+CD161hi), NK
cells (CD32CD56+), and iNKT cells (CD3+Va24Ja18+) on days
0 and 9 postinfection and then after the Coartem treatment on days
28, 56, and 168. The gating strategies used and representative flow
cytometry plots are shown in Supplemental Fig. 2.
We observed a significant increase in the frequency of MAIT
cells within the CD8+ T cell population at 168 d postinfection
FIGURE 1. Changes in the innate-like T lymphocyte and NK cell compartment following intradermal injection of PfSPZs. Changes in the frequency of
MAIT cells within the CD8+ T cell population (A), the NK cell population (shown as frequency in CD32 lymphocyte population) (B), and the iNKT cell
population (C) are shown for the low-dose challenge group (10k PfSPZ, left panels) and the high-dose challenge group (25k PfSPZ, right panels). The
yellow line in each graph represents the median. Volunteer IDs are listed, with each volunteer depicted in a distinct color. Significant changes at time points
following PfSPZ injection (compared with day 0) are indicated with an asterisk (*). Statistical significance comparing control and treated subjects was done
using Type II ANOVA for a linear mixed-effect model. Comparison of time points with each other was done using a paired t test with FDR.
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(p = 0.0174) in the 25K-dose challenge group. Significant changes
in the frequency of MAIT cells within the CD8+ T cell population
following infection with the 10K dose were not observed (Fig. 1A,
left versus right panels), indicating that MAIT cells respond in an
infection dose–dependent manner. This was recapitulated when
calculating the absolute number of CD8+ MAIT cells in the blood
(Supplemental Fig. 1). Importantly, the absolute number of CD3+
T cells (cells per microliter blood) did not change significantly over
time, indicating that this population serves as a suitable reference
point to display T cell subset frequencies (Supplemental Fig. 1). We
next examined the frequencies of NK cells and iNKT cells (Fig. 1B,
1C). NK cell frequencies in the lymphocyte population were re-
duced significantly on day 28 (p = 0.0005) and on day 56
(p = 0.0083) postinfection, particularly in the high challenge group
(Fig. 1B). NK cell frequencies are shown as the percentage of the
CD32 lymphocyte population, but the same result is seen when
analyzing NK cell numbers per microliter of blood (Supplemental
Fig. 1C). In contrast to NK and MAIT cells, iNKT cell frequencies
did not change significantly following the infection, regardless of the
PfSPZ dose (Fig. 1C). Given the changes in the MAIT cell pop-
ulation following CHMI in the 25K challenge group and considering
their functional potential (IFN-g production) and abundance in the
liver (up to 40% of all T cells), we primarily focused on the more
abundant CD8+ MAIT cell subset for the rest of the study to de-
termine the consequences of CHMI on the MAIT cell population.
MAIT cell frequencies change following PfSPZ infection
We examined the frequency of MAIT cells (CD3+Va7.2+CD161hi;
CD8+ and CD82 subsets) on days 0 and 9 postinfection, during the
blood parasitemia stage and then after the Coartem treatment on
days 28, 56, and 168. To better dissect the changes in the
MAIT cell population, we looked at the frequency of all (CD8+
FIGURE 2. MAIT cell frequency is altered following intradermal injection with PfSPZs. Shown are changes in the frequency of MAIT cells over time for
each individual volunteer. Significant changes are indicated with an asterisk (*), and p values were determined using a t test. (A) Percentage of MAIT cells
in the CD3+ population in the blood in the 25K PfSPZ group. Significant changes compared with day-0 baseline were observed at the blood parasitemia
stage (p = 0.0302), on day 56 (p = 0.0022), and on day 168 (p = 0.0072). Frequency of CD8+ MAIT cells (B) and CD82 MAIT cells (C) within the CD3+
cell population. Statistical significance comparing control and treated subjects was done using a Type II ANOVA for a linear mixed-effect model.
Comparison of time points with each other was done using a paired t test with FDR. Significant changes compared with day-0 baseline were observed for
CD8+ MAIT cells at the blood parasitemia stage (p = 0.0278) and on day 168 (p = 0.0239). Significant changes were detected for CD82MAIT cells on day
28 (p = 0.0003), day 56 (p = 0.0008), and day 168 (p = 0.0002). The yellow line in each graph represents the median. Volunteer IDs are listed, with each
volunteer depicted in a distinct color.
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and CD82) MAIT cells within the T cell (CD3+) compartment
(Fig. 2A) and then subdivided the population into the CD8+
(Fig. 2B) and CD82 (Fig. 2C) subsets. We found that the fre-
quency of MAIT cells within the CD3+ population decreased
significantly during the blood parasitemia stage (p = 0.0302) and
rebounded thereafter, with MAIT cell frequencies on day 168
exceeding the initial day-0 baseline level (p = 0.0072, Fig. 2A).
This pattern was also observed when the MAIT population was
divided into CD82 and CD8+ cell subsets (Fig. 2B, 2C). Impor-
tantly, availability of the blood-stage parasitemia samples was
limited to this MAIT cell analysis experiment; thus, these samples
could not be included in any subsequent experiments.
MAIT cell activation occurs in a limited manner during the
course of the infection
Exposure to proinflammatory cytokines is sufficient to induce
MAIT cell activation (23, 24). Release of parasites from the liver
into the bloodstream is associated with a proinflammatory immune
response, which could activate MAIT cells. Thus, we first
addressed whether there are signs of MAIT cell activation on day
9 postinfection. CD69 is an early marker of T cell activation and
although an increase in CD69 surface expression is often used as
an indicator of TCR signaling, inflammatory signals are also
sufficient to induce expression (43). We examined surface ex-
pression levels of CD69 and found no significant changes on day
9 or later (Fig. 3A). Similarly, the frequency of CD25+- and
CD40L+-expressing MAIT cells did not increase significantly on
days 9 and 28 following challenge with PfSPZs (Fig. 3B, 3C).
CD25+ MAIT cells were significantly decreased on day 56
(p = 0.0011) (Fig. 3B). Finally, NKG2D expression did not change
significantly postinfection (Fig. 3D). Together, these flow cytom-
etry data suggest that ex vivo MAIT cell activation is minimal at
the interrogated time points.
MAIT cell effector function is limited on day 9 postinfection
To determine whether there is early (day 9) acquisition of effector
function, we examined the ex vivo expression of TNF-a, IL-17,
IFN-g, and grzB by intracellular cytokine staining and flow
cytometry (Fig. 4). We found no evidence of significant ex vivo
MAIT cell effector function on days 9, 28, 56, and 168 postin-
fection. We considered two possibilities for the lack of ex vivo
effector function: a lack of activating inflammatory signals and
parasite-induced impairment of function. To distinguish between
these two possibilities, we next tested how MAIT cells isolated
before and after blood-stage parasitemia respond to TCR and
cytokine stimulation ex vivo.
MAIT cells remain functional following infection with PfSPZs
We isolated MAIT cells from five donors by FACS and examined
whether their ability to respond to ex vivo stimulation was changed
on days 9 and 28 postinfection compared with day 0. We measured
the ability of MAIT cells to express IFN-g, grzB, and IL-17A/F
FIGURE 3. Limited MAIT cell activation early postinfection. Expression frequency of CD69 (A), CD25 (B), CD40L (C), and NKG2D (D) is shown for
CD8+ MAIT cells in the high-dose (25K PfSPZ) group. Significant changes compared with day 0 are indicated with an asterisk (*). Statistical significance
comparing control and treated subjects was done using a Type II ANOVA for a linear mixed-effect model. Comparison of time points with each other was
done using a paired t test with FDR. The yellow line in each graph represents the median. Volunteer IDs are listed, with each volunteer depicted in a distinct
color.
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following stimulation with proinflammatory cytokines (IL-12/15/
18) or a combination of TCR signals delivered by anti-CD3/
CD28–coated beads and IL-12/15/18. Regardless of the time point
postinfection, MAIT cells responded to both stimulation condi-
tions and almost uniformly expressed grzB (Fig. 5A) and IFN-g
(Fig. 5B). A much smaller fraction expressed IL-17A or IL-17F at
all three time points (Fig. 5C, 5D). Together, these data suggest
that MAIT cells remain responsive to TCR and cytokine–mediated
stimulation on day 9 or 28 postinfection. To determine whether we
can identify MAIT cell activation early postinfection, we next
examined MAIT cells from one donor using single-cell RNAseq.
Single-cell RNAseq analysis of MAIT cells
We isolated MAIT cells by FACS from donor 20064 and used the
C1 Fluidigm system to interrogate changes in gene-expression
signatures on a single-cell level by comparing data from days 0,
9, and 28 after CHMI. Using an analysis method that we developed
previously (23), we found that some, but not all, MAIT cells ex-
press grzB or IFN-g transcripts on day 9 postinfection, but not on
days 0 and 28 (Fig. 6A), suggesting that some MAIT cells are
indeed partially activated on day 9 postinfection.
To acquire a more global understanding of the MAIT cell
changes, we used the single-cell data to compare the tran-
scriptome of these single cells at days 0, 9, and 28 postinfection.We
found that the MAIT cell population displayed a distinct RNA-
expression profile on each day (Fig. 6B), suggesting that they
do respond to the PfSPZ challenge by day 9 and do not return to
baseline transcriptional status by day 28. To better understand the
nature of these changes, we next reconstructed the TCRa and
TCRb sequences from the transcriptome and analyzed the CDR3
region to identify clonal diversity (Fig. 6C, Supplemental Fig. 4).
We did not observe significant changes in the relative distribution
of MAIT cell clones by day 28, suggesting that the expansion of
MAIT cells is not dominated by a distinct TCR-bearing clonal
population. We found an increase in the coexpression of IL-7Ra
and the cg-chain (needed for signal transduction and shared with
other cytokine receptors) on days 9 and 28 (Fig. 6D). Although
IL-7 is typically associated with promoting homeostatic proliferation
(44), recent studies suggest that IL-7 can induce MAIT cell cy-
totoxic function (45, 46). The increase in mRNA encoding for the
cg-chain on MAIT cells was confirmed at the protein level by flow
cytometry staining (Fig. 6E). Given this potential change in re-
sponsiveness to cytokine signals, we next wanted to determine
whether the expanded MAIT cell population is distinct, in terms of
trafficking properties, from the preinfection MAIT cell population.
Trafficking properties in MAIT cells
To determine whether the tissue-trafficking properties of
MAIT cells change postinfection, we used FACS to examine
chemokine receptor expression following CHMI. To specifically
determine the liver- and tissue-homing potential of MAIT cells
during CHMI, we analyzed the expression of CCR6, CXCR6,
and CXCR3. Briefly, CCR6 is a key receptor to enable trafficking to
inflamed tissues, and CXCR6 plays an essential role for trafficking
FIGURE 4. Minimal MAIT cell effector function early postinfection. Expression of grzB (A), IFN-g (B), IL-17A (C), and TNF-a (D) on both MAIT cell
subsets was measured in the 25K PfSPZ cohort. The yellow line in each graph represents the median. Statistical significance comparing control and treated
subjects was done using a Type II ANOVA for a linear mixed-effect model. Comparison of time points with each other was done using a paired t test with
FDR, but no significant changes were detected. Volunteer IDs are listed, with each volunteer depicted in a distinct color.
6 INNATE-LIKE IMMUNITY TO CONTROLLED HUMAN MALARIA INFECTION
 
Page 161 of 222
to the liver (47–49). The majority of MAIT cells expressed CCR6
and CXCR6 on their surface prior to CHMI. Overall, we found
that expression of CCR6 and CXCR6 was fairly stable over time
(Fig. 7A, 7B). Only a small fraction of MAIT cells expressed
CXCR3, which has recently been shown to orchestrate migration
of Ag-specific T cells (50). We observed an initial significant
decrease (day 0 versus day 28, p = 0.0078) in the frequency of
CXCR3+ CD8+ MAIT cells that was followed by an increase over
time that approached the initial expression frequency (Fig. 7C).
Discussion
CHMI is a powerful approach to study immune responses following
defined exposure to P. falciparum in different human populations
(51). We report that a single intradermal infection with aseptic,
purified, cryopreserved PfSPZs has profound long-lasting effects
on the innate-like lymphocyte compartment in the peripheral
blood of adult Tanzanian volunteers pre-exposed to malaria. To
our knowledge, MAIT cells in malaria-naive volunteers under-
going similar CHMI approaches have not been studied (51). We
observed a significant decrease in the frequency of blood-
circulating MAIT cells following intradermal infection with 25K
PfSPZs during early blood-stage parasitemia (days 11–18 post-
infection). This was followed by a rebound in the frequency of
MAIT cells that exceeded the initial baseline frequency and was
sustained for months after the infection (Figs. 1, 2, Supplemental
Fig. 1). The long-lasting (168-d) increase in MAIT cell frequency
that we observed is remarkable, because an acute infection or
vaccine application typically changes the innate immune system
only temporarily before it returns to baseline. In contrast, long-
lasting changes are seen in the adaptive immune system due to
Ag-specific adaptive memory immune responses. This was ele-
gantly demonstrated by Tsang and colleagues (52) on a systems
biology level in the context of the influenza vaccine. Our data
suggest that an acute infection with PfSPZ did not just result in a
temporary immune perturbation but instead had a long-lasting
impact on MAIT cells. Importantly, these changes occurred in
an infection dose–dependent manner in volunteers infected with
25K, but not 10K, PfSPZs (Fig. 1). These two doses resulted in
FIGURE 5. MAIT cells remain functional and responsive to stimulation ex vivo. FACS-purified CD8+CD161hiVa7.2+ cells were stimulated with cy-
tokines (IL-12/15/18) or a combination of a TCR signal plus cytokines (TCR+IL-12/15/18), or were left unstimulated (No stim), for 24 h. Expression of
grzB (A), IFN-g (B), IL-17F (C), and IL-17A (D) was measured in five randomly chosen donors on days 0, 9, and 28. MAIT cells responded to each
stimulation condition, but we did not detect significant changes when comparing MAIT cell responses to cytokine IL-12/15/18 (green bars) or TCR+IL-12/
15/18 (blue bars) stimulation between the different time points (days 0, 9, and 28).
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P. falciparum infections with different geometric mean asexual
erythrocytic stage parasitemia prepatent periods of 15.4 d (10K)
and 13.5 d (25K) by microscopy (p = 0.023) and 12.2 d (10K) and
11.1 d (25K) by quantitative PCR (p = 0.076) (42). This kinetic
difference is presumably due to the release of higher numbers of
merozoites from the liver in the 25K PfSPZ group that resulted in
a shorter prepatent period in comparison with the 10K PfSPZ
group. Malaria treatment decision was based on the detection of
asexual blood-stage parasites in the blood by microscopy. Given
the difference in detection sensitivity between quantitative PCR
and microscopy, the immune system had likely been exposed to
asexual blood-stage parasites for ∼2.5–3 d in both groups before
initiation of Coartem treatment. Based on this similarity in the
duration of the blood-stage phase of infection in the two dosage
groups, the infection dose–dependent differences that we observed
(Fig. 1) are likely due to an increased inflammatory response in
the liver following infection with 25K PfSPZ as opposed to a
prolonged infection during the blood stage.
Interestingly, early after 25K PfSPZ infection, the NK cell
frequency decreased significantly, similarly to MAIT cells
(Fig. 1B), but then slowly (by day 168) returned to baseline lev-
els. This decrease contrasts with data from an animal model
demonstrating that NK cells in the blood expand robustly and
early postinfection (40). Support for the notion that NK cells
contribute to the antiparasite immune response comes from a re-
cent study showing that human NK cells bind to and eliminate
infected RBCs using cell contact–dependent mechanisms (53).
Additional human studies will be required to determine which
aspects of the mouse model system can be used to mimic human
NK cell responses. Finally, iNKT cell frequencies were stable,
regardless of the challenge dose (Fig. 1C). We argue that this is
unexpected given the many similarities between iNKT and
MAIT cells in terms of proinflammatory cytokine responsiveness
(26). Future studies will need to address why MAIT cells, but not
iNKT cells, are affected by CHMI.
To examine whether MAIT cell function is altered in addition to
frequency, we next examined MAIT cells for expression of markers
that indicate recent activation (CD69, CD25), as well as ex vivo
expression of cytokines (IL-17, TNF-a, IFN-g, grzB). MAIT cells
did not show a strong increase in expression of biomarkers that
indicate activation at early or later time points (Fig. 3) or that
displayed ex vivo effector function on day 9 or later postinfection
FIGURE 6. Single-cell RNAseq analysis of MAIT cells reveals partial activation and changes in the composition of the MAIT cell population. CD8+
MAIT cells were sorted by FACS for single-cell RNAseq expression analysis by the Fluidigm C1 system. Cells sorted from donor 20064 on days 0, 9, and
28 are depicted in green, orange, and blue, respectively. (A) IFN-g and grzB message are detected in some MAIT cells on day 9 postinfection but not on
days 0 and 28. (B) Linear discriminant analysis of single MAIT cells sorted on days 0, 9, and 28 postsporozoite challenge. (C) Clonality in the MAIT cell
population was examined by analyzing CDR3 usage from single cells by reconstructing their TCRa- and TCRb-chains. Segments in the circle represent
individual cells yielding a TCR sequence. Arcs connect cells sharing TCR clonotypes (TRA and/or TRB V gene, J gene, and CDR3 junction). (D) Changes
in mRNA coexpression of IL-7Ra and cg-chain (CD132) are shown in a contour plot. (E) The surface expression of CD132, measured by flow cytometry,
increases on day 28, validating the single-cell RNAseq data [donor 20064 was used for (A–E)].
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(Fig. 4). Importantly, MAIT cells remained fully responsive to
activating signals ex vivo (Fig. 5). These data demonstrate that
MAIT cell function is not lost and argue against the existence of
inhibitory signals that impair MAIT cell function following PfSPZ
infection. This is in contrast to reports that suggest parasite-
specific adaptive immune responses are impaired by the pres-
ence of asexual blood-stage parasites (11). Determining that
MAIT cells remain functional is highly relevant, because mech-
anisms that activate MAIT cells in the liver could be of interest as
a potential therapeutic strategy against the liver-stage disease.
Because of their high abundance in the liver (up to 45% of
T cells), MAIT cells may be involved in maintaining liver ho-
meostasis during malaria parasite infections and might provide
early antiparasite effector mediators (e.g., IFN-g production) be-
fore the adaptive immune response is recruited and fully devel-
oped. The size of the MAIT cell population in the liver likely
exceeds the size of the adaptive Ag-specific T cell population that
could be induced by vaccination. In this context, it is also im-
portant to consider that MAIT cells have high expression levels of
CCR6 and CXCR6, allowing them to traffic to the liver. Impor-
tantly, we found evidence of partial activation by single-cell
RNAseq (Fig. 6A), suggesting that there are some activating,
but yet unknown, stimuli early postinfection. It is noteworthy that,
despite minimal initial activation, the MAIT cell transcriptome did
not return to baseline in the time frame tested, because we still
found transcriptional differences on day 28 postinfection
(Fig. 6B). Future studies will need to examine the MAIT cell
transcriptome at later time points postinfection to determine
how long this functional alteration lasts.
Next, we used these single-cell RNAseq MAIT cell tran-
scriptome data to reconstruct TCRa- and b-chain usage in the
MAIT cell population on days 0, 9, and 28 from the same donor.
Although MAIT cells express an invariant a-chain, there are
differences in the CDR3 junctions that allowed us to track distinct
MAIT cell clones (Fig. 6C). Given that we observed an increase in
MAIT cell frequency starting by day 28 in an infection dose–
dependent manner, we asked how the TCR ab distribution
changed at these three time points. We wanted to distinguish
whether the increase on day 28 is due to a relocation of the same
MAIT cell population back into circulation after its sharp decline
on the day of parasitemia or whether it is indicative of replen-
ishment of the MAIT cell population via homeostatic mechanisms
or de novo generation from the thymus. Our single-cell RNAseq
data did not reveal significant changes in the TCR repertoire
among days 0, 9, and 28, indicative of an overall MAIT cell ex-
pansion rather than a clonotype-driven response (Fig. 6C). Inter-
estingly, a previous study reported a sustained expansion of gd
T cells following a primary CHMI in naive volunteers, but it is
FIGURE 7. Changes in chemokine receptor expression months after the infection. The frequency of CCR6-expressing (A), CXCR6-expressing (B), and
CXCR3-expressing (C) CD8+ MAIT cells was determined by FACS in the 25K PfSPZ cohort. Statistical significance comparing control and treated subjects
was done using Type II ANOVA for a linear mixed-effect model. Additional comparison of time points with each other was done using a paired t test with
FDR. Significant changes are indicated with an asterisk (*), and p values were determined using a t test. The yellow line in each graph represents the
median.
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still unclear whether this expansion is polyclonal or clonally
driven (51, 54). Importantly, in the context of the increased IL-
7Ra and cg coexpression on day 28, we argue that the increase in
the MAIT cell population is triggered by homeostatic expansion.
Homeostatic expansion occurs in response to available growth
factors and is typically driven by cytokines (e.g., IL-7 and IL-15)
whose receptor uses the common g-chain (55, 56). Increased re-
sponsiveness to IL-7 through enhanced IL-7Ra expression could
be of specific interest because it also positively affects MAIT cell
effector function (45, 46).
Given the temporary decrease in MAIT cell frequency in the
blood of the 25K PfSPZ group, we considered that MAIT cells
could migrate to other tissues or, alternatively, undergo apopto-
sis. A decrease in blood MAIT cell frequencies following infection
is not unusual and has been reported in several other instances,
including active tuberculosis (57) and HIV (58–60), although the
fate of the MAIT cells in these situations has not been fully re-
solved. In an effort to determine whether migration may play a
role in these MAIT cell changes, we examined the expression
patterns of three highly relevant chemokine receptors for homing
to the liver and other tissues: CCR6, CXCR6, and CXCR3
(Fig. 7). We did not find any significant differences in the ex-
pression pattern of CCR6 and CXCR6, with only a temporary
decrease in CXCR3 expression early postinfection. This shows
that MAIT cells remain responsive to chemotactic signals but does
not provide insight into the relationship between blood and tissue
MAIT cells. Ultimately, it would be necessary to examine human
liver tissue to understand the dynamics of the MAIT cell response.
MAIT cells are rare in mice; however, a recently developed mouse
model with MAIT cell frequencies that approximate those in
humans opens new possibilities for studying MAIT cells in an
animal model (61).
How biologically relevant are these changes in the MAIT cell
and NK cell populations? NK cells play an important and non-
redundant role in host defense against viruses, particularly her-
pesviruses. Although the frequency of NK cells eventually
normalized again, it raises the question whether the PfSPZ-induced
NK cell decrease may have a temporary general negative impact on
host immunity, given the critical role of NK cells for protection
against herpesvirus infections (62). This is particularly interesting
in the context of EBV infections, because coinfection is a major
risk factor for developing Burkitt lymphoma, and exposure to
malaria can affect immune responses against EBV (63–65). Fi-
nally, MAIT cells have been suggested to play a role in antibac-
terial immunity through sensing of MHC-related protein 1–bound
microbial products, but they appear quite sensitive to inflamma-
tory cues in the absence of Ag. Thus, MAIT cells may act as an
amplifier of early proinflammatory signals, and an increase in
MAIT cells may lead to a more profound subsequent proin-
flammatory response. In the context of malaria, these changes in
the early immune response to the parasite may be beneficial and
contribute to clearance, and they may also exacerbate pathologies
that have been associated with excessive inflammatory responses.
It is important to keep in mind that we studied the immune re-
sponse following a defined single malaria infection event initiated
by purified, cryopreserved sporozoites of a defined genotype,
NF54, and treatment occurred upon detection of the blood stage of
infection. Under natural conditions, humans are exposed to mul-
tiple infectious mosquito bites carrying a range of parasite geno-
types, and treatment is typically not immediate. Thus, the
well-defined CHMI approach allows us to study the immune re-
sponse in the context of the liver stage and the early blood stage of
infection, which will help to interpret data from more complex
natural infection studies.
Changes in the initial immune response affect the ensuing
adaptive immune response, which is of relevance in the context of
vaccine efficacy. Our data demonstrate changes in the NK and
MAIT cell compartment months after CHMI. Additional studies
are now required to address how these changes alter the outcome of
repeated malaria infections (delivered by CHMI or natural infec-
tions) that could be beneficial or detrimental for malaria-induced
pathology, viral or bacterial coinfections, and vaccine take and
responsiveness in individuals with recent history of malaria ex-
posure, particularly infants and children (66).
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!
S Fig 1. CD3+, CD8+ MAIT and NK cell counts per microliter blood. The lymphocyte counts per 
microliter blood were determined and subsets counts were calculated based on frequency 
established by FACS. (A) CD3+ cell counts did not chance significantly over time, while (B) CD8+ 
MAIT cell counts increased significantly by day 168 (p < 0.05) going from a mean value 44 (d 0) cells 
to 70 (day 168) cells per microliter blood.  (C) NK cell numbers decreased significantly on days 28 
and 56.  
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S Fig 2. Gating strategy and representative FACS plots. Our gating scheme to identify CD4, CD8, 
iNKT, CD8+ and all MAIT and NK cells is illustrated and representative FACS plots are shown. !
!
Supplemental Figure 2 
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! 
S Fig 3. FACS Panels. Shown are the FACS panels used to examine function ex vivo and iNKT, NK 
and MAIT cell frequencies, chemotaxis and activation characteristics. 
Supplemental Figure 3 
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! 
S Fig 4. (A) single-cell RNAseq was also performed on a 2nd donor, but RNAseq data quality 
(transcript number and length) was substantially lower compared to the donor shown in Fig 6. 
Although not used for whole transcriptome analysis, we used this donor’s data to reconstruct TCR 
sequence information as outlined in Fig. 6 (B) Showing combined data from both subjects. E.cell = 
the number of cells with expanded TCRs (>4); NE. cell = the number of cells with non-expanded 
TCRs (<=4); E.int = E. cells shared between donors. There was not significant difference in the 
distribution of cell with expanded vs. non-expanded TCRs over time (p-value = 0.6364). 
 
Supplemental Figure 4 
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General discussion, conclusion and recommendations 
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6.1. General discussion 
This chapter discusses the outcomes of malaria vaccine and challenge studies 
performed in the context of my PhD thesis. We evaluated the most advanced pre- 
erythrocytic malaria vaccine, RTS,S/AS01 in Bagamoyo, Tanzania – a setting where 
malaria is endemic and where the target population for this vaccine lives. We 
provide novel insights on the immunological evaluation of RTS,S/AS01 induced 
immunity and its relation to measured vaccine efficacy against P. falciparum malaria 
in African children and infants (Chapter 4). In addition we discuss the potential of 
using CHMI in malaria endemic countries as a tool for accelerating malaria vaccine 
and drug development in the relevant target population (Chapter 5). We further give 
recommendations for possible improvement of the current vaccine development 
approaches and outline the contribution of the current PhD work in the field of 
malaria vaccine development. 
 
611  Investigation of safety, efficacy and immunogenicity of RTS,S/AS01    
vaccine in Tanzania paediatric population 
Volunteer safety while receiving a novel, non-registered investigational product is 
top priority in clinical trials, particularly when targeting healthy populations in 
vaccine development. The RTS,S/AS01 malaria vaccine candidate, tested in a 
large phase III trial, is the most advanced vaccine so far in the malaria vaccine 
development pipeline. Despite the large-scale testing of RTS,S/AS01 in eleven African 
centers and the long follow up period of 32 months, important knowledge gaps 
remain. Mode of action, immune correlates of protection and factors driving the 
reduced vaccine efficacy in different malaria endemicities remain unclear. The 
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question of why the RTS,S/AS01 vaccine shows lower efficacy in infants when 
compared to children of 5-17 months and how the different outcomes of the 
vaccine trials are affected by pre-existing malaria endemicity is far from clear. 
 
Moreover, the modest increase of IgG antibody titers to the NANP repeat region 
post-booster dose at month 20 compared to the peak response post-dose three is 
remarkable (JOINT TECHNICAL EXPERT GROUP., 2015). In addition, the 
question of whether children vaccinated with RTS,S/AS01 are prone to a malaria 
rebound when living in higher malaria transmission regions is of serious concern 
(Olotu et al., 2016). Surprisingly, little is known about relevant antibody subclasses 
and the avidity and functionality of protective antibodies required for conferring 
protection. Similarly, the quality, kinetics and quantity of vaccine-specific cellular 
immune response and their relation to long term protection remain obscure. 
 
In Bagamoyo, safety and efficacy was assessed during this phase 3 randomized, 
controlled, double- blinded trial, in infants aged 6-12 weeks at time of enrolment 
(chapter 4; paper I). In this trial, infants were randomly assigned to receive three 
doses of the RTS,S/AS01 vaccine or a comparator vaccine, administered 
intramuscularly at 1-month intervals, with or without a fourth dose given 20 months 
after the first dose and participants were followed up through passive surveillance. 
In this study, we showed that the RTS,S/AS01 vaccine generally demonstrated an 
excellent safety profile. A comparable safety profile was also reported in early 
phases of RTS,S/AS01 when trials were conducted in malaria naïve population in 
the US and Europe (Schwartz et al., 2012). 
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However, several safety signals have become apparent during recent data analysis 
such as the mortality increase in girls (Klein et al., 2016). The Global Advisory 
Committee on Vaccine Safety (GACVS) reported a 2-fold increase mortality in girls 
than in boys vaccinated with RTS,S/AS01; when a combined additional safety 
signal analysis was performed by gender and study arm (WER-WHO, 2016). While 
girls are more at risk of being neglected by their families in certain cultures, there is 
also clear evidence that sex-based differences in susceptibility to infectious 
diseases and immunity against vaccines exist (Klein et al., 2015, 2015; Ruggieri et 
al., 2016). So far, unexplained serious adverse events such as cerebral malaria, 
meningitis and death are slightly higher in the RTS,S/AS01 vaccinees when 
compared to the control group. Such observations could be incidental findings, as 
some of the cases were realized later without any obvious timely relationship to 
vaccination. These safety signals make further investigation of the safety of 
RTS,S/AS01 when deployed under “real life conditions” a must before approval for 
routine use is granted. 
 
We further evaluated the efficacy of the RTS,S/AS01 malaria vaccine in a phase 3 
study that included 6,537 infants expecting that the outcome would be similar or 
even better when compared to what has been observed earlier in phase I and 
phase II studies. However, the efficacy achieved in this phase III trial was lower 
when compared to the efficacy demonstrated in the early studies conducted in a 
comparable environment and age group (Asante et al., 2011). In striking contrast to 
a moderate efficacy observed in the current RTS,S/AS01 vaccine trial in infants; 
the previous trials of RTS,S/AS01 demonstrated superior efficacy when tested in 
malaria naïve subjects (Kester et al., 2007, 2009; Leroux-Roels et al., 2014), semi-
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immune African adults volunteers (Polhemus et al., 2009) and  fairly encouraging 
efficacy in older children (5-17 months) (Agnandji et al., 2011). In order to address 
the question as to why the RTS,S/AS01 vaccine appears to be more efficacious in 
naive and semi-immune children than in infants living in Africa, we have started to 
analyze the blood samples collected from the children cohort during our trial in 
Bagamoyo and the anaylsis is on ongoing.  
 
At the moment, we could hypothesize that the level of efficacy observed in the 
current study is a clear-cut finding, making the effort for designing a second 
generation vaccine crucial. However, age-dependent immune response could be 
another possible explanation. It is well established that resistance to severe 
malaria increases with increase in age and exposure (Doolan et al., 2009; Griffin et 
al., 2015; Olotu et al., 2011). Infant immune systems are not well developed and 
have limited exposure to antigens in utero. Therefore protection against infections 
in this population is thought to be heavily dependent on their provision of protective 
maternal antibodies and well-functioning innate immune systems (PrabhuDas et 
al., 2011). This is also supported by higher anti-CSP antibodies detected in older 
children compared to infants, albeit antibodies have not been well established as 
marker of protective vaccine induced immunity (Kester et al., 2009; Olotu et al., 
2011).  
 
An alternative explanation could be that the RTS,S/AS01 vaccine protects 
individuals from developing blood stage infection, leading to a slower acquisition of 
immunity to blood-stage parasites. Such scenario will result in a rebound of clinical 
malaria cases at a later life stage, as recently demonstrated by Olotu and 
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colleagues (Olotu et al., 2016). It could also be true that other factors such as 
heterogeneity of natural exposure and individual based vaccine intake and 
responses played a role in the observed lower efficacy in the infant group. Co-
administration of RTS,S/AS01 with other EPI vaccines could be another cause of 
inferior efficacy shown in the current trial.  
 
Cellular immune interference has been shown to have an impact when two 
vaccines containing similar protein components are administered in parallel (Dagan 
et al., 1998). The hepatitis B vaccine that was co-administered with RTS,S/AS01 
has a fusion protein that also incorporates the HBsAg. This could also be a reason 
for the disappointing vaccine efficacy observed in the infant cohort. However, this 
tendency warrants further detailed analysis of the impact of co-administering the 
vaccine with EPI vaccines. Presence of maternal antibodies, fetal haemoglobin and 
low exposure in infants has been shown to play critical roles in efficacy of other 
vaccines in infants (Billig et al., 2012; Edwards, 2015). However, despite that in this 
particular study these parameters were not tested, a slightly higher efficacy that 
was reported in children cohort suggests pre-existing hemoglobinopathies might 
not underline lower efficacy in the infant cohort. 
 
Cellular and humoral immune responses are both important in protection against 
malaria infection (Good and Doolan, 1999; Schofield and Mueller, 2006) and are 
likely to be affected by the level of malaria exposure. African field trials of malaria 
vaccines have mostly generated evidences of humoral immune responses, while 
data regarding cellular immunity remains under explored (White et al., 2015). The 
most challenging hurdles in conducting the cellular immune assays in infants and 
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children are a limited blood volume that can be obtained from this population, 
getting an acceptable frequency of repeat sample collection and gaining ethical 
and parental approval for the enrolment of usually healthy children in research 
studies (MOORMANN, 2009). The quality and quantity of the PBMC isolation in 
any cellular immune response assays is also critical. In the current study we 
managed to collect PBMCs and plasma samples at different time points and cryo-
preserved them in liquid nitrogen vapor phase and -80qC, respectively for future 
investigation of vaccine-induced cellular and humoral immune responses. We 
showed that the collected PBMCs were still good quality in terms of viability and 
quantity even after 5 years of storage (chapter 4; paper IV). 
 
In this thesis work, we also demonstrated that Th1 responses could be the best 
immunological markers for RTS,S/AS01 vaccine induced immunity while Th2 
responses, in particular IL5 and RANTES, might represent markers for lack of 
protective immune responses. We detected a lower induction of protective Th1 
(IFN-g, IL15 and GM-CSF) responses by RTS,S/AS01 in infants compared to 
children while Th2 (IL4 and IL13) and the pro- inflammatory markers (TNF and IL-
1β) responses remained similar in both cohorts (chapter 4; paper III). These 
findings provide further supporting evidence as to why infants in the RTS,S/AS01 
phase III study had lower vaccine efficacy compared to the children cohort. 
 
Previous studies of RTS,S/AS01 also reported similar trends of increased 
responses in children rather than in infants when they compared anti-CSP 
antibodies amongst children and infant cohorts (White et al., 2015). The 
accumulating evidence from multiple previous clinical challenge trials the USA, 
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adult or paediatric field trials in different age groups and across the distinct 
transmission settings of The Gambia, Kenya, Mozambique and Tanzania suggest 
that the protective mechanism of the RTS,S/AS01 is strongly supported by 
antibodies against the CSP repeat region (Moorthy and Ballou, 2009). Since 
maternal antibodies have been reported to interfere with antibody generation 
during vaccination (Edwards, 2015; Niewiesk, 2014); we hypothesize that the poor 
efficacy observed in the RTS,S/AS01 infant cohort could also be due to effect of 
maternal antibodies. We argue that vaccine efficacy in young children was much 
better since maternal antibodies persist for a short period in early life and during 
the age of 5-17 months most of the maternal antibodies have disappeared. 
 
We further evaluated the quality of RTS,S/AS01 induced anti-CSP antibodies in a 
phase 2 study aiming to investigate the effect of RTS,S/AS01 vaccination schedule  
on protective efficacy and avidity of anti-CSP antibodies in 6-12 weeks African 
infants (chapter 4; paper II). We showed that the magnitude of increase of anti-
CSP IgG concentration and avidity between second and third vaccine injection and 
not the anti-CSP IgG concentration and avidity alone is associated with a strong 
risk reduction for malaria after immunization. This is in line with the findings of 
recent studies showing that, despite malaria exposed children having a higher 
antibody avidity compared to children with less malaria exposure; the observed 
avidity alone did not predict protection (Olotu et al., 2014). Several explanations for 
lack of correlation between efficacy and avidity of RTS,S/AS01 induced antibodies 
in children could be: First, the co-linearity between antibody concentration and 
avidity might have blurred the effect of avidity in this study.  
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On the other hand, the finding may also suggest that avidity might not be an 
important determinant of vaccine efficacy or that our assay was not sufficient to 
reflect the avidity. Second, our assay was designed to detect antibodies against 
the CSP-repeat region, which was shown to be an immunodominant epitope. 
Neglecting to measure antibodies against the C-terminal flanking region might 
potentially exclude some relevant antibody responses that could explain the 
effectiveness of the vaccine (Watt et al., 2013). The use of new techniques such as 
Surface Plasmon Resonance (SPR) could be an alternative and more sensitive 
method in future to investigate antibody avidity induced by vaccination compared to 
the thiocyanate elusion method (Reddy et al., 2012). 
 
In Conclusion, acquired immunity to malaria develops with increasing age and 
repeated infections. Understanding immune correlates underlying protection 
against malaria in early life will facilitate vaccine development. Our results highlight 
the need for revisiting and designing a vaccination schedule and formulation that 
will modulate the immune system towards a potent Th1 response during the first 
months of life and avoid counteracting responses such as IL-5 and maternal 
antibodies. A complete understanding of the mechanism underlying the acquisition 
of protective immunity in malaria exposed individuals is crucial for outlining the 
strategies for a better malaria vaccine development. 
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612 Controlled human malaria infections as a cornerstone to accelerate 
malaria vaccine development in Africa 
Controlled human malaria infections (CHMI) have provided a landscape for malaria 
researchers to test malaria vaccine efficacy in well-controlled setting. The call for 
urgency in the development of an efficacious malaria vaccine has led to increased 
demand for conducting early stage CHMI-based efficacy studies in malaria 
endemic regions (Laurens et al., 2012). The experimental P.falciparum challenge 
model in human using a syringe and needle was first introduced into African 
settings in 2012. CHMI has demonstrated the greatest ability to predict efficacy of 
malaria vaccines in malaria-naive adults (Spring et al., 2014), and here for the first 
time in the history of malaria vaccine development, we evaluated whether CHMI 
can reproduce such results in pre-exposed population. In this study (chapter 5; 
paper V), we show for the first time that inoculation of healthy, young adult, 
Tanzanian males with aseptic, purified, cryopreserved P. falciparum sporozoites 
(PfSPZ challenge), was safe, well tolerated and was as infective as in malaria 
naïve volunteers. We used samples collected during this CHMI study to explore 
adaptive cellular immune activation following different doses of PfSPZ challenge 
(chapter 5; paper VI), examined the memory B cells, antibodies and their 
opsonising activities before and after CHMI (chapter 5; paper VII), and the impact 
on innate-like lymphocytes such as MAIT cell, iNK T cell and NK cells (chapter 5; 
paper VIII). 
 
To understand the effect of malaria pre-exposure on anti-parasite immunity during 
CHMI, we compared the role of pre-existing antibodies in a CHMI study conducted 
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in malaria naïve Dutch adults and malaria semi-immune Tanzanian adults who 
received essentially the same dose of PfSPZ challenge delivered intradermally 
(chapter 5; paper VI). Here we show that pre-existing antibodies to P. falciparum 
antigens had a significant effect on the outcome of the CHMI as demonstrated by 
the longer prepatency period and lower parasite load at the time of first detection 
as assessed by qPCR in the Tanzanian versus the Dutch cohort. Antibody 
responses in naïve Dutch subjects versus malaria semi-immune Tanzanian 
subjects who received same dose of PfSPZ challenge were also compared. The 
higher fold increase in anti-malaria antibodies observed in Tanzania subjects but 
not in Dutch subjects after CHMI suggests the presence and boosting of pre-
existing humoral immunity (chapter 5; paper VI). However, it remains to be 
answered in the future studies whether and which proportion of these boosted 
humoral responses resulted from naturally acquired immunity; or have been elicited 
by the longer and transient asexual blood stage parasitaemia exposed to the 
immune system before malaria treatment initiation. Our results indicate that the 
immune response against malaria in pre-exposed individuals might differ from that 
of malaria-naïve individuals during CHMI. 
 
In chapter 5, paper VII; we present findings from a merozoite opsonization assay 
that was used as a measure of functionality of antibodies detected before, during 
and after CHMI. We showed that the antibodies produced had a peak level of 
opsonization function one month after CHMI, and these responses remained 
significantly higher after 6 months compared to baseline. Of note, the boosting of 
opsonising antibody responses was evident in volunteers who - at the time of 
intradermal sporozoite injection - showed lower functional antibody levels but not in 
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volunteers with higher levels. These differences in boosting the level of opsonizing 
antibodies observed in lower and higher responders could be explained by the 
differences in malaria pre-exposure status amongst the two groups of naïve and 
pre-exposed adults. Whether, the observed increase in percentage phagocytosis 
reflects the maximum threshold that people in malaria endemic regions could 
achieve remains to be tested in future sporozoite vaccine trials. However, our study 
was not designed to evaluate the impact of increased opsonization activity on 
protective efficacy. In summary, these findings highlight the need for detailed 
investigation to identify and validate the best antibody functional assays that will 
predict and correlate with malaria or vaccine induced humoral immune responses 
in malaria pre-exposed volunteers. 
 
Our findings also show that malaria specific cellular responses, as measured by 
IFN-g secreting CD4 and CD8 T cells subsets, were more pronounced in malaria 
naïve volunteers than in semi-immune volunteers, despite the two cohorts having 
similar baseline responses before CHMI (chapter 5; paper VI). We hypothesize that 
malaria naïve volunteers mount immune responses that are more biased towards T 
cell mediated immune responses, which are likely to be directed toward the liver 
stage parasites (anti-infection), while malaria pre-exposed volunteers mount 
immune response that are more biased towards B cell immune responses directed 
towards blood stage (anti-disease). However, this hypothesis remains to be further 
investigated and validated in PfSPZ vaccine trials comparing malaria naïve and 
pre-exposed volunteers. 
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We further showed that a single dose of PfSPZ challenge boosted MBC against 
MSP-1 and AMA-1 with the maximum peak observed one month after challenge, 
which returned to baseline after 6 months (chapter 5; paper VII). Based on these 
findings, we hypothesize that in malaria semi-immune volunteers the MBC 
responses following CHMI resulted from a secondary response but had short-lived 
plasma cell expansion as we observed peak responses around 2 weeks after 
asexual blood stage detection. The observed decline of MBC after CHMI could also 
be explained by antigen-specific plasma cells that migrate to the bone marrow, the 
predominant site of antibody production (Crotty et al., 2003; Slifka et al., 1995), 
resulting in fewer MBCs recirculating in the peripheral blood. We further showed 
that the quantity of antibodies and opsonising functions after PfSPZ challenge 
followed a similar trend to that observed for MBCs in each individual. We are left 
with an open question as to whether the slow development of natural acquired 
immunity observed in people living in malaria endemic areas is a result of immune 
dysregulation and how should this be overcome during malaria vaccine 
development. 
 
The question as to how the human innate-like lymphocyte compartment is involved 
in malaria infections is not well characterized. In the current study, we showed for 
the first time that CHMI affects innate-like lymphocytes - in particular the MAIT cell 
populations - in a PfSPZ challenge dose-dependent manner. Furthermore, while 
these innate-like responses are perceived to be short-lived, we found that changes 
in the MAIT cell population persisted even 6 months after the infection was cleared. 
It is yet to be investigated if these changes in innate-like lymphocyte composition 
are beneficial or detrimental for immune responses – particularly in populations that 
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live in malaria endemic regions. As the MAIT cells likely play essential roles in the 
timely initiation of adaptive immune responses during infection, the mechanisms 
that activate MAIT cells in the liver could be of interest as a potential therapeutic 
strategy against liver-stage malaria infection. The single-cell RNA-seq analysis 
data also suggests that CHMI leads to a clonally driven increase of innate-like 
lymphocytes that may be mediated by homeostatic expansion-like mechanisms 
through enhanced expression of IL-7 receptors.  
 
Together, our data demonstrates that CHMI studies using PfSPZ challenge can be 
safely performed in malaria endemic African countries where individuals with 
varying degree of pre-exposure reside. These studies will generate essential 
information required for future malaria vaccine design. 
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62 Conclusion 
 
Substantial investment in research and development is needed to develop an 
effective malaria vaccine. The information gained from the RTS,S/AS01 vaccine 
development approach highlights the possible ways to overcome malaria vaccine 
development obstacles. It is obvious that, although recombinant subunit vaccines 
do not yet give the desired levels of protection, these types of vaccine approaches 
can be easily manufactured and feasibly delivered in disease endemic setting. 
Manufacturing of live sporozoite vaccines for mass administration and the 
requirements for the storage remain to be clearly resolved. Studies conducted in 
the US, European and African individuals when testing the whole sporozoite 
approach have shown that malaria-naïve individuals respond better than malaria-
exposed individuals (Jongo et al., 2018; in press). The question remained, “what 
e[actly constitutes the reason for lack of durable protection against malaria 
infection in endemic areas?” The most probable way of accelerating future 
vaccine development is a better understanding of the host-pathogen interaction 
and the nature of acquired immunity that will eventually be translated into better 
vaccine design. Conduct of CHMIs in malaria exposed volunteers has opened new 
doors in the malaria vaccinology field. It is now likely that malaria vaccines and 
drugs could be easily tested for their efficacy in the target population. We have 
established the foundation for using CHMI to assess the efficacy of new 
interventions against malaria and to study the mechanisms of protection conferred 
by different malaria vaccines in endemic settings. Improvements such as direct 
venous inoculation (DVI) of irradiation attenuated sporozoites or live sporozoites 
under chloroquine prophylaxis will provide more information on the protective 
efficacy of the PfSPZ vaccines approach in endemic populations. 
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63 Recommendations 
 
Several recommendations to improve the current vaccine approaches could be 
delineated from our work. These include the use of prime-boost strategies whereby 
a combination of different antigen delivery systems encoding the same epitopes or 
antigen, delivered at an interval of a few weeks apart is applied. Furthermore, 
efficient protection against malaria is likely the result of the combined effect of 
multiple, additive and low levels of a variety of immune responses targeting a broad 
range of antigens resulting in individual protective signatures. Therefore, an 
addition of more PE and/ or asexual blood stage antigens to the current RTS,S 
formulation that covers a wide range of parasites could be one option for 
improvement. This should also include antigens directed against sexual stages or 
ookinetes as they will add the essential transmission blocking component. An 
alternative strategy would be to start from scratch with the vaccine development 
efforts, by identifying novel critical antigens amongst the thousands of antigens 
expressed by the parasite and select those which are strongly provoking the 
immune system and provide solid protection. 
To circumvent the hurdles of generating successful recombinant subunit vaccines, 
whole parasites that are attenuated either by irradiation, drugs or genetic 
modifications could be the better option for achieving higher efficacy. However, 
much work has to be done in this model as we would need to identify the right dose 
and immunization schedule that will induce long-lasting immunity in malaria pre-
exposed populations.  
To date, it is unclear which assay is the best for studying relevant immune 
functions in malaria immunity. Therefore, identifying and validating the best 
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functional assays for characterization of both cellular and humoral immune 
responses will help to identify relevant antigens. Analyses of the host and parasite 
transcriptome, proteome, expression cloning and new imaging technology could 
make our goal for developing a second generation malaria vaccine that protects 
more than 80% against clinical malaria possible. 
The achievement of RTS, S vaccine clinical development has been accelerated by 
collaboration from many international and local organizations working together to 
support a series of clinical trials in Africa. Strengthening this cooperation will further 
build or enable sharing of high technology laboratory capacities that are available 
today to Scientists from economically stronger countries. Human resources and 
expertise for designing better clinical trials in Sub-Saharan Africa is a must. By 
doing so, we will all together to support and thrive, in order to achieve detailed 
investigations on how malaria immunity works in naturally exposed individuals and 
use this platform for designing a better and effective second generation malaria 
vaccine. Additionally, a longer-term follow-up is needed for full assessment of the 
vaccine risks and benefits. A thorough evaluation of the risk-benefit, feasibility and 
cost-effectiveness to determine the overall impact of RTS,S/AS01 in the community 
is highly needed, for the goal of implementation of RTS,S across the continent to 
be unequivocally recommended.   
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64 Contribution of the current thesis  
This PhD thesis has made several contributions to the field of malaria vaccines trials. 
We have reported for the first time through this work that vaccine trials involving 
paediatric populations can feasibly be incorporated into EPI programmes and 
conducted in large populations in the African setting. This information can be adapted 
for testing of other drug and vaccine products in similar settings. Furthermore, we 
have demonstrated that individuals living in different disease endemicity might 
respond differently to the vaccine candidate.  This work also showed that PfSPZ 
challenge response from the malaria naïve population was more biased toward 
cellular immunity while malaria pre-exposed population responded toward humoral 
immunity. Such novel knowledge will contribute to the better design of a second 
generation malaria vaccine that will be more potent in the malaria endemic 
population. Through this PhD work we have also for the first time contributed to 
knowledge that CHMI could safely be conducted in pre-exposed malaria population 
with a similar infectivity outcome. This information led to a series of malaria vaccine 
clinical trials that involved CHMI in large number of African research institutes. 
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71 Appendices  
During the course of this PhD work, several contributions were made to the 
research work published in Lancet infectious disease, Clinical and vaccine 
immunology and PLOS One. The first study (published in Lancet infectious 
disease) aimed to assess the performance of the novel T-cell activation 
marker–tuberculosis (TAM-TB) assay for the diagnosis of active tuberculosis in 
children with symptoms that suggest tuberculosis. The second study (published 
in Clinical and vaccine immunology) aimed to analyze mRNA expression levels 
before and shortly after H1/IC31-Tuberculosis vaccination and correlate these 
with vaccine-specific central (TCM) and effector memory CD4 T cell (TEM) 
responses. The third study (published in PLOs One), aimed to investigate the 
expression of Mip-1β and the T cell maturation marker CD27 within CMVpp65-
specific CD4+ and CD8+ T cells in relation to age, HIV and active Tuberculosis 
(TB) co-infection in a cohort of Tanzanian volunteers. Despite that these studies 
are not directly linked to the topic of my thesis, my contribution in laboratory 
analysis of the samples and the review of manuscripts worth it recognitions. 
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7.1͘ϭ  Assessment  of  the novel  T-cell  activation  marker–tuberculosis 
assay for diagnosis of active  tuberculosis in children: 
a prospective proof-of-concept study 
Damien Portevin, Felicien Moukambi, Petra Clowes, Asli Bauer, Mkunde Chachage, Nyanda E Ntinginya, Elirehema Mﬁnanga, Khadija Said, 
Frederick Haraka, Andrea Rachow, Elmar Saathoﬀ, Maximilian Mpina, Levan Jugheli, Fred Lwilla, Ben J Marais, Michael Hoelscher, 
Claudia Daubenberger, Klaus Reither*, Christof   Geldmacher* 
 
Summary 
Background The diagnosis of paediatric tuberculosis is complicated by non-speciﬁc symptoms, diﬃcult specimen 
collection, and the paucibacillary nature of the disease. We assessed the accuracy of a novel immunodiagnostic T-cell 
activation marker–tuberculosis (TAM-TB) assay in a proof-of-concept study to identify children with active tuberculosis. 
 
Methods Children with symptoms that suggested tuberculosis were prospectively recruited at the NIMR-Mbeya 
Medical Research Center in Mbeya, and the Ifakara Health Institute in Bagamoyo, Tanzania, between May 10, 2011, 
and Sept 4, 2012. Sputum and peripheral blood mononuclear cells were obtained for Mycobacterium tuberculosis 
culture and performance assessment of the TAM-TB assay. The children were assigned to standardised clinical case 
classiﬁcations based on microbiological and clinical   ﬁndings. 
 
Findings Among 2ft0 children screened, we selected a subgroup of 130 to ensure testing of at least 20 with culture- 
conﬁrmed tuberculosis. 17 of 130 children were excluded because of inconclusive TAM-TB assay results. The 
TAM-TB assay enabled detection of 15 of 18 culture-conﬁrmed cases (sensitivity 83·3%, ft5% CI 58·6–ft6·4). 
Speciﬁcity was ft6·8% (ft5% CI 8ft·0–ftft·6) in the cases that were classiﬁed as not tuberculosis (n=63), with little 
eﬀect from latent tuberculosis infection. The TAM-TB assay identiﬁed ﬁve additional patients with highly probable 
or probable tuberculosis, in whom M tuberculosis was not isolated. The median time to diagnosis was 1ft·5 days 
(IQR 14-45) for culture. 
 
Interpretation The sputum-independent TAM-TB assay is a rapid and accurate blood test that has the potential to 
improve the diagnosis of active tuberculosis in  children. 
 
Funding European and Developing Countries Clinical Trials Partnership, German Federal Ministry of Education and 
Research, and Swiss National Science Foundation. 
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Introduction Tuberculosis in children is a serious public health problem. Recent estimates of the tuberculosis disease burden in children, based on the results of a systematic literature review and mathematical modelling, suggest that about 1 million children developed tuberculosis worldwide in 2010, including 280 000 incident cases in the African region.1 Surveillance data for children remain imprecise because paediatric tuberculosis is often either underdiagnosed or overdiagnosed in high-burden countries.2–4 The lack of accurate and rapid diagnostic methods contributes to tuberculosis morbidity and mortality in children and hampers the assessment of new drugs and vaccines in paediatric populations.4 Diagnosis of active tuberculosis in children poses a major challenge. Clinical symptoms of tuberculosis in children are often non-speciﬁc and resemble those of common paediatric illnesses, including pneumonia and malnutrition. Adequate respiratory specimens are 
diﬃcult to obtain for bacterial conﬁrmation, particularly in very young children who are unable to expectorate and in  whom  diagnostic  yields  are  poor  because  of     the 
paucibacillary nature of the disease.2,5 Hence, the diagnosis is routinely made on the basis of a combination of clinical features, contact history, chest radiography, and tuberculin skin test, and often with scoring charts that have poor diagnostic  accuracy.6,7 The Xpert MTB/RIF assay enables timely, sensitive, 
and speciﬁc molecular detection of pulmonary tuberculosis and rifampicin resistance in adults,8 but its value in young children is greatly reduced. In a recent meta-analysis, the calculated pooled sensitivity was 66% for Xpert MTB/RIF against culture in expectorated or induced sputa, or gastric lavage specimens from children with suspected tuberculosis.9 WHO strongly recom- mends Xpert MTB/RIF as the initial diagnostic test in children suspected of having multidrug-resistant or HIV- associated tuberculosis, and only conditionally in all children suspected of having tuberculosis.9 Immunodiagnostic tests, such as the tuberculin skin test and interferon-γ release assays—ie, QuantiFERON- TB Gold and T-SPOT.TB—do not depend on the presence of Mycobacterium tuberculosis in collected samples.  Although  these  tests  have  use  in  screening 
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Figure 1: Study proﬁle 
 special risk populations for latent tuberculosis infection, they cannot enable the crucial distinction between active tuberculosis disease and latent tuberculosis infection.10 Failure to accurately identify cases with active tuberculosis restricts the clinical application of these tests in endemic regions where latent tuberculosis infection is ubiquitous. Results of previous studies in adults showed that ﬂow- cytometric   analysis   of   the   CD27    on    circulating  
M tuberculosis-speciﬁc T cells can discriminate active tuberculosis from latent tuberculosis infection.11–15 Loss of CD27 expression on M tuberculosis-speciﬁc CD4 T cells is a marker of active tuberculosis due to persistent antigenic stimulation16 and probably relates to increased cellular homing to the site of disease.17,18 In a proof-of- concept study, we assessed the performance of the new T-cell activation marker–tuberculosis (TAM-TB) assay for the diagnosis of active tuberculosis in children with symptoms that suggest tuberculosis.  
Methods 
Study population This prospective diagnostic assessment was done at two Tanzanian research sites—the NIMR-Mbeya Medical Research Center, Mbeya, and the Ifakara Health Institute, Bagamoyo. Children older than 6 months and younger than 16 years with signs or symptoms that suggested tuberculosis were enrolled from May 10, 2011, until Sept 4, 2012, and followed up for a minimum of 5 months. At least one of the following eligibility criteria had to be met:  persistent,  non-remitting  cough  for  more     than 14 days that did not respond to antibiotics; repeated episodes of fever within the past 14 days that did not respond to antibiotics, after malaria had been excluded; weight  loss  or  failure  to  thrive  during  the    previous 3 months; and signs and symptoms that suggested extrapulmonary tuberculosis. Children who received tuberculosis  treatment  in  the  past  12  months    were 
 excluded. The children were referred from peripheral health facilities and local hospitals. Because of cost restrictions, a subgroup of 130 children was selected from a larger cohort of 290 children to ensure testing of at least 20 children with culture-conﬁrmed tuberculosis after prevalence estimation at the two sites. All other clinical information was masked from the investigators doing the selection with a list of patient identiﬁcation numbers with corresponding disease classiﬁcations. The Institutional Review Board of the Ifakara Health Institute, the Mbeya Medical Research and Ethics Committee, and the Medical Research Coordinating Committee of Tanzania approved the study protocol. We obtained written informed consent from a literate parent or legal guardian. In cases of illiteracy, informed oral consent was attested by an independent witness. Children older than 7 years provided assent for participation.  
Classiﬁcation and reference standard 
Classiﬁcation of children was based on the results of the clinical and microbiological assessment as culture- 
conﬁrmed tuberculosis (culture-positive for M tuberculosis), highly probable tuberculosis (chest radiograph consistent 
with tuberculosis conﬁrmed by two independent reviewers, histology or cytology typical for tuberculosis, or 
ﬂuorescent or acid-fast bacilli on microscopy), probable tuberculosis (clinically suspected tuberculosis without objective ﬁndings as above), not tuberculosis (alternative diagnosis established and clinical resolution without antituberculosis treatment), or indeterminate (any other combination; appendix). Culture-conﬁrmed tuberculosis was used as the reference standard for sensitivity analysis and not tuberculosis as the reference standard for 
speciﬁcity assessment.  
Clinical and laboratory procedures Clinical procedures at enrolment comprised medical history, physical examination, HIV testing, CD4 T-cell count, interferon-γ release assay (QuantiFERON-TB Gold, Cellestis, Melbourne, VIC, Australia), and chest 
radiography. Chest radiographs were classiﬁed as strongly indicating, uncertain, or not tuberculosis by two independent experts from whom all clinical and diagnostic information was masked. Malnutrition was assessed on the basis of weight-for-age Z score in children aged up to 10 years (less than –2) and body- mass index in those older than 10 years (<2 SD below normal). If feasible, at least three induced or two expectorated respiratory specimens were obtained on consecutive days. Induced sputum was obtained in accordance with a standard protocol.19 Fine-needle aspiration biopsies of enlarged lymph nodes were done when clinically indicated, as per standard protocol.20 After N-acetyl L-cysteine-sodium hydroxide decontam- ination, each sputum sample pellet was assessed    with 
TAM-TB=T-cell activation marker–tuberculosis. *Frequency of interferon-γ-positive CD4 T cells in the negative 
control greater than the median frequency plus 3 SD of the tested sample. †CD4 T cell count of less than 
10 000 per μL and interferon-γ CD4 T cells less than 0·05%. 
microscopy by use of Ziehl-Neelsen staining. At  least one  sample  was  inoculated  on  both  liquid   (BACTEC 
study 
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  All patients 
(n=113) 
Culture-conﬁrmed 
tuberculosis (n=18) 
Highly probable 
tuberculosis (n=8) 
Probable 
tuberculosis (n=12) 
Not tuberculosis 
(n=63) 
Indeterminate 
(n=12) 
 
Age (years) 6·1 (2·1–10·3) 4·6 (1·5–12·7) 8·1 (5·2–11·9) 6 (1·8–10·5) 6·1 (2·0–9·8) 5·4 (2·2–10·5)  
Female sex 52 (46%) 8 (44%) 5 (63%) 6 (50%) 27 (43%) 6 (50%)  
Symptoms at enrolment        
Cough 108 (96%) 16 (89%) 6 (75%) 12 (100%) 62 (98%) 12 (100%)  
Fatigue or lethargy 28 (25%) 8 (44%) 2 (25%) 2 (17%) 16 (25%) 0  
Wheezing 16 (14%) 1 (6%) 1 (13%) 3 (25%) 9 (14%) 2 (17%)  
Breathing diﬃculties 47 (42%) 10 (56%) 4 (50%) 8 (67%) 22 (35%) 3 (25%)  
Fever 82 (73%) 16 (89%) 6 (75%) 9 (75%) 45 (71%) 6 (50%)  
Chest pain 23 (20%) 1 (6%) 0 1 (8%) 18 (29%) 3 (25%)  
Haemoptysis 4 (4%) 1 (6%) 0 1 (8%) 1 (2%) 1 (8%)  
Enlarged lymph nodes 12 (11%) 5 (28%) 1 (13%) 1 (8%) 5 (8%) 0  
Weight loss 55 (49%) 13 (72%) 3 (38%) 5 (42%) 32 (51%) 2 (17%)  
Abdominal pains 20 (18%) 5 (28%) 2 (25%) 3 (25%) 9 (14%) 1 (8%)  
Malnutrition 60 (53%) 12 (67%) 4 (50%) 5 (42%) 24 (38%) 5 (42%)  
HIV infection 33 (29%) 4 (22%) 3 (38%) 7 (58%)* 15 (24%) 4 (33%)  
WHO immunological staging        
Not clinically signiﬁcant 7/33 (21%) 0/4 (0%) 0/3 (0%) 2/7 (29%) 4/15 (27%) 1/4 (25%)  
Mild 6/33 (18%) 1/4 (25%) 1/3 (33%) 2/7 (29%) 2/15 (13%) 0/4 (0%)  
Advanced 1/33 (3%) 1/4 (25%) 0/3 (0%) 0/7 (0%) 0/15 (0%) 0/4 (0%)  
Severe 19/33 (58%) 2/4 (50%) 2/3 (67%) 3/7 (43%) 9/15 (60%) 3/4 (75%)  
On antiretroviral therapy at enrolment 13/33 (39%) 2/4 (50%) 1/3 (33%) 2/7 (29%) 7/15 (47%) 1/4(25%)  
Positive tuberculin skin test 31/103 (30%) 13/17 (76%) 3/8 (38%) 2/11 (18%) 9/57 (16%) 4/10 (40%)  
Positive interferon-γ release assay 27/110 (25%) 13/18 (72%) 1/7 (14%) 3/12 (25%) 8/61 (13%) 4/12 (33%)  
Positive tuberculin skin test or 
interferon-γ release assay 
47/112 (42%) 17/18 (94%) 3/8 (38%) 4/12 (33%) 15/63 (24%) 4/11 (36%)  
 
Data are median (IQR), number (%), or n/N (%). *p=0·033 compared with not tuberculosis distribution (Fisher’s exact test).  
 
 
Table 1: Demographics and clinical characteristics of study participants by classiﬁcation group 
 
 MGIT 960, Becton Dickinson, Franklin Lakes, NJ, USA) and solid media (Loewenstein-Jensen culture). Positive 
cultures were conﬁrmed by use of microscopy, and subsequent MPT64 antigen or molecular tests (Genotype MTBC or CM, Hain Lifescience, Nehren, Germany) or both. GenoType MTBDRplus (Hain Lifescience) or phenotypic drug-susceptibility testing (BACTEC MGIT 960 SIRE kit, Becton Dickinson) was used for resistance testing. Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) was done in at least one sputum sample according to the manufacturer’s  instructions. All tests, including TAM-TB assay, were done by trained laboratory technical staﬀ masked to clinical information and radiological results. Results from established diagnostic procedures were made available to support clinical management in accordance with national and international guidelines. Results of the experimental TAM-TB assay were not released.  
TAM-TB assay Details of the underlying biological principle of the TAM-TB assay, deﬁnition of cutoﬀ values in an optimisation cohort of adults (n=87), and additional background information are provided in the appendix. 
Brieﬂy, the TAM-TB assay is used to measure the CD27 
phenotype of CD4 T cells producing interferon γ in response to M tuberculosis antigens according to a standard intracellular  cytokine  staining  procedure.14  
M tuberculosis-speciﬁc CD4 T-cell responses were judged 
positive when at least ﬁve CD4 T-cell interferon-γ- producing events were detected, and the proportion of interferon-γ producing CD4 T cells after antigen stimulation was greater than 0·05% and was at least twice the frequency of that in the negative controls. Well characterised samples from adults (appendix) 
were used to identify the CD27 median ﬂuorescence intensity (MFI) ratio with optimum discriminatory power between latent tuberculosis infection and active tuberculosis. Cryopreserved peripheral blood mono- nuclear cells obtained at the baseline visit were stimulated for 12–16 h with a set of overlapping ESAT-6/ CFP-10 peptides21 (Elephants and Peptides, Potsdam, 
Germany) and puriﬁed protein derivative (Statens Serum Institut, Copenhagen, Denmark) before staining 
with ﬂuorochrome-labelled antibodies. We compared the  MFI  of  CD27   staining   on   interferon-γ-positive 
M tuberculosis-speciﬁc CD4 T cells to the CD27 MFI 
value for all CD4 T cells to deﬁne the CD27 MFI ratio for a  sample  (appendix).  CD27  MFI  ratio  results      were 
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 consistent in 17 independent quality control assessments of two batches of peripheral blood mononuclear cells (appendix). Adult patients with tuberculosis had signiﬁcantly higher CD27 MFI ratios than did control patients after ESAT-6/ CFP-10 or puriﬁed protein derivative stimulation; area- under-operating-characteristic curves were 0·931% and 0·881%, respectively (appendix). We set CD27 MFI ratio thresholds at greater than 5 for ESAT-6/CFP-10 and greater than 13 for puriﬁed protein derivative responses to achieve a balanced TAM-TB assay sensitivity of 83·3% (95% CI 68·6–93·0) and speciﬁcity of 83·7% (69·3–93·2) in this 
optimisation cohort. Once these cutoﬀ values were ascertained, samples from paediatric tuberculosis suspects                  
Figure 2: Venn diagram of positive Mycobacterium tuberculosis culture, 
Xpert MTB/RIF, and TAM-TB-assay results 
TAM-TB=T-cell  activation  marker–tuberculosis. 
 were tested (validation cohort). TAM-TB assays were done at two independent laboratories according to identical standard  operating procedures.  
Statistical analysis Calculation of medians, IQR, test accuracy measures (sensitivity and speciﬁcity), Kruskall-Wallis ANOVA with post-test correction (Dunn’s), and Mann-Whitney and 
Fisher’s exact tests were done with GraphPad Prism software (version 4.03).  
Role of the funding source The study was funded by the European and Developing Countries Clinical Trials Partnership, which had no role in study design, data gathering, analysis, and inter- pretation, or writing of the report. The corresponding 
author had full access to all the data and ﬁnal responsibility for the decision to submit for publication.  
Results After assay optimisation in adults (optimisation cohort; appendix), the diagnostic performance of the TAM-TB assay was assessed in 130 children suspected to have tuberculosis (validation cohort); samples from 113 (87%) children were eligible for analysis. Figure 1 shows the study proﬁle;22 17 (13%) children were excluded from the study because of inconclusive  results.  18  (16%)  of  113 eligible children had culture-conﬁrmed tuberculosis, eight (7%) highly probable tuberculosis, 12 (11%) probable tuberculosis, 63 (56%) not tuberculosis, and 
12 (11%) indeterminate cases (ﬁgure 1). A ﬁne-needle aspiration biopsy of enlarged lymph nodes was done in 
ﬁve children; the ﬁnal classiﬁcations were culture 
conﬁrmed tuberculosis (n=3), probable tuberculosis (n=1), and not tuberculosis (n=1). All culture-conﬁrmed tuberculosis cases were positive on assessment of a respiratory specimen, including one with additional cytomorphology that suggested tuberculous lymph- adenitis. Nine (50%) of 18 children with culture- 
conﬁrmed tuberculosis were sputum smear-positive. Six of eight patients with highly probable tuberculosis had chest radiographs that strongly suggested tuberculosis, one had chronic granulomatous lymphadenitis, and one was sputum smear-positive. Patients with probable tuberculosis had symptoms that suggested infection, which resolved completely on tuberculosis treatment, but radiographic signs and laboratory investigations were  non-conclusive. Table 1 shows the demographic and clinical charac- teristics   of   the   children.   The   median   age   of     the 113 children included in the analysis was 6·1 years (table 1). 33 of 113 children had HIV infection (table 1). 
According to the WHO immunological classiﬁcation for established HIV infection,23 19 of the HIV-infected 
children had severe immunodeﬁciency (table 1). 37 of 38 children with culture-conﬁrmed, highly probable, or probable tuberculosis received tuberculosis  treatment, 
   
 
  
 
   
 
 
 
 
Culture- 
conﬁrmed 
(n=18) 
 
 
Highly 
probable 
(n=8) 
3 (38%) 
5 (63%) 
Probable 
(n=12) 
Not 
(n=63) 
 
(n=12) 
 
 
2 (17%) 2 (3%) 1 (8%) 
10 (83%) 61 (97%)  
 
Bagamoyo (n=63) Mbeya (n=50) All patients (n=113) 
Sensitivity (95% CI) 83·3% (35·9–99·6) 83·3% (51·6–97·9) 83·3% (58·6–96·4) 
Positive/total 5/6 10/12 15/18 
Speciﬁcity (95% CI) 95·6% (84·9–99·5) 100% (81·5–100) 96·8% (89·0–99·6) 
Negative/total 43/45  18/18 61/63 
7/115 (6%)  22/175 (13%) 29/290 (10%)
Positive predictive value 54·9% 100% 74·5% 
Negative predictive value 98·9% 97·7% 98·1%  
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Clinical case classiﬁcation 
and reason for 
classiﬁcation 
Tuberculin skin test 
or QuantiFERON 
HIV status First-visit clinical diagnosis, 
treatment, and response 
Follow-up clinical diagnosis, treatment, 
and outcome 
Culture-negative  andTAM-TB  assay-positive  cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture-positive and TAM-TB assay-negative cases 
 
 
 
 
 
 
 
 
 
 
 
 
Positive tuberculin skin test suggested by a lesion of at least 10 mm in HIV-uninfected or at least 5 mm in HIV-infected children. TAM-TB=T-cell activation marker– 
tuberculosis. 
 
Table 4: Cases with discrepant culture and TAM-TB assay results: clinical characteristics at enrolment and follow-up visits by age 
15 years Highly probable tuberculosis 
by radiograph 
Positive Negative Pneumonia 
Amoxicillin 
No 
14 years Culture-conﬁrmed 
tuberculosis with 
Mycobacterium tuberculosis in 
sputum 
Positive Negative 
7 years Highly probable tuberculosis 
by sputum smear 
Positive Negative Pneumonia 
Amoxicillin 
No 
9 years Highly probable tuberculosis 
by lymph node cytology 
Positive Positive Lymphadenitis 
Ceftriaxone 
No 
11 years Probable tuberculosis by 
symptoms, resolution after 
treatment 
Negative Positive Pneumonia 
Ceftriaxone 
No 
1 year Probable tuberculosis by 
symptoms, resolution after 
treatment 
Positive Positive Chest infection 
Cefalexin 
No 
5 years Not tuberculosis, no 
treatment, and healthy after 
5 months 
Positive Positive 
Pulmonary tuberculosis later conﬁrmed by 
culture and Xpert MTB/RIF 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and 
4 months of isoniazid and rifampicin 
Resolved 
Pulmonary tuberculosis 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and 
4 months of isoniazid and rifampicin 
Resolved 
Tuberculosis lymphadenitis 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and 
4 months of isoniazid and rifampicin 
Resolved 
Pulmonary tuberculosis 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and 
4 months of isoniazid and rifampicin 
Resolved 
Pulmonary tuberculosis 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and 
4 months of isoniazid and rifampicin 
Resolved 
Recovered from initial diagnosis 
7 years Not tuberculosis, no 
treatment, and healthy after 
5 months 
Positive Positive 
Pneumocystis pneumonia plus 
Mycobacterium interjectum 
Co-trimoxazole 
Resolved 
Pneumonia, urinary tract infection 
Antibiotics 
Resolved 
10 years Indeterminate Positive Positive Bronchiectasis 
Metronidazole 
Moderate 
Intestinal helminths 
Albendazole 
Resolved, new dry cough 6–9 months after 
recruitment 
Bronchiectasis, malaria 
Antimalarial 
Persisting cough, mediastinal 
lymphadenopathy 
8 years Culture conﬁrmed 
tuberculosis with 
Mycobacterium tuberculosis in 
sputum 
Culture conﬁrmed 
tuberculosis with 
Mycobacterium tuberculosis in 
sputum 
Positive Negative 
Pulmonary tuberculosis, Pulmonary tuberculosis 
malnutrition 2 months of isoniazid, rifampicin, 
2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol, and 
pyrazinamide, and ethambutol, 4 months of isoniazid and rifampicin 
and 4 months of isoniazid and Resolved 
rifampicin 
Unchanged 
Nephrotic syndrome 
Furosemide, prednisolone 
Deterioration, hospital admission 
2 years Negative Negative Pulmonary  tuberculosis, 
malnutrition 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, 
and 4 months of isoniazid and 
rifampicin 
Unchanged 
Pulmonary tuberculosis (only retrospectively 
conﬁrmed) 
No tuberculosis treatment 
Death 
Pulmonary tuberculosis 
2 months of isoniazid, rifampicin, 
pyrazinamide, and ethambutol, and 
4 months of isoniazid and rifampicin 
Resolved 
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 and one child died before the positive M tuberculosis culture result became available and treatment could be started. 33 of 37 children reported symptom resolution on treatment, one child with highly probable tuberculosis died, and three who were classiﬁed as culture conﬁrmed, highly probable, or probable tuberculosis were lost to follow-up. No drug resistance was detected in the culture-conﬁrmed  cases. Respiratory specimens could be collected from each child; 103 (91%) of 113 children provided at least three induced or two expectorated sputum samples. Figure 2 shows the overlap between children  with  a  positive  
M tuberculosis culture, Xpert MTB/RIF, or TAM-TB assay, and table 2  shows  the  TAM-TB  assay  results.  15  of  18 children with culture-conﬁrmed tuberculosis had a positive TAM-TB assay result (sensitivity 83·3%, 95% CI 58·6–96·4; table 3). Of the 63 cases classiﬁed as not tuberculosis, 61 had a negative TAM-TB assay (speciﬁcity 96·8%, 89·0–99·6; table 3). Findings were similar at the two independent sites Bagamoyo and Mbeya (table 3). The sensitivity of the TAM-TB assay was 69·2% (48·2–85·6) when both culture-conﬁrmed and highly probable tuberculosis cases were included in the reference standard. Table 4 summarises the clinical characteristics, tuberculin skin test and QuantiFERON-TB Gold results, diagnosis at enrolment, response to antibiotic treatment, and clinical follow-up of all children with discrepant TAM-TB assay and M tuberculosis culture results. Of the eight children who were TAM-TB assay positive but culture-negative (ﬁgure 2), three cases were classiﬁed as highly probable tuberculosis, two as probable tuberculosis, two as not tuberculosis, and one as indeterminate; six were HIV infected (table 4). Of the three children with highly probable tuberculosis, one was sputum smear-positive at enrolment, one was culture-conﬁrmed during follow up, and one had cytological signs (chronic granulomatous lymphadenitis) that suggested tuberculosis. In the two probable tuberculosis cases, broad-spectrum antibiotics had no 
eﬀect, but symptoms resolved on tuberculosis treatment (table 4). The TAM-TB assay was positive in two HIV- infected patients who were classiﬁed as not tuberculosis (table 4). Mycobacterium interjectum was identiﬁed in one case with an induration of 10 mm on the tuberculin skin test and an indeterminate QuantiFERON-TB Gold result. The other patient was QuantiFERON-TB Gold-positive. One HIV-infected child who was classiﬁed as indeterminate, had a complex clinical picture with various disease episodes that never fully resolved. Of the three children who were M tuberculosis culture-positive, but TAM-TB assay negative, two were malnourished (table 4). The third child had a nephrotic syndrome and died before culture results were available (table 4). 
Of the 63 children classiﬁed as not tuberculosis, 15 (24%) had a positive tuberculin skin test or QuantiFERON-TB  Gold  test  at  enrolment,    suggesting 
 probable latent tuberculosis infection. TAM-TB assay was positive in two (13%) of these 15 children. Xpert MTB/RIF enabled detection of 12 (67%) of 18 culture- 
conﬁrmed tuberculosis cases, giving a sensitivity of 66·7% (95% CI 41·1–85·6) when two or more sputum samples obtained on consecutive days were analysed. The sensitivity was 55·6% (31·3–77·6) when only the 
ﬁrst sputum sample was analysed. The speciﬁcity of Xpert MTB/RIF was 100% (94·2–100; data were missing for one person). Xpert MTB/RIF was positive in two of three children with culture-conﬁrmed tuberculosis who were TAM-TB assay negative (ﬁgure 2). The sensitivity achieved with the combination of TAM-TB assay and Xpert MTB/RIF was 94·4% (72·6–99·1). The median time to detection by use of culture, deﬁned as the period between enrolment and ﬁrst M tuberculosis conﬁrmation, was 19·5 days (IQR 14·0–45·0), whereas TAM-TB assay results were obtained within 24 h after recovery of peripheral blood mononuclear cells.  
Discussion The TAM-TB assay showed good sensitivity and excellent 
speciﬁcity with M tuberculosis culture as a reference 
standard. Speciﬁc detection of active tuberculosis in 
children was based on cutoﬀ values set from the optimisation study in adults. Retrospectively lowering CD27 ratio thresholds to 2 for ESAT-6/CFP-10 and 7 for 
puriﬁed protein derivative stimulation, would further improve assay sensitivity from 83·3% to 88·9% (95% CI 88·0–99·4%) without aﬀecting speciﬁcity with additional detection of highly probable (n=1), probable tuberculosis (n=1), and indeterminate (n=1) cases. Hence, cutoﬀ values 
speciﬁcally optimised for children might further improve TAM-TB accuracy. Contrary to molecular-based assays like Xpert MTB/RIF and microbiological tests, the TAM- TB assay can be done on a readily available peripheral blood sample and is not limited by the paucibacillary nature of active tuberculosis in children. Consistent test performance at both study sites suggests the assay is robust and repeatable. Of greatest clinical relevance is that the TAM-TB assay provides an answer within a day of blood collection, which is important because early treatment initiation can be crucial in young children at high risk of disseminated tuberculosis disease.2,24 
Of the children with discrepant results, ﬁve of eight children who were M tuberculosis culture-negative and TAM-TB assay positive had highly probable or probable 
tuberculosis. The clinical classiﬁcation used might have included some overdiagnosis.4 International consensus 
deﬁnitions of intrathoracic tuberculosis were not available when the study was designed.25 However, detailed case assessment suggested that these children probably did have active tuberculosis, suggesting that the TAM-TB   assay  is  probably  at  least  as  sensitive  as   
M tuberculosis culture. Despite access to state-of-the-art tuberculosis diagnostics, most children enrolled in our study were 
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 treated for tuberculosis based on a combination of 
epidemiological and clinical ﬁndings. This shows the poor diagnostic usefulness of M tuberculosis culture in 
clinical practice, related to diﬃcult specimen collection, suboptimum sensitivity in children with paucibacillary disease, and long turnaround times. Suboptimum sensitivity undermines the suitability of the test as a reference standard and complicates optimal assessment of diagnostic accuracy. Consistent with previous paediatric studies, Xpert MTB/RIF enabled the detection of culture-conﬁrmed paediatric cases from expectorated or induced sputa with a sensitivity of 66·7% and a 
speciﬁcity of 100%.26–28 Compared with M tuberculosis culture, the combination of Xpert MTB/RIF and TAM-TB, two assays with a turnaround time of less than 24 h, had a sensitivity of 94%, missing one case. This child had severe nephrotic syndrome and culture- 
conﬁrmation was only achieved after the child had passed away. The combination of TAM-TB assay and Xpert MTB/RIF enabled the detection of more tuberculosis cases than did culture when both culture- 
conﬁrmed and highly probable tuberculosis cases were included in the reference standard. The TAM-TB assay was highly accurate in identifying children without tuberculosis, including 13 children with a positive interferon-γ release assay or the result of the tuberculin skin test. Hence, the assay has a high 
speciﬁcity for tuberculosis disease in children despite immunological evidence of previous M tuberculosis exposure, consistent with data from the adult optimisation cohort and a previous study in adults.15 Only two not tuberculosis cases were incorrectly assigned. Both children were infected with HIV, one had simultaneous infection with non-tuberculous mycobacteria and both had latent tuberculosis infection. These false-positive TAM-TB results were caused by a predominance of mycobacteria-speciﬁc eﬀector memory T-cell responses in peripheral blood. In view of a positive CFP-10/ESAT-6 response in the child without non-tuberculous myco- bacteria infection, the positive TAM-TB assay result might suggest recent M tuberculosis infection that did not progress to active disease during the period of observation. In the other case, the  non-tuberculous  mycobacteria (M interjectum) identiﬁed in the sputum might have elicited the positive TAM-TB assay result. Implementation of additional, highly immunogenic M tuberculosis-speciﬁc antigens in the next generation TAM-TB assay could 
further improve speciﬁcity and  sensitivity. The current version of the TAM-TB assay has several limitations, mainly related to cost and technical complexity. It needs advanced blood processing 
procedures, antigenic stimulations, ﬂow cytometry equipment, and well trained staﬀ. Reﬁnement and 
simpliﬁcation are in progress to optimise diagnostic performance and make it compatible with cytometers that are in widespread use for measurement of CD4 T-cell    counts   in   HIV/AIDS-aﬀected   countries.    The 
 
 TAM-TB assay did not generate valid test results in 13% of the samples of peripheral blood mononuclear cells, but this might be attributed to reduced T-cell viability and decreased cytokine production after cryo- preservation.29 Ideally, the TAM-TB assay should be done on fresh whole blood samples—eg, in antigen-precoated tubes similar to the commercial QuantiFERON In-Tube system (Cellestis).30 Low CD4 T-cell counts due to severe HIV infection might remain a problem even when fresh blood samples are used. The small sample size of this proof-of-concept study resulted in very wide conﬁdence intervals and did not allow systematic assessment of test performance in very young, malnourished, or HIV- infected children who have recently been started on antiretroviral therapy. These factors might negatively 
aﬀect the accuracy of the TAM-TB assay.15,31 Additional 
studies need to be done to speciﬁcally address test performance in these patient groups. The assessment of the TAM-TB assay in a study population enriched for culture-conﬁrmed tuberculosis cases might have been a source of bias, particularly for the analysis including the under-represented classiﬁcation groups. Although the TAM-TB assay cannot provide information about drug susceptibility, use of concomitant Xpert MTB/RIF testing can address this limitation. 
Panel: Research in context 
Systematic review 
We searched PubMed up to June 10, 2014, using the terms 
“CD27”, “diagnosis”, “human”, and “tuberculosis”. Of the 
33 results returned, seven were clinical studies from ﬁve 
independent laboratories and their results showed the 
potential of monitoring CD27 expression on Mycobacterium 
tuberculosis-speciﬁc CD4 T cells to diagnose active 
tuberculosis disease in adults. We did not ﬁnd a report of the 
assessment of the use of M tuberculosis-speciﬁc T-cell 
phenotype for the diagnosis of active childhood tuberculosis. 
Interpretation 
Our report is the ﬁrst to assess the accuracy of using 
CD27-expression analysis for the diagnosis of paediatric 
tuberculosis. Immunological data were generated and 
analysed by investigators from whom clinical information 
was masked. The T-cell activation marker–tuberculosis assay 
showed excellent sensitivity (83·3%) and speciﬁcity (96·8%) 
when M tuberculosis culture positivity was used as a 
reference standard, and enabled the detection of additional 
cases in culture-negative children who were clinically 
suspected of having tuberculosis. Despite a fairly small 
sample size and potential bias originating from cohort 
enrichment in culture-conﬁrmed tuberculosis cases, the 
results of this proof-of-concept study show that 
immunodiagnostic tests that incorporate phenotypic 
characteristics of M tuberculosis-speciﬁc T cells have the 
potential to improve rapid detection of active tuberculosis 
in children. 
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 To our knowledge, this study is the ﬁrst to assess the diagnostic performance of the novel TAM-TB assay in children (panel). Importantly, it was done in a region with a high tuberculosis incidence and recruited children with symptoms that suggested tuberculosis who represent the real-life diagnostic challenge in these settings. Despite a need for further reﬁnement and testing in other regions with high burden of tuberculosis, our results suggest that the sputum-independent TAM- TB assay is a major advance for the rapid and accurate diagnosis of tuberculosis in children. 
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Tuberculosis (TB) remains a global health problem, with vaccination being a necessary strategy for disease containment and 
elimination. A TB vaccine should be safe and immunogenic as well as efficacious in all affected populations, including HIV-in- 
fected individuals. We investigated the induction and maintenance of vaccine-induced memory CD4+ T cells following vaccina- 
tion with the subunit vaccine H1/IC31. H1/IC31 was inoculated twice on study days 0 and 56 among HIV-infected adults with 
CD4+ lymphocyte counts of >350 cells/mm3. Whole venous blood stimulation was conducted with the H1 protein, and memory 
CD4+ T cells were analyzed using intracellular cytokine staining and polychromatic flow cytometry. We identified high respond- 
ers, intermediate responders, and nonresponders based on detection of interleukin-2 (IL-2), tumor necrosis factor alpha (TNF- 
a), and gamma interferon (IFN-ç) expressing central (TCM) and effector memory CD4+ T cells (TEM) 182 days after the first im- 
munization. Amplicon-based transcript quantification using next-generation sequencing was performed to identify 
differentially expressed genes that correlated with vaccine-induced immune responses. Genes implicated in resolution of inflam- 
mation discriminated the responders from the nonresponders 3 days after the first inoculation. The volunteers with higher ex- 
pression levels of genes involved in antiviral innate immunity at baseline showed impaired H1-specific TCM and TEM mainte- 
nance 6 months after vaccination. Our study showed that in HIV-infected volunteers, expression levels of genes involved in the 
antiviral innate immune response affected long-term maintenance of H1/IC31 vaccine-induced cellular immunity. (The clinical 
trial was registered in the Pan African Clinical Trials Registry [PACTR] with the identifier PACTR201105000289276.) 
 
 
accination represents one of the most successful health inter- 
ventions for disease containment, elimination, and eventual 
eradication (1). Despite more than 50 years of widespread vacci- 
nation with Mycobacterium bovis bacille Calmette-Guérin (BCG), 
tuberculosis (TB) remains one of the world’s most serious infec- 
tious diseases. In 2012, the World Health Organization (WHO) 
estimated that there were 9 million new clinical TB cases and 1 
million people died from TB (2). Infection with HIV impairs host 
resistance, leading to a faster and higher rate of progression from 
latent to clinical TB (3). Consequently, there is an urgent need for 
development of improved TB vaccines that are more efficacious, 
safer, and more immunogenic than BCG in all populations, in- 
cluding HIV-infected individuals. H1/IC31 is a protein subunit 
vaccine against Mycobacterium tuberculosis, consisting of a fusion 
protein of the mycobacterial antigen 85B (Ag85B) and early secre- 
tory antigenic target 6 (ESAT-6) called hybrid 1 (H1) in combina- 
tion with the adjuvant IC31. IC31 is composed of the cationic 
polyamino acid KLK and a single-stranded oligodeoxynucleotide 
with alternating sequences of the nucleic acids inosine and cyt- 
idine (ODN1a) (4). KLK enables simultaneous uptake of H1 and 
ODN1a in antigen-presenting cells and provides a platform for 
hyperefficient Toll-like receptor 9 (TLR-9) ligand recognition of 
ODN1a. Upon triggering of TLR-9, conventional dendritic cells 
and monocytes activate the MyD88-NF-nB dependent  signaling 
cascade (5). This leads to secretion of proinflammatory cytokines 
and finally induction of adaptive immune responses. In addition 
to the MyD88-NF-nB-dependent pathway, plasmacytoid den- 
dritic cells (pDC) have the unique ability to signal in a MyD88- 
interferon regulatory factor (IRF7)-dependent way. This    yields 
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production of abundant quantities of type I interferon (IFN) 
(6, 7). 
In HIV-infected individuals, vaccine take and durability of the 
immunity are negatively affected upon manifestation of pro- 
gressed HIV disease (8). The HIV is detected by the innate im- 
mune system, primarily by recognition of viral nucleic acids. En- 
dosomal TLR-7 and -8 and cytosolic RIG-1-like receptors sense 
single-stranded viral RNA (ssRNA), which leads to secretion of 
proinflammatory cytokines and type I IFNs (9). Use of a TLR-9 
agonist as an adjuvant needs to be tested and analyzed carefully in 
HIV-infected individuals, since the downstream signaling cas- 
cades of TLR-7, TLR-8, and TLR-9 are shared (6, 7). 
We conducted a phase II, double-blind, randomized, placebo- 
controlled trial to evaluate the safety and immunogenicity of H1/ 
IC31 in BCG-vaccinated, HIV-infected adults with a CD4+ lym- 
phocyte count of >350 cells/mm3 (10). The principal finding was 
that the vaccine was safe and immunogenic. CD4+ lymphocyte 
counts and viral loads remained stable during the entire study 
period. The aim of this study was to analyze mRNA expression 
levels before and shortly after H1/IC31 vaccination and correlate 
these with vaccine-specific central (TCM) and effector memory 
CD4+ T cell (T    ) responses. A whole venous blood stimulation EM 
assay (10) was used to monitor the vaccine-induced cellular im- 
mune response over a follow-up period of 182 days. With use of 
AmpliSeq and next-generation sequencing the expression changes 
of 1,388 genes in peripheral blood were determined (11). We de- 
scribe for the first time that higher expression levels of genes in- 
volved in antiviral innate immunity at baseline reduce long-term 
maintenance of vaccine responses in HIV-infected volunteers. 
MATERIALS AND METHODS 
Ethics statement. This study was conducted according to good clinical 
practice guidelines and the Declaration of Helsinki. Informed consent was 
obtained from all participants. Detailed descriptions of the ethical ap- 
provals can be obtained from Reither et al. (10). The clinical trial was 
registered in the Pan African Clinical Trials Registry (PACTR) with the 
identifier  PACTR201105000289276. 
Participant enrollment and blood collection. A total of 24 HIV-pos- 
itive, BCG-vaccinated volunteers with CD4+ T cell counts of >350 cells/ 
mm3 from Bagamoyo, United Republic of Tanzania, were enrolled. Par- 
ticipants were randomly allocated in a ratio of 5:1 to receive placebo or 
H1/IC31 vaccine. One H1/IC31 vaccine recipient dropped out before the 
booster vaccination due to pregnancy. Injections of 0.5 ml containing 50 
µg Ag85B-ESAT-6 and 500 nmol KLK plus 20 nmol ODN1a (adjuvant) or 
0.4 ml Tris buffer (placebo) were administered intramuscularly on study 
days 0 and 56. For transcriptomics analysis, 2.5-ml samples of peripheral 
blood were collected via sterile venipuncture in RNA PaxGene Vacutainer 
tubes (PreAnalytiX) on days 0, 3, and 59. Samples of 9 ml of peripheral 
blood were collected in sodium heparin tubes and directly processed in 
whole-blood stimulation assays on days 0, 14, 56, 70, and 182. An ex- 
tended description of the study design can be obtained from Reither et al. 
(10). 
ICS and analysis by flow cytometry. The intercellular cytokine stain- 
ing (ICS) and flow cytometry analyses were described in Reither et al. (10). 
The present project focused on the analysis of cytokine-producing mem- 
ory CD4+ T cell subsets. For whole-blood stimulation and ICS, the pro- 
 
Aldrich). Subsequently, the whole-blood samples were transferred to a 
water bath at 37°C and incubated for an additional 5 h. Afterward, the 
water bath was switched off, and the water and contents were allowed to 
slowly reach room temperature. At 10 h after the water bath was switched 
off, the samples were harvested, EDTA (1.8 mM; Sigma-Aldrich) was 
added, and red blood cells were lysed in fluorescence-activated cell sorter 
(FACS) lysing solution (BD Biosciences). The remaining white blood cells 
were preserved in cryo solution containing 50% RPMI 1640 (Lonza), 40% 
fetal calf serum (BioWest), and 10% dimethyl sulfoxide (DMSO) (Sigma- 
Aldrich). 
For ICS, samples from each phlebotomy date of one particular partic- 
ipant were thawed simultaneously in a water bath at 37°C. Cells were 
transferred to tubes containing phosphate-buffered saline (PBS) (Bio- 
Whittaker), washed, and permeabilized using Perm/Wash solution (BD 
Biosciences). The flow cytometry staining was completed with the follow- 
ing anti-human antibody panel: CD3-BV421 (MOPC-21; BD Biosci- 
ences), CD4-QDot 605 (S3.5; Invitrogen), CD8-peridinin chlorophyll 
protein (PerCP)-Cy5.5 (SK1; BD Biosciences), CCR7-phycoerythrin (PE) 
(150503; eBioscience), IFN-μ-Alexa 700 (B27; BD Biosciences), tumor 
necrosis factor alpha (TNF-a)-Cy7-PE (Mb11; eBioscience), interleu- 
kin-2 (IL-2)-fluorescein isothiocyanate (FITC) (5344.111; BD Biosci- 
ences), IL-17-Alexa 647 (SCPL1362; eBioscience), and CD45RA-BV570 
(HI100; eBioscience) (see Table 2.1 in the MyFlowCyt Reporting Stan- 
dard in the supplemental material). For each fluorochrome, a single- 
stained mouse n CompBead (BD Biosciences) control was included. The 
samples were acquired on an LSR II flow cytometer (BD Biosciences, San 
Jose CA) equipped with green (532 nm), red (640 nm), violet (405 nm), 
and blue lasers (488 nm) (see Table 3.1 in the MyFlowCyt Reporting 
Standard in the supplemental material). On average, 900,000 events per 
sample were recorded. Data analysis was performed using FlowJo soft- 
ware version 10.0.7 (Tree Star). The following gating strategy was used 
(Fig. 1): CD3-positive cells were gated by plotting CD3-BV421 versus side 
scatter area (SSC-A). The singlets were selected by plotting forward scatter 
area (FSC-A) versus forward scatter height (FSC-H), and the lymphocytes 
were gated with FSC-A versus SSC-A. Time versus IL-2-FITC was gated to 
exclude bubbles and various fluidics pressures. The IFN-μ-Alexa 700 ver- 
sus CD8-PerCp-Cy5.5 plot was used to gate the CD8-negative cells. The 
CD4-positive cells were selected by plotting IFN-μ-Alexa 700 versus CD4- 
QDot 605. The memory subsets were defined using the CD45RA-BV570 
versus CCR7-PE plot. To identify cytokine-positive cells from all 4 mem- 
ory subsets, each cytokine was plotted against CD4-QDot 605. FlowJo 
version 10.0.7 was used for the analysis. This project focused on the de- 
tection of the cytokines IL-2, IFN-μ, and TNF-a. The production of IL-17 
by CD4+ T cells was not significantly different after booster vaccination 
(10). 
A detailed description following the MIFlowCyt Reporting Standard 
for flow cytometry experiments (13) can be accessed in the supplemental 
material. 
Extraction of total RNA. Total RNA was directly extracted from Pax- 
Gene blood RNA tubes using the PaxGene blood RNA kit (PreAnalytiX; 
Hombrechtikon, Switzerland) according to the manufacturer’s protocol. 
The concentration of total RNA and the RNA integrity number were 
determined by an Agilent RNA 6000 nano kit (Agilent Technologies, 
Waldbronn, Germany). RNA samples were stored at —80°C. 
AmpliSeq panels. We used two custom-made AmpliSeq primer pan- 
els to quantify gene expression. The Pathway Reporter Panel covered 917 
genes, providing a general snapshot of the whole human transcriptome. 
tocol of Hanekom et al. was followed (12v).ivBoriefly, ex whole blood was The rationale and design of this panel are described elsewhere (35). The 
directly stimulated with either the H1 fusion protein (5 µg/ml; Statens 
Serum Institute [SSI]) or phytohemagglutinin (5 µg/ml; BioWeb) or left 
unstimulated. The costimulatory antibodies anti-CD28 and anti-CD49d 
(0.5 µg/ml; Becton Dickinson [BD] Biosciences) were included in all assay 
conditions. Whole-blood samples were incubated for 7 h at 37°C and 5% 
CO2 in an incubator and then treated with brefeldin A (10 µg/ml; Sigma- 
second AmpliSeq primer panel, the Immune Response Panel, was devel- 
oped based on a literature-driven collection of 826 genes implicated in 
innate and adaptive immune responses. Functional enrichment analysis 
with the biological process (BP) terms of Gene Ontology suggests that the 
prioritized genes are highly enriched in innate and adaptive immune re- 
sponse pathways. The selected genes were submitted via a web interface 
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FIG 1 Gating strategy used for flow cytometric analysis of H1-induced memory CD4+ T cell cytokine expression. The plots show the sequential gating hierarchy 
of one representative sample: CD3+ T cells; single cells; lymphocytes; time; and CD8+ T cells, which were further gated for CD4+ cells and split into all memory 
subsets on the basis of CCR7 and CD45RA surface markers. The bottom row comprises the plots with the cytokine expression gate s for H1 fusion protein- 
stimulated TEM at day 182. IL-2, TNF-a, and IFN-μ expression levels were measured. TCM, central memory CD4 T cells; TEM, effector memory CD4 T cells; 
H1, hybrid 1. 
 
 
for primer design and synthesis using proprietary algorithms (Ampliseq; 
Life Technologies). 
Amplicon-based transcript quantification by semiconductor se- 
quencing. The amplicon-based transcript quantification was performed 
using an ion proton semiconductor sequencer. This methodology was 
previously described by Zhang et al. (11) and strictly followed. Briefly, 
AmpliSeq libraries were prepared using 30 ng total RNA according to the 
protocol supplied with the ion AmpliSeq RNA library kit (catalog no. 
4472335; Life Technologies, Carlsbad, CA, USA). The amplified and pu- 
rified libraries were stored at —20°C. Library size distribution and con- 
centration were measured using an Agilent high-sensitivity DNA kit (Agi- 
lent Technologies) according to the manufacturer’s recommendation. 
Following library preparation, barcoded samples were pooled and pro- 
cessed together. The multiplexed library (total 8 pM) was linked to ion 
sphere particles and clonally amplified by emulsion PCR using the Ion PI 
template OT2 200 kit v3 with the Ion OneTouch 2 instrument according 
to the manufacturer’s protocol (Life Technologies). Sequencing was per- 
formed using the Ion PI sequencing 200 kit v3 and the Ion Proton chip I, 
following the manufacturer’s instructions, on the Ion Proton sequencer 
(Life Technologies). The generated reads were aligned to the Homo sapi- 
ens RNA canonical transcript reference hg19 and mapped to the genes of 
the corresponding AmpliSeq panel using the Torrent Mapping Alignment 
Program. Simultaneously, single nucleotide polymorphisms (SNPs) 
within the amplicons were identified during this process using the Ion 
Torrent Variant Caller. 
Statistical analysis. (i) Analysis of memory CD4+ T cells. A two- 
sided Wilcoxon signed-rank test was performed to test for the significance 
of  the  polyfunctional  memory  CD4+ T  cell  subset  between  study days. 
The participants’ responses to the vaccine were calculated using the Mi- 
mosa package within R software (14, 15). After correction for the T cell 
response obtained from unstimulated controls, absolute counts of cyto- 
kine (IFN-μ and/or IL-2 and/or TNF-a)-expressing TCM or TEM and 
counts of TCM or TEM negative for cytokine expression were compared 
between day 0 and each follow-up (day 14, day 56, day 70, and day 182) 
(see Table 2). Final responders were defined based on a comparison of day 
0 to day 182 and with a false discovery rate (FDR) of >0.0001 for a non- 
responder, an FDR of >1015 for an intermediate responder, and an FDR 
of <1015 for a high responder. 
(ii) AmpliSeq data analysis. AmpliSeq data were analyzed based on 
negative binomial distribution using the Bioconductor edgeR package 
(16). For each vaccine responder group, we performed differential expres- 
sion analysis through the time course, comparing the two postvaccination 
time points to the prevaccination time point. Furthermore, gene expres- 
sion was compared between the vaccine responder groups in order to 
identify values that differed from baseline. Standard settings were used, 
and only those genes with expression higher than 5 counts per million 
reads in at least 3 samples and an FDR of <0.1 were considered differen- 
tially expressed. Annotation of differentially expressed genes was per- 
formed using the previously published blood transcription modules 
(BTMs) (17). Statistical analysis was performed and plots were made us- 
ing R version 3.1.0 (15). 
 
RESULTS 
H1/IC31 phase II clinical trial design. We conducted a phase II, 
double-blind,  randomized,  placebo-controlled  trial  in Bagamoyo, 
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TABLE 1 H1/IC31 clinical trial overview and results 
 
 
 
 
 
 
 
 
vaccination (self-report) 
No. (%) ART naive 4 (100) 19 (100) 
 
for transcriptome analysis were taken on study days 0, 3, and 59 
after each vaccination. Whole-blood samples for immunoge- 
nicity assays were taken on study days 0, 14, 56, 70, and 182 for 
long-term follow-up. All volunteers were BCG vaccinated prior 
to the study and were antiretroviral therapy (ART) naive with 
CD4 counts of >350 cells/mm3 (Table 1). Generally, the H1/ 
IC31 vaccine was safe and well tolerated with no significant 
impact on the CD4+ lymphocyte count and HIV load after 
vaccination. 
Cytokine-producing memory CD4+ T cell subsets. Based on 
CD4 count (median [IQR]) 575.3 (425–617)b 656.9 (532—745)b chemokine receptor CCR7 and surface marker CD45RA expres- 
from baseline sion, two subsets of CD4
+ memory T  cells, T and T , were 
EM 
(cells/mm3) 
Viral load (median [IQR]) 
from baseline 
(copies/ml) 
a 
 
33,802 (514–49,875)b 
 
37,932 (8,754—50,950)b 
identified (Fig. 1) (18). We measured the development and mag- 
nitude of the H1/IC31-induced memory CD4+ T cell subsets ex- 
pressing IL-2, IFN-μ, and TNF-a following in vitro stimulation 
with the H1 protein. At day 182, TCM and TEM were significantly 
IQR, interquartile range; F, female; M, male. 
b No significant difference over the 182-day follow-up. 
 
 
Tanzania (10). Twenty-four HIV-positive volunteers were en- 
rolled and vaccinated twice with H1/IC31 (n = 20) or placebo 
(n = 4) at baseline (day 0) and day 56. One H1/IC31-vaccinated 
volunteer dropped out due to pregnancy. Whole-blood    samples 
elevated compared to levels in placebo controls (see Fig. S1 in the 
supplemental material). To measure the quality of the immune 
response, we discriminated the memory CD4+ T cell subsets ac- 
cording to their polyfunctional cytokine expression profile. Figure 
2A displays the mean percentages of cytokine expression of all 
memory subsets according to their polyfunctionality. In agree- 
ment with Reither et al. (10), the H1/IC31-specific TCM and  TEM 
 
A. Total cytokine production of H1 specific CD4+ T cell memory subsets 
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FIG 2 Cytokine expression profile of memory CD4+ T cell subsets following H1 fusion protein stimulation. Volunteers receiving H1/IC31 at days 0 and 56 are 
included. (A) Mean percentages of all memory CD4+ T cell subsets on the basis of all possible combinations of IL-2, IFN-μ, and TNF-a expression are given. 
Radii and not area of each segment represent the percentages of CD4+ T cells. T (B) and T (C) expressing all combinations of IL-2, IFN-μ, and TNF-a 
expression following stimulation with H1. P values correspond to significance testing comparing each study day to study day 0 (*, P < 0.0125; **, P < 0.001; + 
***, P < 0.0001). A two-sided Wilcoxon signed-rank test with the Bonferroni correction was applied. TCM, central memory CD4 
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 H1/IC31 vaccinated 
 
Characteristica 
Placebo group 
(n = 4) 
group 
(n = 19) 
Age (median [IQR]) (yr) 38 (28—49) 39 (34—45) 
Gender (F/M) 3/1 9/10 
No. (%) with prior BCG 4 (100) 19 (100) 
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TABLE 2 Overview of responder groups based on either TCM or TEM 
No. of nonresponders/intermediate responders/high 
responders at: 
 
T cell type Day 14 Day 56 Day 70 Day 182 
TCM 6/6/7 11/3/5 5/6/8 8/5/6 
TEM 3/5/11 4/5/10 2/2/5 4/6/9 
 
 
were predominantly trifunctional or bifunctional, expressing IL-2 
and TNF-a. 
In Fig. 2B and C, TCM and TEM are displayed separately. In a 
comparison of day 0 to day 182, statistically significant increases of 
bifunctional TCM expressing IL-2 with TNF-a (P < 0.05) were 
observed. This was also observed in bifunctional TCM expressing 
IL-2 with IFN-μ, although at extremely low percentages. 
Trifunctional and bifunctional (IL-2 and TNF-a) TEM were 
most significantly elevated in the comparison of day 182 to day 0 
(P < 0.01), followed by monofunctional (IL-2 or TNF-a) TEM 
(P < 0.05). 
Definition of vaccine responder groups. To investigate poten- 
tial innate immune mechanisms that yield differential vaccine im- 
munogenicity in our study participants, we divided the volunteers 
according to their cytokine responses (IFN-μ, IL-2, and/or TNF- 
a), comparing H1-specific TCM  and TEM. 
An overview of potential responder groupings comparing each 
study day to the baseline at day 0 is given in Table 2. In a compar- 
ison of day 70 to day 182, several volunteers shifted from respond- 
ers to nonresponders, indicating discriminative memory mainte- 
nance. 
No significant difference in relation to the viral load and CD4+ 
lymphocyte counts between these groups was observed (Table 3). 
Grouping the volunteers based on a comparison of day 0 to day 
182 allowed us to identify the innate immune mechanisms    that 
potentially lead to improved TCM and TEM maintenance. 
Gene expression data. On average, 4,686,802 reads (95% con- 
fidence interval [CI], ±712,607 reads) per sample were generated 
and mapped to either the 826 genes of the AmpliSeq Immune 
Response Panel or the 917 genes of the Pathway Reporter Panel. A 
dynamic range of 5 orders of magnitude was observed, ranging 
from genes with no detectable expression like IFN-n to genes ex- 
pressing more than 160,000 reads like lysozyme and CD74. Both 
 
AmpliSeq panels shared 355 genes, whose transcript abundance 
measurements closely correlated (R2 = 0.9829). 
The expression levels of nine endogenous control genes did not 
differ significantly between the 24 volunteers included here across 
all time points, supporting the robustness of the AmpliSeq-based 
targeted transcriptome measurement approach (Fig.  3A). 
Vaccine-induced differential gene expression. Next we ad- 
dressed if early changes in the whole-blood gene expression levels 
of the targeted 1,388 genes might distinguish the three responder 
groups of each memory subset. The results are shown in Fig. 3B, 
and more detailed information is provided in Table S1 in the sup- 
plemental material. TCM and TEM intermediate and high respond- 
ers showed upregulated gene expression levels 3 days postvaccina- 
tion. For TCM responders, 5 genes, namely, COL1A1, ELN, CTGF, 
SERPINE1, and POSTN, were identified as upregulated. TEM re- 
sponders had an additional 5 genes, including COL3A1, COL1A2, 
FN1, ID1, and DCN, with increased expression levels. 
Most of the 10 differentially expressed genes are either anno- 
tated in BTMs involved in integrin interactions or extracellular 
matrix and cell adhesion (COL1A1, COL1A2, COL3A1, CTGF, 
FN1, and POSTN) or known to be part of extracellular matrix 
remodeling (ELN or SERPINE1). ID1 is involved in leukocyte 
differentiation. HSPA1A is the only gene which was upregulated 
in a TEM nonresponder. This gene encodes a heat shock protein 
and is involved in the stress response. No differential gene expres- 
sion was observed in the placebo controls. 
Differential immune activation at baseline. Next we ad- 
dressed if gene expression levels at baseline before the first vacci- 
nation could distinguish the responder groups. Table 4 shows an 
overview of all genes that differed significantly at baseline between 
the vaccine responder groups based either on TCM or TEM. Com- 
pared to levels in nonresponders, higher gene expression levels 
were observed for ITGB4, CLEC1C, and CXCL6 for TCM high 
responders and for PRKDC, CD19, DNAJB5, MARCO, and IRS2 
for TEM high responders. TGM2, OAS1, and IFI27 showed the 
lowest expression levels among TCM high responders, whereas 
AICDA, NFATC2, IFI27, IFIT3, IFIT1, and CXCL10 were ex- 
pressed at lower levels in TEM high responders. Tissue transglu- 
taminase (TGM) has a role in HIV pathogenesis and enhanced 
levels of its degradation product, H(μ-glutamyl)lysine, are found 
in the blood of patients with progressed HIV disease (19). AICDA 
and NFATC2 take part in the antiviral immune response with the 
 
 
TABLE 3 Demographics including information about HIV infection status of final responder groups based on the comparison of day 0 to day 182 
 
Day 182 responder group 
No. of 
volunteers 
Age 
(yr)a 
 
No. F/no. Mb 
Viral load 
(log2)
a 
CD4+ count 
(cells/mm3)a 
Placebo 4 38 ± 13 3/1 11.5 ± 5.3 575 ± 250 
TCM      
High responder 6 35 ± 5 2/4 12.1 ± 3.8 823 ± 266 
Intermediate responder 5 46 ± 5 2/3 14.0 ± 3.1 529 ± 64 
Nonresponder 8 38 ± 6 6/2 14.3 ± 2.7 618 ± 181 
 
TEM 
     
High responder 9 38 ± 7 4/5 12.3 ± 3.4 698 ± 284 
Intermediate responder 6 40 ± 9 2/4 14.4 ± 3.4 604 ± 90 
Nonresponder 4 39 ± 5 4/0 14.9 ± 1.2 644 ± 226 
a Data are means ± SD.      b F, female; M, male. 
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FIG 3 (A) Gene expression of endogenous control genes. Variations in expression levels of nine control genes between subjects and o ver time and log2-fold 
changes between baseline and the two visits after each vaccination for all 24 volunteers are shown. (B) Heat map showing vaccine-induced differential gene 
expression levels between TCM and TEM responder groups. Log2-fold changes in gene expression levels 3 or 59 days after vaccination compared to prevaccination 
levels are shown. Differentially expressed genes were identified using edgeR with an FDR of <0.1 (**, significant for TCM and TEM; *, significant for TEM only). 
Only changes in gene expression 3 days after vaccination were significant. 
 
 
roles of affinity maturation and class switching of antibodies and 
inhibition of viral replication (19, 20). According to annotation 
with BTMs, the lower expressed genes indicated in bold above are 
involved in innate antiviral immunity. We analyzed the expres- 
sion levels of all genes available in both AmpliSeq panels that be- 
longed to these BTMs (Fig. 4A). Clearly, at baseline both nonre- 
sponder groups showed higher transcription levels of members of 
BTM M150 (innate antiviral response), M165 (enriched in acti- 
vated dendritic cells), M75 (antiviral IFN signature), M127 (type I 
interferon response), M13 (innate activation by cytosolic DNA 
sensing), and M68 (RIG-1-like receptor signaling). 
The expression levels of genes involved in innate immunity to 
viruses (IRF7, IFI27, IFIT3, EIF2AK2, DHX58, IFIT1, CCL8, and 
OAS1) showed an association with HIV-1 viral loads (Fig. 4B). 
Toll-like receptor 8 variant. The AmpliSeq approach allows 
for nucleotide sequencing of the amplified fragments using the 
Ion Torrent approach. We are aware that this study was not de- 
signed (e.g., powered) to assess the association of polymorphic 
 
 
TABLE 4 Genes which are differentially expressed between the different 
vaccine responder groups for TCM and  TEM 
Genes with expression levels:a 
 
genes with vaccine-induced immune responses. One single nucle- 
otide polymorphism (SNP) in TLR-8 (rs3764880) was previously 
reported to result in slower disease progression in HIV-infected 
individuals and reduced activation of the NF-nB pathway (21). 
The functional variant of TLR-8 showed the A1G polymorphism 
(rs3764880) that alters the start ATG codon of TLR-8 into a GTG 
triplet. The resulting truncated TLR-8 (1,038 amino acids [aa]) 
exhibits a shorter signal peptide. Seven volunteers expressed the 
TLR-8 A1G; of these, three volunteers harbored the homozygous 
TLR-8 A1G. Interestingly, none of the volunteers with the TLR-8 
A1G belonged to the TEM nonresponder group, and all three sub- 
jects expressing the homozygous TLR-8 A1G were TEM high re- 
sponders. Importantly, subjects with the homozygous TLR-8 A1G 
have a reduced expression of antiviral gene signatures at baseline 
(Fig. 5A). Independent of the responder grouping, at day 182 vol- 
unteers with the homozygous TLR-8 A1G have on average the 
highest percentages of trifunctional and bifunctional (IL-2 and 
TNF-a) TCM and TEM (Fig. 5B and  C). 
 
DISCUSSION 
The study presented here provides the first insights into the pos- 
sible link between chronic immune activation in HIV infection 
and lack of maintenance of vaccine-induced TCM and TEM re- 
 
T cell type 
Higher than those 
in nonresponders 
Lower than those in 
nonrespondersb 
sponses. Data on the impact of chronic, untreated HIV infection 
on experimental and routine vaccination outcomes are  scarce 
TCM ITGB4 TGM2 
CLEC1A OAS1 
CXCL6 IFI27 
(22). The identification of immune-related genes that are   ex- 
pressed before vaccination or induced shortly after vaccination 
influencing cellular immune responses in HIV-positive volun- 
teers will be of great value (23). 
TEM PRKDC AICDA 
CD19 NFATC2 
DNAJB5 IFI27 
MARCO IFIT3 
IRS2 IFIT1 
CXCL10 
a Differentially expressed genes were identified using edgeR with an FDR of <0.1 and 
are grouped as having higher or lower expression levels in the high-responder group 
than in the nonresponder group. 
b Genes in bold are involved in innate antiviral immunity. 
Determinants of induction and long-term maintenance of 
memory CD4+ T cell responses generally in humans are only par- 
tially known (24). The H1/IC31 vaccine has been tested in several 
phase I clinical trials, including HIV-negative and BCG-unvacci- 
nated and BCG-vaccinated and M. tuberculosis-exposed European 
volunteers (4, 25). In the BCG- and M. tuberculosis-naive Euro- 
pean volunteers, IFN-μ-producing H1-specific T cells were de- 
tectable by ELISpot analysis until 131 weeks after the first vacci- 
nation. Only limited retraction of IFN-μ production in cell culture 
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FIG 4 Differential gene expression at baseline prior to vaccination. (A) Innate antiviral signature at baseline. The expression levels of the five genes involved in 
innate antiviral immunity with their corresponding members of BTMs are shown for TCM and TEM responder groups. (B) Correlation of innate antiviral markers 
and viral load. Pearson correlation coefficients and 95% confidence intervals are shown. Only genes with Pearson correlation coefficients of >0.4 were 
considered. TCM, central memory CD4  T cells; TEM, effector memory CD4  T cells. 
 
supernatants from H1-stimulated peripheral blood mononuclear 
cells (PBMCs) was measured between study weeks 14 and 131 (4). 
In the current study, we observed an expansion of H1-specific 
TCM and TEM in all volunteers at study day 70, which is 2 weeks 
after the booster vaccination. However, when followed up until 
day 182, a retraction of H1-specific TCM and TEM was observed. 
Interestingly, this retraction differed greatly between volunteers, 
which allowed us to group them based on the comparison of H1/ 
IC31-induced TCM and TEM responses on day 182 in relation to 
those on day 0. 
Compared with microarray analyses, the AmpliSeq approach 
has a higher sensitivity and dynamic range, and its results compare 
precisely with RNA sequencing-derived whole-transcriptome 
data (11). Results obtained with both gene panels strongly sup- 
ported the idea that the AmpliSeq-based transcriptome monitor- 
ing approach is very robust and results in highly reproducible data 
sets suitable for high-throughput analysis of clinical samples. 
Here, to our knowledge, we have employed this targeted tran- 
scriptome monitoring tool in an experimental vaccine trial for the 
first time. 
Higher expression levels of genes involved in the extracellular 
matrix and integrin interactions and cell adhesion were observed 
in volunteers who maintained H1-specific TCM and TEM responses 
until day 182. Searching the literature, we found that cells involved 
in wound healing like alternatively activated macrophages (26), 
μ6-T cells (27), monocyte-derived multipotential cells (28), fibro- 
cytes (17), and endothelial progenitor cells (29) have all been de- 
scribed to express these particular genes. 
Muyanja et al. showed that the cellular and humoral immune 
responses to the highly efficacious live yellow fever vaccine YF- 
17D in East African individuals were substantially lower than 
those of European volunteers treated identically (30). Prior to 
vaccination, the East African volunteers presented an increased 
activated immune microenvironment with higher frequencies of 
exhausted and activated natural killer cells, differentiated B and T 
cells, and proinflammatory monocytes (30). We therefore com- 
pared the gene expression profiles measured at baseline between 
our responder groups. Significantly higher expression levels of 
genes involved in innate antiviral immune responses like type I 
IFN signaling and viral sensing through cytosolic RIG-1-like re- 
ceptors were observed in the nonresponders. A close correlation 
between HIV loads and expression levels of this group of genes 
indicates that the chronic HIV infection is driving the higher ex- 
pression levels of these antiviral responses. In line with these re- 
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of TLR signaling and thus supports our findings (33). The HIV 
was found to specifically infect activated memory CD4+ T cells 
with potential consequences for the maintenance of vaccine-spe- 
cific memory responses (34). In conclusion, higher activation of 
the components of the innate immunity due to HIV stimulation at 
baseline results in impaired H1-specific TCM and TEM mainte- 
nance. 
In addition to access to the expression level, the AmpliSeq ap- 
proach also provides access to the nucleotide sequence of the re- 
spective amplified gene fragment. This enabled us to identify vol- 
unteers carrying the previously known TLR-8 A1G single 
nucleotide sequence variant. Volunteers expressing this TLR-8 
A1G gene on both chromosomes had lower gene expression levels 
of the innate antiviral immune response genes. This was linked to 
longer maintenance of vaccine-specific TEM responses until day 
182 compared to that for the wild-type TLR-8 carriers. 
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The inverse relationship between chronic innate antiviral im- 
mune activation by HIV and sustained H1/IC31-induced vaccine- 
specific cellular immune responses has high relevance for future 
vaccine development and monitoring programs. Patients receiv- 
ing ART potentially present with lower activation of innate anti- 
viral immunity, and thus the effect of treating patients with ART 
prior to vaccination has to be evaluated. The presence of the 
TLR-8 A1G variant in HIV-infected individuals might provide an 
immune genetic background, supporting a more desired vaccina- 
tion outcome. This observation warrants future studies using 
larger numbers of HIV-infected and -noninfected volunteers un- 
dergoing experimental or routine vaccination. 
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Abstract 
It is well accepted that aging and HIV infection are associated with quantitative and function- 
al changes of CMV-specific T cell responses. We studied here the expression of Mip-1β 
and the T cell maturation marker CD27 within CMVpp65-specific CD4+ and CD8+ T cells in 
relation to age, HIV and active Tuberculosis (TB) co-infection in a cohort of Tanzanian vol- 
unteers (Ç16 years of age, n = 108 and Ç18 years, n = 79). Independent of HIV co-infection, 
IFNγ+ CMVpp65-specific CD4+ T cell frequencies increased with age. In adults, HIV co-in- 
fection further increased the frequencies of these cells. A high capacity for Mip-1β produc- 
tion together with a CD27low phenotype was characteristic for these cells in children and 
adults. Interestingly, in addition to HIV co-infection active TB disease was linked to further 
down regulation of CD27 and increased capacity of Mip-1β production in CMVpp65-specific 
CD4+ T cells. These phenotypic and functional changes of CMVpp65-specific CD4 T cells 
observed during HIV infection and active TB could be associated with increased CMV 
reactivation rates. 
 
 
 
 
 
Introduction 
Primary cytomegalovirus (CMV) infection occurs often at birth or during adolescence with 
prolonged viral shedding into the urine and saliva that can persist for years. In adults, primary 
CMV infection is typically controlled within 6 months [1]. Thereafter, CMV persists lifelong in 
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Impact of Age, HIV and MTB Infections on CMV-Specific T Cell Responses 
 
 
 
a state of clinical latency [2,3]. The CMV-specific adaptive immune response efficiently sup- 
presses overt viral replication and prevents viral shedding for decades. Aging is notably associ- 
ated with accumulation of high frequencies of oligoclonal CMV-specific CD8+ T cells [4]. In 
late-stage AIDS patients (CD4 counts <50/μl), CMV infection can cause disseminated or local- 
ized end-organ disease [5]. CMV-specific CD4+ T cell responses appear to be crucial for CMV 
control in murine models and in humans [6],[4]. In adults, these CMV-specific CD4+ T cells 
are characterized by: (i) highly differentiated CD27-/CCR7- effector memory phenotype; (ii) 
propensity to secrete the CCR5 ligand Mip-1β and (iii) high cytolytic activity against CMV in- 
fected cells and these characteristics differ from HIV- or Vaccinia virus-specific CD4+ T cells 
[7]. 
CMV-specific CD4+ T cells are relatively resistant to HIV infection and HIV mediated de- 
pletion [8], [9], [10], and this has been linked to their propensity to secrete Mip-1β. Mip-1β has 
also been connected to the expression of the immune senescence marker CD57 [11]. However, 
the underlying immunological mechanisms that “imprint” this particular phenotype and high 
capacity for Mip-1βproduction are unclear. Recent or on-going antigen exposure causes differ- 
entiation of pathogen-specific CD4+ T cells into CD27- effector memory phenotype and can in- 
flict functional changes [7,10,12–14]. One factor contributing to an increased capacity to 
produce Mip-1β could be recurrent or transient, subclinical reactivation of CMV throughout 
life. To address this hypothesis, we studied cell frequencies, Mip-1β production and CD27 ex- 
pression of CMV-specific CD4+ and CD8+ T cells in children, adolescence and adults in rela- 
tion to age, HIV and active tuberculosis infection in individuals from Tanzania, where CMV 
infection prevalence reaches up to 100% in adults [15]. 
 
 
Results and Discussion 
Detection of CMV-specific T cell responses using polychromatic flow cytometry after in vitro 
stimulation is a reliable marker for determining the CMV infection status in children [16]. 
CMVpp65-specific CD4+ and CD8+ T cell responses were characterized in a Tanzanian cohort 
(n = 187) encompassing children (<10 years of age, n = 79), adolescents (10–16 years of age, 
n = 29) and adults (>18 years of age, n = 79). This Tanzanian cohort is described in greater de- 
tail [17]. The gating strategy and representative flow cytometry plots are shown in Fig 1. Study 
subjects were stratified according to age and their HIV and TB co-infection status. In the ab- 
sence of a reliable test for definite childhood TB classification, HIV- paediatric TB suspects in- 
cluded culture-confirmed TB (n = 14) and uncertain TB classification (n = 16). HIV+ 
paediatric TB suspects (n = 31) included culture confirmed TB (n = 4), and 13 subjects with 
uncertain TB classification (n = 13). In 46 HIV- and 13 HIV+ children an alternative diagnosis 
could be established after 5 months of clinical follow-up excluding active TB [17]. 
As expected, the prevalence of CMVpp65-specific T cell responses increased with age (Fig 
2A). In the HIV- group, CMVpp65-specific T cell responses were detectable in 48.5% (16 of 
33) of children <5 years of age, in 77.3% (17 of 22, Fig 2B) of children between 5 and 10 years, 
in 81% (17 of 21) of adolescents (10–16 years) and 96% (48 of 50) of adults (Fig 2A, 
P<0.0001). In the HIV+/AIDS group, CMVpp65-specific T cell responses were detectable in 
70% (7 of 10) of children <5 years of age, in 92.8% (13 of 14) of children (5–10 years), in 87.5% 
(7 of 8) of adolescents (10–16 years) and 89.7% (26 of 29) of adults. Interestingly, in children 
<10 years of age, HIV infection was associated with an increased prevalence of CMVpp65-spe- 
cific T cell responses (p = 0.067). These data suggest that within the studied Tanzanian popula- 
tion, CMV infections are mostly acquired within the first 10 years of life with HIV infection 
being a potential risk factor for early acquisition of CMV infection. When compared to West- 
African populations, CMV infection seems to be acquired at an older age where by the age of 
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Fig 1. Gating strategies and CMV responses evaluation. A) Morphological and CD marker expression gating strategy of CD4 and CD8 T cell. B) 
Representative CD4 and CD8 T cell IFNγ response from a significant responder. C) Gating strategy for the CD27 MFI Fold Change calculation of IFNγ 
producing cells compared to all CD4 or CD8 T cells. D) Gating strategy for the determination of IFNγ producing cells that were also positive for 
Mip1β production. 
 
doi:10.1371/journal.pone.0126716.g001 
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Fig 2. CMVpp65-specific T cell responses in relation to age and HIV infection status. (A) Frequency of 
subjects with or without CMVpp65-specific T cell responses (CD4+ or CD8+) is shown stratified by age group 
and HIV status. B) The frequency of subjects with CMVpp65-specific T cell responses distributed within the 
CD4+ and/or CD8+ T cell compartment is shown after stratification by HIV status. The number of subjects in 
each group is indicated within brackets. CMVpp65-specific T cell responses were considered positive if the 
frequency of IFNγ+ T cells was 2-fold above the negative control and at least 0.05% of the parent population. 
Statistical analysis was performed using the chi-square test for trend (A) and chi-square test (B). 
 
doi:10.1371/journal.pone.0126716.g002 
 
12 months close to 100% of children showed serological evidence of CMV infection or had re- 
leased CMV DNA in urine [18,19]. 
CD4 T cell responses targeting purified protein derivatives (PPD) followed a similar trend 
(data not shown), indicating that detection of Mycobacteria-specific T cells in adolescents and 
adults are not a consequence of BCG vaccination during early infancy (BCG vaccination cover- 
age for patients <18 years was 97.7% (43 of 44, unknown status n = 1). These findings are con- 
sistent with the disappearance of circulating Mycobacteria-specific CD4 T cell responses upon 
BCG vaccination within one year following vaccination [20]. 
Next, we compared the contribution of CD4+ or CD8+ T cells to the CMV-specific T cell re- 
sponses in children (<10 years) and adults (>18 years). A high number of children (36.4% for 
HIV- and 45% for HIV+) mounted CMV responses exclusively within the CD8+ T cell subset 
irrespective of their HIV status. In HIV+ individuals, the difference between children and 
adults reached statistical significance with more individuals having both CD4+ and CD8+ 
CMV-specific T cell responses in the adult HIV+ group (Fig 2B, P = 0.037). 
Adults showed increased frequencies of CMVpp65-specific CD4+ T cells compared to chil- 
dren <10 years regardless of their HIV infection status (Fig 3A, HIV-: median 0.15% vs. 0.06%, 
P = 0.0004; HIV+: median 0.26 vs. 0.07%, P = 0.002). A higher frequency of CMVpp65-specific 
CD8+ T cell responses in adults was also observed, particularly within the context of HIV 
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Fig 3. Frequencies and absolute counts of IFNγ+-CMVpp65–specific CD4+ or CD8+ T cell in children below 10 years of age and adults. Scatter-plots 
depicting A) the frequencies or absolute counts of CMV specific IFNγ+-CD4+ T cells s and C) frequencies of CMV specific IFNγ+-CD8+ T cells in the two-age 
groups and according to HIV status. 
 
doi:10.1371/journal.pone.0126716.g003 
 
infection (Fig 3C, median 0.15% vs. 0.37%, P = 0.017) [4,21]. Absolute counts of 
CMVpp65-specific CD4+ T cells no longer increased with age and were significantly affected 
by HIV co-infection in children and adults (Fig 3B, P = 0.045 and P = 0.0276 respectively). In 
line with previous reports showing age related differences in the proportion of IFNγ+ T cells in 
response to SEB stimulation [22–24], we also observed significantly reduced frequencies and 
absolute counts of IFNγ+-CD4+ T cell responses after SEB stimulation in children (Fig 4). This 
could reflect the higher proportion of naïve T cells in children, that cannot express IFNγ [25] 
and might also be linked to IFNγ promoter hyper methylation of naïve T cells in infants [26]. 
Importantly, the proportion of responders with CMVpp65-specific CD4+ T cells was similar 
between HIV+ (12 of 19, 63.1%) and HIV- (11 of 20, 55%) children (P = 0.53). This demon- 
strates that CMV-specific CD4+ T cells persisted in children <10 years of age during concur- 
rent HIV infection as described previously for adults [10,27], even though absolute numbers of 
CMVpp65-specific CD4+ T cells were reduced in HIV+ adults and children (Fig 3B). Relative 
resistance of CMV-specific CD4+ T cells to HIV-induced depletion has been linked to their 
high capacity for Mip-1β secretion [7] together with their mature phenotype, characterized by 
a high proportion of cells expressing the senescence marker CD57 [28]. Expression of CD57 on 
 
 
Fig 4. Frequencies and absolute counts of IFNγ+-SEB–specific CD4+ or CD8+ T cell in children below 10 years of age and adults. Scatter-plots 
depicting A) the frequencies or B) absolute counts of SEB specific IFNγ+-CD4+ T cells s and C) frequencies of SEB specific IFNγ+-CD8+ T cells in the two- 
age groups and according to HIV status. 
 
doi:10.1371/journal.pone.0126716.g004 
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Fig 5.  CD27 and Mip-1β expression of CMV specific IFNγ producing CD4 T cell responses are influenced by HIV as well as tuberculosis co-       
infection in adults. Scatter-plots illustrating (A) the CD27 MFI fold-change to all CD4+ T cells and B) the proportion of cells producing Mip-1β of CMV specific 
IFNγ+-CD4+ T cell in patients under 10 or over 18 years old and according to HIV and TB infection status. 
 
doi:10.1371/journal.pone.0126716.g005 
 
CMV-specific CD4+ T cells correlates with an increased capacity to produce Mip-1β [10]. We 
thus wanted to determine whether the capacity for Mip-1β production is associated with aging 
in our cohort. There was no linear relationship between age and capacity for Mip-1βproduction 
in IFNγ+ CMV-specific CD4+ T cells in HIV- subjects (data not shown). Both HIV- adults and 
children had IFNγ+ CMV-specific CD4+ T cells characterized by a CD27low phenotype 
(P = 0.332) and a similar capacity to co-express Mip-1β (median 32.4% v 50%, P = 0.372, Fig 5 
and Fig 1C and 1D for gating strategy details). A previous study reported a predominance of 
undifferentiated CD27+ CMV-specific CD4 T cells in infants [29] and an unusual immature 
CD27 phenotype predominance in adults contrasting with several other reports [10],[30],[31]. 
Differences in study population or methodology could account for this discrepancy. Interest- 
ingly, down regulation of CD27 and increased frequencies of Mip-1β co-producing CD4+ T 
cells occurred in adults with active TB (P = 0.036 and 0.0596) and particularly in those co-in- 
fected with HIV (P = 0.008 and 0.002). This result demonstrates to our knowledge for the first 
time that active TB infection alone is associated with phenotypic and functional changes in 
CMV-specific CD4+ T cell response in adults. A significant impact of HIV and active 
 
 
Fig 6. CD27 and Mip-1β expression of CMV specific IFNγ producing CD8 T cell responses are not significantly influenced by HIV as well as 
tuberculosis co-infection in adults. Scatter-plots illustrating (A) the CD27 MFI fold-change to all CD8+ T cells and B) the proportion of cells producing Mip- 
1β of CMV specific IFNγ+-CD8+ T cell in patients under 10 or over 18 years old and according to HIV and TB infection status. 
 
doi:10.1371/journal.pone.0126716.g006 
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tuberculosis on the CD27 phenotype of CMV-specific CD8+ T cells was not observed (Fig 6A 
and 6B). Based on these results, we hypothesis that that the CMV virus might reactivate during 
active TB, particularly so in HIV+ subjects – driving further antigen-driven CMV-specific cel- 
lular maturation and increased Mip-1β production [9,10]. This is supported by the known he- 
matopoietic niche for latent CMV viruses which reactivate upon differentiation of myeloid 
precursor into tissue macrophages [32]. Cellular recruitment including monocyte-derived 
macrophages is essential for the granuloma formation that typifies tuberculosis pathogenesis 
[33]. Similar changes were not detected in HIV+ children. However, the number of children in- 
cluded in the analyses and the fact that all enrolled children were TB suspects limits the validity 
of this finding. 
 
Conclusion 
We show that CMVpp65-specific T cell responses are detectable in the peripheral blood of 
most Tanzanian children indicating that acquisition of CMV infection typically occurs during 
infancy and early childhood with HIV being a risk factor. In comparison to adults, there was 
an increased proportion of CD8+ T cells participating in the response and this was particularly 
apparent in HIV+ children. In children, CMVpp65-specific CD4+ T cells had a mature 
CD27low effector memory phenotype and a high capacity for Mip-1β production similar to 
those detected in adults, and there was no apparent effect of HIV co-infection. Despite some 
limitations of the current study, such as the hospital based inclusion of children, our results 
suggest that the high capacity for Mip-1βproduction of CMV-specific CD4+ T cells is indepen- 
dent of age. Importantly, we observed for the first time that active TB impacts on the CMV- 
specific CD4+ T cell phenotype. This may reflect recent CMV reactivation and would indicate 
a previously unknown interplay between CMV virus infection and active 
tuberculosis pathogenesis. 
 
Materials and Methods 
Ethics Statement 
The study was conducted at two Tanzanian research sites—the NIMR-Mbeya Medical Re- 
search Center, Mbeya, and the Ifakara Health Institute, Bagamoyo. The Institutional Review 
Board of the Ifakara Health Institute, the Mbeya Medical Research and Ethics Committee, and 
the Medical Research Coordinating Committee of Tanzania approved the study protocols. We 
obtained written informed consents from adults or for children from a literate parent or legal 
guardian who participated in the TB child study [17] or the Worm HIV Interaction study 
(adults only) [34]. 
 
Study subjects and blood sampling 
Children older than 7 years provided assent for participation. Children and adolescents (Ç16 
years old) were enrolled in the context of clinical consultation for illnesses that resemble active 
tuberculosis. HIV-/TB- healthy controls and MTB culture-confirmed TB cases were enrolled into 
the adult group (Ç18 years old). Blood was collected into Vacuette CPDA tubes and PBMC isola- 
tion performed using Ficoll gradient centrifugation (Leucosep, Greiner Bio-One GmbH) before 
cryopreservation in fetal calf serum containing 10% DMSO within 6h of phlebotomy. 
 
Reagents 
Complete Medium (CM) (RPMI 1640 W/Glutamax and Penicillin-Streptomycin (Gibco, Invi- 
trogen), 100μg/ml, 10% heat-inactivated FCS (FBS Gold A11-151, PAA Germany). Anti- 
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CD4-PerCP Cy5.5 (Oct4) and HLA-DR Pe-Cy7 (LN3) were purchased from eBioscience. Anti- 
CD8 Horizon V500 (RPA-T8); anti-CD27-APC H7 (M-T271); anti-CD3-Pac Blue (UCHT-1); 
anti-IFNγ-FITC (B27); anti-CD154-APC (TRAP1); anti-Mip-1β-PE (D21-1351); CST and 
compensation beads were obtained from BD Pharmingen. 
 
Intracellular cytokine staining 
PBMC were thawed and washed twice in CM containing benzonase (Novagen, 25KU, 1/5000 
V/V). Viability was assessed using trypan blue exclusion after a resting period of 2–6 hours at 
37°C in complete medium. Cells were stimulated for 12h to 16h in complete medium contain- 
ing Brefeldin A (Sigma-Aldrich, 5ug/ml) and CD28/CD49d antibodies (Pharmingen, 1ug/ml) 
with CMVpp65 peptide set (JPT Peptide Technologies, 2ug/ml), Staphylococcal Enterotoxin B 
(Sigma-Aldrich, 0.8ug/ml) or nothing as a negative control. Intracellular cytokine staining was 
performed using a standard staining protocol [10]. Acquisition of cells was performed on BD 
FACS Canto2 (NIMR-MMRC, Mbeya) or BD Fortessa (IHI-BRTC, Bagamoyo). Instruments 
were calibrated before each run using BD Cytometer Setup and Tracking Beads according to 
manufacturer’s recommendations. Data were analysed using FlowJo 9.X (Tree Star). T cell re- 
sponses were considered positive, if the frequency of IFNγ+ cells was above 0.05% of the parent 
population and >2-fold the background frequency in the unstimulated control. GraphPad 
Prism (San Diego, CA, USA), version 4.03, was used for statistical analysis. Anonymized pa- 
tient characteristics and the respective flow cytometry data statistics are provided as S1 Table. 
 
Supporting Information 
S1 Table. Participant level data; anonymized patient characteristics and respective flow cy- 
tometry data statistics. Column legends: A) Tuberculosis classification (see [17]); B) Age 
(years); C) HIV status (1: positive, 2: negative); D) CD4 cell counts per μl of blood; E) CD4 T 
cell percentages observed after PBMC stimulation; F) Signif: CD4 T cell response to CMVpp65 
stimulation passed threshold for significance (see methods), NS: Not significant; G to I) Per- 
centages of CD4 T cell producing one or both of the indicated cytokine(s) observed after 
PBMC stimulation with CMVpp65 (γ: IFN-γ, MIP: Mip-1β); J) Proportion of CD4 T cell pro- 
ducing Mip-1β that also produced IFN-γ; K) CD27 MFI Fold Change of IFNγ producing cells 
compared to all CD4 T cells (see Fig 1 for gating strategy); L to Q) as for F to K) but for CD8 T 
cell responses to CMVpp65 PBMC stimulation. 
(XLSX) 
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